<SEC-DOCUMENT>0001654954-25-009568.txt : 20250814
<SEC-HEADER>0001654954-25-009568.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814093138
ACCESSION NUMBER:		0001654954-25-009568
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		251214948

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:cvm="http://cvm.com/20250630"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-10-01to2025-06-30" id="ixv-7985">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-10-01to2025-06-30" format="ixt:booleanfalse" id="ixv-7986">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2024-10-01to2025-06-30" id="ixv-7987">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2024-10-01to2025-06-30" id="ixv-7988">Q3</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2024-10-01to2025-06-30" id="ixv-7989">2025</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-7990">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-7991">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-7992">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30" unitRef="Shares" decimals="0" id="ixv-7993">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-7994">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-7995">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-7996">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" unitRef="Shares" decimals="0" id="ixv-7997">5321341</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-7998">2126682</ix:nonFraction><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="From2024-10-01to2025-06-30" id="ixv-7999">false</ix:nonNumeric><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="From2024-10-01to2025-06-30" id="ixv-8000">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="From2024-10-01to2025-06-30" id="ixv-8001">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="From2024-10-01to2025-06-30" id="ixv-8002">false</ix:nonNumeric><ix:nonFraction name="us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" contextRef="AsOf2024-09-30" unitRef="USD" decimals="0" id="ixv-8003">250000</ix:nonFraction><ix:nonFraction name="cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsOneMember" unitRef="Shares" decimals="0" id="ixv-8004">285917</ix:nonFraction><ix:nonFraction name="cvm:LeaseExpenseUnderOperatingLeases" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-8005">100000</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-8006">300000</ix:nonFraction><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-04-01to2024-06-30" unitRef="USD" decimals="0" id="ixv-8007">7000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-10-01to2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-07-14_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-01-11_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-05-01to2025-05-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-05-01to2024-05-04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_ChangesInEquityWarrantsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_ChangesInEquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-10-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-31_cvm_PreFundedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_cvm_PreFundedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-04-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-12-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-03-01to2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-05-01to2025-05-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-10-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_ConsultingAgreementsOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_TopMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_BottomMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_ConsultantsOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2025-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-04-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-08-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2024-10-01to2025-06-30" id="ixv-8981">10-Q</ix:nonNumeric></span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:boolballotbox" id="ixv-8982">&#9746;</ix:nonNumeric>&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2024-10-01to2025-06-30" format="ixt:datemonthdayyearen" id="ixv-8983">June 30, 2025</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:boolballotbox" id="ixv-8984">&#9744;</ix:nonNumeric>&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _________ to __________.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission file number <strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2024-10-01to2025-06-30" id="ixv-8985">1-11889</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:45%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:88%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2024-10-01to2025-06-30" id="ixv-8986">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:stateprovnameen" id="ixv-8987">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2024-10-01to2025-06-30" id="ixv-8988">84-0916344</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;State or other jurisdiction incorporation</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2024-10-01to2025-06-30" id="ixv-8989">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2024-10-01to2025-06-30" id="ixv-8990">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2024-10-01to2025-06-30" id="ixv-8991">Vienna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:stateprovnameen" id="ixv-8992">Virginia</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2024-10-01to2025-06-30" id="ixv-8993">22182</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2024-10-01to2025-06-30" id="ixv-8994">703</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2024-10-01to2025-06-30" id="ixv-8995">506-9460</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of Each Class</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of Each Exchange on Which Registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2024-10-01to2025-06-30" id="ixv-8996">Common Stock</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2024-10-01to2025-06-30" id="ixv-8997">CVM</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:exchnameen" id="ixv-8998">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2024-10-01to2025-06-30" id="ixv-8999">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2024-10-01to2025-06-30" id="ixv-9000">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="ixv-9001">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:boolballotbox" id="ixv-9002">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:boolballotbox" id="ixv-9003">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:boolballotbox" id="ixv-9004">&#9744;</ix:nonNumeric>&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Class of Stock</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;No. Shares Outstanding</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-08-13" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-9005">6,882,156</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">August 13, 2025</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a1">Item 1.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a2">Condensed Balance Sheets at June 30, 2025 (unaudited) and September 30, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a3">Condensed Statements of Operations for the nine months ended June 30, 2025 and 2024 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a4">Condensed Statements of Operations for the three months ended June 30, 2025 and 2024 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a5">Condensed Statements of Stockholders&#8217; Equity for the nine months ended June 30, 2025 and 2024 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a6">Condensed Statements of Cash Flows for the nine months ended June 30, 2025 and 2024 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a7">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a8">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a8">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a9">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a9">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">33</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a10">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">33</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#a11">PART II</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a12">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a12">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">34</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a13">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a13">Other Information</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">34</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a14">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a14">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">34</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#a15">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">35</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a1">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a2">CONDENSED BALANCE SHEETS</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASSETS</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,792,856</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,738,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">304,133</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_4" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">294,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_5" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">518,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_6" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,019,908</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_7" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9" name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,622,529</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,055,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,998,731</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,350,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_13" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,332,096</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,495,937</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,578,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_16" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,129,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_17" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">130,585</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_18" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">165,492</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1171" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_21" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,354,478</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_22" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,475,441</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_23" name="us-gaap:Assets" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,336,199</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_24" name="us-gaap:Assets" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Liabilities: </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,577,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_28" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,448,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_29" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">475,602</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_30" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">566,042</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" name="cvm:DueToEmployeeCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,169,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" name="cvm:DueToEmployeeCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">363,306</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease liabilities, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,205,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_34" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,010,995</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_35" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">187,739</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_36" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">226,969</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_37" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,616,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,615,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="MARGIN: 0px 0px 0px 15px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_39" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,271,813</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,957,925</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_41" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,298,398</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,425,979</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_43" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_44" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_45" name="us-gaap:Liabilities" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,311,259</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_46" name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,124,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_63" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_64" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_66" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_50" name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_51" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_71" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_72" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_76" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,321,341</ix:nonFraction> and <ix:nonFraction id="fid_77" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,126,682</ix:nonFraction> shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_52" name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_53" name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_54" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">540,293,742</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_55" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,857,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_56" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">533,322,016</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_57" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">514,011,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_58" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,024,940</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_59" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,867,083</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_60" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,336,199</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_61" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a3">CONDENSED STATEMENTS OF OPERATIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2025 and 2024</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2025</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_79" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,184,276</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_80" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,684,204</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_81" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,592,128</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_82" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,547,866</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_83" name="us-gaap:OperatingExpenses" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,776,404</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_84" name="us-gaap:OperatingExpenses" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,232,070</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_85" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,776,404</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_86" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20,232,070</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_87" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">520,439</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_88" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">571,102</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_89" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">13,312</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_90" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,801</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_91" name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">19,310,155</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_92" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20,810,973</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_93" name="cvm:ModificationOfWarrants" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_94" name="cvm:ModificationOfWarrants" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">659,456</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_95" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">19,310,155</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_96" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,470,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_97" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">6.34</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_98" name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">12.51</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_99" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,046,400</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_100" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,715,982</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a4">CONDENSED STATEMENTS OF OPERATIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED JUNE 30, 2025 and 2024</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2025</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_102" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,739,948</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_103" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,703,160</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_104" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,748,935</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_105" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,967,075</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_106" name="us-gaap:OperatingExpenses" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,488,883</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_107" name="us-gaap:OperatingExpenses" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,670,235</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_108" name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,488,883</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_109" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,670,235</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_110" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">172,050</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_111" name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">190,705</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_112" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,771</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_113" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,382</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_114" name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,664,704</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_115" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_116" name="cvm:ModificationOfWarrants" contextRef="From2025-04-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_117" name="cvm:ModificationOfWarrants" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">659,456</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_118" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,664,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_119" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,516,014</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_120" name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">1.36</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_121" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">4.18</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_122" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,150,702</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_123" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,799,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a5">STATEMENT OF STOCKHOLDERS' EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,126,682</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">21,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,857,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_720" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">514,011,861</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,867,083</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrant exercises</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_939" name="cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">48,333</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">483</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1002" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">483</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1003" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1004" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2024-10-01to2024-12-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_918" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,761</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1005" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">57,086</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1006" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1007" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">57,134</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_925" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,154</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_730" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">396,035</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1009" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1010" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">396,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_932" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">251,750</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_734" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,518</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1011" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,997,782</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1012" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1013" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,000,300</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_738" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">100</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_739" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1014" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">711,382</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1015" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1016" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">711,381</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_743" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1017" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">650,291</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1018" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1019" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">650,291</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_747" name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1020" name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1021" name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1022" name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,073,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, DECEMBER 31, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_751" name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,436,580</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_752" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">24,366</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_753" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">532,369,189</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_754" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">521,084,923</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_755" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,308,632</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrant exercises</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_940" name="cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">199,250</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_756" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,993</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1023" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,993</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_919" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,524</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_760" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">75</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,979</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1028" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,054</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_926" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,667</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,185</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,202</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_933" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">133,750</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_768" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,338</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1032" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,558,662</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1033" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,560,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares issued for settlement of clinical development costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_950" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">33,333</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_772" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">333</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,552</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1036" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1037" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,885</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_776" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">685,668</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">685,668</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_780" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1041" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">449,197</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1042" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1043" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">449,197</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_784" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1045" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,572,389</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1046" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,572,389</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, MARCH 31, 2025</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_788" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,812,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_789" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">28,122</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_790" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">535,627,045</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_791" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">527,657,312</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_792" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,997,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-funded warrant exercises</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_941" name="cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">486,251</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_793" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,862</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1047" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,862</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1048" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2025-04-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_920" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">22,986</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_797" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">230</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1050" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,093</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1051" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,323</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_801" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">127,158</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">127,158</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_934" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,000,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_805" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1056" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,980,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,000,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_809" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1059" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">73,442</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">73,442</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_813" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1060" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">562,134</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1064" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">562,134</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_817" name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1066" name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,664,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1067" name="us-gaap:NetIncomeLoss" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,664,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, JUNE 30, 2025</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_821" name="us-gaap:SharesIssued" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,321,341</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_822" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,214</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_823" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">540,293,742</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_824" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">533,322,016</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_825" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,024,940</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENT OF STOCKHOLDERS' EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_826" name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,581,188</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_827" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,811</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_828" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,290,475</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_829" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_830" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_914" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">591</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_831" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_951" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48,901</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_952" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_953" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48,907</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_921" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,952</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_835" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_954" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">202,277</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_955" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_956" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">202,307</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_928" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">83,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_839" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">830</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_957" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,979,170</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_958" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_959" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,980,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_843" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_960" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,383,909</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_961" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_962" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,383,909</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_847" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_963" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">470,229</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_964" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_965" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">470,229</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_851" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_966" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_967" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_968" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, DECEMBER 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_855" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,667,731</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_856" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,677</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_857" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">506,434,503</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_858" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_859" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_915" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">912</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_860" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,476</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_970" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_971" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">53,485</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,425</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_864" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_972" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">380,816</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_973" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_974" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">380,870</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_929" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">129,167</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_868" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,292</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_975" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,748,708</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_976" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_977" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,750,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_872" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_978" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,432,540</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_979" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_980" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,432,540</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_876" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_981" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">717,621</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_982" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_983" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">717,621</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_984" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_985" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_986" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, MARCH 31, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_884" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,803,235</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_885" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,032</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">515,332,422</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_887" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">501,045,811</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_888" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,304,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_916" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,524</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_889" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_987" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,562</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_988" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_989" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">60,577</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_923" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,348</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_893" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_990" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">155,632</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_992" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">155,655</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchase of stock by officers and directors</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_944" name="cvm:PurchaseOfStockByOfficersAndDirectorsShares" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,933</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_897" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_993" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,601</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_994" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_995" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_901" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_996" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_997" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_905" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_999" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1000" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1001" name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,856,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, JUNE 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_909" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,809,040</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_910" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,089</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_911" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">516,357,337</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_912" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">507,902,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,473,057</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="a6">CONDENSED STATEMENTS OF CASH FLOWS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2025 and 2024</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2025</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_234" name="us-gaap:ProfitLoss" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">19,310,155</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_235" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">20,810,973</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_237" name="us-gaap:DepreciationAndAmortization" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,924,303</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_238" name="us-gaap:DepreciationAndAmortization" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,977,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_239" name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,970</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_240" name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,008</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_241" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">587,285</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_242" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">778,571</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_243" name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,470,491</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_244" name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,544,569</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_245" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">164,510</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_246" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">162,969</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Shares issued for settlement of clinical development costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_247" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,885</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_248" name="cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts" contextRef="From2023-10-01to2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on patent impairment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_249" name="cvm:GainLossOnPatentImpairment" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,312</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_250" name="cvm:GainLossOnPatentImpairment" contextRef="From2023-10-01to2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_252" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,874</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_253" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,708</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_254" name="cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">622,831</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_255" name="cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">304,097</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_256" name="us-gaap:IncreaseDecreaseInDeposits" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_257" name="us-gaap:IncreaseDecreaseInDeposits" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">46,884</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_259" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,444</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_260" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">592,370</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_261" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">60,490</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_262" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">167,568</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_263" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">806,214</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_264" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">139,243</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_265" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">12,449,214</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_266" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">13,994,501</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_268" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,954</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_269" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">75,122</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_270" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_271" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_272" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,954</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_273" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">88,333</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock and pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,560,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,730,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_277" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,531,832</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_278" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,173,577</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_280" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_283" name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_285" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,491,617</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_286" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,315,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_287" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,536,851</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,321,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET DECREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,945,317</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_290" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,761,083</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_291" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,738,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_292" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_293" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,792,856</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_294" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">384,652</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NINE MONTHS ENDED JUNE 30, 2025 and 2024</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2025</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_296" name="cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">838</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" name="cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets purchased under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_298" name="cvm:PurchaseOfAssetsUnderFinanceLeases" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_299" name="cvm:PurchaseOfAssetsUnderFinanceLeases" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Obligations paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_300" name="cvm:ObligationServicesPaidWithIssuanceOfCommonStock" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">583,447</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" name="cvm:ObligationServicesPaidWithIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">738,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" name="cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" name="cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">110,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_304" name="cvm:NonCashFinancingCostsIncludedInCurrentLiabilities" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">168,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_305" name="cvm:NonCashFinancingCostsIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">91,975</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment purchases included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_306" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2024-10-01to2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_307" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,770</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" name="us-gaap:InterestPaidNet" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">592,644</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" name="us-gaap:InterestPaidNet" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">706,517</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a7">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NINE MONTHS ENDED JUNE 30, 2025 and 2024 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_311" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_7cef95"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of June 30, 2025 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 19, 2025, the Company&#8217;s shareholders approved a reverse split of the Company&#8217;s common stock which became effective on the NYSE American on May 20, 2025. On that date, every thirty issued and outstanding shares of the Company&#8217;s common stock automatically converted into one outstanding share. As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock decreased from <ix:nonFraction id="fid_639" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_cvm_TopMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">94,037,256</ix:nonFraction> (pre-split) shares to <ix:nonFraction id="fid_638" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30_cvm_BottomMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,135,021</ix:nonFraction> (post-split) shares. In addition, by reducing the number of the Company&#8217;s outstanding shares, the Company&#8217;s loss per share in all prior periods will increase by a factor of thirty. The reverse stock split affected all stockholders of the Company&#8217;s common stock uniformly and did not affect any stockholder&#8217;s percentage of ownership interest. The par value of the Company&#8217;s stock remained unchanged at $<ix:nonFraction id="fid_640" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> per share and the number of authorized shares of common stock remained the same after the reverse stock split.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As the par value per share of the Company&#8217;s common stock remained unchanged at $0.01 per share, a total of $<ix:nonFraction id="fid_641" name="cvm:AdjustmentsToAdditionalPaidInCapitalStockIssued" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">909,021</ix:nonFraction> was reclassified from common stock to additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company&#8217;s incentive and non-qualified stock option plans, as well as the shares of common stock underlying outstanding stock options and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_320" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_7cef95" continuedAt="cont_ce2c1f"><ix:nonNumeric id="fid_321" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_322" name="us-gaap:InventoryPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_323" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_324" name="cvm:LeasesPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities and are expensed as incurred.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_325" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_8a1f55"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and have been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_ce2c1f" continuedAt="cont_af3ff3"><ix:continuation id="cont_8a1f55"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_326" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_327" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_328" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $<ix:nonFraction id="fid_633" name="us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,000</ix:nonFraction> at June 30, 2025 and September 30, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_329" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2025 and September 30, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_330" name="cvm:ImpairmentOfLongLivedAssetsPolicyTextblock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_727654"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_af3ff3" continuedAt="cont_7b529f"><ix:continuation id="cont_727654"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at $<ix:nonFraction id="fid_635" name="us-gaap:FinancialInstrumentsOwnedOtherAtFairValue" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,000</ix:nonFraction> and $<ix:nonFraction id="fid_636" name="us-gaap:FinancialInstrumentsOwnedOtherAtFairValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,480,000</ix:nonFraction> as of June 30, 2025 and September 30, 2024, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_332" name="us-gaap:UseOfEstimates" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_333" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_b43252"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07,&#160;<em>Segment Reporting</em>&#160;(Topic 280):&#160;<em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em>&#160;which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. &#160;The Company is currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_7b529f"><ix:continuation id="cont_b43252"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p></ix:continuation></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><ix:nonNumeric id="fid_312" name="cvm:LiquidityDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_313" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_08e12e"><p style="font-size:10pt;font-family:times new roman;margin:0px">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In May 2025, the Company sold <ix:nonFraction id="fid_658" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-01to2025-05-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,000,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_660" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-05-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.50</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_661" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-05-01to2025-05-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_662" name="cvm:StockIssuanceCost" contextRef="From2025-05-01to2025-05-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2025, the Company sold <ix:nonFraction id="fid_665" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-03-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">133,750</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction id="fid_666" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">4.80</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction id="fid_668" name="us-gaap:ExcessStockSharesIssued" contextRef="AsOf2025-05-31_cvm_PreFundedMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">399,584</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction id="fid_669" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-05-31_cvm_PreFundedMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">4.79</ix:nonFraction>7 per pre-funded warrant, for proceeds of approximately $<ix:nonFraction id="fid_667" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-03-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.1</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_670" name="cvm:StockIssuanceCost" contextRef="From2025-03-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million. As of June 30, 2025, all of the pre-funded warrants in connection with the March 2025 offering have been exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2024, the Company sold <ix:nonFraction id="fid_671" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-12-01to2024-12-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">251,750</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction id="fid_526" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.30</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction id="fid_519" name="us-gaap:ExcessStockSharesIssued" contextRef="AsOf2024-12-31_cvm_PreFundedMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">285,917</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction id="fid_527" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-12-31_cvm_PreFundedMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.29</ix:nonFraction>7 per pre-funded warrant, for proceeds of approximately $<ix:nonFraction id="fid_532" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.4</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_534" name="cvm:StockIssuanceCost" contextRef="From2024-12-01to2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.6</ix:nonFraction> million. As of June 30, 2025, <ix:nonFraction id="fid_672" name="cvm:StockWarrantsExercised" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">285,917</ix:nonFraction> of the pre-funded warrants in connection with the December 2024 offering have been exercised.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_08e12e" continuedAt="cont_9b3717"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the March 2025 and December 2024 offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the financings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold <ix:nonFraction id="fid_675" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">129,167</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_676" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-02-29" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">60.00</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_677" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">7.0</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_678" name="cvm:StockIssuanceCost" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold <ix:nonFraction id="fid_680" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">83,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_528" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-11-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">60.00</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_533" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_535" name="cvm:StockIssuanceCost" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#8220;Ergomed&#8221;) pursuant to which the Company issued <ix:nonFraction id="fid_524" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-10-31_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">33,334</ix:nonFraction> shares of common stock in exchange for services. The shares are legally issued and outstanding. The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares were not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $<ix:nonFraction id="fid_517" name="cvm:StockIssuanceCost" contextRef="From2024-10-01to2024-10-31_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">61,000</ix:nonFraction> to issue the shares from this agreement which were immediately expensed. During the nine months ended June 30, 2025, <ix:nonFraction id="fid_684" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">33,334</ix:nonFraction> shares were sold by Ergomed and the proceeds used to settle $<ix:nonFraction id="fid_690" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,885</ix:nonFraction> in outstanding payables for services provided to the Company. As of June 30, 2025, Ergomed held did not hold any shares of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of June 30, 2025 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_334" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" name="cvm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" contextRef="AsOf2025-06-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,613</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">709,573</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_cvm_StockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">59,460</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_632" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_us-gaap_StockCompensationPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">21,134</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_629" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">21,334</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Option Activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_335" name="cvm:ScheduleOfStockOptionActivityTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,136</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">65,584</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,957</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,767</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">906</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">903</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_642" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,017</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_643" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">65,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,033</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_648" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">905</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_9b3717" continuedAt="cont_05ed95"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of <ix:nonFraction id="fid_691" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-04-01to2024-04-19" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,811</ix:nonFraction> stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date.&#160; This resulted in remaining compensation cost of approximately $<ix:nonFraction id="fid_693" name="cvm:CompensationCost" contextRef="From2024-04-01to2024-04-19" format="ixt:numdotdecimal" unitRef="USD" decimals="0">260,000</ix:nonFraction> that will be amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $<ix:nonFraction id="fid_696" name="cvm:CompensationCost" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">101,000</ix:nonFraction> as of March 31, 2024 was expensed during the three months ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_336" name="cvm:ScheduleOfCompensatingBalancesTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_464" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-10-01to2025-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,470,491</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_650" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,544,569</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_466" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-10-01to2025-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">587,285</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_651" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">600,841</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_652" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">73,442</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_653" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">728,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_654" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2025-04-01to2025-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,525</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_655" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2024-04-01to2024-06-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">230,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at June 30, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_337" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:12%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_468" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesNMember">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_478" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,845</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_487" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">90.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_497" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesNMember">8/18/2026</ix:nonNumeric>&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_469" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesUUMember">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_479" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,120</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_488" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">84.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_498" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesUUMember">6/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_470" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesXMember">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_480" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_489" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">277.50</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_499" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesXMember">7/13/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_471" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesYMember">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_481" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">867</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_490" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">360.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_500" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesYMember">8/15/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_472" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesMMMember">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_482" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,115</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_491" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">55.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_501" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesMMMember">6/22/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_473" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesNNMember">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_483" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,670</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_492" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">75.60</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_502" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesNNMember">7/24/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_474" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_SeriesRRMember">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_484" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,801</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_493" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">49.50</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_503" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_SeriesRRMember">10/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_476" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_477" name="cvm:IssueDate1" contextRef="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember">11/19/2024</ix:nonNumeric> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_486" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" contextRef="AsOf2025-06-30_cvm_ConsultantsOptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">20,333</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$<ix:nonFraction id="fid_495" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_BottomMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">21.00</ix:nonFraction> - $<ix:nonFraction id="fid_496" name="cvm:ExercisePrice" contextRef="AsOf2025-06-30_cvm_TopMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">65.40</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_504" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember">7/27/2027</ix:nonNumeric> - <ix:nonNumeric id="fid_505" name="cvm:ExpirationDate" contextRef="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember">11/1/2034</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_05ed95"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, <ix:nonFraction id="fid_698" name="cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted" contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">399,583</ix:nonFraction> and 285,917 pre-funded warrants at an offering price of $<ix:nonFraction id="fid_700" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-06-30_cvm_ChangesInEquityWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">4.80</ix:nonFraction> and $<ix:nonFraction id="fid_702" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-06-30_cvm_ChangesInEquityWarrantsOneMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.30</ix:nonFraction>, respectively, were issued. No pre-funded warrants or warrants recorded as equity were issued during the nine months ended June 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, <ix:nonFraction id="fid_704" name="cvm:ShareBasedPaymentArrangementNumberOfInstrumentsExercised" contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">733,834</ix:nonFraction> pre-funded warrants were exercised. No pre-funded warrants or warrants recorded as equity were exercised during the nine months ended June 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the nine months ended June 30, 2025 and 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025 and 2024, the Company issued <ix:nonFraction id="fid_514" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,821</ix:nonFraction> and <ix:nonFraction id="fid_708" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,726</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">26.13</ix:nonFraction> and $<ix:nonFraction id="fid_709" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">55.29</ix:nonFraction> during the nine months ended June 30, 2025 and 2024, respectively. During the three months ended June 30, 2025 and 2024, the Company issued <ix:nonFraction id="fid_512" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-01to2025-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">0</ix:nonFraction> and <ix:nonFraction id="fid_710" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,348</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">39.86</ix:nonFraction> during the three months ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, <ix:nonFraction id="fid_711" name="cvm:hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,667</ix:nonFraction> options with an exercise price of $<ix:nonFraction id="fid_508" name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">21.00</ix:nonFraction> were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the nine months ended June 30, 2024.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $<ix:nonFraction id="fid_712" name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">587,000</ix:nonFraction> and $<ix:nonFraction id="fid_713" name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">601,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $<ix:nonFraction id="fid_716" name="us-gaap:ShareBasedCompensation" contextRef="From2025-04-01to2025-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">81,000</ix:nonFraction> and $<ix:nonFraction id="fid_714" name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">231,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. On June 30, 2025 and September 30, 2024, consulting fees of approximately $<ix:nonFraction id="fid_699" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-06-30_cvm_ConsultingAgreementsOtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">48,000</ix:nonFraction> and $<ix:nonFraction id="fid_510" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,000</ix:nonFraction>, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_314" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no related party transactions during the nine months ended June 30, 2025. During the nine months ended June 30, 2024, certain officers and directors purchased <ix:nonFraction id="fid_1069" name="cvm:RestrictedCommonStockSharesIssued" contextRef="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,933</ix:nonFraction> shares of restricted common stock at an aggregate fair market value of approximately $<ix:nonFraction id="fid_1070" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, <ix:nonNumeric id="fid_1068" name="cvm:DescriptionOfModificationOfWarrants" contextRef="From2024-05-01to2024-05-04">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend</ix:nonNumeric> in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_315" name="us-gaap:MortgageNotesPayableDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">NOTES PAYABLE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of May 8, 2025, the Company entered into a promissory note agreement for a principal amount of $<ix:nonFraction id="fid_1071" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-05-01to2025-05-08" format="ixt:numdotdecimal" unitRef="USD" decimals="0">350,000</ix:nonFraction> (the &#8220;Note Payable&#8221;). The Note Payable bears interest at a fixed rate of <ix:nonFraction id="fid_1072" name="us-gaap:InvestmentInterestRate" contextRef="AsOf2025-06-30" unitRef="Pure" decimals="1" scale="-2">10</ix:nonFraction>% per annum. As of June 30, 2025, the Note Payable was repaid in full.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_316" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true" continuedAt="cont_0e9b56"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">F. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Clinical Research Agreements</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $<ix:nonFraction id="fid_1116" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">0.7</ix:nonFraction> million as of June 30, 2025. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_0e9b56" continuedAt="cont_bce60b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $<ix:nonFraction id="fid_1098" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">6.0</ix:nonFraction> million and $<ix:nonFraction id="fid_1099" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">7.4</ix:nonFraction> million and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_1100" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">8.5</ix:nonFraction> million and $<ix:nonFraction id="fid_1101" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">10.0</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1102" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.2</ix:nonFraction> million and $<ix:nonFraction id="fid_1103" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">2.0</ix:nonFraction> million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the nine months ended June 30, 2025 and 2024, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $<ix:nonFraction id="fid_1117" name="us-gaap:Depreciation" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.4</ix:nonFraction> million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the nine months ended June 30, 2025 and 2024, was approximately $<ix:nonFraction id="fid_1118" name="cvm:FinanceLeasePrincipalPayment" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.1</ix:nonFraction> million and $<ix:nonFraction id="fid_1120" name="cvm:FinanceLeasePrincipalPayment" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.0</ix:nonFraction> million, respectively, of which approximately $<ix:nonFraction id="fid_1121" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">0.6</ix:nonFraction> million and $<ix:nonFraction id="fid_1122" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">0.7</ix:nonFraction> million was for interest, respectively. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of June 30, 2025, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_1096" name="cvm:AnnualIncreaseToInterestPayments" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" unitRef="Pure" decimals="4" scale="-2">8.46</ix:nonFraction>% and the weighted average remaining lease term is <ix:nonNumeric id="fid_1115" name="cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt-sec:duryear">3.34</ix:nonNumeric> years. During the nine months ended June 30, 2025 and 2024, total finance lease costs were approximately $<ix:nonFraction id="fid_1110" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.9</ix:nonFraction> million and $<ix:nonFraction id="fid_1119" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.1</ix:nonFraction> million, respectively, consisting of approximately $<ix:nonFraction id="fid_1111" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.4</ix:nonFraction> million of lease asset amortization for both periods and approximately $<ix:nonFraction id="fid_1112" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">0.6</ix:nonFraction> million and $<ix:nonFraction id="fid_1123" name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the nine months ended June 30, 2025, there were approximately $<ix:nonFraction id="fid_1124" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_1104" name="us-gaap:SecurityDeposit" contextRef="AsOf2023-01-11_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of June 30, 2025 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_338" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1073" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">688,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1074" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,838,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1075" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,929,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1076" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,021,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1078" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2025-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,731,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1080" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,253,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1081" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,478,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1082" name="cvm:FinanceLeaseLiabilityCurrentPortion" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,206,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,272,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_bce60b"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $<ix:nonFraction id="fid_1105" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.3</ix:nonFraction> million and $<ix:nonFraction id="fid_1106" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.5</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_1107" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.5</ix:nonFraction> million and $<ix:nonFraction id="fid_1108" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1109" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-4" scale="5">0.2</ix:nonFraction> million is current in both periods. During the nine months ended June 30, 2025 and 2024, the Company incurred lease expense under operating leases of approximately $<ix:nonFraction id="fid_1113" name="cvm:LeaseExpenseUnderOperatingLeases" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.1</ix:nonFraction> million in both periods, respectively, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the nine months ended June 30, 2025 and 2024 was approximately $<ix:nonFraction id="fid_1114" name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.3</ix:nonFraction> million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_1097" name="cvm:AnnualIncreaseToInterestPaymentsOperating" contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember" unitRef="Pure" decimals="4" scale="-2">8.95</ix:nonFraction>% and the weighted average the remaining lease term is <ix:nonNumeric id="fid_1127" name="cvm:OperatingLeaseWeightedAverageRemainingLeaseTerm" contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember" format="ixt-sec:duryear">6.49</ix:nonNumeric> years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025, approximate future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_339" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">93,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1085" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">303,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1090" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">443,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1091" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,982,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1092" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">496,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,486,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1094" name="cvm:OperatingLeaseLiabilityCurrentPortion" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">188,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1095" name="cvm:OperatingLeaseLiabilityNoncurrentPortion" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,298,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_317" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, the Company abandoned four patents which resulted in an impairment of $<ix:nonFraction id="fid_1136" name="us-gaap:AssetImpairmentCharges" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,312</ix:nonFraction> on patent costs. During the three months ended June 30, 2025, the Company abandoned one patent which resulted in an impairment of $<ix:nonFraction id="fid_1169" name="us-gaap:AssetImpairmentCharges" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,770</ix:nonFraction> on patent costs. During the nine and three months ended June 30, 2024, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;<ix:nonNumeric id="fid_1139" name="cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" contextRef="From2024-10-01to2025-06-30" format="ixt-sec:duryear">7</ix:nonNumeric>&#160;years. For the nine months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_1137" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,000</ix:nonFraction> and $<ix:nonFraction id="fid_1140" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,000</ix:nonFraction>, respectively. For the three months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_1138" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,000</ix:nonFraction> for both periods. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_340" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1128" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1129" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1130" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1131" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1132" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1133" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1134" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">33,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1135" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">131,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_318" name="us-gaap:EarningsPerShareTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_450" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1142" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">19,310,155</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1143" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,470,429</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1149" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,664,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1150" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,516,014</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1145" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,046,400</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1146" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,715,982</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1151" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,150,702</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1152" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,799,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1147" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">6.34</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1148" name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">12.51</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1153" name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-01to2025-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">1.36</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1154" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-01to2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">4.18</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_451" name="cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1155" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-10-01to2025-06-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">583,312</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1156" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">583,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1157" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-10-01to2025-06-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1158" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,909</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1159" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-10-01to2025-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">588,121</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1160" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">588,158</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_319" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2024-10-01to2025-06-30" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">I. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 4, 2025, the One&#160;Big Beautiful Bill&#160;Act (&#8220;OBBBA&#8221;) was enacted in the United States. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC 740, <em>Income Taxes</em>, requires the effects of changes in tax rates and laws on deferred tax balances to be recognized in the period in which the legislation is enacted. Consequently, as of the date of enactment, we will evaluate all deferred tax balances under the newly enacted tax law and identify any other changes required to our financial statements as a result of the OBBBA. The Company is currently evaluating the impact of the OBBBA on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 14, 2025, the Company sold <ix:nonFraction id="fid_1164" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,500,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction id="fid_1166" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-14_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.82</ix:nonFraction> per share, priced at-the-market under NYSE American rules, for gross proceeds of approximately $<ix:nonFraction id="fid_1165" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">5.7</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 25, 2025, the CEO and a director purchased <ix:nonFraction id="fid_1167" name="cvm:RestrictedCommonStockSharesIssued" contextRef="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,116</ix:nonFraction> shares of restricted common stock at an aggregate fair market value of approximately $<ix:nonFraction id="fid_1168" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">219,995</ix:nonFraction>.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a8">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Company Overview</span>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis, before any other treatment including surgery</span>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET imaging)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Keytruda was approved by FDA in June 2025 as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level. In Merck&#8217;s Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30%, compared with standard of care, in patients whose tumors expressed PD-L1 (CPS &#8805;1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit from Keytruda.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In contrast to the results of the KEYNOTE-689, CEL-SCI&#8217;s Phase 3 study showed that Multikine treated patients whose tumors expressed low (Tumor Proportion Score [TPS &lt;10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI&#8217;s Phase 3 study had low to zero levels of PD-L1.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI believes Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In March 2025, CEL-SCI published a comprehensive presentation of results from the Phase 3 trial in the peer reviewed journal Pathology and Oncology Research (POR). The article is titled &#8220;Neoadjuvant Leukocyte Interleukin Injection Immunotherapy Improves Overall Survival in Low-risk Locally Advanced Head and Neck Squamous Cell Carcinoma -The IT-MATTERS Study&#8221;. &#160;CEL-SCI also published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference on Head and Neck Oncology (ECHNO), the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and the 2023 American Head and Neck Society (AHNS).These publications can be accessed at http://www.cel-sci.com.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine</span></strong><strong><span style="text-decoration:underline"> works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine causes pre-surgical responses;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-surgical responses lead to longer life;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.&#160; These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg1.jpg" alt="cvm_10qimg1.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was not enough for CEL-SCI to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&#160; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg2.jpg" alt="cvm_10qimg2.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg3.jpg" alt="cvm_10qimg3.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg4.jpg" alt="cvm_10qimg4.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s physician consultants have informed CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval &#8211; for the hazard ratio &#8211; in this case) is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&#160; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&#160; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg5.jpg" alt="cvm_10qimg5.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg6.jpg" alt="cvm_10qimg6.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial. CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful? </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg7.jpg" alt="cvm_10qimg7.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has been shown to be safe. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IN CONCLUSION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data:</strong> Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit (95% Confidence Interval) of 0.66.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need:</strong> Multikine focuses on the 70% of patients (based on our 928 patient Phase 3 study) not well served by Keytruda.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population:</strong> The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FDA pathway:</strong> CEL-SCI&#8217;s goal is to begin the 212-patient confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later with the potential to seek early approval after full enrollment.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company&#8217;s liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cost of the confirmatory registration study is estimated to be about $30 million. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.&#160; However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, the Company&#8217;s cash decreased by approximately $2.9 million.&#160;Significant components of this decrease included net proceeds from the December 2024, March 2025 and June 2025 financings of $11.0 million offset by cash used to fund the Company&#8217;s regular operations of approximately $12.5 million and approximately $1.5 million in payments on the Company&#8217;s finance lease obligations.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2024, the Company&#8217;s cash decreased by approximately $3.8 million.&#160; The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $14.0 million and approximately $1.3 million in payments on their finance lease obligations offset by net proceeds from the November 2023 and February 2024 financing of $11.6 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, all remaining 733,834 pre-funded warrants were exercised. No warrants were exercised during the nine months ended June 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred a net operating loss of approximately $18.8 million for the nine months ended June 30, 2025. This net operating loss consists of significant non-cash expenses including approximately $2.1 million in share-based compensation to employees and non-employees, and approximately $2.9 million in depreciation and amortization expense. The Company incurred a net operating loss of approximately $20.2 million for the nine months ended June 30, 2024. This net operating loss consists of significant non-cash expenses including approximately $4.1 million in share-based compensation to employees and non-employees, and approximately $3.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development expenses consist primarily of costs incurred for our research activities, including the development of our products, and include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">employee&#8209;related expenses, including salaries, related benefits and stock&#8209;based compensation expense for employees engaged in research and development functions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">fees paid to consultants for services directly related to our product development and regulatory efforts;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">expenses incurred under agreements with Clinical Research Organizations, or CROs, and consultants that conduct and provide supplies for our clinical studies and clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">costs associated with clinical activities and development activities; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">costs related to compliance with regulatory requirements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes our research and development expenses for the nine months ended June 30, 2025 and 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(in thousands)</em></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;</strong><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clinical trial expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies &amp; materials</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,766</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,225</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Personnel-related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,558</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,534</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">567</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Depreciation and amortization expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,894</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,702</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,845</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,188</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,184</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,684</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, research and development expenses decreased by approximately $1.5 million, or 11%, compared to the nine months ended June 30, 2024. The major components of the decrease in research and development expenses over the prior period include an approximate $1.9 million of employee stock compensation expense due to the options issued in the prior period having a higher fair value because of the Company&#8217;s stock price, and an approximate $0.3 million of other research and development expenses, &#160;offset by an increase of $0.5 million in costs incurred for supplies and materials related to the manufacturing of a clinical lot and an increase of $0.2 million in depreciation and amortization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2025, research and development expenses decreased by approximately $1.0 million, or 21%, compared to the three months ended June 30, 2024. The major components of the decrease in research and development expenses over the prior period include an approximate $0.9 million of employee stock compensation expense due to the forfeiture of milestone options, and an approximate $0.1 million decrease in expenses related to the Phase 3 clinical study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>General and Administrative Expenses</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, general and administrative expenses remained constant at $6.6 million compared to the nine months ended June 30, 2024. The major components of general and administrative expenses include an approximate $0.2 million decrease of employee stock compensation expense due to the options issued in the prior period having a higher fair value because of the Company&#8217;s stock price, an approximate $0.3 million decrease in depreciation and amortization, and an approximate decrease of $0.1 million in consulting expenses due to larger costs incurred in the prior period for the preparation of the confirmatory study, offset by an approximate $0.2 million increase in legal and accounting fees due to out of scope work and an approximate $0.4 million increase in public relations costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2025, general and administrative expenses decreased by approximately $0.2 million, or 11%, compared to the three months ended June 30, 2024. The major components of the decrease in general and administrative expenses include an approximate $0.4 million over the prior period in public relation expenses primarily due to increased public relations hirings in the prior year, offset by an approximate $0.2 million increase of employee stock compensation expense due to options forfeited by board members in the prior period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Interest Expense, Net</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, net interest expense decreased by approximately $0.1 million or 9% compared to the nine months ended June 30, 2024 which is primarily due to less interest paid on leases as higher principal balances have been paid over the last nine months. During the three months ended June 30, 2025 and 2024, net interest expense remained constant at approximately $0.2 million, which is primarily due to the interest paid on the Company&#8217;s lease liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,686,548</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,615,922</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,282,979</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,681,127</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(502,272</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">68,282</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(543,031</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,033</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,184,276</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,684,204</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,739,948</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,703,160</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Critical Accounting Estimates </span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI's significant accounting estimates are more fully described in Part II, Item&#160;7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024. However, certain accounting estimates are particularly important to the portrayal of CEL-SCI&#8217;s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those estimates, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management believes that the following critical accounting estimates require the most significant judgments and estimates with respect to the preparation of CEL-SCI&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Lease Accounting&#160;</em>&#8211; The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting estimate. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Share-based Compensation&#160;</em>&#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718,&#160;<em>Compensation &#8211; Stock Compensation</em>&#160;(&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by CEL-SCI&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, CEL-SCI has based its assumption for stock price volatility on the variance of daily closing prices of CEL-SCI&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a9">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not believe that it has any significant exposure to market risk.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a10">Item 4.&#160; CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial and Operations Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2025. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company&#8217;s Chief Executive Officer and Chief Financial and Operations Officer has concluded that the Company&#8217;s disclosure controls and procedures were not effective as of June 30, 2025 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the nine months ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a11">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="a12">Item 2.&#160; Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended June 30, 2025, the Company issued 6,821 restricted shares of common stock to consultants for investor relations services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="a13">Item 5.&#160; Other Information</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending June 30, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span class="atag" style="display: inline" id="a14"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Number</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exhibit</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="a15">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date:&#160; August 14, 2025</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:&#160;&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Executive Officer&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Patricia Prichep</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Financial Officer&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px"><strong>EXHIBIT 31</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>CERTIFICATIONS</strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I, Geert Kersten, certify that: </p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">1.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">2.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">3.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">4.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">c)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">d)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 50%;">August __, 2025</td> <td style="WIDTH: 3%;">By: </td> <td style="WIDTH: 35%; BORDER-BOTTOM: black 1px solid;">/s/ Geert Kersten&nbsp;</td> <td style="WIDTH: 12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Executive Officer</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;width:100%;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>CERTIFICATIONS</strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I, Patricia Prichep, certify that: </p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">1.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">2.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">3.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">4.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">c)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">d)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;width:100%;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 50%;">August __, 2025</td> <td style="WIDTH: 3%;">By: </td> <td style="WIDTH: 35%; BORDER-BOTTOM: black 1px solid;">/s/ Patricia Prichep</td> <td style="WIDTH: 12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Patricia Prichep</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Financial Officer</td> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <table style="border-spacing:0;width:100%;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px"><strong>EXHIBIT 32</strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:45px">In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive Officer of the Company and Patricia Prichep, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="WIDTH: 4%; VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(1)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(2)</p></td> <td style="VERTICAL-ALIGN: top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;width:100%;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td style="WIDTH: 50%;">August __, 2025</td> <td style="WIDTH: 3%;">By: </td> <td style="WIDTH: 35%; BORDER-BOTTOM: black 1px solid;">/s/ Geert Kersten</td> <td style="WIDTH: 12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert Kersten</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Principal Executive Officer</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Patricia Prichep</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Financial Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-types="http://fasb.org/us-types/2025" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cyd="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:cvm="http://cvm.com/20250630" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20250630">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>110200 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
        <link:definition>148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/InsiderTradingArragements" id="InsiderTradingArragements">
        <link:definition>995445 - Disclosure - Insider Trading Arragements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>995447 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>995448 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995449 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NotesPayable" id="NotesPayable">
        <link:definition>995450 - Disclosure - NOTES PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995451 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>995452 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>995453 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995454 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>995458 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>995459 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>995461 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
        <link:definition>995467 - Disclosure - NOTES PAYABLE (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>995471 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>995472 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>995473 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingCurrent" name="SuppliesUsedForRDAndManufacturingCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" name="SuppliesUsedForRDAndManufacturingNonCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DueToEmployeeCurrent" name="DueToEmployeeCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CostIncurredInIssuanceOfStock" name="CostIncurredInIssuanceOfStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsShares" name="PurchaseOfStockByOfficersAndDirectorsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" name="PurchaseOfStockByOfficersAndDirectorsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" name="SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" name="SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" name="SharesIssuedForSettlementOfClinicalDevelopmentCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossOnPatentImpairment" name="GainLossOnPatentImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" name="IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" name="NonCashFinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfAssetsUnderFinanceLeases" name="PurchaseOfAssetsUnderFinanceLeases" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ObligationServicesPaidWithIssuanceOfCommonStock" name="ObligationServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" name="NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" name="NonCashFinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" name="ImpairmentOfLongLivedAssetsPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfStockOptionActivityTableTextBlock" name="ScheduleOfStockOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfCompensatingBalancesTableTextBlock" name="ScheduleOfCompensatingBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" name="ScheduleOfAntiDilutiveSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" name="AdjustmentsToAdditionalPaidInCapitalStockIssued" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" name="hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuanceCost" name="StockIssuanceCost" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" name="ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" name="ShareBasedPaymentArrangementNumberOfInstrumentsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" name="ShareBasedPaymentArrangementNumberOfInstrumentsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockWarrantsExercised" name="StockWarrantsExercised" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CompensationCost" name="CompensationCost" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RestrictedCommonStockSharesIssued" name="RestrictedCommonStockSharesIssued" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DescriptionOfModificationOfWarrants" name="DescriptionOfModificationOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityCurrentPortion" name="OperatingLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityNoncurrentPortion" name="OperatingLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AnnualIncreaseToInterestPayments" name="AnnualIncreaseToInterestPayments" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AnnualIncreaseToInterestPaymentsOperating" name="AnnualIncreaseToInterestPaymentsOperating" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" name="OperatingLeaseWeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseExpenseUnderOperatingLeases" name="LeaseExpenseUnderOperatingLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeasePrincipalPayment" name="FinanceLeasePrincipalPayment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" name="FinanceLeaseWeightedAverageRemainingLeaseTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" name="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonEmployeesMember" id="cvm_NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PreFundedMember" id="cvm_PreFundedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BottomMember" id="cvm_BottomMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TopMember" id="cvm_TopMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOptionMember" id="cvm_ConsultantsOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsOtherMember" id="cvm_ConsultingAgreementsOtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ChangesInEquityWarrantsMember" id="cvm_ChangesInEquityWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ChangesInEquityWarrantsOneMember" id="cvm_ChangesInEquityWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OfficerAndDirectorMember" id="cvm_OfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_9cd280" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_9cd280" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl_cc0b74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl_cc0b74" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_81ce61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_81ce61" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_58cf03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_58cf03" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_c8fe33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_c8fe33" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_a1fcc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_a1fcc6" xml:lang="en-US">Deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_de3582" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_de3582" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_bf0287" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_bf0287" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_81ecf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_81ecf4" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_412a75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_412a75" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_a16847" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_a16847" xml:lang="en-US">Patent costs, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_80280c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_80280c" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_0fd3be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_0fd3be" xml:lang="en-US">Supplies used for R&amp;D and manufacturing, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_193d85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_193d85" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_14" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_e26a11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_e26a11" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_01f273" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_01f273" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_a16ad4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_a16ad4" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_1ca81e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_1ca81e" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DueToEmployeeCurrent" xlink:label="cvm_DueToEmployeeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DueToEmployeeCurrent" xlink:to="cvm_DueToEmployeeCurrent_lbl_252fff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DueToEmployeeCurrent_lbl_252fff" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_75fc0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_75fc0d" xml:lang="en-US">Finance lease liabilities, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_04de36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_04de36" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_0063ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_0063ec" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_22" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_61de44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_61de44" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_b24af4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_b24af4" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_a08288" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_a08288" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_95bc94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_95bc94" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_84068c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_84068c" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_6bae1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_6bae1b" xml:lang="en-US">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_a80c68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_a80c68" xml:lang="en-US">Common stock, $0.01 par value; 600,000,000 shares authorized; 5,321,341 and 2,126,237 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_e56ce5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_e56ce5" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_8176c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_8176c2" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_bf77a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_bf77a8" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_32" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_a8d772" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_a8d772" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_86cf56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_86cf56" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_e9cc39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_e9cc39" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_f5c3fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_f5c3fc" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_099675" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_099675" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c47cf2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c47cf2" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_b50ed5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_b50ed5" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_597291" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_597291" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_a87fec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_a87fec" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_ec72a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_ec72a6" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_604b17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_604b17" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_a405fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_a405fb" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_ec3100" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_ec3100" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_9b8586" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_9b8586" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_c104c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_c104c4" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_beec51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_beec51" xml:lang="en-US">Interest expense, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_0889aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_0889aa" xml:lang="en-US">Other expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_4ee74e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_4ee74e" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_9" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_a640c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_a640c2" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_ebe980" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_ebe980" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_bd2daf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_bd2daf" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_ae355d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_ae355d" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_eb72b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_eb72b4" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_53c42a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_53c42a" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_06ed21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_06ed21" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_e6b309" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_e6b309" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_0b42fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_0b42fe" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_d4028f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_d4028f" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_4f663e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_4f663e" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_c7ac3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_c7ac3c" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_64031a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_64031a" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_8dc82b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_8dc82b" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_8e41ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_8e41ef" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_d4eecb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_d4eecb" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_e14f55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_e14f55" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_a165d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_a165d7" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_18fa9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_18fa9e" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_bcb3bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_bcb3bb" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="cvm_CostIncurredInIssuanceOfStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CostIncurredInIssuanceOfStock" xlink:to="cvm_CostIncurredInIssuanceOfStock_lbl_e414dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CostIncurredInIssuanceOfStock_lbl_e414dc" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_ef9cd9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_ef9cd9" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsShares_lbl_86cde0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsShares_lbl_86cde0" xml:lang="en-US">Purchase of stock by officers and directors, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_8fa82f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_8fa82f" xml:lang="en-US">Purchase of stock by officers and directors, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_d66ae8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_d66ae8" xml:lang="en-US">Pre-funded warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_e5e0cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_e5e0cb" xml:lang="en-US">Pre-funded warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_fb3ecf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_fb3ecf" xml:lang="en-US">Equity based compensation - employees, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" xlink:to="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares_lbl_6cf2e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares_lbl_6cf2e5" xml:lang="en-US">Shares issued for settlement of clinical development costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" xlink:to="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount_lbl_ce18c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount_lbl_ce18c9" xml:lang="en-US">Shares issued for settlement of clinical development costs, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_79e88b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_79e88b" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_dd1c58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_dd1c58" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_a9e5ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_a9e5ad" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_446b13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_446b13" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_d7871b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_d7871b" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_3" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_6e280c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_6e280c" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_e974fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_e974fd" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl_67b319" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl_67b319" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl_6" xml:lang="en-US">[Other Noncash Income (Expense)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_014b2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_014b2d" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_5a570d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_5a570d" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_84ca95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_84ca95" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" xlink:to="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts_lbl_6f887f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts_lbl_6f887f" xml:lang="en-US">Shares issued for settlement of clinical development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_GainLossOnPatentImpairment" xlink:label="cvm_GainLossOnPatentImpairment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossOnPatentImpairment" xlink:to="cvm_GainLossOnPatentImpairment_lbl_868b17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossOnPatentImpairment_lbl_868b17" xml:lang="en-US">Loss on patent impairment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_2f0346" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_2f0346" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_e82ab0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_e82ab0" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_13" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:to="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_c124ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_c124ab" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:to="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing_lbl_14" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl_7f9976" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl_7f9976" xml:lang="en-US">Increase (Decrease) in Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_0e739b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_0e739b" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_6b4eb6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_6b4eb6" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_10ed5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_10ed5a" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_4db781" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_4db781" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_19" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f1d110" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f1d110" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xml:lang="en-US">[Cash Provided by (Used in) Operating Activity, Including Discontinued Operation]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_fae3bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_fae3bc" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_24f76f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_24f76f" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_22" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_dfa889" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_dfa889" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_23" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_1a070a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_1a070a" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_24" xml:lang="en-US">[Cash Provided by (Used in) Investing Activity, Including Discontinued Operation]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_300de8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_300de8" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a6d241" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a6d241" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_b95ffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_b95ffd" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_27" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl_f99176" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl_f99176" xml:lang="en-US">Proceeds from the purchase of stock by officers and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl_8c3ec3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl_8c3ec3" xml:lang="en-US">Proceeds from notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_869f7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_869f7f" xml:lang="en-US">Payments of notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_30" xml:lang="en-US">[Repayments of Notes Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_b7ccd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_b7ccd1" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_31" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b163c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b163c7" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xml:lang="en-US">[Cash Provided by (Used in) Financing Activity, Including Discontinued Operation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_493477" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_493477" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_33" xml:lang="en-US">[Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9c2541" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9c2541" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_f8cf31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_f8cf31" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_8fd773" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_8fd773" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable_lbl_cf5d7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable_lbl_cf5d7a" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:label="cvm_PurchaseOfAssetsUnderFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:to="cvm_PurchaseOfAssetsUnderFinanceLeases_lbl_0bab91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfAssetsUnderFinanceLeases_lbl_0bab91" xml:lang="en-US">Assets purchased under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ObligationServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_ObligationServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ObligationServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_ObligationServicesPaidWithIssuanceOfCommonStock_lbl_ce1d8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ObligationServicesPaidWithIssuanceOfCommonStock_lbl_ce1d8e" xml:lang="en-US">Obligations paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock_lbl_4b9d82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock_lbl_4b9d82" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities_lbl_01e29a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonCashFinancingCostsIncludedInCurrentLiabilities_lbl_01e29a" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_b20f3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_b20f3e" xml:lang="en-US">Property and equipment purchases included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_11bb23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_11bb23" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_4c8c38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_4c8c38" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl_4abc6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl_4abc6c" xml:lang="en-US">Insider Trading Arragements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl_991bda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl_991bda" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl_7f86fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl_7f86fe" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl_e4e1f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl_e4e1f6" xml:lang="en-US">Non Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl_0a4fb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl_0a4fb4" xml:lang="en-US">Non Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_bf6362" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_bf6362" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_e02063" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_e02063" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_c807e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_c807e1" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_7a7bc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_7a7bc7" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="cvm_LiquidityDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_131c0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_131c0d" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_ac9652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_ac9652" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_f7633d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_f7633d" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_35dcc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_35dcc4" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl_e36e77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl_e36e77" xml:lang="en-US">NOTES PAYABLE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl_67959c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl_67959c" xml:lang="en-US">Mortgage Notes Payable Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="cvm_CommitmentsAndContingenciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesAbstract" xlink:to="cvm_CommitmentsAndContingenciesAbstract_lbl_5aa77f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesAbstract_lbl_5aa77f" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_ff2c38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_ff2c38" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_66b7a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_66b7a9" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_ff48eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_ff48eb" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_336615" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_336615" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_9a52bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_9a52bf" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_794e6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_794e6c" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_b26e56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_b26e56" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_2ef67f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_2ef67f" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_23fb19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_23fb19" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_e51997" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_e51997" xml:lang="en-US">Supplies used for R&amp;amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_d39311" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_d39311" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_db9762" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_db9762" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_52a8a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_52a8a7" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_984eb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_984eb3" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_9f688a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_9f688a" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_7d8115" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_7d8115" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_b5765b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_b5765b" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:to="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_22de98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_22de98" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_0535f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl_0535f5" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_c5bffe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_c5bffe" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_20a2f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_20a2f6" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_79cd26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_79cd26" xml:lang="en-US">Schedule of equity compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:to="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_102c2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_102c2b" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:to="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_92be3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_92be3b" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_268b61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_268b61" xml:lang="en-US">Schedule of warrants and non-employee options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_0cdad9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_0cdad9" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_4714e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_4714e0" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_8fce43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_8fce43" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_667b25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_667b25" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_8ea6ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_8ea6ae" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_a166ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_a166ae" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_BottomMember" xlink:label="cvm_BottomMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BottomMember" xlink:to="cvm_BottomMember_lbl_82c0c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_BottomMember_lbl_82c0c8" xml:lang="en-US">Bottom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_TopMember" xlink:label="cvm_TopMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TopMember" xlink:to="cvm_TopMember_lbl_ddf8ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TopMember_lbl_ddf8ae" xml:lang="en-US">Top [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:label="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:to="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_lbl_528400" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_lbl_528400" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue_lbl_b61eb7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedOtherAtFairValue_lbl_b61eb7" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_752177" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_752177" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:to="cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl_de5394" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued_lbl_de5394" xml:lang="en-US">Reclassification from common stock to APIC</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_b518e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_b518e3" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_1f0b33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_1f0b33" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_0896ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_0896ab" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_870de5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_870de5" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_1b8502" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_1b8502" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_60c801" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_60c801" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_f96e3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_f96e3e" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_26" xml:lang="en-US">[Incentive Stock Bonus Plan [Member]]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" xlink:to="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_lbl_33a4e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_lbl_33a4e1" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" xlink:label="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" xlink:to="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_lbl_2" xml:lang="en-US">[Remaining Options/shares Under Plans]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_05523d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_05523d" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9a4ca1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9a4ca1" xml:lang="en-US">Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_a0454c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_a0454c" xml:lang="en-US">Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_a3e14a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_a3e14a" xml:lang="en-US">Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_11b696" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_11b696" xml:lang="en-US">Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_a1329a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_a1329a" xml:lang="en-US">Subsidiary Sale Of Stock Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl_66cafa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl_66cafa" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonEmployeesMember" xlink:label="cvm_NonEmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonEmployeesMember" xlink:to="cvm_NonEmployeesMember_lbl_7a6410" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonEmployeesMember_lbl_7a6410" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_787735" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_787735" xml:lang="en-US">Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_5a3cce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_5a3cce" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_ad0713" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_ad0713" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_eb622c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_eb622c" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_b4cb52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_b4cb52" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_7144e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_7144e8" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_f10949" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_f10949" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_6e86b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_6e86b9" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_258b3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_258b3c" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_60a036" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_60a036" xml:lang="en-US">Series RR [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BottomMember" xlink:to="cvm_BottomMember_lbl_33d39d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_BottomMember_lbl_33d39d" xml:lang="en-US">Bottom [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_601074" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_601074" xml:lang="en-US">Consultants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TopMember" xlink:to="cvm_TopMember_lbl_702288" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_TopMember_lbl_702288" xml:lang="en-US">Top [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsOptionMember" xlink:label="cvm_ConsultantsOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOptionMember" xlink:to="cvm_ConsultantsOptionMember_lbl_384a20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOptionMember_lbl_384a20" xml:lang="en-US">Consultants Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_beca99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_beca99" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_4a9166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_4a9166" xml:lang="en-US">Shares Issuable Upon Exercise Of Warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_c5185f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_c5185f" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_ff7381" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_ff7381" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_80526a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_80526a" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl_e81e37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl_e81e37" xml:lang="en-US">Trading Activity By Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PreFundedMember" xlink:label="cvm_PreFundedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PreFundedMember" xlink:to="cvm_PreFundedMember_lbl_b1eeb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PreFundedMember_lbl_b1eeb0" xml:lang="en-US">Pre-Funded [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_bb136f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_bb136f" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_96b57c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_96b57c" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_fcb03b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_fcb03b" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="cvm_ConsultingAgreementsOtherMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsOtherMember" xlink:to="cvm_ConsultingAgreementsOtherMember_lbl_0bbea5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsOtherMember_lbl_0bbea5" xml:lang="en-US">Consulting Agreements Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_401241" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_401241" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="cvm_ChangesInEquityWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ChangesInEquityWarrantsMember" xlink:to="cvm_ChangesInEquityWarrantsMember_lbl_29d1cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ChangesInEquityWarrantsMember_lbl_29d1cb" xml:lang="en-US">Changes in Equity Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsOneMember" xlink:label="cvm_ChangesInEquityWarrantsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ChangesInEquityWarrantsOneMember" xlink:to="cvm_ChangesInEquityWarrantsOneMember_lbl_f1c159" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ChangesInEquityWarrantsOneMember_lbl_f1c159" xml:lang="en-US">Changes in Equity Warrants One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_109fae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_109fae" xml:lang="en-US">Consulting fees inclued prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_877505" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_877505" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl_4329c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl_4329c9" xml:lang="en-US">Exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_109c84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_109c84" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_9655b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_9655b0" xml:lang="en-US">Number of options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_7a7636" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_7a7636" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuanceCost" xlink:label="cvm_StockIssuanceCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuanceCost" xlink:to="cvm_StockIssuanceCost_lbl_a56817" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuanceCost_lbl_a56817" xml:lang="en-US">Stock issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_310c69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_310c69" xml:lang="en-US">Sale of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_e0a447" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_e0a447" xml:lang="en-US">Stock options vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" xlink:to="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20_lbl_48e9ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20_lbl_48e9ee" xml:lang="en-US">Number of pre-funded warrants issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" xlink:to="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20_lbl_11" xml:lang="en-US">[Number of pre-funded warrants issued]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" xlink:to="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted_lbl_4e1290" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted_lbl_4e1290" xml:lang="en-US">Number of pre-funded warrants issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl_4de2e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl_4de2e5" xml:lang="en-US">Common stock shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" xlink:to="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised_lbl_24d834" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised_lbl_24d834" xml:lang="en-US">Number of pre-funded warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" xlink:to="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised_lbl_14" xml:lang="en-US">[Number of pre-funded warrants exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_453b61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_453b61" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_aa3f84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_aa3f84" xml:lang="en-US">Public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_b19fd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_b19fd7" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockWarrantsExercised" xlink:label="cvm_StockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockWarrantsExercised" xlink:to="cvm_StockWarrantsExercised_lbl_6e8198" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockWarrantsExercised_lbl_6e8198" xml:lang="en-US">Number of pre-funded warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CompensationCost" xlink:label="cvm_CompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CompensationCost" xlink:to="cvm_CompensationCost_lbl_ee2b18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CompensationCost_lbl_ee2b18" xml:lang="en-US">Compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OfficerAndDirectorMember" xlink:label="cvm_OfficerAndDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OfficerAndDirectorMember" xlink:to="cvm_OfficerAndDirectorMember_lbl_a8b58c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OfficerAndDirectorMember_lbl_a8b58c" xml:lang="en-US">Officer and Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="cvm_RestrictedCommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedCommonStockSharesIssued" xlink:to="cvm_RestrictedCommonStockSharesIssued_lbl_2d1c35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedCommonStockSharesIssued_lbl_2d1c35" xml:lang="en-US">Issuance of restricted common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_e8bb65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_e8bb65" xml:lang="en-US">Proceeds from issuance of restricted common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="cvm_DescriptionOfModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DescriptionOfModificationOfWarrants" xlink:to="cvm_DescriptionOfModificationOfWarrants_lbl_d8a5a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DescriptionOfModificationOfWarrants_lbl_d8a5a2" xml:lang="en-US">Description of modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl_c03304" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl_c03304" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl_7d70b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl_7d70b0" xml:lang="en-US">Proceeds from issuance of promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_0d20cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_0d20cb" xml:lang="en-US">Three months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_8a9ccd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_8a9ccd" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_a0661a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_a0661a" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_ad70ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_ad70ac" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_09c1f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_09c1f6" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_524710" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_524710" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_14c01e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_14c01e" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_0d92c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_0d92c6" xml:lang="en-US">Less imputed interest on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_5ca222" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_5ca222" xml:lang="en-US">Net present value of financing lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_d68980" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_d68980" xml:lang="en-US">Less net present value of financing lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_b9c0fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_b9c0fd" xml:lang="en-US">Net present value of financing lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_7bec7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_7bec7f" xml:lang="en-US">Three months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_812491" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_812491" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_a3ec66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_a3ec66" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_25ecf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_25ecf6" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_1b9087" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_1b9087" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_e98cbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_e98cbe" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_72ed75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_72ed75" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_762c14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_762c14" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_2dd1ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_2dd1ff" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_906487" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_906487" xml:lang="en-US">Net Present Value Of Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_d5f2f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_d5f2f4" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_e817c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_e817c2" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_9353f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_9353f2" xml:lang="en-US">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl_3ef851" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl_3ef851" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="cvm_AnnualIncreaseToInterestPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AnnualIncreaseToInterestPayments" xlink:to="cvm_AnnualIncreaseToInterestPayments_lbl_498657" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AnnualIncreaseToInterestPayments_lbl_498657" xml:lang="en-US">Annual increase to interest payments</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="cvm_AnnualIncreaseToInterestPaymentsOperating" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:to="cvm_AnnualIncreaseToInterestPaymentsOperating_lbl_43b1aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AnnualIncreaseToInterestPaymentsOperating_lbl_43b1aa" xml:lang="en-US">Annual increase to interest payments operating</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_6eb46f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_6eb46f" xml:lang="en-US">Finance lease right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_6b4b1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl_6b4b1b" xml:lang="en-US">Finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:to="cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm_lbl_fed1ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm_lbl_fed1ce" xml:lang="en-US">Weighted average time of maturity of operating leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_24bc1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_24bc1d" xml:lang="en-US">Finance lease liability current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl_c01494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl_c01494" xml:lang="en-US">Security Deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f182de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f182de" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_6ad75a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_6ad75a" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_6bf619" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_6bf619" xml:lang="en-US">Operating lease liability current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_6691a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_6691a6" xml:lang="en-US">Depreciation expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_e803f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_e803f5" xml:lang="en-US">Finance Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_eecede" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_eecede" xml:lang="en-US">Amortization of Finance Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl_22a79e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl_22a79e" xml:lang="en-US">Interest Expense on Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="cvm_LeaseExpenseUnderOperatingLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseExpenseUnderOperatingLeases" xlink:to="cvm_LeaseExpenseUnderOperatingLeases_lbl_7ece33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseExpenseUnderOperatingLeases_lbl_7ece33" xml:lang="en-US">Incurred lease expense under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_7c9011" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_7c9011" xml:lang="en-US">Interest payment to lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl_e644fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl_e644fa" xml:lang="en-US">Total cash payment for oprating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeasePrincipalPayment" xlink:label="cvm_FinanceLeasePrincipalPayment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeasePrincipalPayment" xlink:to="cvm_FinanceLeasePrincipalPayment_lbl_a9bbbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeasePrincipalPayment_lbl_a9bbbf" xml:lang="en-US">Cash paid related to finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:to="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_e4506f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_e4506f" xml:lang="en-US">Weighted average time of maturity of finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_108de2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_108de2" xml:lang="en-US">Research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_6193fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_6193fb" xml:lang="en-US">Three months ending September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_1a8aac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_1a8aac" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_88892e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_88892e" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_28c131" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_28c131" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_5db40b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_5db40b" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_495604" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_495604" xml:lang="en-US">2030</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_901e67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_901e67" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_858a4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_858a4b" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xml:lang="en-US">[Other Indefinite-Lived Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl_574dc3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl_574dc3" xml:lang="en-US">Impairment patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_d8650c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_d8650c" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:to="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_e83ffa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_e83ffa" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl_f438d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl_f438d8" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl_e44f28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl_e44f28" xml:lang="en-US">Loss per share- basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_b3cd62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_b3cd62" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_3827e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_3827e7" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_295655" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_295655" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_4fcd82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_4fcd82" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_99b684" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_99b684" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_17d885" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_17d885" xml:lang="en-US">Subsequent Event Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_8090cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_8090cf" xml:lang="en-US">Subsequent Event Member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_65b842" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_65b842" xml:lang="en-US">Sale of common stock at a public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_861a43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_861a43" xml:lang="en-US">Public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_3" xml:lang="en-US">[Class of Warrant or Right, Exercise Price of Warrants or Rights]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedCommonStockSharesIssued" xlink:to="cvm_RestrictedCommonStockSharesIssued_lbl_38b196" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_RestrictedCommonStockSharesIssued_lbl_38b196" xml:lang="en-US">Issuance of restricted common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_64233f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_64233f" xml:lang="en-US">Proceeds from newly issued shares</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20250630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20250630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20250630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20250630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20250630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20250630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20250630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayable" xlink:href="cvm-20250630.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20250630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20250630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20250630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20250630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20250630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20250630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20250630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20250630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:href="cvm-20250630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20250630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20250630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20250630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="110200 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmDueToEmployeeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCosts" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCosts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_GainLossOnPatentImpairment" xlink:label="loc_cvmGainLossOnPatentImpairment" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmGainLossOnPatentImpairment" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="995447 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="995448 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="995449 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayable" xlink:title="995450 - Disclosure - NOTES PAYABLE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="995451 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="995452 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="995453 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="995454 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="995458 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="995459 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="995461 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:title="995467 - Disclosure - NOTES PAYABLE (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="995471 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="995472 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="995473 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20250630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20250630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20250630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20250630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20250630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20250630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20250630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayable" xlink:href="cvm-20250630.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20250630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20250630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20250630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20250630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20250630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20250630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20250630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20250630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:href="cvm-20250630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20250630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20250630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20250630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="110200 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag_9fca48" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3f8fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3f8fc" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_6198af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapPrepaidExpenseCurrent_6198af" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_557185" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_557185" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_4bea8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapDepositsAssetsCurrent_4bea8f" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_09e01d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapAssetsCurrent_09e01d" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_e64809" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_e64809" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_fb1a70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_fb1a70" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_9ac423" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_9ac423" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_ff8583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_ff8583" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_6f3de0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_6f3de0" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_dc17b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_dc17b1" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_5fa504" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapAssets_5fa504" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_556d9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_556d9e" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_481155" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_481155" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_cfc07c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_481155" xlink:to="loc_us-gaapAccountsPayableCurrent_cfc07c" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_b51d76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_481155" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_b51d76" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent_a8612e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_481155" xlink:to="loc_cvmDueToEmployeeCurrent_a8612e" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_2afe85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_481155" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_2afe85" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_67df3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_67df3d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_3a2904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapLiabilitiesCurrent_3a2904" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_e95589" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_e95589" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_3893b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_3893b5" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_911f6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_911f6a" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_c71e5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapLiabilities_c71e5f" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_bf1d2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapStockholdersEquityAbstract_bf1d2c" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_46d5f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_bf1d2c" xlink:to="loc_us-gaapPreferredStockValue_46d5f0" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_5d11a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_bf1d2c" xlink:to="loc_us-gaapCommonStockValue_5d11a3" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_c99779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_bf1d2c" xlink:to="loc_us-gaapAdditionalPaidInCapital_c99779" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_edb52d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_bf1d2c" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_edb52d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_e3beaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_bf1d2c" xlink:to="loc_us-gaapStockholdersEquity_e3beaf" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_a14bc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_117ad1" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_a14bc2" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_c3a58b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_c3a58b" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_2e1c2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_2e1c2e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_64b12b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapPreferredStockSharesIssued_64b12b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_3dd22f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_3dd22f" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_4d3600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_4d3600" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_6acb9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapCommonStockSharesAuthorized_6acb9c" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_af0e69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapCommonStockSharesIssued_af0e69" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2d7187" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_e4b4a2" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2d7187" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_086a41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_b898ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_us-gaapOperatingExpensesAbstract_b898ba" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_368e5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_368e5d" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_5bbf95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_5bbf95" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_26d6d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapOperatingExpenses_26d6d6" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_c1b998" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapOperatingIncomeLoss_c1b998" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_c8b407" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapInterestIncomeExpenseNet_c8b407" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_64ed3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_b898ba" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_64ed3c" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_37c74a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_us-gaapNetIncomeLoss_37c74a" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_52d762" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_cvmModificationOfWarrants_52d762" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_e45b64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_e45b64" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_90f47f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_us-gaapEarningsPerShareDiluted_90f47f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_2243f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_086a41" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_2243f8" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_5e4381" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_af2460" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_5e4381" xlink:to="loc_us-gaapStatementTable_af2460" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1eaa86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_af2460" xlink:to="loc_us-gaapStatementLineItems_1eaa86" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_14872f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_af2460" xlink:to="loc_us-gaapStatementEquityComponentsAxis_14872f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_37b9a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_14872f" xlink:to="loc_us-gaapEquityComponentDomain_37b9a3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_13d570" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_37b9a3" xlink:to="loc_us-gaapCommonStockMember_13d570" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_5dceca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_37b9a3" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_5dceca" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_6ada1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_37b9a3" xlink:to="loc_us-gaapRetainedEarningsMember_6ada1e" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_44bf6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapSharesIssued_44bf6d" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_43a3e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockholdersEquity_43a3e0" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_090618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_090618" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_897231" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_897231" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_c9964e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_c9964e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_9c2f4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_9c2f4c" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_e158cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_e158cc" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_f75f65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_f75f65" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_52b57c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_52b57c" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock_8cc1dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmCostIncurredInIssuanceOfStock_8cc1dd" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_1c1ae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapNetIncomeLoss_1c1ae2" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares_258c4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares_258c4a" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_b16893" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_b16893" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_cad4ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_cad4ee" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_507817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_507817" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_023393" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_023393" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsShares_b547ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsShares_b547ef" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsAmount_0db50b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsAmount_0db50b" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_d62e8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapSharesIssued_d62e8d" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_62ce0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eaa86" xlink:to="loc_us-gaapStockholdersEquity_62ce0f" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_f67174" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_804358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_804358" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_0c15ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_804358" xlink:to="loc_us-gaapProfitLoss_0c15ca" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_804358" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_7db752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_us-gaapDepreciationAndAmortization_7db752" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense_4e4d98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_us-gaapOtherNoncashIncomeExpense_4e4d98" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_39c20e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_39c20e" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_d2ea7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_us-gaapShareBasedCompensation_d2ea7d" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_7191bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_7191bc" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCosts_63ade4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCosts_63ade4" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_GainLossOnPatentImpairment" xlink:label="loc_cvmGainLossOnPatentImpairment_3542eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_cvmGainLossOnPatentImpairment_3542eb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_694e2b" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_d27d34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_d27d34" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing" xlink:label="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing_7f51f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" xlink:to="loc_cvmIncreaseDecreaseInSuppliesUsedForRDAndManufacturing_7f51f2" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits_32c799" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits_32c799" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_a5a743" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_1c20da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_1c20da" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_31c06f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_31c06f" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_c20a09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_c20a09" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_7527e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_212e7e" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_7527e6" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_22fccf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_22fccf" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_b1deff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_22fccf" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_b1deff" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_7c2a59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_22fccf" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_7c2a59" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_f3c788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_22fccf" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_f3c788" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_7319f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_7319f4" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_8fb836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_8fb836" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_68651c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_68651c" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_9bd030" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" xlink:to="loc_us-gaapProceedsFromNotesPayable_9bd030" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_53dbbd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_5e4464" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_53dbbd" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_469df4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_469df4" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9d1872" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9d1872" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a3ec52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a3ec52" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_524a66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_524a66" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5563f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5563f4" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmNonCashFinanceLeaseObligationIncludedInAccountsPayable_909d64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmNonCashFinanceLeaseObligationIncludedInAccountsPayable_909d64" order="36" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:label="loc_cvmPurchaseOfAssetsUnderFinanceLeases_55b8c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmPurchaseOfAssetsUnderFinanceLeases_55b8c1" order="37" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ObligationServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmObligationServicesPaidWithIssuanceOfCommonStock_a8003e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmObligationServicesPaidWithIssuanceOfCommonStock_a8003e" order="38" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmNonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock_ebe4f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmNonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock_ebe4f6" order="39" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonCashFinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmNonCashFinancingCostsIncludedInCurrentLiabilities_60b04d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmNonCashFinancingCostsIncludedInCurrentLiabilities_60b04d" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_7b71b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_d21713" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_7b71b7" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_bcf324" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_f67174" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_bcf324" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_40031b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_bcf324" xlink:to="loc_us-gaapInterestPaidNet_40031b" order="43" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arragements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems_621fd7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag_b40045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_621fd7" xlink:to="loc_ecdRule10b51ArrAdoptedFlag_b40045" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag_e9876c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_621fd7" xlink:to="loc_ecdRule10b51ArrTrmntdFlag_e9876c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag_9cc742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_621fd7" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag_9cc742" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag_f0a348" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_621fd7" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag_f0a348" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_f6b3b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_effa12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f6b3b3" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_effa12" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="995447 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_57ee28" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="loc_cvmLiquidityDisclosureTextBlock_b4e925" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_57ee28" xlink:to="loc_cvmLiquidityDisclosureTextBlock_b4e925" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="995448 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_d30a24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f21954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d30a24" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f21954" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="995449 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_b4ca23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_446b8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b4ca23" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_446b8d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayable" xlink:title="995450 - Disclosure - NOTES PAYABLE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_348ea1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:label="loc_us-gaapMortgageNotesPayableDisclosureTextBlock_353225" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_348ea1" xlink:to="loc_us-gaapMortgageNotesPayableDisclosureTextBlock_353225" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="995451 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_e0d722" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_4c83fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_e0d722" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_4c83fc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="995452 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_09a9f7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_3b57a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_09a9f7" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_3b57a1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="995453 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_3b7deb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_566aac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_3b7deb" xlink:to="loc_us-gaapEarningsPerShareTextBlock_566aac" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="995454 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_107517" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_6d1820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_107517" xlink:to="loc_us-gaapSubsequentEventsTextBlock_6d1820" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_205d15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_6f6920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_6f6920" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_8c3eb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_8c3eb0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_ec7ad0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapInventoryPolicyTextBlock_ec7ad0" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_12f909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_12f909" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_6bc57f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_cvmLeasesPolicyTextBlock_6bc57f" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_2f303b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_2f303b" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_9d01de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_9d01de" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_fc925a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_fc925a" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_9eee59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_9eee59" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_b248cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_b248cb" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_514870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_514870" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a7a763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock_a7a763" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_ab760b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapUseOfEstimates_ab760b" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_c0e104" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_205d15" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_c0e104" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_82a249" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_214447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_82a249" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_214447" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="loc_cvmScheduleOfStockOptionActivityTableTextBlock_c0319f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_82a249" xlink:to="loc_cvmScheduleOfStockOptionActivityTableTextBlock_c0319f" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_dca6f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_82a249" xlink:to="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_dca6f4" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_8ec511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_82a249" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_8ec511" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_cfe1ab" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_45808a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_cfe1ab" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_45808a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_d1311b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_cfe1ab" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_d1311b" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="995458 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_8f5812" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_63b15e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_8f5812" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_63b15e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="995459 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_337e6d" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_0abdfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_337e6d" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_0abdfc" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_6e76d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_337e6d" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_6e76d5" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_3d89ce" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ef3e44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3d89ce" xlink:to="loc_us-gaapStatementTable_ef3e44" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_29cc10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ef3e44" xlink:to="loc_us-gaapStatementLineItems_29cc10" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_1281d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ef3e44" xlink:to="loc_us-gaapPlanNameAxis_1281d8" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_b7030f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_1281d8" xlink:to="loc_us-gaapPlanNameDomain_b7030f" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember_529f91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b7030f" xlink:to="loc_cvmBottomMember_529f91" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember_b615cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b7030f" xlink:to="loc_cvmTopMember_b615cc" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:label="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_46af3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_29cc10" xlink:to="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets_46af3d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue_805059" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_29cc10" xlink:to="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue_805059" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_29c4f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_29cc10" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_29c4f4" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="loc_cvmAdjustmentsToAdditionalPaidInCapitalStockIssued_a69b30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_29cc10" xlink:to="loc_cvmAdjustmentsToAdditionalPaidInCapitalStockIssued_a69b30" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_68abff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_29cc10" xlink:to="loc_us-gaapCommonStockSharesOutstanding_68abff" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="995461 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2d5a44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a056d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2d5a44" xlink:to="loc_us-gaapStatementTable_a056d3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_807a25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a056d3" xlink:to="loc_us-gaapStatementLineItems_807a25" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_82244c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a056d3" xlink:to="loc_us-gaapAwardTypeAxis_82244c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_82244c" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_7a4831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" xlink:to="loc_cvmIncentiveStockBonusPlansMember_7a4831" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_a9f8c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_a9f8c2" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_874b71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" xlink:to="loc_cvmStockBonusPlansMember_874b71" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_363bbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" xlink:to="loc_us-gaapStockCompensationPlanMember_363bbc" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_e1a337" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95eab1" xlink:to="loc_cvmIncentiveStockBonusPlanMember_e1a337" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" xlink:label="loc_cvmShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_10611a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_807a25" xlink:to="loc_cvmShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93_10611a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d4b35d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_807a25" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d4b35d" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_426976" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3fc865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_426976" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3fc865" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_cadcca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_426976" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_cadcca" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_abaa02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_426976" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_abaa02" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_38b402" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_426976" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_38b402" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_e2ac80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b9b377" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_e2ac80" xlink:to="loc_us-gaapStatementTable_b9b377" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_05d620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b9b377" xlink:to="loc_us-gaapStatementLineItems_05d620" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_5c2ab5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b9b377" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_5c2ab5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_ad3d93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_5c2ab5" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_ad3d93" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_b63591" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_ad3d93" xlink:to="loc_us-gaapEmployeeStockMember_b63591" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember_daf6b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_ad3d93" xlink:to="loc_cvmNonEmployeesMember_daf6b0" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ae4f65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_05d620" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ae4f65" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_ec164c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_39dc8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_ec164c" xlink:to="loc_us-gaapStatementTable_39dc8f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9eef20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_39dc8f" xlink:to="loc_us-gaapStatementLineItems_9eef20" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_b443bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_39dc8f" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_b443bd" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_b443bd" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_4494bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_39dc8f" xlink:to="loc_us-gaapPlanNameAxis_4494bd" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_22b88b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_4494bd" xlink:to="loc_us-gaapPlanNameDomain_22b88b" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_847e8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_39dc8f" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_847e8e" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_e74b5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_847e8e" xlink:to="loc_us-gaapRelatedPartyDomain_e74b5f" order="50" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_ec172f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesNMember_ec172f" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_c7cafa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesUUMember_c7cafa" order="52" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_43c6c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesXMember_43c6c1" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_28be98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesYMember_28be98" order="54" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_937b3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesMMMember_937b3f" order="55" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_e780cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesNNMember_e780cc" order="56" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_489451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_586fcb" xlink:to="loc_cvmSeriesRRMember_489451" order="57" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember_58909a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_22b88b" xlink:to="loc_cvmBottomMember_58909a" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_3d42b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_e74b5f" xlink:to="loc_cvmConsultantsMember_3d42b8" order="59" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember_281678" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_22b88b" xlink:to="loc_cvmTopMember_281678" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember_9e9aa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_e74b5f" xlink:to="loc_cvmConsultantsOptionMember_9e9aa6" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_2cb04f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9eef20" xlink:to="loc_cvmIssueDate1_2cb04f" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_83ff4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9eef20" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_83ff4c" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_e8e742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9eef20" xlink:to="loc_cvmExercisePrice_e8e742" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_0f9589" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9eef20" xlink:to="loc_cvmExpirationDate_0f9589" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_978f80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2f0eae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_978f80" xlink:to="loc_us-gaapStatementTable_2f0eae" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4a46d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapStatementLineItems_4a46d2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_ceae88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_ceae88" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_6e4846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_ceae88" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_6e4846" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ee961d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ee961d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_6297fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ee961d" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_6297fc" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c6e9e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c6e9e3" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_5bd9f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_c6e9e3" xlink:to="loc_us-gaapRelatedPartyDomain_5bd9f0" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_33b6ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapPlanNameAxis_33b6ce" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_56c5b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_33b6ce" xlink:to="loc_us-gaapPlanNameDomain_56c5b9" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis_276cd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2f0eae" xlink:to="loc_us-gaapTradingActivityByTypeAxis_276cd5" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_104ee8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeAxis_276cd5" xlink:to="loc_us-gaapTradingActivityByTypeDomain_104ee8" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember_7660de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6e4846" xlink:to="loc_cvmPreFundedMember_7660de" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_5418c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_6297fc" xlink:to="loc_cvmRestrictedStocksMember_5418c8" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_5e3cc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_5bd9f0" xlink:to="loc_cvmConsultantsMember_5e3cc7" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_7138d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_56c5b9" xlink:to="loc_cvmConsultingAgreementsMember_7138d0" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember_bab936" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_56c5b9" xlink:to="loc_cvmConsultingAgreementsOtherMember_bab936" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_eb8342" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_56c5b9" xlink:to="loc_cvmErgomedMember_eb8342" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="loc_cvmChangesInEquityWarrantsMember_b3dd06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain_104ee8" xlink:to="loc_cvmChangesInEquityWarrantsMember_b3dd06" order="77" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsOneMember" xlink:label="loc_cvmChangesInEquityWarrantsOneMember_fa474f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain_104ee8" xlink:to="loc_cvmChangesInEquityWarrantsOneMember_fa474f" order="78" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_8691a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapPrepaidExpenseCurrent_8691a9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b226b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b226b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_3a4e78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_3a4e78" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_c294ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_c294ec" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_cvmhareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_41d8af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmhareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_41d8af" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_d2d2c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapShareBasedCompensation_d2d2c1" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuanceCost" xlink:label="loc_cvmStockIssuanceCost_96eed6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmStockIssuanceCost_96eed6" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_f2e770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_f2e770" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3cd1ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3cd1ac" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted20_842902" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted20_842902" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted_6f58b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted_6f58b9" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued_9e4dbf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapExcessStockSharesIssued_9e4dbf" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsExercised_e111af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsExercised_e111af" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_6da04f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapCommonStockSharesIssued_6da04f" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_9bcf21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapSaleOfStockPricePerShare_9bcf21" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_d804bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_d804bf" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockWarrantsExercised" xlink:label="loc_cvmStockWarrantsExercised_091a31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmStockWarrantsExercised_091a31" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CompensationCost" xlink:label="loc_cvmCompensationCost_f32b40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4a46d2" xlink:to="loc_cvmCompensationCost_f32b40" order="18" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_b331f6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_803687" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_b331f6" xlink:to="loc_us-gaapStatementTable_803687" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_54b25d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_803687" xlink:to="loc_us-gaapStatementLineItems_54b25d" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2b51cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_803687" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2b51cb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_008a39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_2b51cb" xlink:to="loc_us-gaapRelatedPartyDomain_008a39" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember_3f1a86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_008a39" xlink:to="loc_cvmOfficerAndDirectorMember_3f1a86" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued_3283f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_54b25d" xlink:to="loc_cvmRestrictedCommonStockSharesIssued_3283f8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_a4f975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_54b25d" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_a4f975" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="loc_cvmDescriptionOfModificationOfWarrants_b18312" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_54b25d" xlink:to="loc_cvmDescriptionOfModificationOfWarrants_b18312" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:title="995467 - Disclosure - NOTES PAYABLE (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_6942f4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate_e0b00c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_6942f4" xlink:to="loc_us-gaapInvestmentInterestRate_e0b00c" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_56995f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_6942f4" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_56995f" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_01527c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_257cb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_257cb0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_998b55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_998b55" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_a2dc63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_a2dc63" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_94e64c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_94e64c" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_8274a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_8274a0" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_fc0b7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_fc0b7f" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_4442a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_4442a3" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_8e9fdc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_8e9fdc" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_87ecfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_us-gaapFinanceLeaseLiability_87ecfe" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_07e0ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_07e0ad" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_f13858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_01527c" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_f13858" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb504e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb504e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6ff4b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6ff4b3" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8db5e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8db5e9" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1f2b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_c1f2b3" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d6d6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d6d6b" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_c67189" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_c67189" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7dc45f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7dc45f" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_5c42c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_5c42c6" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b465f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b465f0" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_7930a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_us-gaapOperatingLeaseLiability_7930a0" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityCurrentPortion_424bf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_cvmOperatingLeaseLiabilityCurrentPortion_424bf7" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_d4be9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_bf497f" xlink:to="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_d4be9a" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_9465b4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_46d2a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_9465b4" xlink:to="loc_us-gaapStatementTable_46d2a3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f01ba4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_46d2a3" xlink:to="loc_us-gaapStatementLineItems_f01ba4" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_7d82c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_46d2a3" xlink:to="loc_us-gaapPlanNameAxis_7d82c7" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_eec84c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_7d82c7" xlink:to="loc_us-gaapPlanNameDomain_eec84c" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_f05d02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_46d2a3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_f05d02" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_edb6e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_f05d02" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_edb6e2" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_b379d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_eec84c" xlink:to="loc_cvmErgomedMember_b379d2" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_204253" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_edb6e2" xlink:to="loc_us-gaapLeaseAgreementsMember_204253" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments_43b3ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmAnnualIncreaseToInterestPayments_43b3ab" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="loc_cvmAnnualIncreaseToInterestPaymentsOperating_eea6a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmAnnualIncreaseToInterestPaymentsOperating_eea6a7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_dccd16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_dccd16" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_1d8fd1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseLiability_1d8fd1" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTerm_2772bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTerm_2772bf" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_82d42f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_82d42f" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_b5b627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapSecurityDeposit_b5b627" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_b6af82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_b6af82" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_f429ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapOperatingLeaseLiability_f429ba" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_c88948" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_c88948" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_3b75d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapDepreciation_3b75d2" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_19f294" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_19f294" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_ddd29e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_ddd29e" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_1c816b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_1c816b" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="loc_cvmLeaseExpenseUnderOperatingLeases_27ddd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmLeaseExpenseUnderOperatingLeases_27ddd5" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_7a455d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_7a455d" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_4a5d8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_4a5d8a" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeasePrincipalPayment" xlink:label="loc_cvmFinanceLeasePrincipalPayment_3b383d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmFinanceLeasePrincipalPayment_3b383d" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_3c31f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_3c31f2" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_bf1f76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f01ba4" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_bf1f76" order="20" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="995471 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_877c5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_877c5f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_296042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_296042" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5804e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5804e7" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b1b025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b1b025" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e98c5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e98c5c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd6603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fd6603" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_808a9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_808a9c" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_80d27b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_ae0185" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_80d27b" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="995472 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_814d28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_d9b734" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_814d28" xlink:to="loc_us-gaapAssetImpairmentCharges_d9b734" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_062b41" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_814d28" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_062b41" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_e574d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_814d28" xlink:to="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_e574d0" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="995473 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_db8f35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAvailableToCommonShareholdersBasic_936e95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_db8f35" xlink:to="loc_us-gaapUndistributedEarningsLossAvailableToCommonShareholdersBasic_936e95" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareDilutedAbstract_6bb520" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_db8f35" xlink:to="loc_us-gaapEarningsPerShareDilutedAbstract_6bb520" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_b6ca69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_db8f35" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_b6ca69" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_567749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_db8f35" xlink:to="loc_us-gaapEarningsPerShareDiluted_567749" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_e396aa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c4ce11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_e396aa" xlink:to="loc_us-gaapStatementTable_c4ce11" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4e6def" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c4ce11" xlink:to="loc_us-gaapStatementLineItems_4e6def" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_433854" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c4ce11" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_433854" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_e77944" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_433854" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_e77944" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_3c27ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_e77944" xlink:to="loc_cvmOptionsMember_3c27ef" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_284265" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_e77944" xlink:to="loc_cvmUnvestedRestrictedStockMember_284265" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_af38b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4e6def" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_af38b5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_7ce8fb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fd523b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_7ce8fb" xlink:to="loc_us-gaapStatementTable_fd523b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_dbbcc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd523b" xlink:to="loc_us-gaapStatementLineItems_dbbcc5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_b18c32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd523b" xlink:to="loc_us-gaapSubsequentEventTypeAxis_b18c32" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_f3a937" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_b18c32" xlink:to="loc_us-gaapSubsequentEventTypeDomain_f3a937" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_e1af39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_f3a937" xlink:to="loc_us-gaapSubsequentEventMember_e1af39" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_714b76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbbcc5" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_714b76" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ada2d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbbcc5" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ada2d7" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued_71c854" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbbcc5" xlink:to="loc_cvmRestrictedCommonStockSharesIssued_71c854" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_2a3e9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbbcc5" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_2a3e9e" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_ab525d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbbcc5" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_ab525d" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/14/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20250630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20250630.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20250630.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20250630.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20250630.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20250630.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20250630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20250630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayable" xlink:href="cvm-20250630.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20250630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20250630.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20250630.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20250630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20250630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20250630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20250630.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20250630.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20250630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20250630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20250630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:href="cvm-20250630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20250630.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20250630.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20250630.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20250630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="110200 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCostIncurredInIssuanceOfStock" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsShares" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" xlink:label="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuedForSettlementOfClinicalDevelopmentCostsAmount" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="995447 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="995448 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="995449 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayable" xlink:title="995450 - Disclosure - NOTES PAYABLE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="995451 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="995452 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="995453 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="995454 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="995458 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="995459 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmBottomMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmTopMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" xlink:label="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedOtherAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedOtherAtFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued" xlink:label="loc_cvmAdjustmentsToAdditionalPaidInCapitalStockIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdjustmentsToAdditionalPaidInCapitalStockIssued" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="995461 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" xlink:label="loc_cvmShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmNonEmployeesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="56" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="57" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmBottomMember" order="58" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="59" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmTopMember" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOptionMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_PreFundedMember" xlink:label="loc_cvmPreFundedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmPreFundedMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="74" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ConsultingAgreementsOtherMember" xlink:label="loc_cvmConsultingAgreementsOtherMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsOtherMember" order="75" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="76" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsMember" xlink:label="loc_cvmChangesInEquityWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_cvmChangesInEquityWarrantsMember" order="77" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ChangesInEquityWarrantsOneMember" xlink:label="loc_cvmChangesInEquityWarrantsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_cvmChangesInEquityWarrantsOneMember" order="78" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_cvmhareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmhareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockIssuanceCost" xlink:label="loc_cvmStockIssuanceCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuanceCost" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted20" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted20" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsGranted" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised" xlink:label="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareBasedPaymentArrangementNumberOfInstrumentsExercised" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_StockWarrantsExercised" xlink:label="loc_cvmStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockWarrantsExercised" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_CompensationCost" xlink:label="loc_cvmCompensationCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCompensationCost" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmOfficerAndDirectorMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRestrictedCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="loc_cvmDescriptionOfModificationOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDescriptionOfModificationOfWarrants" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NotesPayableDetailsNarrative" xlink:title="995467 - Disclosure - NOTES PAYABLE (Details Narrative )" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLeaseAgreementsMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPayments" xlink:label="loc_cvmAnnualIncreaseToInterestPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAnnualIncreaseToInterestPayments" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_AnnualIncreaseToInterestPaymentsOperating" xlink:label="loc_cvmAnnualIncreaseToInterestPaymentsOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAnnualIncreaseToInterestPaymentsOperating" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTerm" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_LeaseExpenseUnderOperatingLeases" xlink:label="loc_cvmLeaseExpenseUnderOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmLeaseExpenseUnderOperatingLeases" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeasePrincipalPayment" xlink:label="loc_cvmFinanceLeasePrincipalPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeasePrincipalPayment" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="20" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="995471 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="995472 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="995473 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20250630.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRestrictedCommonStockSharesIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="5" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_10qimg7.jpg
<TEXT>
begin 644 cvm_10qimg7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH **
M** "BBB@ HHHH 3O5*^O[2P@$MW-Y:LP51@EG8] H')/L*O5AA%F\73,XW&U
MM(_*S_ 79]Q'N0BC\*$D]Q-ERTO7O0Q-A=6JC!#3JJ[OH,DC\0*-5U*VT?1[
MO5+PL+>TB::0H,G:HR<#O5^N8\?_ /)-O$7_ &#YO_0#512E)(F3:BV8Z?%7
MP[(BR)9ZDR,,AA ""/\ OJG?\+3T#_GQU3_P''_Q5?%\\\Z3NJ3.J@\ ,1BH
M_M5S_P _$G_?9KZ1971\_O/)^N5?(^U/^%J:!_SXZI_X#C_XJC_A:F@?\^.J
M?^ X_P#BJ^,95U2W0/<1W<*-P&D5U!_$U#]JN/\ GXD_[[-/^RZ'G]X?7*OD
M?:G_  M30/\ GQU3_P !Q_\ %4?\+4T#_GQU3_P''_Q5?%7VNX_Y^)/^^S1]
MKGP#]IDY_P!LT?V70\_O%]=J>1]J_P#"U- _Y\=4_P# <?\ Q5'_  M30/\
MGQU3_P !Q_\ %5\5?:[CC_29.?\ ;-!N[@#FXD_[[-']ET//[P^NU/(^U?\
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M*_M5S_S\2?\ ?9H^U7/_ #\2?]]FC^RJ7G]X?7:OD?:G_"T_#_\ SXZI_P"
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M3Z4Z26.%#)*ZQH.K,<"@"2BHPZ%]@=2V,XSSCUH5T<91@PSC(.>: )*R(/\
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MBBB@ HHHH **** "BBB@ HHHH *WO!?_ "/_ (>_["$'_H8K!K>\%_\ (_\
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M% !1110 4444 %%%% !6]X+_ .1_\/?]A"#_ -#%8-;W@O\ Y'_P]_V$(/\
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M=-%B9)4D^V6D=VNW/RJ^< ^_%4E"]D%Y;DFG:O)I]EJ%B;.VO+:_15DCG#$
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M=&6RFM[N]<)$L\3)G/\ %TSM]ZOF6]Q69ET5;FL);>V#R[DN//:!K9HF5U(
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MXD?5"G\+/BFQU<Z2^K1#3;*]^WVS6VZZBWF#)SOC]&]ZQ>1T)!'0CJ*FN?\
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M#7G,EO<PW'V::VEBGR!Y3QE7YZ<'FKMMHM[<#45>)K:6PMOM4D4T;*[+O5,
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M9),$#[A !X;!)& *V->N9K3QIKU]J7B&WFT;[(\#V!N,M(3  D(@[$.5;=C
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M(S[?)2_\+PUC_H/ZI_X#VW_Q%>Q_9=;NOQ_R.'ZY3[,^K>/;\J./;\J^4O\
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MWY4<>WY5\I?\+PUC_H/ZI_X#VW_Q%'_"\-8_Z#^J?^ ]M_\ $4?V56[K\?\
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M_@/;?_$4?V56[K\?\@^N4^S/JW/^<49_SBOE+_A>&L?]!_5/_ >V_P#B*/\
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MMO\ XBC^RJW=?C_D'URGV9]6Y_SBC/\ G%?*7_"\-8_Z#^J?^ ]M_P#$4?\
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M]YJD%A!<2210>;'(P=DQD,RJ0G) &>OTYIUKX<>]TB2\L]1@FN([=KEK41R
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M)4DA5E61201R&(*D8_*BS\56>F3P?V;HQBM[?4K?4$CDN"Y;RD*D,V.K9SD
M =A0_:--#7)<C@\-RW]E$NG/:RQM>SQ?;&+IB..)79F!'"*"3TR3GVHM_"%S
M?S6O]EZA!>6L\CQ-.(Y$\ID0R$,A7<<HI(P#NQ@<U9L?&$6C-''H]A/';)=3
MS%9KC]XT<L2QLFY0,'C(8#@X]*AN_$UM<S6D;G6KBU@=I6:?4B9MY&%9"!M4
MKS@XR<G-/][T#W#"U"UMK2=4M=1BOT9<EHXWC*'NK*X!!K2'AMYM&FU"RU&"
M[>WA%Q+!'%("$R =KE0KE2PR ?SQ3?$FMIKLMH4CGQ;0F'[1=2"2XGRQ.Z1@
M #C.![#J:VI_&\4B:B\5G>I-J%E]D:(W?^CVQPN&BCV\#*@X/3)^M6W4LK(2
M4;NYE7OAI; RVT^N6']IP%%FL1OW(6(!4-C:S+GE0>.>N#4]SX.EL]2O[.YU
MJP5-,R+ZX4NR6[;]BIPN7=CT"Y[Y(P:9J&NZ+J%Q/JKZ),NL7,BRRO\ :?W"
MR;@S.B ;LL0>"2!N/M1_PDEM<:IKSZAI[RZ=K4YGDABE"20L'+HR,01D;B.1
M@@FI7M+?\-Y?\$/=!/"%R\[,NH6[Z<+0WRWT2.ZO$'"'" ;]P<X*XX[\<U'!
MX;BFMKJ_;7+5--MYDMQ>+%*ZN[+N&5"Y4 #DL!SP,U8'B2P%Y9I#9ZA966GP
M&&S:TO-EQ&6<N[L^W#%B3D8  QCI5N/QC9_V_-JYM-2M9F\L V=XL9G5% Q,
M"FURQ&20!R3Q1>K_ %8=H'+VEG'=:D+1[Z&!,L//8,RG']T*"S9[#'-="GAE
M+.WU26Z=+R$Z/+>V<ZJ\?S+*B'*L 0P)8$$=ZHZ;K\=EK^H:E)9&.._26,I9
MOY3VP=LYB8@[2,8^A([UJ/XRLYK>*RN-/O9K1-/GTYG>\WS.LD@D#[BN 05Q
MC&,=*<W4NK(4>6VID>)+"WL=9@M;&$JLEG:R; 22SO"C-^;$U9E\-0V-ZMK=
M:W82WL$\4=U8*7#KN<*R*^-KL,X(!XYZXJGK.L0ZG=V%];6\MK=P6\,4C-('
M5FB555E& 1PH)!SS5R_UW1;RZFU9-#F35[B99Y&-SFW23<&9D0#=\Q!X8D#)
MQVH]^R0>[=FC-X2?4-6O-/TJ*UMU_MFZLX9)9&!58T+A"3P%P.O7/7BJMEX6
M#36%S:7^GZO:W+7$#$>8B)+'"9"#D GY<%2.#BK,GC6T349KFTTJ9(YKVXOF
M26<,0TT!C900HX!;(]N*S-$\2C1]/M;0V?G^1<S7&[?C=YEN8<=.V<_I4)5;
M?UY_\ ?N7(W\.K;V*/>ZU96M_);"Z2QEWARA7<H+ ;5=EY"D]QTS0?#C/HDV
MIVFI079MHEGGA2*1=J%@I*NRA7P6 (!XSWJ2YUK1]0M5N-2T>:?5DMEMO-2Y
MV02%4V)(R8W;@ . P!(Y[UI7GC6"YMM65+.]#ZI:?9I(GN\V]L05(,48'"Y0
M<'H"0/6FW4TT_(5HF/XGL;33_&FIZ=:@6UI#<F-,Y;8O'XFMC5O!]FOB;Q!;
M:;J]M!IND%&EEN=X\M6;:%Z9<@XZ#G/%87B/5+;6]>N-5MK66U:ZQ)+')('
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MCTG5[62R$,"(+93<,C '&2I7&<YY&:R]=BU _%P_VS RM-JJE1+&%#PF?"G
M&"I'?O355MV:$X*USCYD\B>2&1DW1L4)5@02#C@]Q[TPD X) KT^74AI.H^'
M;:PM+%$N]3NX[IFMT<S1?;601MN!PFTG@8_05#]EU6SM[2W\%Z;!=P&XN8K_
M '01S9D69@L<Q<';&(PA'('+'.:7MNZ#V9YY/;O;Q022-'MGC\Q=KAB!DCYL
M?=.0>#SC![U)/97%M96=Y,@6"\1GA;<#N"L5/TY!KT&SM_+T.VGT:SMI?$*Z
M0CVR+&DC8^US"9T4Y#.%"@=3MR1TK02 S)HS:U:I%K":1<M;0Q01LQN/M&3^
MZ)"^;Y9+!3CG!QFI=>PU3/),@C((Q1N!&01CUKU 2VL4LUU>:6\VIQ:/>3%]
M3M8HS* 4\IGB4_>4[L$@$C'4"H;*7^UM.TO598+2Y\0O8WD=H'AC43S1RILR
M@ 5G$;2;01R0O7 JO;=;![/S/-<KC<",>M&Y<9R,>M>E:9#J,UU=W'B.R,.N
MK8!]/$=I%]IE'FC>YB. 9 N=NX9QD@' J0.(]5CD70]2EU/["WGW*6L N8\R
M#RYA!D@L "IR 2"#QU)[;6UOQ%[,\RR,9SQZT@VC@8%=%XA6ZT?QD9I)X;RY
MB,-P2;=8@25#;9(QPK=F'KFNT70]'NM&FL89+6)=0E_M*VE.-\.F95IUSV96
M! '7"/ZU4JJBD^XE!MM'E)91U(I<CUKTVQN(-0T8:KHEK<Q7EU?3"ZBL+"&X
M,2?*((V#GY8]GH,$YR:IZK=:1:Z3''9V,-E97FM7$%PQ1))8H L&]$89"KDN
M1M/3@&DJUW:P^32]SSW()P",T$@=2!7I_B6.VALM<BFL;M]-C!73S]D@B@A)
M8>4T4BMN<%>H&20237.V.IRZ-\/!?6$5LNH-JK(MS)"DDD:"%3A=P( )]OYF
MG&KS*Z0.%G9LY(D 9) %6$M+A[":^2,FVA=(Y),C"L^2H_':WY5Z5JMO=VMW
MK,O@S3H7U(ZD!<)!;I*\,+0HR!$(($;.TF2!V .!3-16Z70?%NF:#%&0);&6
M\MK-%=(F,+_:-O7"!^,@X':H]O>UE_6@_9V/,"0.I ^M3R6[Q6L%R[1[)]VT
M!P6&TX.X=5]L]:Z[P6;G[#=I:6%[YLT\:#4+*UCNGAX/[MXW_@;()(QT[UMP
MZ?%;10Q6T=A>Z[%#J(LS'&ACGG6Y4;E4\,0F\HI_#H*J5;E=A*%U<\OR#R"*
MFM8'O)C%"\88*SDNX484$GD]\#@=SQ7J%I'<"TT2^\0Z3:&^:/57E2:!4,^R
MW4IYJC'.?8'IZU0TNY&MZ1IE_JL5K+=*-4@WB!(\HMJ'0$* /E9CM.,BI]MI
MM_6O^0_9_P!?=_F<<^@WT>FPWTLEI&LT!N4A>Y02F+L^S.<'!QZUDY&<9&?2
MO2;Z^EU*<1:A*D\4/A))4S&F4<Q)EA@?>]/2H]<M=;EN;NPLK*QA\)DQBUNG
MAC$$<3,H259?O%S_ !<EOO CC@C5>T@<%T/.@RG.".*<@,DJQ)AG8A0,]23@
M5ZVU@9H)8M3M;AGT_5K&.![JSAMU*&?9)Y83DQD%>#D<CG-8QU=[J#7F>&SM
MX]*U6UDL5B@1!; W#(P4XR05QG)/3-"KWV7]?TP=.V[.*FTG4+>"_FF@\M=/
MN!:W.6&8Y#NPOO\ <;IZ51R*]0\0KKB3^,[N:T>2YM]7M[U%>(8,"O-M<J!@
MITY[YK$\16>GZ5HUQ?V4<9C\1RK/9#@F"V'S2*/0^:?+^D9]:<*U]_ZT0I0L
M<2S*@RQ %:TWA_58+X6#P(;LSQVRP+(I=G=0R@#/(((YZ G%=!I<>J+X&@D\
M+6,=W>RW4L>I8@2:15POE(P8';$1OR1@$YR>!79EUMOB!'>1+;Q3_P#"1V:"
M1 K 1FT&54\_+2G6:;MY_@.-.^YYA)X;OHH[V4W6GM!9D)),MXAC=R"1&C9^
M=\ _*/2L4,"< C-=Y;ZU<77@A8M5OO\ 0[GQ J796- 3"8ANQA<C@=16OK4=
MO'_:,-W8W;V"3(E@6LX(8(291Y;12*V74KG(&[(.30JLD[20<B:NCRS(QG(Q
M1D8SD8KU%9[6\\4>+$BMTAO-/E:/3(+"TB=DC\YO-9$; =\;3DY(!..G$5Q<
M6MG:ZS>_V:!JT&EPL[W]M$K&1KE0LOE*2%<(<'(YX)%/VW2W],/9^9YU;VL]
MU#<S6\?F1VL7G3,"/D3<%S^; ?C4)( R3@5ZE97FJ7=I<7&FJCZKJGAH/*L$
M";KB1+K;NVXQNV+S@<XS7)>$K2X:]O[JW>03V,&\0P6Z3SR9<*?+5^ 1G)/)
M IJK=-OH)PVL<SD8SD8HW+Q\PYZ<]:]3U81:99:CJT5E"+^71[*8M<P1;HYS
M<LC/L7*A\ 9&.O)&:9%J7VWQ!HMC+:V @UC1_.U +;QC[1*8I/G)Q\K HI&W
M'//<TO;W5TOZW'[/6USR_(SC(SZ4;@#@D5Z?IEO<M<:+;06%M)X,FLHI+ZX:
M%"A^3]^\DA&Y95?=@9!&% &#RS2KY(M4\%Z+%:V0L=1L$2]WP(S7(>25?G8C
M(( &,8P>:'6[+^OZ0>S\SS,D X)&:6O3]!M[\W?A*VT;3+:[\/W'D?;GD@1U
MDF\S]\)G(RI7@*,CC&,YKSB^ 74[Q5& )Y  !C W&KA4YFT1*-E<KT445J2%
M;W@O_D?_  ]_V$(/_0Q6#6]X,_Y'[P]_V$(/_0Q45/A8(^XJ*7\**^2/4->B
MBBN$](**B22.0L$=6*G# '.#[U+0 453AOK*>[FM(;R&6YAP984D!>//3<!R
M/QJV2 ,DX% "T444 %9$'_(W7W_7G!_Z'+6O61!_R-U]_P!><'_H<M-=27T-
M;^*N8\?_ /)-O$7_ &#YO_0#73_Q5S'C_P#Y)MXB_P"P?-_Z :NE_$CZH4_A
M9\*W/_'S)]:9%')-/'#"I:21@B*.I). /S-.N?\ CYD^M7-"G:U\2Z7<*ZH8
M[N)MS $#YQDG/%?<-V5T?.(HS126US+;S*8YH7:-U)Y5@<$?@:9NX";S@'(7
M/3WQ7HVO3ZCIUOXOOK[3H5U-]6CB@EN;5-R1,)_F12,<A1\V/?KS5[4+?2;6
M*:&&SO+KPXM@)4\JPA$3 Q#]Z+@MN\S?U[Y!7;VK'VWE_6G^9K[,\J+*,Y8<
M<GGI5B\MKJPN&LKQ&AD3:YB8]-RA@?3D$'\:]'GTN6+PWK>FW<3W"Z?I7VJV
MN%L(HK<RC8P:&0?._!;.<[AG(%6->GOEUGQ'K%_8PSA=(M9+"6>V0H23 "Z<
M8;!8^OITXI>WN[)?UH'L[+4\I#X96#X/8@\_A2[R)-V\B3.=V><_6O3[345O
M-?\ "MK-8:?LUNQ_XF1%K&#<MNE0,>/D("*?EQSS1IMOI\6EZ$MK:75YI4]F
MDE\L6GPR1S/SYPDF9@49>0.5VX4C.>1UK;H%3OLSR[(SR1DGUZU8GMKJ"WM)
M)T98KB,R0$G(90Q4D>GS*1^%>BZ;=6R:[X0T2#3[+^S]2L46\\R!&DN%=I0-
MS$9!  Y7'(S6%XBEU2Y\">$97C:33XK1X_-6)0JR">0!2P'7;C@GW]Z:JMM*
MW]:_Y"Y$E?\ KH<?D9P3SZ4I<G:&<G;PH)Z?2O4/"6EF2'1M-NX7N]/U2!Y)
M3%8Q&!0=X"R3'YO,4@="".  :ATNZC35?!^A#3['['J.EQK?;K=&>X+>8,LQ
M&01@8QCD9H=75I+8:I['G=I:SW^H6]A:KYEQ<R+%&F<;F)P!S[U'('21DD)W
M(2IR<X(XKT_P[%J,.K>$$T72[>XT*5;>6YN&@1@T^[]\993RC(W &1@!< YY
MY;PY;QR^*=31K>*XU".&X:QM[A05DN0?E4J>&.-Q"GJP YZ4HU=_(3AL<ON!
M&=V1ZYH#D [7(##!P?O?7UKT*SAUVXFGNM5T6W_M];!I-,CEM$CDN")%#N8L
M .ZH6*Y7G'?%6XD6.&/4M<TFT.M_V1?336\T"H'52OD2R1C 5^6[ D*">O(Z
MUN@>S/.;2VN;V8QV:-+)'&\V%."JHI9C^ !-0;LG.[))SG/?UKU+0-0OKMM$
MU*&. ZM>:=JMLS0VT8,^R/,0V!<%N<#C)&!S6;";.*+P?I6LV=K;0WKR'4Y9
M(E25L7+@(S=47(P<8X/H!2]J[V:_K7_(?)IO_6APD$<MY>1V\),D\\BQJ"W+
M,3@ GZXI+B&6VN9;:==LL#M&ZYSM93@_J*]&A35&1I_%NEV^FR6NI6BZ>PMD
MMR'\X;XTV@;XPF3GD#"G/-8]M8(GQ6N[35[-0YN;EXK>[&Q)9?G:%6S_  LV
MWV.1V-6JN_D)PV.-W[F\S>2V<[LY/YTOF$/YOF$/G._=SGZUZGI-MJ5Y;Z;/
MXIT:"*Z/B"T@W2VB0221%9-R,H ^3(&#C\3CC&L;J_O-(U/4M#TVVEUJ&Z2
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M*0RE0LH/RJ!E 3@'&.< UH^#-/8Q:%:W(FN]+U,L;GRK:'[,@+,I2:1OFWC
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M HHHH **** *Z06\4CS1P1H\GWF5 "WU/>IBH9<$ @]0:** (_LMO_S[Q?\
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M0?9+?_GWB_[X%'V2W_Y]XO\ O@444<S"R#[);_\ /O%_WP*/LEO_ ,^\7_?
MHHHYF%D'V2W_ .?>+_O@4?9+?_GWB_[X%%%',PL@^R6__/O%_P!\"C[);_\
M/O%_WP***.9A9!]DM_\ GWB_[X%'V2W_ .?>+_O@444<S"R#[);_ //O%_WP
M*/LEO_S[Q?\ ? HHHYF%D'V2W_Y]XO\ O@4?9+?_ )]XO^^!111S,+(/LEO_
M ,^\7_? H^R6_P#S[Q?]\"BBCF860?9+?_GWB_[X%,^SVW_/O%_WP***?,PL
/B;RH_P"XOY4444KLH__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_10qimg1.jpg
<TEXT>
begin 644 cvm_10qimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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M^5()$?B5N1E5'7KQV--'Q8\7>%_A%X**:KI/B?Q)J&ERW\P>.>=[B-22"#$
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MQBI_$.A^*],?7=/\-_VFVDO+83R*\TLS.A+"X"'=O.<(6"D$C/K0!W][\.O
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M4/VB#_GJG_?5'VB#_GJG_?5 $U%'444 %%%% !1110 4444 %%%% !112$@
MDG '<T +5=YCN,<*[W[^B_6F[GGXB)2+N_=OI_C4Z1I&@1!@4 1)"JDM)^\D
M/5F'\O05-Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
M-\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
M-\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
M-\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B_E1Y:?W%_*G44
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M&8<<X].E-_M)O^@=>?\ ? _QJ2Y_X^K/_KH?_035OBGHB=64/[2?_H'7G_?
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MR/6O?]?TW_H9JG8:'K.KQ2RZ7I=U>QP_?:"(L%]B1W]JN^,O^1[U[_K^F_\
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M8I2;331E['V51:WN8=?;'[/'_)%]/_Z^)_\ T8:^)Z^V/V>/^2+Z?_U\3_\
MHPU\UFO\%>I[&"_B?(]:]*KWO_'C/_US;^56/2J][_QXS_\ 7-OY5\O'='LL
M?;_\>L7^X/Y5-4-O_P >L7^X/Y5-0]P6P4444#"BBB@ HHHH **** "BBB@
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M:H1:@$$!..!D XJ6+P3X1A\6OXMA\.V,>O29W:@(AYS97:<MUZ<4 =)1110
M4444 %%%% !0>E%!Z4 ?#_C0_P#%>Z]_U_S?^AFL#-;OC0_\5]K_ /U_S?\
MH9K S7ZMA7^YCZ(^*K?&_4=FC--S1FNBYD.S6#KY_>0?0UN9K-O].O-3O;>"
MTA+G!W-_"H]2:Y<7)1HMR=D;T$W421SB(\CJD:EW8X"J,DFOJ;X3?$'3?!7P
M[L]!U:PO'NHY))&,(0J S$@<L.:\DT?P_;Z3&'"&6Y(^:4KT]AZ5K;6_NG\J
M^ QV+5;W(+0^FPV'=/WI;GT#_P +P\-?] S4O^^8_P#XNH;CXV>&Y;62(:9J
M0+J5&5C]/]ZO!-K?W3^5&UO[I_*O+6C.UGOT7QM\-I#&ATS4LJH'W8_3_>J3
M_A>'AK_H&:E_WS'_ /%U\^$%0200!W(K/N+W.4A.!W;_  I,#ZK\*_$O1/%N
MMMI.GVUW%.L1E)F"[<#'HQYYKNZ^8_@-_P E!G_Z\W_FM?3E !1110 4444
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M=R<U>\^#_GM'_P!]"JUG''Y][\B_Z[T_V5JX(X_[B_E3EN"V&^?!_P ]H_\
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M37G^OP7CZU=ZI%<VDUE(6@-^;_:+4,% 38,_,K D!>237IZ#]TH)+?*.2.M
M'EFFM9-\/]$CB/FZ=9:L3>)M9@L7FRE2P(R1DQG]:E70QJFC7]]%)';Z?%=W
MA@6:W+K]GD"9>->,,"K%?J?6O4 J@$!0 >HQ2X&,8X]* /.=(U/5[#Q-%9SV
MZ>9?R1R31O"YE9&C.&#] L855((ZYYYKT>DP,YQS2T 0)"%?>YWR'^(]O8>E
M3T44 %%%% #2*Q]>\0:/X9TJ75-:O8[.VC'WG/+'L%'4GV%:YKYV_:&^;6=$
MC?YD\ESM/(SNZUV8'"K%5XT6[7_0YL56]A2<TKG ?$CXR:OXS>72]+,FG:)G
M'E!L27'NY';_ &1Q]:\JKK;+2;C4;C[-I^FR7DV,^7!"7;'K@"H[FP:SN'MK
MRR:WGC.'CECVLI]P>E?H5#!4J"]E3:1\O4Q$JCYYG+45VUQX9UBTLVN[O0+R
MWME 8S2VK*@!Z')&*CFT._MGMDN-&N86NL>0KV[*9L]-N1\W4=*U4:;VFC/G
M:WB<;5>6XQE8^3ZUT>KVP@L+E'@$4J?*P*X*D'!'M7(UA73@U%,VI>^KGO7[
M,!)^(6KDG)_LT_\ HU*^N*^1_P!E_P#Y*#J__8-/_HU*^N*^#S+^._D?1X3^
M$BG9_P"OO/\ KM_[*M7!5.S_ -?>?]=O_95JX*\][G6MA:***!A1110 4444
M %!Z44'I0!\*^-S_ ,7!\0?]?\__ *&:Y[-;_C@_\7 \0?\ 7_/_ .C#7/9K
M]/PW\*/HCXVK\;'9HS3<T9KHN0.S7;^!D22UOT<9!9?Y5PV:[CP(<07W^\O\
MJ\C./]UG\OS1W8'^/'Y_D=4=.M"N#&#3AI]H,8B7CVJ7=1NK\_/IR);"U5LB
M(?E0-/M%?>(AN]<5+NHW4 5-;('AZ] X B->9EJ]'UMO^)!>_P#7,UYH30!Z
M[\ 3_P 7#G_Z\W_FM?45?+?P /\ Q<.?_KS?_P!"6OJ2@ HHHH **** "BBB
M@ JK>0O<6%Q;QOY;RQLBO_=)& :M44 >:6'@W7K'4[&^6S\/;[2W6!0J2@%A
M_P M<=-^,\D9Y/->DC.!G&>^*=10 4444 %%%% !1110 44UF5%+,0 .I-5_
MWD_K'%^3-_@* %:?G;&AD(ZD'@?C7SW^T$SMKFB;HRG^COU.?XJ^B=JHH50
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MGXB:Q_V##_Z-2OL"OB\P_COY'O87^&4[/_7WG_7;_P!E6K@JG9_Z^\_Z[?\
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M% #5547:JA1Z"G444 %%%% #37S;^T@<:_H?_7N__H5?21KYJ_:3./$&@_\
M7M)_Z%7K9/\ [W'Y_D>?C_X#^7YGANZC=4.ZC=7Z#<^9L3;J-U0[J-U%PL0Z
MFW_$LG^@_G7*DUTNI-_Q+)OH/YURQ->7C'[Z]#MH+W3Z!_97.?B+K'_8,;_T
M;'7V :^/?V5#GXBZS_V#&_\ 1L=?81KXK'_QW\CW\-_#*MG_ *^\_P"NW_LJ
MU;%5+/\ U]Y_UV_]E6K8KA>YTK86BBB@84444 %%%% !0>E%!Z4 ?!7CH_\
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M[B2T\F0;3M=73<<$''<U\7C)1J56XO0]_#Q<8),^Q([1XGE9;J3,C;SE5ZX
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M(^1G\3'9]Z,^]-S1FM[F8[/O75^$3^ZN_P#>7^5<EFNJ\)G]U=?[RUY6;/\
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M5T#2?C!H&BWVGMHFO7F+1[734EE8PZ>S\/(J$XW;"P&.FXU]W_:4_P">4O\
MWP:7[2O_ #SE_P"^#0!\M#1/%WC[PU!I%_X)NM.FEDMI;MYYV>+=!%Y2>6A
MV CDCGFO8_ _POTWPW;QS742RW0 [<"O0OM*_P#/.7_O@T?:5_YYR_\ ?!H
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M_"/^(?\ H :C_P" [5]<?:5_YYR_]\&C[2O_ #SE_P"^#7E'<?(__"/^(?\
MH :C_P" [4?\(_XA_P"@!J/_ (#M7UQ]I7_GG+_WP:/M*_\ /.7_ +X- 'Q]
M?^&/$MSI\\$7A_42[K@9MR*TO!WP6\07]U'+J=D]I$#DF08/X"OJ_P"TK_SS
ME_[X-'VE?^><O_?!H P_#?A+2_#=DD-K N\#EL<FNCJ#[2O_ #SE_P"^#3XY
M1)G"NN/[PQ0!)1110 4444 %%%% !1110 4444 9FJ:3:ZM;QPW+2Q^5()8I
M87*/&XR,J1TX)'XU'%HEC#H;:+$)%M75@Y$AWON.6);J223D^]:]% &(GAW3
M4UT:P@E693N$0D/E!]FS>$Z;MGRY]*VZ** "BBB@ HHHH **R/$5S-9^%=7O
M+9_+G@LYI(W'\+!"0?S%>?:#XLN[87=Y%K=SXDTFVTIKVZDDB53#.,$1JX4
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M=6;.2(^G4DXZ<U7LO!&B6.K6^H6\]]FUE>:WMVNF:&$L"&"H> /F/':NMHH
MY.R\":)8:K;W\+WK?9I))(()+EFAAW@A@J'@ [CQ3[+P7I%B+J")[Y[&XB>#
M[%+=.T$:/U"*3Q_3M74T4 <W:^$-*M;:V@=[J]2VBE@7[7.92R2 !E8GJ,*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10qimg2.jpg
<TEXT>
begin 644 cvm_10qimg2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M$OAJYN=&F\81KX=N=+OYPPL+B5L17"[25#J-V=I]* /I&BOFSQ-\3/&/P_\
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ME1Y$7_/)/RJ6B@"+R(O^>2?E1Y$7_/)/RJ6B@"+R(O\ GDGY5(  , 8%+10
M4444 %%%% !1110 4444 %%%% !115=Y&9C'" S#JQZ+_P#7H ?)*L8 P68]
M%'4U&L;,PDGP6'(4=%_Q-21Q+'DY+.>K'J:EH ***K%WFXA.U.\GK]/\: )6
MFB1MK2*#Z9I/M$'_ #U7\Z$C2-=JK^?4U)@>@H C^T0?\]5_.C[1!_SU7\ZD
MP/048'H* (_M$'_/5?SH^T0?\]5_.I,#T%&!Z"@"+[1!_P ]5_.LS4+EFOK"
M"&Z\I97?>5QD@(2.OO6O@>@K,O@/[8TK@??D_P#19IPW^\F6P[R5_P"@I/\
MFO\ A1Y"_P#04G_-?\*TL#VHP/:GS,=D9OD+_P!!2?\ -?\ "CR%_P"@I/\
MFO\ A6E@>U&![4<S"R,WR%_Z"D_YK_A1Y"_]!2?\U_PK2P/:C ]J.9A9&;Y"
M_P#04G_-?\*/(7_H*3_FO^%:6![48'M1S,+(S?(7_H*3_FO^%'D+_P!!2?\
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MH_AYJOBG4M3U >-)M0M=92)2VEM8"&S@7=UAE!;SN>-Q?/L*[;R&_P"@A?\
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MV3_O@U,#D CO0 M%%% !1110 445GZF^H1VOF:>;574Y=KHL%"XY/% &A17
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M_P"%^:K_ - "T_[^M1_POS5?^@!:_P#?UJ\9HH_M7%?S_@O\@_LC!_R?B_\
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M)_SZR?FO^-'G2?\ /K)^:_XU-12&0^=)_P ^LGYK_C1YTG_/K)^:_P"-344
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MS_\ 7-OY46G_ !YP?]<U_E3Z"ZE6);G^TKG][']Q/X#[^]6MMU_SUC_[X/\
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M 'NGZG'C?X$CYMS1FFYHS7Z=<^1L.S1FFYHS1<+#LT9IN:,T7"P[-=OX</\
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MO^?EO^^11Y4W_/RW_?(K[D^#"[_X\Y_^N;?RHM/^/.#_ *YK_*H;F*7['/\
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MK'X-P0R_"?2V=,G?-W/_ #U:@#TBBJ_V2W_YY_J:/LEO_P \_P!30!8HJO\
M9+?_ )Y_J:/LEO\ \\_U- %BBJ_V2W_YY_J:/LEO_P \_P!30!8HJO\ 9+?_
M )Y_J:G "@ =!0 M%%% !1169K5O<W6@WUM9,4N98'2,AMOS$<<]OKVH Y.]
M-\=?B%A=ZQ+-]M7?"]@BP"/>-_[PQCY0N<'))Q[UV]U<P65I+=W4JQ0Q*6=V
MZ 5PJ:7J]]J']MR65W:74=Q:P6<,D^3!"I'G,P5BI# OUR3@5T^N:3<:JMH(
M;\VWV>7S=IB$BR$#C<#Z'D>^* *Y\5Z>]CIEW:VUY=C4XS-;QP0Y<J "202,
M=14Y\1:<NJPZ;)Y\<\@7.Z,[8F92RHYZ!B 3CVKEX?#FI0>#='TZ_P!(.JW]
MM Z++#<K;M;.1@<@C(]2"3QT-7[KPI)<6M@\\LD^I%(8;R<2E4;:NUI2O\3X
M+*#_ +7M0!T]C>P:C91WEODPR9*%AC<,XS]#5ZN/\,Z7KFG:C=_;BZVVS8H:
M<.LC!SM9%_@4)M7''3\:Z]E#J5;H: *YD9F*08.."_8?XFI8XEC!QDL>K'J:
M<JA5"J  .@%.H *0D $DX [U')(D:Y8]> !U/TJ,1O*0TW"CI'V_'UH -SS\
M1DI'_?[GZ?XU.B+&H5!@"G44 )7B7[1W_(E:7_U_#_T!J]J:2-.&=5/N<5XC
M^T9(C>"=+VLK?Z=V/^PU=^7?[U3]3DQG\&1\Q9HS3,T9K]&N?*C\T9IF:,T7
M ?FC-,S1FBX#\UV.@'_B31_[S?SKB\UV.@G_ (DT?^\W\Z_/>/?^1='U7Y'W
M7!7_ ",)?X7^:-;-&:9GWHS[U^#G[1<?FC-,S[T9]Z N/S1FF9]Z,^] 7%D/
M[F3_ '3_ "KIM/?_ (E=K_UR7^5<M(?W,G^Z?Y5T-@__ !++7_KDO\J^QX:W
MG\CXKB?:'S_0T&E51DUIS^&[BVN$B#6TM])@-:Q2;IDR,_,,<<=>>*YV\1YK
M<K&VU@<@UK/XIU5KR'4ETG3UU  K/<@-NN%*[2&YP,@]17VA\.31^%[]KARF
ME,TJ%0>G5AE<'/.<<8JV?#^J_9;6>.!9$N8FE4(XRJ@X.1VZ50'BG6AY*K:V
MR102V\D,8+800YVIG.2#DY)YIB^(]4-L(GL[?S%MY[99=S B.5BQ&,XX)X-
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MN--TVYLM)N+BXOK5KPVP90T42XW$D\$Y(  ZFG)XSL9;^WCAMY&M)DB9KHL
M$,D9D0%>I&U3D]J .LHJAIM\FH:?%>+&8A(-P1B-P!Z$^F1@_C5XD 9/ H 6
MH'E._P N(;W_ $7ZTW>TW$9*Q]W]?I_C4R1I&FU!@?SH CCBVMO=M\AZL>WL
M/2IZ*:[JBEG8 #N: '56,K.Q2+MU<]!]/4TAWS?>!2+TZ%OKZ"K  50J@ #H
M!0!$((U'*AR>K,,DUXI^T:B+X)TK:BC_ $[L/^F;5[C7A_[2'_(D:5_U_?\
MM-J[\N_WJGZG+B_X,CY<S1FFYHS7Z)<^6'9HS3<T9HN [-&:;FC-%P'9KL-!
M.-'C_P!YOYUQN:Z_0C_Q)X_]YOYU^?<=_P#(NC_B7Y,^XX,_W^7H_P!#6W4;
MJ9FC-?A5C]FN/W4;J9FC-%@N/W4;J9FC-%@N+(W[F3_=/\JW;!O^);;?]<U_
ME7/R']R_^Z?Y5M6+?\2VV_ZYK_*OL>&]Y_(^+XGVA\_T+^ZC=4&ZC=7V1\06
M PI=U5PU+NH GW4;J@W4;J ,SQ.W_%/R?[ZUP!:NY\3-_P 2"3_?7^=<"6H
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M% ')>'O#5YHVK7EW+-"Z2*8U\K=NF^<L'DSP& .WC/'Y5U;*&4JPR#V-.HH
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MGL/2@!HC:8AIAA>T?^/K5FBB@!O<5X;^TI_R)&D_]?\ _P"TVKW+O7AG[2K
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M7]\_D:Y,74EBZ?LJ[YHWO9]SJPS>%E[2C[KVNCQ[_A0MI_T'I?\ OR/\:/\
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MS_WR:/M4/]\_]\F@">BH/M4/]\_]\FC[5#_?/_?)H GHJ))8Y<[23CV(J6@
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10qimg3.jpg
<TEXT>
begin 644 cvm_10qimg3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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M!#MYX%?7=% 'F?PPT;5/A]\%K&W\3^;+?6L<UW<6]JC3&'>[2>3&JY+;00H
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MHH *\M\0WNI6?Q-CNF2*=;>.".PLY878S>8Q$KQL.%<< D]A[UZE28!(/<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH .U)Q1VJO/<+#MW)(VXX^1"V/KBE*2BKL$FW9%FBJOVM-\B>5+
MF,9)V'!^GK2?;$Q$?)F_>G ^0_+]?2HYUW'ROL6Z*J&[3,H\J7]WU^0_-]/6
M@7:$Q#RI?WO3Y#\OU]*.==PY7V+=%4_MJ;)6\F;]T<$;#EOIZTINT,D:>5+E
MQD'8<#ZGM1SKN'*^Q:I:I?;4\J23R9L(<$>6<GZ#O5+4?$.D:1-;Q:G=?96G
M4M&9%.&QC/..HR/SIJ<7HF)IK5FS17*_\)]X3\DR_P!JK@-MQY;9_+'2I/\
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MUW>U2'2=<TSQ FI:#HL,,4\K1"(J#L3>,ELGY=PR<CH HQ0!Z51110 4444
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M^02G^_)_Z&U:59NB?\@E/]^3_P!#:M*LI?$S>A_#CZ(=1114FX4444 %%%%
M!1110 4444 %%%% !1110 5S/B7C6?"__81;_P!)YJZ:N8\3_P#(7\+_ /82
M;_TGFI/8#9S1FHLT9K,LES1NJ+-&: )MU+FH,TNZ@";-&:BW49H ES1FHLT9
MH EW4NZH<T;J +"GYU^M87@7GPE$W]ZXN#_Y&>MB-OWB_45B^ \_\(9:Y[S7
M!_\ ([U<1,ZBBBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "LO5]7T[0=)NM7U:[CL["V7?+/*V%0=/YX&.Y-:E>2_%_[7%I<8O?'6
MG^'='N)K>)([BP6:4W F4I(K-(HPK;&/!P%)- '6Z!\0O"GB?43IVC:A-<7(
M0R%7LYHAM&,G+H!W]:ZVO+?"7B.]G\9P:+<_$G1O%#SVLLWD:78HOEA"HW/(
MLK[?O8 (Y_"O4J "BBB@ HHHH **** "BBB@ HHHH ;7-:]_R,>C_P#7*?\
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M=I_(T6"Y]*APP#*00>00<@TNZL#PBW_%">'LG)_LZWZ_]<Q6WNH <[8BD/\
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M%]+.+_T 5PNJOC1-0/I;2?\ H)KOM!&WPSI8]+2+_P! %-"9I44450@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\2ZKI&C>'YK[6XQ
M)IZ/&DH:,.J[W50S \!06!)/  )[5NUQOQ%N(+;P!?\ GZ3:ZLDSPVPM;TX@
M9I)4C5I, _(I8,>.@H V["PT&WG\[2K+3XIBOW[>-%8K]5'2M>OG_P"%[V]C
M\2VTZ3PQX,TV\\N]MW;0XG6YA>"54(D#'Y4<$,#CGBOH"@ HHHH *J7L=O)8
M3QW3!(&0K(Q?8 IZ\]JMU#-#%<P/!/&LL3@JR,,AAZ$4 >063(UFVBW=P]KI
M+^(#;SI'=,\:1>3N1!+G.&8 GG@G%0I)?VVFV6NKK4O[IYH;8MN=Q;1NZB3K
M@KM(/(R2%YKUA=#T==+.EKIML+$\FW$8V$^N*G&GV(BV"SA""+R-NP8\O^[C
MT]J *'AJ[L;K08#IYF\F$F B?EPRG#;CW.>];=5K6UMK*V2WM($@A3A8XUV@
M?A5F@ HHHH 82 "3P!U)KE=9GAF\1Z3Y4R28BGSL8'',==2RJRE6 *D8(/>N
M&N_"XT&];5- LTDA.3+:@?,HZDQG_P!E_*M*5E+4PK)N.B.H'2E'05G:9JUK
MJ=N)('YZ%3P0?0CM2WFH+#(MO C3W+_<B3J?<^@]ZW2;9QU)Q4?4M:+/#_9Z
M0B:/S-\@V;AG[[=JV,8'-<WI/ABSM+XZM<01-J#9.Y5X3/7'J?>NC_BKGG;F
M=F=E!-4XJ2LTA]%%%0;C20!DUY3I]S=>+?%5U<-J^H6UA-*T=HEM<-&HB08W
M8'7<03GTQ75>.]4ET[PN]M:-MOM2<6<!'52WWF_X"H8_@*Y[P?%';Z]9P0KM
MCBC**/0!<"DV4:%OHVC75S<6UOXUU.6:VR9D74"3'CKGGM5Q_"=K%''))XIU
MA4E8*C&^;#$] /K7.V_AW6]-NI]36WGN'N!?PQP[5!M&D9F1QC[RM@ YSC(J
M:XL_%L[S010S3.DEK- ]R,10NN,KM'4 \Y'T-,DZ/_A"5_Z&36__  ,:JTOA
M6S@N(8)O%.LI+.2L:&^;+D#)P*G<ZVW@NW$2W@OE=1=!R//*[OWNP],XSMQV
MQ5#1=.U63Q=9ZC?+=FU@@N8X&G;Y@A=-@D'][&[WP!F@"W)X1MH7B27Q1K*-
M*VQ UZPW'&<#\ :F_P"$)7_H9-;_ / QJQ=;L_$=QXD66".Y>Z@N9)+-C_QZ
MI'Y!"D_[6\\Y_E5)G\;1:3%Y27UQ<"=7!(*^60!O4@\N"<X[#\J .@D\)VT4
MT4,GBC6DDF)$:F^8%R!DX_"BZ\*VEE:R75WXJUB"",9>1[Y@%'UK)_L/5KC5
M(XYFU13%J%U.9S)PD;(_E[#V'(! K?MM2O#X3E;4M)N;[4+2!#+;F(9N)=H8
M!>QYQSV- &+/I_AZVM8+NX\=:C'!< M%(=0;:X'7!S5E/#^E2O(D?C+56:(J
M' OVRI;IW[U3T[2KK4_"]EIDFE36@N[YI]1%Q$$V+GS&5!SA6.%'MFGZIH]]
M8^(CJNBZ69 DN-CY97=OF+!<\+N.,]B2>U &;KFGSZ5JC6D6N:NZA0V6O7SS
M7.W+7 \1>'A)J%]<*;M_DGN&D7_4OS@]ZZ[Q86.ODL,-Y29'H<5R%Y_R,/AW
M_K[?_P!$O4/<KH=?NHW5'FC- $FZC=4>:,T 2;J-U1YHS0!)NHW5'FC- $FZ
MEW5%FC- $VZC=4.?>EW4 5M9;'A_4CZ6LO\ Z :]&T48\/Z</2VC_P#0!7F>
MN-CPWJAS_P NDO\ Z :].T@8T+3QZ6\?_H(JD)EZBBBF(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Y+XA7NI:?X"U*ZTN,-.OEAW^S_
M &@PQ&11)*(OXRB%GV]]M=;7,^,GM(/!]_+?:GJ6EP*J_P"DZ8K-<HVX;=@5
M6)).!C!SGF@#S/X5^)H-=\4Q_P!F7\6O3"*]CU75/L*12NJ3@6K22JBY9DS\
MGH,X&*]RKQKPQKOQ?%VS'PV=6\/ C9<:OY>FZBX)Y/EH64X'/S",FO9: "BB
MB@!*KEY_M!41 Q;<A]W)/IBK/XTGXU+5^H+0J>=>>4K?9DWEL%?,X ]<XIWF
M7'FNODC8%RK;_O'TQVJQBC%3R/N_P'==BKYMWMC/V9-Q.'7S/NCUZ<TOFW6^
M0>2NU1\AW_>/OQQ5G%&*7(^[_ =UV*WFW6(_W"Y;[_[S[OTXYH\V[_>X@7Y?
M]7\_W_KQQ5G%&*.1]W^ KKL5O,NLQ#R%PWWSO^Y]..:3S;O;(?LZ;E/R#S/O
M#\N*M8HQ3Y'W?X!==CF-1\/R7.H1ZAIX%C=L!YLBG*O[,O<^]7["P;3X)#%:
MK)<L?FD>3+2>Y../I6Q15/G:Y>9V^1FH04N;E5ROYEQYRCR1Y97);=R#Z8IO
MG7GD[OLR;]V-OF<8]<XJU1BHY'W?X&MUV*_F7'G%?)'E[<AMW.?3%-\Z\\E6
M^S)O+8*^9P!ZYQ5K%&*?(^[_  %==CS+Q/I?B'7_ !Z8]+>P$6E6:[4NV<#=
M,6RXVCKA-OY^M16WA?X@6DJSVT^A1RKT822\?I74Q2>7\1-;'K86;?\ C\X_
MI6S]H/K5*+!R.-^P?%/_ *">B_\ ?R7_  JS8V_Q,M[I&N;O0YX21O4O+G'?
M''6NI^T'UH^T'UIV9/,B1;O80EW&83V;JA_'_&K@((R""#W%9YGR"#R#U!%0
M#,)W6LAA_P!CJA_#M^%.S"Z.=U6U\=OK=S'HVHZ>MH,.@NF</@]?NC& :J_V
M?\4_^@EHO_?R7_"NGN;THJW$T1CEA_B7E74]1[>OX5<%QD @Y!Y!I68[G'?V
M?\4_^@GHO_?<O^%']G_%/_H)Z+_WW+_A78_:#ZT?:#ZT<K%S(X[^S_BG_P!!
M/1?^^Y?\*/[/^*?_ $$]%_[[E_PKLOM'O2_:/>BS#F1Y]=>%_B#>SF>ZN-#E
MD(QN,DW3\JP=6\/>)-*UGP]=:NVF&W^VL@^RM(7W&&3'WAC'%>O_ &@^M<;X
M\EW?\(Z/^HE_[0DHY6/F,[?1OJ'=1NJ2B;?1OJ'=1NH FWT;ZAW4;J )M]&Z
MH=U&Z@";=1NJ+?2[J )-U&ZH]U&Z@"GKK?\ %-:I[VLH_P#'37K&FC&D60](
M$_\ 017D6NM_Q3>I>]NX_2O7[$8T^U'I$O\ (52$RS1113$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %8VOZW8^&]"GU>_65H82JB.!"
M\DKLP5$11U9F8 #U-;-<SXVTXZEX-O[,:5<ZLS!&6VM;A;>;<KAE>.1B KJ0
M&!)ZJ* ,#P!XBM)K2'3YAJ,=WJ-S?W*1WZ -&4N")(20S#*[A@ XQ7HM>-?#
M?3_#.G>*GMY]8\23>)!%/+%8>(U5)8(Y) \KQA%"-N;&Y@6[=!7LM !1110
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MLX!Z1K_*O$]<.?#]Z/5,?J*]OB&((QZ*!^E-"9)1113$%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH KRW,EGJ>C7$6-Z:C"1D9'4UZ@?%VJYZQ_\ ?->4WW-]HP];^/\
MK7:'K0!T/_"7ZKZQ_P#?-'_"7ZKZQ_\ ?-<]10!T/_"7ZKZQ_P#?-'_"7ZKZ
MQ_\ ?-<]10!T/_"7ZKZQ_P#?-'_"7ZKZQ_\ ?-<]10!T/_"7ZKZQ_P#?-;OA
MW7Y=3FEM[O:)0-R8&,CO7 U8LKJ2QOH;J(_-&V<>H[B@#UNBH;>:.YMH[B,Y
M210PJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS
MI?%NOOJ(F@M;>:ROIKFTL8!D2"6)6(9FZ$,4;CMQ0!Z+17%>'->UG4[Y;+48
MH[=[<MYY==C29 **$R<'J3[ >M=K0!2U*]33].FNG_@'RCU/85Y9+*\TSRR'
M+N2Q-=?XJ-[=S16=M;RO%'\S$*<%NWY5S/\ 9>H_\^<O_?)H IT5<_LO4?\
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M=?\ /I<_]^'_ ,*/K-+^=?>@^KU?Y']S(J*E^S77_/I<_P#?A_\ "C[-=?\
M/I<_]^'_ ,*/K-+^=?>@^KU?Y']S(J*E^S77_/I<_P#?A_\ "C[-=?\ /I<_
M]^'_ ,*GZQ2_G7WH?U>K_(_N9%VK9\)_\COI/^_)_P"BVK+^S77_ #Z7/_?A
M_P#"M;PQ'+;^+],GG@GCB1W+.T+@+^[8<\5Y^8UZ;PTTI+;N>CEU"HL5!N+W
M[,]DS1FJ?]IV'_/Q_P".-_A1_:=A_P _'_CC?X5^;GZ67,T9JG_:=A_S\?\
MCC?X4?VG8?\ /Q_XXW^% %S-&:I_VG8?\_'_ (XW^%']IV'_ #\?^.-_A0!<
MS1FJ?]IV'_/Q_P".-_A1_:=A_P _'_CC?X4 7,T9JG_:=A_S\?\ CC?X4?VG
M8?\ /Q_XXW^% %S-&:I_VG8?\_'_ (XW^%']IV'_ #\?^.-_A0 7?.J:&/6_
M3_T%J[.N)BD34O$6A6]CON)1>;RJ(W $;\GCI7H7]EZC_P ^<O\ WR: *=%7
M/[+U'_GSE_[Y-']EZC_SYR_]\F@"G15S^R]1_P"?.7_ODT?V7J/_ #YR_P#?
M)H IT5<_LO4?^?.7_ODT?V7J/_/G+_WR: *=%7/[+U'_ )\Y?^^31_9>H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10qimg4.jpg
<TEXT>
begin 644 cvm_10qimg4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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M_P!!#4/_  (:C^QH_P#H(:A_X$-0!J45E_V-'_T$-0_\"&H_L:/_ *"&H?\
M@0U &I167_8T?_00U#_P(:C^QH_^@AJ'_@0U &I167_8T?\ T$-0_P# AJ/[
M&C_Z"&H?^!#4 :E%9?\ 8T?_ $$-0_\  AJ/[&C_ .@AJ'_@0U &I167_8T?
M_00U#_P(:C^QH_\ H(:A_P"!#4 :E%9?]C1_]!#4/_ AJ/[&C_Z"&H?^!#4
M:E%91T:,#)U'4./^GAJQHG2>,2PQ:])$WW7$O##UZT ==17*;6_Y]O$'_?W_
M .O1M;_GV\0?]_?_ *] '5T5RFUO^?;Q!_W]_P#KT;6_Y]O$'_?W_P"O0!U=
M%<E(PBB:22'7U1 68^;T _&M.#3()[>.>/4=0*2*'7-PW0C- &U167_8T?\
MT$-0_P# AJ/[&C_Z"&H?^!#4 :E%9?\ 8T?_ $$-0_\  AJ/[&C_ .@AJ'_@
M0U &I167_8T?_00U#_P(:C^QH_\ H(:A_P"!#4 :E%9?]C1_]!#4/_ AJ/[&
MC_Z"&H?^!#4 :E%9?]C1_P#00U#_ ,"&H_L:/_H(:A_X$-0!J45E_P!C1_\
M00U#_P "&H_L:/\ Z"&H?^!#4 :E%9?]C1_]!#4/_ AJS[^V@L6@0W6JSR3L
M51(IR2<#)_2@#I**Y3:W_/MX@_[^_P#UZ-K?\^WB#_O[_P#7H ZNBN4VM_S[
M>(/^_O\ ]>C:W_/MX@_[^_\ UZ .KHKE-K?\^WB#_O[_ /7HVM_S[>(/^_O_
M ->@#JZ*Y3:W_/MX@_[^_P#UZ-K?\^WB#_O[_P#7H ZNBN4VM_S[>(/^_O\
M]>C:W_/MX@_[^_\ UZ .KHKE-K?\^WB#_O[_ /7HVM_S[>(/^_O_ ->@#JZ*
MY-##]J@@G_MJW,[[$>24[=V,XX/M6GH#2M8SI--),8KF6-6D.6VAN 3WH V:
M*** "BBB@ HHHH **** "BBB@ HHHH **H:CJ>GZ39/?:G>16ELA :65MH!)
MP!^=9ESXO\-6DEW'<:S!')9LJS*225)Z <<^^,X[T 6O$O\ R+=W]!_Z$*V!
MTK#U^6.?PO<RQ.LD;HK*RG(8$C!%;@Z4 %%%% !1110 4444 %%%% !1110
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MCLUBT[4M.M6U!3%#J,_F/_JSD@9)49[$G/7BNG\/_P#'K=_]?DW_ *%1K/\
MQ]Z3_P!?8_\ 06H\/_\ 'K=_]?DW_H5 &Q1110 4444 %%%% !1110 4444
M%%%% &3KVCQZ]H-UI4KB,3K@.4#;#G(.#WKCKSX;R3Z@U]!KGE2022/9AK<,
M(O,/[T/S\^><=,>]>CT4 <CJN@V-IX1C@*/(UC!'#&[.0<*1C(!Q76C[M9'B
M7_D6[OZ#_P!"%; Z4 <WJ6@V\DL=U;6C2R^=OD7SV7>._?%0S6<-O \TFAR!
M8U+-B[)X'XUU'-,D1)8VCD4,C A@>XH4Y+9M$<O8S(]$TJ2-7%NV" 1F5_\
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M6S.F6\$8VI'' RJH]  U;E% &5Y?B'_GYL/^_3__ !5'E^(?^?FP_P"_3_\
MQ5:M% &&UCJMU>6LEY<VHCMY?-VQ1,"QP1C)/O3_  ]_QZ7?_7Y-_P"A5LUC
M>'O^/2[_ .OR;_T*@#9HHHH **** "BBB@ HHHH **** "BBB@ KR6_^)VJV
MWBF^T!-.LXY4D80RS,PCC52<F1NAW <8Z'@UZU63)X?T.3[49=(LW-XP:XW0
MJ?-(Z%N.<4 8NJ:VE[X.AN&M+B-KVWBF $194W$'!;H*[ =*QO$8"^&;I5
M"J !V^85LCI0 4444 &*Q=4,MG<)JB1QND<9CD#-M."PY!K9J.2-)HVCD4.C
M#!5AD&DU=":N"2)(,HZM]#FGUS]S9ZE9ZI'/HEI9F&4*DZR,4V@$\C YJ];:
MA(]S<V]XL,,D.WE7R&!&>^*2?1B4NC-2BF)(DF=CJV/0YI]44<[<V]QI5S%<
MVDUS+ ]P6FA50X ;.2 !GK6K9WD-_;B>$MLR5PRE2"#@@@U<K).AVWF2/'-<
MQ>8Q<JD[*N3UXJ^927O:/N+;8UJ*P9+&]LKNWN=/-Q<J-RRQ2W)P01P1N]#5
MG[;JW_0&/_@0M+V=]8M?>D,U:#61)J&IQQ-(VC'"@L?](7M5JVOK>YM8;CS$
M02H'VEAD9'2DX26O_!_("]1547MF93"+J(R ;BN\9 ]:$OK.52T=S$X!*DAP
M>1U%+EEV M9HJ$7%N3@3QD_[PJ:E9K< HHHI@%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5C>'O^/2[_Z_)O\ T*MFL;P]_P >EW_U^3?^
MA4 ;-%%% !1110 4444 %%%% !6%J^NS:?-':V>C7VIW+KNV6Z (H]6=B%'T
MSFMVO*OB2WB35-:M/"VAI<+#J,0%Q+]Z)5W\D@<KC')) (XP: /0-)U8ZK"[
M/I]W82Q-MDANH]K ^Q&0P]P:U:YOPE9+I7AVUT<REY[-2DJF<3%"23C/8>@P
M,# KI* "BBO$]0\/^-Y_%.OW#6=_-I=Q<!S#'=[3(@X0(=W8X8_=P!CF@#U3
MQ+_R+=W]!_Z$*V!TKCM3L]8C\'0"\U'$T5O$MR@0-YC@C<=U=B.E !1110 4
M444 %59K&SN'\R:UBD?&-S("<5:HH Q#83VFHM<:=!;+')&$9"2G(/7@>]7+
M"YGN%G2XB2.2&380C9!X!S^M7:R;>22#7)[60(4N 9T8-R,8!!%+8BUF;%%%
M%,L**** $(##!&15#^R-,_Z!\'_?L5H<T4)M;,#(7P_HBW;W:Z7;"=U",_EC
M) [4MOX?T2U1H[?2[:-68N0L8Y)ZFM7\*/PJN>7=BT,>\T2QGL)HH+.WCE9"
M$;RQP>QXINGZU8RZ="\]S#!-MPZ&094C@]?I6U@5$882<F)#_P !%'-=6EJ%
MNPR"\M+K=]FN8YL==C XJ>LB:PO8]1>[T^>WB$D:HR21$]">1@CUI_EZ_P#\
M_5G_ -^6_P#BJ'%/9_>.YJYHK*\K7_\ G[L_^_+?_%54OH?%9M2+"_T])]PP
M9(&(QGG^+TH4+]4*YT-)6#=S:W8VINI9;69(R"Z)"P)&><<FK7]O:7_S\G_O
MVW^%/V<K::^@7-7BDK+_ +>TO_GY/_?MO\*K7'BK1+:XMX)KLJ]PQ2,>4_)Q
MGTH5*;VB_N"Z-W\*,UD3>(M(@@DFEN2J1J68^6W 'X55_P"$P\/[;1OMC8O#
MB']T_P W&?3BFJ-1[1?W!='09]Z=7,2>./#D5P\$E^5=)5A;,3X#-TYQ72YR
M,BHE3G"W,FK]P33V'4444AE#5;QK+3I+A!E@.*\K\)?&32O%&HZM9:?*\D^F
M2F&XBDCV%6R1D>HR#S7I7B/_ ) LU? VAV'BK2I_$/C;P5$]WJ(UF[TJZM@"
MP>.3[CX']UN:ZZ,8\MVKG'5E+FLG8^L?#?QBTKQ!XQU7P]93---I1 NB(\(,
MG&%;O@\5W5]XHLUM&^R2;ICT&.E?#VF>'I_"!^*.D074LM[;:##)+.CG>TS?
M,[ ]>I-=5<^+M,O+_P"#MK8Z_'--YL1O$BGR5S&%Q)@]2V>#S6RIP>LE9_\
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M/I^(TJ3^T_N7^9M[U_O"C>O]X5C?\(OHO_/JW_?U_P#&C_A%M%_Y]&_[^O\
MXT[R[?B/EI?S/[E_F;.]?[PHWK_>%8W_  B^B_\ /JW_ ']?_&C_ (1?1?\
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M2!@\ 5LXI:35Q-)F;YFK_P#/"U_[^-_A5/3M0U4736^MP6EO(P9XS!*6!4,
M,Y YYK<J&:TMKG;]HMXY=O3>H.*5GW)L^C'?:8/^>T?_ 'T*3[3;_P#/:/\
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M3 **** "BBB@ HHHH **** "BBB@ K&\/?\ 'I=_]?DW_H5;-8WA[_CTN_\
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MSWK&K3E-)1E8]' 8NEAIN56DIIJVM]/-=#,75-<VC_BG7/'_ #\)2_VGKO\
MT+K?^!"5N  #%+5V??\ +_(Y/:0_D7X_YF%_:>N_]"ZW_@0E']IZ[_T+K?\
M@0E;M%%GW_+_ "#VD/Y5^/\ F87]IZ[_ -"ZW_@0E']IZ[_T+K?^!"5NT46?
M?\O\@]I#^5?C_F87]IZ[_P!"ZW_@0E']IZ[_ -"ZW_@0E;M%%GW_ "_R#VD/
MY5^/^9A?VGKO_0NM_P"!"4?VGKO_ $+K?^!"5NT46??\O\@]I#^5?C_F87]I
MZ[_T+K?^!"4?VGKO_0NM_P"!"5NT46??\O\ (/:0_E7X_P"9A?VGKO\ T+K?
M^!"4?VGKO_0NM_X$)6[119]_R_R#VD/Y5^/^9A?VGKO_ $+K?^!"4?VGKO\
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MH **** "BBB@ HHHH **** "BBB@ K&\/?\ 'I=_]?DW_H5;-8WA[_CTN_\
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MWDZO_P _L'_?D_XT>3J__/[!_P!^3_C1?R"_D:/X4?A6=Y.K_P#/[!_WY/\
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MD^6_UF1M'S <\XZ5+I_Q=^(GB*W\&Z;H2^'HM4UV^U2Q-_/%*]I<+:(&6XA
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MYX]:=8^-_$%ZFI30)I[N;*>ZMK1PRM:&)@-LQ!).[.>@Z4 >HG[I^E9GA_\
MY %I_NG_ -"-<;8>+M4G\7Z5:7C6T>FWMI"%6(*[O</&7((W;D4#H<$>]=EH
M'_( M?H?_0C0!J4444 %%%% !1110 4444 %%%% !1110 4444 <[KW_ "%=
M#_Z^_P#VFU= .E<_KW_(5T/_ *^__:;5T Z5*W-JG\.'H_S'44451B%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>'O\
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MI5GI<%K+K-B[QKAF6=0"<YXYII\/Z0=72^^Q6818C#Y?DIRQ;/YUH?V+H_\
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M,"]3^%0V.@Z/;V,5J=/LI6A4(S>0O7\J +7]M:/_ -!:S_[_ *?XT?VUH_\
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MET2+4H].;5+<W,DAAV!P=KA=VUO[IQR,]:GO]9TW38WEN[I%6)T23:=QC+'
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MBG5G:39KI^BV5BL;1K;PI&%9]Y7 Q@MW^M:/44 ,5U;.U@V#@X/0T^N:\*Z
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M5T895E.01Z@U+7/^$],N-'\/1VEVL<<ADDE\B(Y2 ,Q81J?10<5T% !1110
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MXYQU/2MJ2PL9KM;N6TA>X12BRM&"X4]0#UQ4MO;P6MNEO;0)!"@PL<:A57Z
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M%8GB;5)M%\,WFI01J\L2C;O^ZN2!N;V&<GZ5MU#)&DT;12HKHX*LK#((]"*
M,;PMJUQK/A]+RZ,32K+)"98?]7-L8KO7_9.,UOU!!!#;PI!;Q)%%&-JHBA54
M>@ Z5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10qimg5.jpg
<TEXT>
begin 644 cvm_10qimg5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &# 9@# 2(  A$! Q$!_\0
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MYEEP+:W$32DIQ\Y&0.H &:]:' H **** "BBB@ HHHH **** "BBB@ HHHH
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M_0B:G_X$VW_QRC_A)/$'_0B:G_X$VW_QRNHHH Y?_A)/$'_0B:G_ .!-M_\
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M^$_\%_\ 0SV'_?T4?\)_X+_Z&>P_[^BNFHH YG_A/_!?_0SV'_?T4?\ "?\
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M\^(NN6NAZ9<0IH]_=Z@68&UE)B@40^9Y<A)&'/0'/J<=J .U_MWQ9_T(LO\
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M_P!"++_X,8/\:ZFB@#EO[=\6?]"++_X,8/\ &C^W?%G_ $(LO_@Q@_QKJ:*
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MBS_H1)?_  8P?XUT%M++):127$!MY60%XBP;8<<C(X./:K5% !1110 4444
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M4_AG59X;NS&G7ES(AN(I456;83M+@XSUX)]:NR:?I$1DNI;"T5ECVO*T2@A
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M2Z][>"?$'_?J'_X[0!U5%<K_ ,);>_\ 0E>(/^_</_QVC_A+KW./^$)\0?\
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M7FE>$%M+ZTGM9#=7$JQW+AY C2LREB"><$5V%<K_ ,*_\,?\\+[_ ,&5S_\
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M%=6PRI%<'\4+ 7G@IG5+@SQ75OL-L[JX#3(K?<.2-I.?:@#2\WXB?\^_AO\
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M !%_Y]O#?_?^?_XBNKHH Y3?\1?^?;PW_P!_Y_\ XBC?\1?^?;PW_P!_Y_\
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ME57Y?E0%B=HXR>E0)X&\36XV6-EH,$<FH)J5PC7=U()Y5.03N!QS@\>@KK_
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MVM@J/F.023QQFI;CXG>%[>YOXVFG*60;]XJ K(RLJE%YX.YU'S8!YQT-6X_
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MORG*.Y;U/RD<&O9[%Y7LH7N HG:)2X7. V.<9YQFL#_A%=<_Z'S6/^_5O_\
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M_&C_ (35?^A4\2?^"X_XUUE% ')_\)JO_0J>)/\ P7'_ !H_X35?^A4\2?\
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M$ML9G:4%1P2WF$*RXVU]"44 >06MKI=OX4O/#;:#XKDM;HH"PTU4=53&T J
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M &/GRVQC..,]*^8O!-OI,&IZ*NL:-XFF^*$>JSOJ$T7G(I^9SNED;]V;8KL
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M0>9&T;95B#\K $<C\:TZ3 /)%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10qimg6.jpg
<TEXT>
begin 644 cvm_10qimg6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &F ;T# 2(  A$! Q$!_\0
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M&6*[=TSJ&DR"-BDGB@#VNBJEG/\ :;*"Y\MXC-&LFQ\97(S@XXS5N@ HHHH
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MA(D0J'7_ &L&O2Z\M^/,#'X(>([^&]N[.ZTZW-U;S6MPT++(O R5(R.3P>*
M*5]\"M F;1KO3-;U'2=4TS3(=(-W"L4GVB",84.DB,N[C[P -=-K7P]@U;X7
M'X?PZ]J-E9-;BTDNE*/-+%@AE8E<?,"0< >V*\RC\7^,?"^E_"_P;X)M-/U2
M]\2Z5)=23Z[=3/ME6))"2X).,LW&#V Q7H'PO\6WGQ,^%D>KZS9QV%W.]Q97
M4=G*P4,CM&S(V=RYQD<Y'K0!6TSX265A;^"XKGQ%J.H-X0GDFLGG" LC1^6(
MVV@?*HZ=_4UGCX$>&UTC[+!JVIVNH0:Q-K=GJ4#JLUI/)C<%R""G X(YKAO
M?ABW/Q^\?:1+K&NS6/AM;:73X9=6G=49X\MNRWS@GLV:P_A!\1?&OAG1/ 6E
M:GI]A>>&/$.H7UG%=?:)7OED661LL#\H7/ ')P.HH ]PTSX9V]EXNT+Q3?\
MB+5-7U/2(+F 37C*3/YQ!8G:  !C@  "L>X^!^B'Q1?:SI>N:GI4&J7?VV^L
MK<0LDTN02RLZ%X\D<A37%^$?CWXS\5>*]/E@\"NWA:^U![$SQ6TQDME#%5D>
M8_NVYZJ "/6MS]I/3#!\*-0\6V6J:G8:MIPBC@DM+Z2% &F4-N12%8X)Y(H
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ME3CC([]>* .B\2_L]>'?$?B+6=9?6]3M?[8N8;RZMHQ$RM+&000S*7 X^Z&
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MTG2;32[(,MM:1)!$&8L0J@ 9)Z\"K]%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$ X/7%;U% !17S[XQ\2>.=;^*VM>'_!=]JB?V7]@MHA9PJUJDSR>9.URY!
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MU_SV3_OC_P"O1LNO^>R?]\?_ %ZGHH @V77_ #V3_OC_ .O1LNO^>R?]\?\
MUZGHH @V77_/9/\ OC_Z]&RZ_P">R?\ ?'_UZGHH @V77_/9/^^/_KT;+K_G
MLG_?'_UZGHH @V77_/9/^^/_ *]&RZ_Y[)_WQ_\ 7J>B@"#9=?\ /9/^^/\
MZ]&RZ_Y[)_WQ_P#7J>B@"#9=?\]D_P"^/_KT;+K_ )[)_P!\?_7J>B@"#9=?
M\]D_[X_^O1LNO^>R?]\?_7J>B@"#9=?\]D_[X_\ KT;+K_GLG_?'_P!>IZ*
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M=X49B4ZDJ*OR_P"HD_W3_*JVD_\ ($L?^N$?_H(I-W6H[69/LNO^>R?]\?\
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MF>+[;R.9HKIMB?W%_*C8G]Q?RH^J^8>V\CEW=8URQJE+,TA]%]*T]? %Y%@
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ME:/T1#T_'O0!:HJO]F_Z>)O^^Z/LW_3Q-_WW0!8HJO\ 9O\ IXF_[[H^S?\
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M3T4 0?9+;_GA'_WS1]DMO^>$?_?-3T4 0?9+;_GA'_WS1]DMO^>$?_?-3T4
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M110 4444 %%%% !1110 4=JYS5O$O]F:G;Z?'82W3OL,KJX585=]BDYY)SV
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M_P">A_[Y/^%6:* *WVR#_GH?^^3_ (4?;(/^>A_[Y/\ A5FB@ HHHH ****
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M&E\"/L7]F'_DF=[_ -?[?^@+7NU>"?LRR2#X9WVV%G_T]N00/X5]:]S\Z?\
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M)8_]<(__ $$5<ZC!IJJJJ%4!5 P .U<M]+&MM;CZ***!A1110 4444 %%%%
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MW#87]KJFF6VI64GF6US&)8VQC<I&0<&KM<UX#_Y)SX>_Z\(?_0172T %%%%
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M%"32Z_F?)8YR>(DE_6A0^PVO_/%:/L-K_P \5K5M-(U:_@:XL-,O+J%>#)#
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M_P"-&+O^]#_WR?\ &IZ* (,7?]Z'_OD_XT8N_P"]#_WR?\:GHH \2_:$\T>
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MQL7D8YQUKI_#<&HVV@0Q:B)1,))"JS2>9(D9=C&K-DY(7:"<]JWJ* (WC20
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M.KO_ *Z&LXM0!]R?#W_DF?AO_L'P_P#H KIZY?X>?\DQ\-_]@^'_ - %=10
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MU%-HH [KP8V-+N/^NO\ 2NGWURG@\XTRX_ZZ_P!*Z3=7Y_F/^\S]?T/J,)_
MB3[Z-]0;J-U>>=1/OHWU!NHW4 <#K#?\3J[_ .NAK/)JYJ[?\3F[_P"NAK/)
MH ^Z_AW_ ,DQ\-?]@^'_ - %=17+?#H_\6O\,_\ 8.A_] %=3D>M !11D>M&
M1ZT %%&1ZT9'K0 4444 %%%% !1110 4444 %%%% !1110 4455:5Y#LM\8[
MR'H/IZF@!TDVP[$&^0]%'\SZ"FBV#_-<'>Y[ D ?2I8HDB4A1DGDL>I^M2T
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M/[Y_[Y- %BN8\4Z_>:58N;&PFNIB. BDUO\ VN#^^?\ ODTGVNW_ +Y_[Y-
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M\FC[7!_?/_?)H ECBCAC"1J%4= *?5?[7!_?/_?)J<$$ CH: %HHHH ****
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M2QU.&*W:YNT\V.)9"R1% H!Z?Q'GF@#O**\P/B74Y[99I=3MI/M=M=/)8+&
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M-I*+R6\@CAEB$:1&/?L)?.?X,'MSVH ]#HKE?">K7.I6MU%>7+SW5M(JR91
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MN@U'P-X1U;4)=0U+P_9W5U,07ED3+-@8Y_ 5JKI5C'+8R10B/["C1P!> BD
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MC0R+'*\T,YN?.DD+N\A4IN8GK\IQCH* -^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,882,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,792,856<span></span>
</td>
<td class="nump">$ 4,738,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">304,133<span></span>
</td>
<td class="nump">294,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">518,040<span></span>
</td>
<td class="nump">1,019,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposit</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,622,529<span></span>
</td>
<td class="nump">6,055,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">5,998,731<span></span>
</td>
<td class="nump">7,350,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,332,096<span></span>
</td>
<td class="nump">1,495,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,578,679<span></span>
</td>
<td class="nump">8,129,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">130,585<span></span>
</td>
<td class="nump">165,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent', window );">Supplies used for R&amp;D and manufacturing, Noncurrent</a></td>
<td class="nump">1,354,478<span></span>
</td>
<td class="nump">1,475,441<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,336,199<span></span>
</td>
<td class="nump">26,991,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,577,215<span></span>
</td>
<td class="nump">1,448,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">475,602<span></span>
</td>
<td class="nump">566,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DueToEmployeeCurrent', window );">Due to employees</a></td>
<td class="nump">1,169,520<span></span>
</td>
<td class="nump">363,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current portion</a></td>
<td class="nump">2,205,972<span></span>
</td>
<td class="nump">2,010,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">187,739<span></span>
</td>
<td class="nump">226,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,616,048<span></span>
</td>
<td class="nump">4,615,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">6,271,813<span></span>
</td>
<td class="nump">7,957,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,298,398<span></span>
</td>
<td class="nump">1,425,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,311,259<span></span>
</td>
<td class="nump">14,124,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 600,000,000 shares authorized; 5,321,341 and 2,126,237 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively</a></td>
<td class="nump">53,214<span></span>
</td>
<td class="nump">21,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">540,293,742<span></span>
</td>
<td class="nump">526,857,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(533,322,016)<span></span>
</td>
<td class="num">(514,011,861)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">7,024,940<span></span>
</td>
<td class="nump">12,867,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 20,336,199<span></span>
</td>
<td class="nump">$ 26,991,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DueToEmployeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DueToEmployeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,321,341<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,321,341<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,739,948<span></span>
</td>
<td class="nump">$ 4,703,160<span></span>
</td>
<td class="nump">$ 12,184,276<span></span>
</td>
<td class="nump">$ 13,684,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,748,935<span></span>
</td>
<td class="nump">1,967,075<span></span>
</td>
<td class="nump">6,592,128<span></span>
</td>
<td class="nump">6,547,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,488,883<span></span>
</td>
<td class="nump">6,670,235<span></span>
</td>
<td class="nump">18,776,404<span></span>
</td>
<td class="nump">20,232,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,488,883)<span></span>
</td>
<td class="num">(6,670,235)<span></span>
</td>
<td class="num">(18,776,404)<span></span>
</td>
<td class="num">(20,232,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(172,050)<span></span>
</td>
<td class="num">(190,705)<span></span>
</td>
<td class="num">(520,439)<span></span>
</td>
<td class="num">(571,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(3,771)<span></span>
</td>
<td class="nump">4,382<span></span>
</td>
<td class="num">(13,312)<span></span>
</td>
<td class="num">(7,801)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,664,704)<span></span>
</td>
<td class="num">(6,856,558)<span></span>
</td>
<td class="num">(19,310,155)<span></span>
</td>
<td class="num">(20,810,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(659,456)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(659,456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (5,664,704)<span></span>
</td>
<td class="num">$ (7,516,014)<span></span>
</td>
<td class="num">$ (19,310,155)<span></span>
</td>
<td class="num">$ (21,470,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (4.18)<span></span>
</td>
<td class="num">$ (6.34)<span></span>
</td>
<td class="num">$ (12.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">4,150,702<span></span>
</td>
<td class="nump">1,799,813<span></span>
</td>
<td class="nump">3,046,400<span></span>
</td>
<td class="nump">1,715,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,581,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">$ 13,214,890<span></span>
</td>
<td class="nump">$ 15,811<span></span>
</td>
<td class="nump">$ 500,290,475<span></span>
</td>
<td class="num">$ (487,091,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">48,901<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">202,277<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">4,979,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 16,677<span></span>
</td>
<td class="nump">506,434,503<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,581,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 15,811<span></span>
</td>
<td class="nump">500,290,475<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,810,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="nump">8,473,057<span></span>
</td>
<td class="nump">$ 18,089<span></span>
</td>
<td class="nump">516,357,337<span></span>
</td>
<td class="num">(507,902,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 16,677<span></span>
</td>
<td class="nump">506,434,503<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">53,485<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">53,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">380,870<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">380,816<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">7,750,000<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">7,748,708<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,244,891)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,244,891)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,803,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">14,304,643<span></span>
</td>
<td class="nump">$ 18,032<span></span>
</td>
<td class="nump">515,332,422<span></span>
</td>
<td class="num">(501,045,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">60,577<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">60,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">155,655<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">155,632<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">728,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">728,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,856,558)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,856,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsShares', window );">Purchase of stock by officers and directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount', window );">Purchase of stock by officers and directors, amount</a></td>
<td class="nump">80,620<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">80,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="nump">8,473,057<span></span>
</td>
<td class="nump">$ 18,089<span></span>
</td>
<td class="nump">516,357,337<span></span>
</td>
<td class="num">(507,902,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="nump">12,867,083<span></span>
</td>
<td class="nump">$ 21,266<span></span>
</td>
<td class="nump">526,857,678<span></span>
</td>
<td class="num">(514,011,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">57,134<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">57,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">396,087<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">396,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">5,000,300<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
<td class="nump">4,997,782<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">711,381<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">711,382<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(650,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(650,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,073,062)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,073,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Pre-funded warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Pre-funded warrant exercises, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity based compensation - employees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,436,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="nump">11,308,632<span></span>
</td>
<td class="nump">$ 24,366<span></span>
</td>
<td class="nump">532,369,189<span></span>
</td>
<td class="num">(521,084,923)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="nump">12,867,083<span></span>
</td>
<td class="nump">$ 21,266<span></span>
</td>
<td class="nump">526,857,678<span></span>
</td>
<td class="num">(514,011,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,310,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2025</a></td>
<td class="nump">7,024,940<span></span>
</td>
<td class="nump">$ 53,214<span></span>
</td>
<td class="nump">540,293,742<span></span>
</td>
<td class="num">(533,322,016)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,436,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="nump">11,308,632<span></span>
</td>
<td class="nump">$ 24,366<span></span>
</td>
<td class="nump">532,369,189<span></span>
</td>
<td class="num">(521,084,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">54,054<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">53,979<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">60,202<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">60,185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">2,558,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">685,668<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">685,668<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(449,197)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(449,197)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,572,389)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,572,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Pre-funded warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Pre-funded warrant exercises, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares', window );">Shares issued for settlement of clinical development costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount', window );">Shares issued for settlement of clinical development costs, amount</a></td>
<td class="nump">350,885<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">350,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,812,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2025</a></td>
<td class="nump">7,997,855<span></span>
</td>
<td class="nump">$ 28,122<span></span>
</td>
<td class="nump">535,627,045<span></span>
</td>
<td class="num">(527,657,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">53,323<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">53,093<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">127,158<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">127,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">73,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="num">(562,134)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(562,134)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,664,704)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,664,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Pre-funded warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Pre-funded warrant exercises, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,862<span></span>
</td>
<td class="num">(4,862)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2025</a></td>
<td class="nump">$ 7,024,940<span></span>
</td>
<td class="nump">$ 53,214<span></span>
</td>
<td class="nump">$ 540,293,742<span></span>
</td>
<td class="num">$ (533,322,016)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CostIncurredInIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CostIncurredInIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (19,310,155)<span></span>
</td>
<td class="num">$ (20,810,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,924,303<span></span>
</td>
<td class="nump">2,977,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash lease expense</a></td>
<td class="num">(2,970)<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">587,285<span></span>
</td>
<td class="nump">778,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,470,491<span></span>
</td>
<td class="nump">3,544,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">164,510<span></span>
</td>
<td class="nump">162,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts', window );">Shares issued for settlement of clinical development costs</a></td>
<td class="nump">350,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_GainLossOnPatentImpairment', window );">Loss on patent impairment</a></td>
<td class="nump">13,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(13,874)<span></span>
</td>
<td class="num">(15,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">622,831<span></span>
</td>
<td class="num">(304,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Increase (Decrease) in Deposits</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(46,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="num">(592,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(60,490)<span></span>
</td>
<td class="nump">167,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">806,214<span></span>
</td>
<td class="nump">139,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,449,214)<span></span>
</td>
<td class="num">(13,994,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(32,954)<span></span>
</td>
<td class="num">(75,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,211)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(32,954)<span></span>
</td>
<td class="num">(88,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">12,560,300<span></span>
</td>
<td class="nump">12,730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(1,531,832)<span></span>
</td>
<td class="num">(1,173,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the purchase of stock by officers and directors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of notes payable</a></td>
<td class="num">(350,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(1,491,617)<span></span>
</td>
<td class="num">(1,315,291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,536,851<span></span>
</td>
<td class="nump">10,321,752<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(2,945,317)<span></span>
</td>
<td class="num">(3,761,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">4,738,173<span></span>
</td>
<td class="nump">4,145,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">1,792,856<span></span>
</td>
<td class="nump">384,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfAssetsUnderFinanceLeases', window );">Assets purchased under finance leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ObligationServicesPaidWithIssuanceOfCommonStock', window );">Obligations paid with issuance of common stock</a></td>
<td class="nump">583,447<span></span>
</td>
<td class="nump">738,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NonCashFinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">168,740<span></span>
</td>
<td class="nump">91,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment purchases included in current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 592,644<span></span>
</td>
<td class="nump">$ 706,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossOnPatentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossOnPatentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NonCashFinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NonCashFinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ObligationServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ObligationServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfAssetsUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfAssetsUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479024/942-230-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arragements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of June 30, 2025 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 19, 2025, the Company&#8217;s shareholders approved a reverse split of the Company&#8217;s common stock which became effective on the NYSE American on May 20, 2025. On that date, every thirty issued and outstanding shares of the Company&#8217;s common stock automatically converted into one outstanding share. As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock decreased from 94,037,256 (pre-split) shares to 3,135,021 (post-split) shares. In addition, by reducing the number of the Company&#8217;s outstanding shares, the Company&#8217;s loss per share in all prior periods will increase by a factor of thirty. The reverse stock split affected all stockholders of the Company&#8217;s common stock uniformly and did not affect any stockholder&#8217;s percentage of ownership interest. The par value of the Company&#8217;s stock remained unchanged at $0.01 per share and the number of authorized shares of common stock remained the same after the reverse stock split.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As the par value per share of the Company&#8217;s common stock remained unchanged at $0.01 per share, a total of $909,021 was reclassified from common stock to additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company&#8217;s incentive and non-qualified stock option plans, as well as the shares of common stock underlying outstanding stock options and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities and are expensed as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and have been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at June 30, 2025 and September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2025 and September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at $1,000 and $3,480,000 as of June 30, 2025 and September 30, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07,&#160;<em>Segment Reporting</em>&#160;(Topic 280):&#160;<em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em>&#160;which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. &#160;The Company is currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In May 2025, the Company sold 2,000,000 shares of common stock at a public offering price of $2.50 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2025, the Company sold 133,750 shares of common stock at an offering price of $4.80 per share and pre-funded warrants to purchase up to 399,584 shares of common stock, at an offering price of $4.797 per pre-funded warrant, for proceeds of approximately $2.1 million, net of issuance costs of approximately $0.5 million. As of June 30, 2025, all of the pre-funded warrants in connection with the March 2025 offering have been exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2024, the Company sold 251,750 shares of common stock at an offering price of $9.30 per share and pre-funded warrants to purchase up to 285,917 shares of common stock, at an offering price of $9.297 per pre-funded warrant, for proceeds of approximately $4.4 million, net of issuance costs of approximately $0.6 million. As of June 30, 2025, 285,917 of the pre-funded warrants in connection with the December 2024 offering have been exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the March 2025 and December 2024 offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the financings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold 129,167 shares of common stock at a public offering price of $60.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 83,000 shares of common stock at a public offering price of $60.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#8220;Ergomed&#8221;) pursuant to which the Company issued 33,334 shares of common stock in exchange for services. The shares are legally issued and outstanding. The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares were not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $61,000 to issue the shares from this agreement which were immediately expensed. During the nine months ended June 30, 2025, 33,334 shares were sold by Ergomed and the proceeds used to settle $350,885 in outstanding payables for services provided to the Company. As of June 30, 2025, Ergomed held did not hold any shares of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of June 30, 2025 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">709,573</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,460</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,134</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Option Activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,136</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,584</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,957</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,767</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">906</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">903</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,017</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,484</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">905</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of 7,811 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date.&#160; This resulted in remaining compensation cost of approximately $260,000 that will be amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,470,491</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587,285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,442</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,525</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at June 30, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:12%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2,845</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">90.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,120</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">84.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">277.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">360.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,115</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">55.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">75.60</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">7,801</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">49.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 11/19/2024 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">20,333</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$21.00 - $65.40</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 - 11/1/2034</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, 399,583 and 285,917 pre-funded warrants at an offering price of $4.80 and $9.30, respectively, were issued. No pre-funded warrants or warrants recorded as equity were issued during the nine months ended June 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, 733,834 pre-funded warrants were exercised. No pre-funded warrants or warrants recorded as equity were exercised during the nine months ended June 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the nine months ended June 30, 2025 and 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025 and 2024, the Company issued 6,821 and 10,726 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $26.13 and $55.29 during the nine months ended June 30, 2025 and 2024, respectively. During the three months ended June 30, 2025 and 2024, the Company issued 0 and 2,348 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $39.86 during the three months ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, 16,667 options with an exercise price of $21.00 were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the nine months ended June 30, 2024.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $587,000 and $601,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $81,000 and $231,000, respectively, relating to the share-based compensation under various consulting agreements. On June 30, 2025 and September 30, 2024, consulting fees of approximately $48,000 and $52,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no related party transactions during the nine months ended June 30, 2025. During the nine months ended June 30, 2024, certain officers and directors purchased 1,933 shares of restricted common stock at an aggregate fair market value of approximately $80,620.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageNotesPayableDisclosureTextBlock', window );">Mortgage Notes Payable Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">NOTES PAYABLE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of May 8, 2025, the Company entered into a promissory note agreement for a principal amount of $350,000 (the &#8220;Note Payable&#8221;). The Note Payable bears interest at a fixed rate of 10% per annum. As of June 30, 2025, the Note Payable was repaid in full.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for mortgage notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">F. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"><em>Clinical Research Agreements</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.7 million as of June 30, 2025. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $6.0 million and $7.4 million and the balance of the finance lease liability is approximately $8.5 million and $10.0 million, of which approximately $2.2 million and $2.0 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the nine months ended June 30, 2025 and 2024, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.4 million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the nine months ended June 30, 2025 and 2024, was approximately $2.1 million and $2.0 million, respectively, of which approximately $0.6 million and $0.7 million was for interest, respectively. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of June 30, 2025, the weighted average discount rate of the Company&#8217;s finance leases is 8.46% and the weighted average remaining lease term is 3.34 years. During the nine months ended June 30, 2025 and 2024, total finance lease costs were approximately $1.9 million and $2.1 million, respectively, consisting of approximately $1.4 million of lease asset amortization for both periods and approximately $0.6 million and $0.7 million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the nine months ended June 30, 2025, there were approximately $0.7 million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of June 30, 2025 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,731,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,253,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,206,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,272,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $1.3 million and $1.5 million and the balance of the operating lease liability is approximately $1.5 million and $1.7 million, of which approximately $0.2 million is current in both periods. During the nine months ended June 30, 2025 and 2024, the Company incurred lease expense under operating leases of approximately $0.1 million in both periods, respectively, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the nine months ended June 30, 2025 and 2024 was approximately $0.3 million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is 8.95% and the weighted average the remaining lease term is 6.49 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of June 30, 2025, approximate future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">443,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,982,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(496,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(188,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,298,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine months ended June 30, 2025, the Company abandoned four patents which resulted in an impairment of $13,312 on patent costs. During the three months ended June 30, 2025, the Company abandoned one patent which resulted in an impairment of $3,770 on patent costs. During the nine and three months ended June 30, 2024, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;7&#160;years. For the nine months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $22,000 and $25,000, respectively. For the three months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $7,000 for both periods. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">131,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,310,155</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,664,704</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,046,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,715,982</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,150,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,799,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6.34</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(12.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1.36</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,312</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,249</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,809</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,909</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">588,121</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">588,158</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">I. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 4, 2025, the One&#160;Big Beautiful Bill&#160;Act (&#8220;OBBBA&#8221;) was enacted in the United States. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC 740, <em>Income Taxes</em>, requires the effects of changes in tax rates and laws on deferred tax balances to be recognized in the period in which the legislation is enacted. Consequently, as of the date of enactment, we will evaluate all deferred tax balances under the newly enacted tax law and identify any other changes required to our financial statements as a result of the OBBBA. The Company is currently evaluating the impact of the OBBBA on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 14, 2025, the Company sold 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules, for gross proceeds of approximately $5.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 25, 2025, the CEO and a director purchased 32,116 shares of restricted common stock at an aggregate fair market value of approximately $219,995.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities and are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and have been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at June 30, 2025 and September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2025 and September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Fair Value Measurements -</em> In accordance with the provisions of ASC 820, <em>Fair Value Measurements</em>, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#8217;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#8217;s money market funds approximated their fair value at $1,000 and $3,480,000 as of June 30, 2025 and September 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07,&#160;<em>Segment Reporting</em>&#160;(Topic 280):&#160;<em>Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;),</em>&#160;which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. &#160;The Company is currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ImpairmentOfLongLivedAssetsPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of equity compensation plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,613</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">709,573</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,460</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,134</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,136</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,584</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,957</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,767</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">906</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">903</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,017</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,484</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">905</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,470,491</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,544,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587,285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600,841</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,442</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">728,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,525</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">230,678</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock', window );">Schedule of warrants and non-employee options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:12%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2,845</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">90.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,120</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">84.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">277.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">867</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">360.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">11,115</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">55.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,670</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">75.60</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">7,801</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">49.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 11/19/2024 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">20,333</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$21.00 - $65.40</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 - 11/1/2034</p></td><td>&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfCompensatingBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,731,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,253,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,478,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,206,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,272,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">443,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,982,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(496,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,486,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(188,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,298,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three months ending September 30, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2030</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">131,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,310,155</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21,470,429</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,664,704</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,516,014</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,046,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,715,982</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,150,702</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,799,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6.34</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(12.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1.36</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,312</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">583,249</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,809</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,909</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">588,121</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">588,158</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets', window );">Concentration Risk, Credit Risk, Financial Instruments</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedOtherAtFairValue', window );">Fair Value of Financial Instruments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued', window );">Reclassification from common stock to APIC</a></td>
<td class="nump">$ 909,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,321,341<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_BottomMember', window );">Bottom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,135,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_TopMember', window );">Top [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">94,037,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative asset subject to concentration of credit or market risk or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedOtherAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of firm holdings in securities classified as other. Includes pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedOtherAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">21,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">709,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">59,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">21,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">4,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">65,484<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">65,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">11,033<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
<td class="nump">9,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 73,442<span></span>
</td>
<td class="nump">$ 728,120<span></span>
</td>
<td class="nump">$ 1,470,491<span></span>
</td>
<td class="nump">$ 3,544,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 80,525<span></span>
</td>
<td class="nump">$ 230,678<span></span>
</td>
<td class="nump">$ 587,285<span></span>
</td>
<td class="nump">$ 600,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember', window );">Consultants Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">20,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_BottomMember', window );">Bottom [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 21.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_TopMember', window );">Top [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">11/19/2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 65.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">11/1/2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">2,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 90.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 84.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/30/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 277.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/13/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 360.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/15/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">11,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 55.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">6,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 75.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">7,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 49.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Apr. 19, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,491<span></span>
</td>
<td class="nump">$ 3,544,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuanceCost', window );">Stock issuance cost</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Common Stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">133,750<span></span>
</td>
<td class="nump">251,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,167<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,560,300<span></span>
</td>
<td class="nump">$ 12,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockWarrantsExercised', window );">Number of pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CompensationCost', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember', window );">Changes in Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted', window );">Number of pre-funded warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised', window );">Number of pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsOneMember', window );">Changes in Equity Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20', window );">Number of pre-funded warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.13<span></span>
</td>
<td class="nump">$ 55.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,821<span></span>
</td>
<td class="nump">10,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">$ 231,000<span></span>
</td>
<td class="nump">$ 587,000<span></span>
</td>
<td class="nump">$ 601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember', window );">Consulting Agreements Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuanceCost', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember', window );">Pre-Funded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">399,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=cvm_ChangesInEquityWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_PreFundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 04, 2024</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 12,560,300<span></span>
</td>
<td class="nump">$ 12,730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DescriptionOfModificationOfWarrants', window );">Description of modification of warrants</a></td>
<td class="text">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember', window );">Officer and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RestrictedCommonStockSharesIssued', window );">Issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DescriptionOfModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DescriptionOfModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RestrictedCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RestrictedCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative ) - USD ($)<br></strong></div></th>
<th class="th"><div>May 08, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory note</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2025</a></td>
<td class="nump">$ 688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">2,838,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,929,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">3,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">9,731,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on finance lease obligations</a></td>
<td class="num">(1,253,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of financing lease obligations</a></td>
<td class="nump">8,478,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Less net present value of financing lease obligations - current portion</a></td>
<td class="num">(2,206,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of financing lease obligations - non-current portion</a></td>
<td class="nump">$ 6,272,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2025</a></td>
<td class="nump">$ 93,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">443,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">1,982,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(496,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net Present Value Of Operating Lease Obligation</a></td>
<td class="nump">1,486,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="num">(188,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 1,298,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jan. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset</a></td>
<td class="nump">$ 5,998,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,350,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">8,478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability current</a></td>
<td class="nump">2,205,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,332,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability current</a></td>
<td class="nump">$ 187,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AnnualIncreaseToInterestPayments', window );">Annual increase to interest payments</a></td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AnnualIncreaseToInterestPaymentsOperating', window );">Annual increase to interest payments operating</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm', window );">Weighted average time of maturity of operating leases</a></td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability current</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability current</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease Costs</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of Finance Lease Assets</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest Expense on Lease Liabilities</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeaseExpenseUnderOperatingLeases', window );">Incurred lease expense under operating leases</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Interest payment to lease liability</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeasePrincipalPayment', window );">Cash paid related to finance leases</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne', window );">Weighted average time of maturity of finance leases</a></td>
<td class="text">3 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease Costs</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AnnualIncreaseToInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AnnualIncreaseToInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AnnualIncreaseToInterestPaymentsOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AnnualIncreaseToInterestPaymentsOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeasePrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeasePrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseExpenseUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseExpenseUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Three months ending September 30, 2025</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 131,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment patent costs</a></td>
<td class="nump">$ 3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (5,664,704)<span></span>
</td>
<td class="num">$ (7,516,014)<span></span>
</td>
<td class="num">$ (19,310,155)<span></span>
</td>
<td class="num">$ (21,470,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per share- basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">4,150,702<span></span>
</td>
<td class="nump">1,799,813<span></span>
</td>
<td class="nump">3,046,400<span></span>
</td>
<td class="nump">1,715,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (4.18)<span></span>
</td>
<td class="num">$ (6.34)<span></span>
</td>
<td class="num">$ (12.51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">588,121<span></span>
</td>
<td class="nump">588,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">583,312<span></span>
</td>
<td class="nump">583,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">4,809<span></span>
</td>
<td class="nump">4,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2025</div></th>
<th class="th"><div>Jul. 25, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">133,750<span></span>
</td>
<td class="nump">251,750<span></span>
</td>
<td class="nump">129,167<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 2,560,000<span></span>
</td>
<td class="nump">$ 5,000,300<span></span>
</td>
<td class="nump">$ 7,750,000<span></span>
</td>
<td class="nump">$ 4,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,560,300<span></span>
</td>
<td class="nump">$ 12,730,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Public offering price</a></td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RestrictedCommonStockSharesIssued', window );">Issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RestrictedCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RestrictedCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>110200 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995448 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995449 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995450 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cvm.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995451 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995452 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995453 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995454 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995458 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995459 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995461 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995467 - Disclosure - NOTES PAYABLE (Details Narrative )</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cvm.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NotesPayable</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995471 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995472 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995473 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20250630.xsd</File>
    <File>cvm-20250630_cal.xml</File>
    <File>cvm-20250630_def.xml</File>
    <File>cvm-20250630_lab.xml</File>
    <File>cvm-20250630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cvm_10q.htm">cvm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10qimg1.jpg</File>
    <File>cvm_10qimg2.jpg</File>
    <File>cvm_10qimg3.jpg</File>
    <File>cvm_10qimg4.jpg</File>
    <File>cvm_10qimg5.jpg</File>
    <File>cvm_10qimg6.jpg</File>
    <File>cvm_10qimg7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="505">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10q.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "cvm-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    }
   },
   "keyStandard": 188,
   "keyCustom": 55,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 26,
   "hidden": {
    "total": 23,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://cvm.com/20250630": 2,
    "http://fasb.org/us-gaap/2025": 12
   },
   "contextCount": 134,
   "entityCount": 1,
   "segmentCount": 33,
   "elementCount": 327,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 505,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "longName": "110200 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "cvm:SuppliesUsedForRDAndManufacturingCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "110201 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "124100 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
     "longName": "148600 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "170000 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995446 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "995447 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "995448 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "995449 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/NotesPayable",
     "longName": "995450 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "995451 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "995452 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/LossPerCommonShare",
     "longName": "995453 - Disclosure - LOSS PER COMMON SHARE",
     "shortName": "LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "995454 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995455 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "longName": "995456 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "995457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "995458 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "longName": "995459 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995460 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "longName": "995461 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "longName": "995462 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "longName": "995463 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "longName": "995464 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "995465 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2025-05-31",
      "name": "cvm:StockIssuanceCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995466 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2025-05-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-01to2024-05-04",
      "name": "cvm:DescriptionOfModificationOfWarrants",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/NotesPayableDetailsNarrative",
     "longName": "995467 - Disclosure - NOTES PAYABLE (Details Narrative )",
     "shortName": "NOTES PAYABLE (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "us-gaap:MortgageNotesPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "us-gaap:MortgageNotesPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "995468 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "995469 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995470 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_us-gaap_LeaseAgreementsMember",
      "name": "cvm:AnnualIncreaseToInterestPayments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "995471 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "995472 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "longName": "995473 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-01to2025-06-30",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "longName": "995474 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "995475 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2025-05-31",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r477"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r477",
      "r585"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r515",
      "r516",
      "r517",
      "r518",
      "r575",
      "r587"
     ]
    },
    "cvm_AdjustmentsToAdditionalPaidInCapitalStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssued",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from common stock to APIC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r80",
      "r146",
      "r152",
      "r427",
      "r429",
      "r430",
      "r432",
      "r434"
     ]
    },
    "cvm_AnnualIncreaseToInterestPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "AnnualIncreaseToInterestPayments",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual increase to interest payments"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AnnualIncreaseToInterestPaymentsOperating": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "AnnualIncreaseToInterestPaymentsOperating",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual increase to interest payments operating"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment patent costs",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17",
      "r478",
      "r479"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r54",
      "r67",
      "r87",
      "r88",
      "r89",
      "r126",
      "r132",
      "r133",
      "r134",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r256",
      "r260",
      "r287",
      "r326",
      "r327",
      "r330",
      "r379",
      "r442",
      "r443",
      "r444",
      "r477",
      "r480",
      "r481",
      "r492",
      "r541",
      "r542",
      "r579"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70",
      "r87",
      "r88",
      "r89",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r256",
      "r260",
      "r287",
      "r477",
      "r541",
      "r542",
      "r579"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "cvm_BottomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "BottomMember",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom [Member]",
        "verboseLabel": "Bottom [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r41",
      "r86"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation]",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41"
     ]
    },
    "cvm_ChangesInEquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ChangesInEquityWarrantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Equity Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ChangesInEquityWarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ChangesInEquityWarrantsOneMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Equity Warrants One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price",
        "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r90",
      "r194"
     ]
    },
    "cvm_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r159",
      "r160",
      "r424",
      "r539",
      "r540"
     ]
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r515",
      "r516",
      "r518",
      "r575",
      "r584",
      "r587"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r367"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r367",
      "r385",
      "r587",
      "r588"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value; 600,000,000 shares authorized; 5,321,341 and 2,126,237 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r173",
      "r179",
      "r333",
      "r477"
     ]
    },
    "cvm_CompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "CompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286"
     ]
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ConsultantsOptionMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ConsultingAgreementsOtherMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CostIncurredInIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "CostIncurredInIssuanceOfStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18",
      "r79",
      "r429",
      "r430",
      "r432",
      "r434"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18"
     ]
    },
    "cvm_DescriptionOfModificationOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "DescriptionOfModificationOfWarrants",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DueToEmployeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "DueToEmployeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted",
        "verboseLabel": "Basic and diluted loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r77",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r113",
      "r117",
      "r119",
      "r120",
      "r125",
      "r171",
      "r229",
      "r251",
      "r254",
      "r281",
      "r282",
      "r325",
      "r342",
      "r438"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r122"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121",
      "r123",
      "r124"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60",
      "r61",
      "r62",
      "r74",
      "r75",
      "r76",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r127",
      "r137",
      "r138",
      "r158",
      "r170",
      "r195",
      "r229",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r307",
      "r341",
      "r343",
      "r344",
      "r345",
      "r357",
      "r406"
     ]
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ExpirationDate",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instruments",
        "documentation": "Fair value of derivative asset subject to concentration of credit or market risk or both."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r501",
      "r502",
      "r503"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense on Lease Liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r303",
      "r476"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payment to lease liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r304"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations",
        "verboseLabel": "Finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r305"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities, current portion",
        "verboseLabel": "Finance lease liability current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less net present value of financing lease obligations - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three months ending September 30, 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest on finance lease obligations",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "cvm_FinanceLeasePrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "FinanceLeasePrincipalPayment",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Costs",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r304"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right-of-use assets",
        "verboseLabel": "Finance lease right-of-use asset",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Finance Lease Assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r303",
      "r476"
     ]
    },
    "cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTermOne",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsOwnedOtherAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsOwnedOtherAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Fair value of firm holdings in securities classified as other. Includes pledged and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r426",
      "r427"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2025",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r426",
      "r427"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r426",
      "r427"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r426",
      "r427"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r426",
      "r427"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets By Major Class Axis",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r322",
      "r323",
      "r348",
      "r426",
      "r427",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r348",
      "r426",
      "r427",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r534"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_GainLossOnPatentImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "GainLossOnPatentImpairment",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on patent impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r388"
     ]
    },
    "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "IncentiveStockBonusPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive Stock Bonus Plan [Member]",
        "label": "[Incentive Stock Bonus Plan [Member]]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "IncentiveStockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r350"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeposits",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deposits",
        "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "IncreaseDecreaseInSuppliesUsedForRDAndManufacturing",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Supplies used for R&amp;D and manufacturing]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arragements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r156",
      "r157",
      "r425",
      "r426"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r322",
      "r436",
      "r528"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r433",
      "r521"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r85"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;amp;D and manufacturing",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r66",
      "r68",
      "r139",
      "r140",
      "r141",
      "r317",
      "r437"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://cvm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r484",
      "r525",
      "r526"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IssueDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "IssueDate1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538"
     ]
    },
    "cvm_LeaseExpenseUnderOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "LeaseExpenseUnderOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred lease expense under operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r511",
      "r514",
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r87",
      "r88",
      "r89",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r257",
      "r260",
      "r261",
      "r287",
      "r366",
      "r440",
      "r444",
      "r492",
      "r541",
      "r579",
      "r580"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r50",
      "r335",
      "r477",
      "r480",
      "r481",
      "r510",
      "r513",
      "r527",
      "r576"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r65",
      "r87",
      "r88",
      "r89",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r257",
      "r260",
      "r261",
      "r287",
      "r477",
      "r541",
      "r579",
      "r580"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MortgageNotesPayableDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MortgageNotesPayableDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mortgage Notes Payable Disclosure [Text Block]",
        "documentation": "The entire disclosure for mortgage notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Cash Provided by (Used in) Financing Activity, Including Discontinued Operation]",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Cash Provided by (Used in) Investing Activity, Including Discontinued Operation]",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Cash Provided by (Used in) Operating Activity, Including Discontinued Operation]",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r43",
      "r51",
      "r62",
      "r63",
      "r71",
      "r72",
      "r76",
      "r87",
      "r88",
      "r89",
      "r92",
      "r96",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r114",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r174",
      "r176",
      "r180",
      "r229",
      "r251",
      "r254",
      "r282",
      "r287",
      "r340",
      "r386",
      "r404",
      "r405",
      "r431",
      "r433",
      "r435",
      "r490",
      "r541"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r78",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r111",
      "r116",
      "r120",
      "r174",
      "r176",
      "r180",
      "r254"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashFinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "NonCashFinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonCashFinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "NonCashFinancingCostsIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:",
        "verboseLabel": "Non Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ObligationServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ObligationServicesPaidWithIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligations paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OfficerAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "OfficerAndDirectorMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r431",
      "r435",
      "r441",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Present Value Of Operating Lease Obligation",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current portion",
        "verboseLabel": "Operating lease liability current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvm_OperatingLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "OperatingLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "cvm_OperatingLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "OperatingLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for oprating lease",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r304"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "cvm_OperatingLeaseWeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Other Indefinite-Lived Intangible Assets]",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r536"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash lease expense",
        "label": "[Other Noncash Income (Expense)]",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r474"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ]
    },
    "cvm_PreFundedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "PreFundedMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r182"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r367"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r182"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r367",
      "r385",
      "r587",
      "r588"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r173",
      "r178",
      "r332",
      "r477"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "verboseLabel": "Consulting fees inclued prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r142",
      "r143",
      "r428"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and pre-funded warrants",
        "verboseLabel": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from issuance of restricted common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory note",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the purchase of stock by officers and directors",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r71",
      "r72",
      "r82",
      "r87",
      "r88",
      "r89",
      "r92",
      "r96",
      "r104",
      "r107",
      "r108",
      "r136",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r229",
      "r251",
      "r254",
      "r255",
      "r258",
      "r259",
      "r282",
      "r287",
      "r326",
      "r328",
      "r339",
      "r356",
      "r386",
      "r404",
      "r405",
      "r472",
      "r473",
      "r491",
      "r507",
      "r541"
     ]
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment purchases included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r306",
      "r329",
      "r338",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r58",
      "r59",
      "r337"
     ]
    },
    "cvm_PurchaseOfAssetsUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "PurchaseOfAssetsUnderFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchased under finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "PurchaseOfStockByOfficersAndDirectorsAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "PurchaseOfStockByOfficersAndDirectorsShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r91",
      "r92",
      "r135",
      "r196",
      "r197",
      "r311",
      "r312",
      "r331",
      "r336",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r384",
      "r413",
      "r586"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r91",
      "r92",
      "r135",
      "r196",
      "r197",
      "r311",
      "r312",
      "r331",
      "r336",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r384",
      "r413",
      "r578",
      "r586"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r353",
      "r354",
      "r355",
      "r389",
      "r390",
      "r391",
      "r410",
      "r412"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of notes payable",
        "label": "[Repayments of Notes Payable]",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r426",
      "r431",
      "r432",
      "r442",
      "r581"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "cvm_RestrictedCommonStockSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "RestrictedCommonStockSharesIssued",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock",
        "verboseLabel": "Issuance of restricted common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r47",
      "r334",
      "r346",
      "r347",
      "r352",
      "r368",
      "r477"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r137",
      "r138",
      "r158",
      "r170",
      "r229",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r269",
      "r271",
      "r272",
      "r274",
      "r280",
      "r295",
      "r296",
      "r343",
      "r345",
      "r357",
      "r587"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Common Stock",
        "verboseLabel": "Sale of common stock at a public offering price",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfCompensatingBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ScheduleOfCompensatingBalancesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity compensation plans",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r48"
     ]
    },
    "cvm_ScheduleOfStockOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ScheduleOfStockOptionActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r535"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "verboseLabel": "Total share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Options/shares Under Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "cvm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining Options/shares Under Plans",
        "label": "[Remaining Options/shares Under Plans]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Exercised",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r202",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "cvm_ShareBasedPaymentArrangementNumberOfInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ShareBasedPaymentArrangementNumberOfInstrumentsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of pre-funded warrants exercised",
        "label": "[Number of pre-funded warrants exercised]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ShareBasedPaymentArrangementNumberOfInstrumentsGranted",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of pre-funded warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ShareBasedPaymentArrangementNumberOfInstrumentsGranted20": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "ShareBasedPaymentArrangementNumberOfInstrumentsGranted20",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of pre-funded warrants issued",
        "label": "[Number of pre-funded warrants issued]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Upon Exercise Of Warrant/options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cvm_SharesIssuedForSettlementOfClinicalDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SharesIssuedForSettlementOfClinicalDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical development costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical development costs, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SharesIssuedForSettlementOfClinicalDevelopmentCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SharesIssuedForSettlementOfClinicalDevelopmentCostsShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for settlement of clinical development costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r33",
      "r34",
      "r60",
      "r61",
      "r62",
      "r74",
      "r75",
      "r76",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r108",
      "r127",
      "r137",
      "r138",
      "r158",
      "r170",
      "r195",
      "r229",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r307",
      "r341",
      "r343",
      "r344",
      "r345",
      "r357",
      "r406"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r127",
      "r172",
      "r173",
      "r175",
      "r177",
      "r296",
      "r321",
      "r349",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r433",
      "r435",
      "r485",
      "r586"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r127",
      "r135",
      "r172",
      "r173",
      "r175",
      "r177",
      "r296",
      "r321",
      "r349",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r406",
      "r433",
      "r435",
      "r485",
      "r586"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plan [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "cvm_StockIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "StockIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "verboseLabel": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r30",
      "r47",
      "r351",
      "r406",
      "r422"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r30",
      "r47"
     ]
    },
    "cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount",
        "verboseLabel": "Proceeds from newly issued shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r30",
      "r47",
      "r357",
      "r406",
      "r422",
      "r491"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r29",
      "r30",
      "r47"
     ]
    },
    "cvm_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "cvm_StockWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "StockWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of pre-funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r33",
      "r34",
      "r44",
      "r369",
      "r385",
      "r407",
      "r408",
      "r477",
      "r492",
      "r510",
      "r512",
      "r513",
      "r527",
      "r576",
      "r587"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r268",
      "r279",
      "r409",
      "r411",
      "r423"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Member",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r315"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type Axis",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r315"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r315"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r316"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Sale Of Stock Axis",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SuppliesUsedForRDAndManufacturingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "SuppliesUsedForRDAndManufacturingNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TopMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "TopMember",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top [Member]",
        "verboseLabel": "Top [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity By Type Axis",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r475",
      "r574"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r475",
      "r574"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted",
        "documentation": "Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118"
     ]
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r128",
      "r129",
      "r130",
      "r131",
      "r326",
      "r328",
      "r439"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted",
        "verboseLabel": "Weighted average shares outstanding - basic and diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r120"
     ]
    },
    "cvm_hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20250630",
     "localname": "hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options granted"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001654954-25-009568-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-009568-xbrl.zip
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M\6:#N0QM8/&%F%>LLH@<5NDB B4(W20(O<G=W7#AA;QBZ8586"RP@W&SND9
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MZF*YWA4MWT>9GL/XD,CXS1J2(6.ND,>_9"3024543]6F+C77L!?PY;S93Y8
M#*+BB*:/*3(A*F$RSQ:"5XTE4VVU?DSR_R7:Z1NQ,ZBD7<A23U"EY&($(JLO
MW=Y4=NUA(BN#*3=X0M3$3$2*O@<]BO6D(.>(_)MAN^@H98LY:PJY9TJI"ZQ\
M<\2Y1S%9]F"_+RX%ZZ,=LIVM*!2^*C&KG]/ :>&O+GA\QC^G@7H.!O]T1(Q@
M<<SN72%I'6*'&T30$O,IB'E8O:JP'!DYU6X*/&,(U-4*GPQ,Q"'9A'AGR</-
MUL!T$PDC"REJJ1.$513!FMQ'WO^'1!GH!\H>QUK/:2TV+^)"-$R$'".ASN3!
MQBO9)2AJNY8(/?W/@ ZW>7B6.)J[GL8XQ&DZ8XBS>V(A&E4N(UXMH*SEN#_@
M,T=T!U$HH(*M+YBO#]N+B.,.%*[.5DOM_0$+ Q*$$N^+,=<6KXQ5LL5S&ZGG
MX(_-99'($2O280[[N8$1-AZPC3D^S(5C&.MI@JEWSK<'[RV^7I +<S#32YGB
M.0W4TR0C#'I8XD..\ V*!7KB-W9D/BAH*D?RWEWNUSQHX]DZ2(<LOU_=IX7/
MJ3RYU(<0:K(<.60UPCMD>:O-0=J'J"J5.$ZNG_CY!LNU@Z3(9"O8=9/C77#M
M10JK:BPUTA#\_Q819HA5PK^ZFZE4+,53(QV#O ;X/E@1@CV>AQ&;N%S^Q SH
MHM+[Z'9J9(L9,AU8"VWL9Z,7:R0/K V9Z"-6'Q%G@^7Q+).UXH-\4V8#;;%'
MGB(JMX]B#+C>RR3*\?*7]%DC&^N$8RDZ>+DY,F&;Q;%Z5I7D.KF>NO4?EWD?
M-BP<W;+D"TR&+4)+B!^,+>:&'4DU!HI69ZMGV"%'HOS9J(,;!%<O/(-WB_/-
M_D "VTI1I#\:U((A_X H+! R^Z+O#"S5@TWY)^%5KBYCZ9GOU8-R^&2>D[U,
M[E(B*WY7JQO&!=&28_.J7*0Q7BZ=)F2XWX)_][/@H=_W'7TZBU:"XY1F#\2:
M4FR&^9%D854!A4O9^G[Y^0)NL8>L& H'"1.E)QT?Q\Y)?PC("0C[+._()5#Q
MI1NMQ\&4\,]BIYTZ=XI4U#(%DS;V 8K MPYA&E#Y@TV>^9%U<9YVW)7Y3W^F
M5%GNYVG]-],Y?9AZ//_I9VGQ$?%11][?<7F(.L>H7\DHKZ5;F2&Q!)E<NOD@
MV1H]@PL4*D-82PW[B)D4;[W=7?&[4.5(3[K41P]+@D3HWD^,3AWJ=>MI4XZT
MEJ^L98H^=KQ7NLHIFD5=2UW]WS0CJS*8EB7^.VF:BVL%^EKJJQ/B&G9P[+UP
MAA!;@+OD_J(<NIT2=$<N<:9XI^ [:Q&B5%:=*,,)]8J/KB](_%8ULO0=$K]X
M-4,; Y.@<H'H)GM0EF$[<KT(2E_D& ?VJ^(7W>1Y>UR#<!26H*MGTBOJ_J>P
MQIIX*U)W^^B+-@J:^BNF'&@3@K*4+<EWXC%Z*SXU1?+@#;P%;%4P".,=P842
MZQOA[?\K^XMG*H[F/O7,#'[_2P=N*K]9\Z=B1D5"5L.O.4T46G!_4%*7<J2U
MT"Y\30T>Q#F'?.G<(2X3KUJR.R0VSJWHFW"%=$<?AEB.&+//4P)BI%^#7QZ/
M'/IF:U**^*3J**"H*0+!(6R6P5-UI[4O=(/8.&77>'$-1+R_SY;Q4%X#(;]F
MR_BU1B)^RQ;Q6XU$O+O+EO%07@,AQWESIDZ39C;+%O)0?E(AIQ3=NK#AL))2
MIBI.*N:-P[FS2<H8+SVI@/X;M2)+F90RH^JDHBZ<;5+$2%%=K.B%006VC!.<
M5.Q#>EX&0ZD1D%=?!UN+[=F*(N]GQG/,G4E3.^$G?(UH&0UBA"=58T!7SB;M
M>Q/%I[7T6AQ>LB'Q[L8/CF)2=BXF.ZD*_HXJ*7*B^*0BWI,=^ AD)3Q%4F0%
MV4E5R-F2E]RYUT*%G$$\(:CD<(]0GG;$>]_J1S[53PW^7(J_4O /'>]ZF)_^
M!U!+ P04    " #Q2PY;:^M<]=T-  "FFP  %    &-V;2TR,#(U,#8S,%]C
M86PN>&ULS5U;<^(X%G[?JOT/VNS#]%0M 9+T)5W3,^6 T^U: @PF,]-/4XX1
M037&9BR;A/WU*QE#C&U=C!%R5W5W CKR=\ZG<W1T]4^_O"X]L(8A1H'_Y:)[
MV;D T'>#&?*?OUS$N.5@%Z$+@"/'GSE>X,,O%QN(+W[Y^9__^.E?K=8?=Y,!
MZ =NO(1^!'HA="(X R\H6@#ZU8.#(QBV6FGIW[;/^0RN+J\O.Y_VG]\YF$@%
M?B)#ONSNO^F3^D P!RZM.1'M?&IW;]I7G:OW^T)V,(]>G! ")W07*()N%(>.
M!V80HV<?$.!@J]!G8/S@@O[""9?.*H1+QZ=* 6,=7>[KZ@6K38B>%Q%XY_X(
MZ&. U1J:4W 78^1#C($=>#&%@O\#+-^]!(;G@0F5P& ",0S7<)96YR'_K\_T
MGR>B'R"&]O'G5XR^7"RB:/6YW7YY>;E\N;X,PF>B3Z?;_N-A8+L+@JN%?&IP
M%U[LI&@M97+=V]O;=O+MKFBAY.M3Z.V><=W>P2'%,?J,D\<- C<QKH088):@
MO[5VQ5KTHU;WJG7=O7S%LPMB#0"V]@@##T[@'-#_'R?6_IGN>GGI!LLV_;S=
M"TB3)! 3B44(YU\NR/<M2D?GPW6'UOGO@S+19D5:)D;+E4=4:U=_GC^#/FF$
M=XY'[6XO((RP$ !/2 FB,6GE?K2 $7(=[RAXI36<"JL=$7>ED0"/YJ,5#)-6
MA1]])YX1MYS) I:LIB;J[%/L*'#_6@3>C 0H\^\811M9T!5K46'IGH,7]U[P
M4L_0[%IJ8B;!'9'ZQR$)CGZ4<&GX,SM>+IUP0XQ&8C2:D];H1X;K!K$?D4@]
M#CSD(BCRP%-475.[@?7KH]6WIM\%4 OE:K?>?%L3-E260$TD$^C13I\$EF@S
M#1T?.V[BKP(\(K&:J(9!!$FPVSA/5)R+I*QH;3]=+E&4>!9ID,3?:,LC>96X
M24M(UL0V-J;F<&H+<.1*U?62 .,Q#*ER@6^3!$S$"5N@KM_$3QC^'1/[FFMJ
M9)'7,(K71B$3HB2CX'&5G3S^3*G_"+$*Q-3YG10\:?FZ/DA"'WF&%*;2LB?W
M1RDH(C&-F4(?1@[R\- ):;JX%L47%8\ZN4>E#ZKL4CDY5;BZQP+KJD9V=2RR
M*]7(KH]%=JT:F:SGR%>@**^LB+=J-2?,.RLBE1%5US_*!1OY"I0C%86?"C4H
MQRK;!(ZHZ329B!S[Y85/BD#64@*ID^='<@82RJG")7(&L>")QU55>Q5)<39*
MU_'<V$LRN0'Y_: \?"6-9?8VHT412TP\1RBBY3K;/UW0>EOIR/Q(UQ=,XJC1
M!EC^/ B7"08UX+@3SENTW6[GJM,A />3>^3GWFC8-X>VV0=WQL 8]DQ@?S--
M,KQ/,.Y0>H%[@,RCZP)!;AZ> L,$63+[/W?P4[($$./6L^.LDG69-O0BO/LD
MH3FA./W@3P-C@KH7AW0B>E>WYSQ!+WGBGVFY7+&V!J1D=+!RT,Q\75&K"Q$S
MBA\BS[0$(W1!$)(\ZLO%/N]T0O> _^(Z2UJBC>E8A5;30H3FG?P\#)8\,Z9&
M"V2 9PU,GGH!7B!=YB)-3 \==(::_J59Y]KQ:)B80!R%R"7Y'?V"=)F''V1*
MLFFK6:T,O==:Z3V)W4[6# JAGWSPIQVO5AY)<AY)<+L/PDF?0'IP_'CNT+5<
MD@.QG8^(RTO+D'6CAZQ*>C3--?MP%6!$DE:YV,XH+L/.>ZVNQ-6S.71LX8GZ
M5CF#?U!L<(:E&V[A>^33#&P '0R3S1^C.?':!#3;[%PA&2X^ZN%"0MGF,)-N
M&/"?JW$C$)-AYY,>=J04;@X_XS @@*/-V*.3Z_Z,YAHK.DP9\NCA2\FP<ZN'
M'1EUFT,.\72BZH ,N&>6'SG^,WKRM@T)<^D1R<D0U.UHBVX2.FO.?X>!7R\%
MSE8@Q4;WS&Q45:)IKG.8&A*D;K4L."LA19#J.0.I%+BH9W,8&2#G"7DH(BU*
M."(I*ZLE<]^N-N^6@<2S9(SR4BU(W;0$V_3Y-)^K;W/:$L$9QG!6I4EQ1*38
M43</484=OM9J>\5^#*>!N5QYP09R7($4+2\I969U$PIB,S.1-ZWY9T> .[4V
M0@_@2TFQHV[V0=H)9'1O#E.'HT%YKD1R4FRIFY^09DM._^;PE5%,*CN19$+=
M7$0)X!P%9^@NU 0TF:1=*"A%C[K)"#$]DJHWARN&2\NP)2$JM3RK;FI"S)>T
M^@UB+%K ,*.9%%4<&2F.U$U82' D5+@YY+ / A5)*2NK:2?&'!)[SA) OSE>
M#-F@2PM+-2%U4RJ<TU>%O1@L39O3A-)M9!)<%$M*$:%N9D*:"):.S6'!F,T0
M5=CQQ@Z:67[/6:'H[5!OR8P$2T"*$W7S$=*<"#1N#C43NGW1AS/3"7W2<V/#
M=>-EG&Q$[\,Y<A&G(Y21E2),W<R&-&'R=F@.=YENG!X)JM!;BB6E>#O+G =7
M-?: K@I=#/7.,DE013W1R>AR+7]JYY4<D-_/M.>W_!:'S ;@KN0&8/#NH*H?
ME6Y;EKW7(=7CZJ;+V<AL3XVI^4#/*(/1/1B-S8DQM49#HM'CT'CL6U.S_Z..
M[<W[X5JZG98SK5-25$]GA2&].8?X3!^NH1<D^Q-23+Q^BBNF=]LSDX5"!R6A
M>W/ZIJ_0)WIY!*TQ6R(?X6A[/$)(EE!0[S9F6;HD]6\.87O%+)_$0TB/X4C$
M@VQAO5N6.?A9TU0%"HMDM#2Q,821# ^Y8CJ06GX$0XA3'*E)N5NPV!)ZMU67
MVCS7=D3:'I]MJLNE9?3B>4]S0A2=NQP&?G (5MBEB.3T;FB6HD=*\^8P=:"3
ML7:01_?,3(/,5%4ZC*'76[B2 4ZF(KW;GX_4.\=V>8M0NH'E(9@EMXA0%4?S
MW^EAUO*C:*0PJZS>O<TU3<_1JS$C[*HW^*6CTYM/'PJCT\,QJ3T=]?[[;33H
MFQ/[!V#^^FA-OQ^,3L\UUN9<[9<J\Y$><)8<:O<,^QNX'XQ^US[4)HV3JC8.
M@S4BUKG;T(W#EK_O=0V7C T$6RNJU*'IN,0<1?Q\-5M&[["[.B/%XQ(Y=9O3
M_?;A*H0NVET692R#,$+_2T_[L[CA"ND==-<F2\(@S6'/PCBF$ZAID"=X=WW1
M?1#:,%PC%^)1V/,<M.3X6L5J]([>:S-\E-&:PWERT4ERN3C)5VA2+W!65GGM
M(^AZ+/+-H#8%SB2*]#JC$#W%)/]XV_)\!WU((CX]'E>>%U>J0/N4P)%$5=7S
M',PEK0;3")"<QK)A1')%FAN2A)+(TN6BS)1Y+\"LD<U1%6F?/3B>R1J&4\OH
M5P?Y-+4:^=O;LZSERD'ADGFJ@E=>^XS \?R(S="<'HP,OD.Z[;,/M_];_N%E
M/;SY8)&D]IF%FKF)I&E.M_Y0ZE1%&,)CK.7>=E1%F@]6U_+#&I9KT)I248O<
MF<8J+EH0U7Q46X&3,JS3Y)!;/ 99D=."M.8#WFIH9=BHR<SNDNOTDN C&>;5
MHOD@M@*FQ39K#N.[%3Z7V*#BLF:)B.9CV[6Y%%JCT=WJ[N*)*I[Y)J/Y++@"
M/\S;HSE>QU#6\M<0UUR7*:U#R[J,LTE6UZ:!X?X=HQ#F[P[B+->(136?C:].
M8'X91]8Z#8HX!<S,J[LJ4,NI0_.)^M-S++17@\AF:+\]&UTO1)76H6GIV(5P
MAN\)]6\+.9EY9NZ*LDA4\S4$U0DLKC3+6:<Y_>K.X]+5N!UJUM1[SD_+I31?
M5U"?1@F;-"CNE+>Z[8K!HT^L3?(\H@Y:0WJ"J73=CH973(IY,7VG<:+U:)6<
MI*GJSR=[K.8[%!3%@A.STJ XDE&W[.67_/9S**'Y:H:34L]^$6@36)O U3[6
MR;'&EM!\&T)MUD2V:%#$ST+MPR>:&*?'UI/[7$9/'GIV!.&[2AV:[U<X*;5R
M]FH0V;5>M3&&(0IF^8D>\S7M4\@/"S*&AA,G@N9\#EW../3<.#1?(*''[,7S
M!56G^(X_1*]NIK+)MN1-3AQO2W7S:$VV)2\BZS^44>?]O'LUMH<;;F_?W]Q\
MH&]L0]CU AR'D/QR9]A6<IQA/#%M<SA-+@\ QK /[,>'!V/R/3G!87T=6O=6
MSQA.@='KC1Z'4VOX%8Q' ZMGF;:* QP#Z]='JV]-OY=I\3&O1:;TZ:%P[L7(
M8/J4QY0]]I*>>E&!CO5>US*,MWF,$W-@3,T^&!N3Z7<PG1A#V^@EUT>H@%J:
MH;[!>]_)PQN.IJ9-P'TW[@:FFF-"S/>,E@'LY@'V1@\/UG1[)(CZ3&^4>(8Y
M5.468T(7>5@9N*L\N'U9!=Y9>(UF&:+K@IN.;$*G.4GL1L*,_<V8*.$U_QK-
M,G0W!8=]O+.)GQ*; ?,W59:3"]V<$/[^?1&W;* &[W85*SET5PR44^KJI5H4
M.J*2< G>;>45G1!DNCX;=:'CX08 I?C3%_^RL18ZI#0>*$55# QL@(7>J#0\
M*(5;)[UBOIKW3<4/A1[M%.D6>)<^&NR??29WSK_$.:-IH6LL]>>T@O/"[9;A
M+?26/+R@>U[$5V6("[TI%_'5>1%?ER$N]K \Q-?G1<SUVV(?RT.NU@U9";Z,
M'H5>EIWPEZ@#E.B3'07(Z%#H<P]&!6>#S<D7.&&QT D+$@:5 5*L06FD+'33
M<BHHBIEB)7B-Z6.A0Y941JV+I[D<NQU]+'2O^V1.98LYQ,4U+&OT>2X3%A-/
MCC7E!J9J;<L$7.:$'PM=*1^QJH0E-ZR6:1@EP]7<,)O=1-))5OK/DX/AS_\'
M4$L#!!0    ( /%+#ELL0C&?S!8  $); 0 4    8W9M+3(P,C4P-C,P7V1E
M9BYX;6SM75ESX[@1?D]5_@/C/&12%1_R,3.>RB1%2?2.*K:HE>39\=,434$R
MLQ2I!2G;RJ\/0!(2;X"70-C*PV;70@/=_0$-H-G=^.>_7Y>F] R@8]C6UZ/.
MR=F1!"S=GAG6XNO1VCG6'-TPCB3'U:R99MH6^'JT <[1O__UYS_]\R_'QS^Z
MXUNI;^OK);!<J0>!YH*9]&*X3Q+^Z4YS7 "/CX/6W_UQODCG)Q<G9Y^W?^]J
M#J*R+8\&_=C9_M)'_4GV7-)QSQ[IV>?3SN7I^=GYU;;1Q)Z[+QH$D@;U)\,%
MNKN&FBG-@&,L+ DQ+OD"?9'DO^E2_TF#2VT%P5*SL%"2_.R>;/OJV:L--!9/
MKO1!_[N$AY$&QT-E*G77CF$!QY$FMKG&K#C_D :6?B+)IBF-,84CC8$#X#.8
M!=V9AO7[%_R/1R2?A!1M.5]>'>/KT9/KKKZ<GKZ\O)R\7)S8<('D.>N<_KB[
MG>A/B*]CP\(*U\$1H<*]I-%UKJ^O3[U?2=-$R]=':)(Q+DX).]N>T:\S=TL0
M;GQUZO^(FCK&%\?C[-;6/1P81I R6^#_.B;-CO&?CCOGQQ>=DU=G=H04)TF^
MZJ!M@C&82_C_[\>#[9CZ\_)$MY>G^.^G/1O-7L2B1_$$P?SK$?K]&"-W]O'B
M#/?YUT@;=[-"D]@QEBL3:>&T^'C6#%AHOG8U$T,T>0+ =:@,Y!$UPM$(+0C+
M?0*NH6MF*?92>ZB+UXF+5C8V&HXZ5U< >K/*N;>T]0RMX!DKPXS=5.0Z/,K$
MM?7?GVQSAFR9\L?:<#>L3!?LI0E-]S3GZ<:T7ZHI.KN7BCRC?<! _8\@LJ.6
MZV$I6[/)>KG4X 8I#9ES8XYFH^7*NFZO+1<9]9%M&KH!:"NPCJXK2G<[^/5^
MT!],'RBL)MI5GKWQN4:=J%D$%3D9 Q.?#Y!A<3=3J%F.IGOKE<(/C:PB5T/;
M!<C8;;1'3)[+25K3RNMTN31<;V6A"8G6&YYYZ A&G](,E!5Y&\E393B=4/B(
MM:JZ2FS'&0&(A;.M"3JKT3#))JBZ;M:/#OACC?2K/&,ETU9-1O/*7+"8*$8K
M6*ZSVNW/%*\?*J\4LN;6'1-[S/15UR R?6@,)IY2V]:^'IE8H9%Q/"GT@:L9
MIC/4(#XN/M/L2Q-#U;ZB@H$*+ZD875-\=<HRUFF:L_.RG)TWS=E%6<XNFN:,
M=>6P=]#0N;(@OT6[J?'<69!3%M+F]D<V8\/>0>.<TLQ/@1X:YY5U"I3HJ9Z3
M"!OZZ8UKY8!54Q2JVL]'; JBTC7%%VTQT EKOE<5W548R;.YU*!.&$UK&AX]
MPX=-7./8>7WE<?6$NH#Z^A$<SPRT*/%GCB,I&"BLB6TOAN6>HJ:G09O3U Z:
MYGH[U/',7FI&09:3U(WSZXUSO 3+1^S0+\1LE+1I3C73+,:?1] T5Y;MRD49
M(S1[G(M@KJU-M_1D).1ACM$?#<O Q[E;])\1KL$KVA]F.R<V[H[A6Y-KN+C=
MF?^_CG2\^PYZ+'DMI9&V -+ FMMPZ=T;_8];A"73UB-\F/C;F@V3ZG.(W [0
M3Q;V\^D,&-X74/POGG'T%0B,G]ZX\J/C0G1V)3V9VB,PO?Y_HC:!$(%R3E.T
M4[_:<K]^^7KL=,[05$"JVWYIP&I4AWUE.%'Z4E>^E8<]19I\4Q3L:VP 6_9O
M8"&..XP<2Q\B7?V]20E8/XH%8IQ?=G(4/YG*4^4..W@E]4921\I8G@[4(1+H
M?BC?]P=3I=^$,$4_E@6R7'[^F) E*L%DJO;^\TV][2OCR=\DY=?[P?0A(DO%
M-3K7G$?/0*V=XX6FK?R%"DS7(7_9K=C@#S^WW"*%@0'Z5R=EZ0:-T]J>\N1Y
M&OX8DL-OT"[*ZVZNR##*-;+KI-/ Q#/NH3[-'-I+JMZ"\>Q<AFV(YMW7(V2<
MSA"%MVE]T=%U"\UEQ?0:HHT/+/"_['XW;;0.OQZY<)T0><_P^ L&G>97MN5=
M%E\-EMF53M8D>*D'8!J8D<F7!62Z+%M<^0 48ZH?G*"S@,EHWB0@R>,]#8V\
MN18#)T.> )0+@4'YV4DPWQ@NY*3;-#">3 $VEPQFD =V@<,"GQ7N@DM>%FXI
M31L%+'KUS  K=^[%0$H1@)BS#A_MR[.9IR_-'&G&;&#UM)7A:B8-"0J96*A0
MA"$(G?-!:(S]9!:8*1JT#&OAT*#):B\6)EE2$# N.!W/L%_5&3C.>G>'23F-
M15KQ5SS[&3K">*!K3I8I.YHM[?B;;"N2VE/8)Q.=H_+]>=!?0QP9 :!AS_SY
MH2Q7IKT!H LLI%5W9&HY9ZWB/8D&7"'AR$&Y5;!^U\PUJ /5[([$!S5;-G+
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ML3(R&"NC!E@9Z</*#?KC-GP.OOI5?<Q2:L!)65 F2BYDIF&D)%D%0C ]V(8
M<^C#!S&CMN%#&+QYOLVWC7GD&I#"$9D)EP*M:9AABU<!'&KY(N2D;/K0\Q"@
M@_W^?WM'X;F*3:P!.4QQF;C)49J&&I9P%9BA+ #QJ#\J846W"J'%P4C^9T4Q
M;0R1SG%LF=\,F'F&.*5X-3+3B$;]W.)7B/N'U\#GN]C*)&KFF"=:.L_%WPV8
M:XY(Q?DF9(#0Z3BW/D'[%"+(#4>[9R_>L]9TF43-G/-$2^>\^+L!<\X1J3CG
M*1E =( 0*IWSY]#"[ONG]\,N8/6B\+N:V68*E4YU[D<#YIDE3W&2$QI B;0L
MZO4W^Q6)!#EOS=AD:A<W2\3B L_2&##Y K&X"SVE5?_6++T@_O/)"F,8[M]I
M*)K@XKE$J?;BGB-H\>*^0&8 +L22<2_NS^1)D*">9V>AY4<>=IY7PJ-,JO@Y
M&D?4TM.T IU!".&(QG^R=J;7@9'TK@^!U+)C[PW>6K&5!+8*K@;9Y&KO744B
M%R]<6;0&8$9"/.X5ZYD'!YA::3!RA^!QK6A'^G&*KE\LZT@1!/=QE/[+!4K)
M/_R->+PPK+?N)\^W?-M#QZ2 PIN3 J$>:_\0:](5#+<Z?'AN_[:TG=%BH!&!
MS24N^36V][?K^Z?U+?BXNEO=WZS!TY_6Z^>G'E09M)T$B+9SP1_ZR]_ND<8]
M[>%PL)L.5V'X'![\V&$\RZV@[1]A4L)B2 D)R8S8]F WGVC$4 T1>8\WK2B"
M<?1[S9KKQHI>\?_6_SAY;]8>"18]0H1]SXZA@W]8^4[^'S*4G(75LDUUNJZ3
MSF>58*L&"6P60QO.A@9HQPZ[4EH!B)@FT,-_@!<VS6OA(81'RW/6WX[0CR#;
M&JR@58==H;!93#()R01-%[8[&!N -0D1BQA*6 "D/"VA8[\="!P&L_& 0 +]
MP]^>3L?CWH/1EP@ZGX+P\18A_K/EGUP+IX+T_!<V0NJQ]@^8)EW!^*G#1W>\
MA0O'.N'47.*2CRMI!9QP"E$W",'COUB'XQ]NB=HZ9-O3K+-NT=D9F:S1BE@3
M8IW%H56GLX3"9G46DY!,F35T;7MF@,Z2$+'D^Z L?,3T./250U[NAP/'T\5(
MT5#'F=27S/$6R%>ZI<!M 3MG9VM>IC++4]NR;("-N0$KD"U5$0R_4K*KU%/4
M98;$)DB@K@9X!ZT(D@3/6Q?M541(3C^%'.I0(B%X%C,"<C)7.W<P6I@ (VE!
MB\A*&,$><P*2WOLZ<*^1R6"&SMD>(7Z*XK_4P%H%CSJT20F?Q9N0(3F/0MO5
MZ31J(&H1<V=68U'W$ 9(QOC] <D=(^,;>P6.V,MZSP6=F$7ED;I:]/S)FD]/
MIG$R'%GSJ0&(DY>T?,ZFG.3@ U.V*^!#W7<N2/UZ,;SSWJ"S\6,DL[?;TR44
M\:%6Q:1T.Y40O["C"CB2H\=L,3%D4Y66M00Y*\9VNQU$V&S3#[3\2>\>36V-
M4W:67-=!NRPR_ZQ]H:4;$;)]!K8!@)*3DG/BUN(=1#*V<!!FN0WQ$98[).TF
MO+"2^1JXSG@'-:*JE= MG(57X()<C6X@_AF?]'2X'#L+56:+I.,G+QC;XV.$
M_9L?869?U/MVJB;<A%-141Z.(T>W_^;.LW;>WHO1@D<*@Z21>0WV#@PC;%3'
M[Q7A/O+LZC!2MTM9%,GRDGF%HYDU-.%RNYG4I6<NF]7'S=WF>;-^ JO[6_#T
MO+WY]S]M[V[7CT^_ >L_?]D\_V(.6I.]3!Z?)08MB.2(S<%@@9INW$-W-#?A
MFEM63E[$4(9?=]C0RK9Q8IOHP7JWT,FNXF*#0ZQP%Q2*F]L5F93I@=5RC-@I
M)60LE9)(>,"1,NG'3WB"3GE%\+O,HU>*(K'0!2"QB:F%8UN+H<X34$TQ&7#"
M;'V&W]R>X'.P/ASWP3OD*!@^F9HCLTC$]&S,HB%C.YJ.7-?5? BNEJ[D4CE!
M$ < )CRZCUO9V[L4Q.]B72)FT7.ARA.==Z-:I*?7WU/7'C@&*!5Y2<5WJON+
M5KHZQW.0I/-!EQEIVE^N2B*OBDG7]:H,^L0<U("=.'!L0FQ6'5FK;EB;85#I
MV4CN3$2[C;98J,J?7^G:JQ)2'-B5F1GC3MG2'=9[JJZ!G)&J2,!Z)^B+;"5_
MX5UVY1H8_7762Y57BI5<FHT6\05C!0N9P=G0@1,3SM:UA*UAO?@P!H'[?1@Q
ME7B4X--NRH@Q6<E$0_]&$\O B+%*<6O9-&8B,WZ%84:!5T-2P* 0BY5BYT#(
MI::^O,%BM%B8@#Y).4NPPWQR9IH:JZ?"W*&/O:<[>ZEJS=>QD//2L4UC(TWB
MZJYI,H)EX# RX3S+%$ID[^HV<VM?BYMQ$5[OZKOBVG@Q&<P6)H3.R<I9BFLR
M[SK[ 34#T<Y#K^Q_MO:G8@XX(:72U]D\00MOLXMD](2QL^!P9P!V*@5DO,NF
M#"#"'%?@?PQ^' S!T0K!&^;^ T ?OAH,!B"BM9>L4_P:A-X_H?,'</Y'+XKP
M[1*.GPMZJ<W4*%7&I>:4"'EE,H4)+3@BYG)4%&BH#;<8V#,3;$VQ=*7("%K,
MBP>U&84:#V[3J_%H>#6># G01E?#T>QJ-)Z+00BL&/RODP_!>' %,$8(P1.:
M&(@3W:;_/+D"J(TC)*FJ]EV6P&QTW>XX)*V1M7^P/&?CWUA'#]F+O#MA'K7"
MJW:QP+F+=C8I#=V:SFQHP@,<*2%+E^QG)H!S75Q[/K IGV8X/<+8\GSHK*W0
M1TLB6MGVZ7#:6S%T;J'KV1[/S)-A5 <R^6YD\5;-E3SAF\]L$WSF=>5EA'JD
M],"A#%K.\64S5LXH3Q[QSN>6JOVM\E1?)23[<!]EN'Y#WN+%NO<5_IQ4]ECO
MN:X&=,8F+&*1;"5' "6X JLX#KW=*<;Q?CAFY\&JN )3XW9A1EQ7^&*8/(EM
MZ,SGQF0IJ2=R:9UOGU=WX/L**Q?.9LW1,>G10V- :DV!55]2D1N1'&TH@VZ/
M8MX1@339-B3Y6QUR2GR (2GE+.7%X#/K\@]5=8?O,N)Q4I-N9KM3$_S7362N
M="R=S_E&(9-6%%^=O0Q2(U)FTH5$GOA\!!8YZ)%V:=OCI7'($\M:B;B2"\E
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M!<D5,>_UQ@<W1B97%**,1ZPOB2(?5VQ*>IWKSF9C$W24C(RB!(FW.A,D5CS
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MH_T'.IDHX H,27&I 5*-#J1HDF"AGKGY .W;FB%56]C26YC OSZWD&"+MD'
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MT=((S2\G)JO2+F4#F ]LTYQ[F%5W 9@D[1012'AESZ146.B%+VBNN$N9+'F
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M%V8)#W*_ACDO%#[KYDEZ6*<2>]MFJ0]^N!R[9H5N==NO[[(00(>@Z7Y\#7E
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M9I#,X0;1NT8O>=K#/)63R!F%$3YL8!JR%F'DG!!8O$G9E_C\FIKJ/SDO_OK
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MUSMQ9RCYQH@VS+]?ABF_3\BN(9D%.!^&/AK4\P#1ZYL!#D#CA;?W30B#^"F
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M1V^3P7*Z&Z5W:0[NAUVWTM&;95F\00'R_(2\=%##>(.6P-@:Z\5$C0,:#VW
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M]Z\V47I9/;QVV:8CR*-;/7#7 ''&4X_!Z<=ADN4\(.^A_NHG+ZPW<KB5AHT
M:&)!"Q*XT .#;>%G=/88?KY?"/:>TK=A$&_7!%4'<CLU"9"-5$^0PWQ_"VU'
M863$]QAR?K(#X ZE=X;'E?^6O'I"LG!6N9*?;R0LS0!];(]546SE/>^DC020
M)9IJY]E)WT3W'H5Y9\)LNVA!;NOF@&$;DBU(HOT^MMS.@LC(YA1=GD;&IAH
M7&<:P"SPPFBS(Z,^XRI; \!V/*7H'C0TK:<IVHQ=3L^^SX($80DG9#.9H\IX
MT9."0,4RE01)%M)4YE3BR@!F!!WT\4MF<TZ%$"/GQ^?P[3-RW)T!9!;$/N[$
M*H+$.#PAJ<.>=]F=#UAVF9PM2U-5;?1I=.?'SCJ,MQ'"?]E7'^WKCT@#6?V.
M0R[?U=UH<]SC(,-_ 86^WV?9N2EC#5<H+P]T6?+<'APWZCO]N%TC:6QK$O[^
MQ U?$^1^64-:/@5<NJ0PL/$(4GD_'LDFT=,)P8#IF)#WNF2LHDV0,')Q+ N0
M91HZ;[^I'JB@0.HOR6P]$_@XU&AFE)<'EN,8Q3UO&(PPP.HO$VQC5NJF2&EQ
MX(VAHO(.=>B'$PJJQAE;*T)OK_:@PPV,_7CA/>0Y"-SE=K.!T?O"6_K/@>_Y
M#@D"V]E;R4M/X=IW<HI9_FR@GY\-;B;+6?JNP\/C=#F=KR:KV6(^FLSO1LNG
MKU\GC[^1WY:SG^:S+[/;R7PUFMS>+I[FJ]G\I]'#XGYV.YLN>3S^4(3+D!V]
MM X^TMN*S2E1=PG'5=2N\ BZ65=&+71I%2#/@\5W,CDE@*MGC7J>[T4 QT<A
M!K1HW,]^?IK=S5:_T58 XWP%.);NR9)T:+!B1N)RA6) ,Q!JZ=%+[XC_KZWO
M^LG[$6_5Q"%]JJB!S[[(*@:W7'E25 JN8'QBPC/(,5[^;E5^L)OG@WVY6MS^
M_6^+^[OIXW(TQ7)L->P[+_F['M?O6*?E@*N,(:\ NJ+ B4<WV\PZ&-48FP">
M+&'ZQ-A_2CB@&_\:(QSDY-MGN'F 4?*.3^E!C 63]W3/3T'K? H^3N\GJ^G=
MZ&'RN/IMM'J<S)>36W+JY'*.+(-2/S?K:N+UU8$RIS-E6><:S=<&C0"L6MBB
MO.K(S QU#K=!/<A93 M<RLU<;7P^<^>+U72)Y^UODYO[*8_)2D)&CCVJGZ+T
M\D!1300YW:9]#:/D&3ZCO/ ;34K&!H"B*3+WTRH;#]1IV!3G^?-]5WQS<[/Q
M=PG*23A3F&J4*"BQP&C2^:RZ77S].EOMWM<D=I?;16I=F<Y;FE9*WP4IZ62U
MEL90$:"Q:\B<[B\K^M=H6C5K!ZB.J7B\+Q0:TD.=9BUQ#W+#>\#G3CS+:+-2
M/I^565D^5_(G29OF*#D$!OT4ANXW?[UFR>_,W@H86]#R.(7$GW>TT;1EJ P4
M6S.*VSVO5)(M6"ES5V!&/LC92E[V>$#1WJ>1Y'N@35RE8,Y<+/$9=?J8[JN+
M^6CYM\DCE\/J%$8!9I5@2'O/8.TIJ8%Y--SBPSQ\8#!,RM(J0--U"'EOFZS2
MIDZ[>FR#G&S+K1VC?VUQ2].W$K\B32T84Y]NEM.?G_ ^.9K^PFNW/.\YBS\B
MO0:0QH8F<=H%SSO%8DXMJP)T5S*+65]Y^>;52)MN2*W%-M!IQG)Q7W&!KQ6<
M^]BOZ4=_RAK^\P>XL9?'FLOK#8Y]R.MY3#_IXCN+KLE2'>B>;HDRB1EXH&N7
MC9">FW"NGIJ+GE*9F5?6%H#I*,@>.+6-P?;G,MI.RR3[2!B],[-95@,@QX#N
MP-FK!=>?6VD?-H$O?N GZ-Y_0^ZNP^P6@4)5(,F>)<J+).WY8T79R1.5[E:3
M!@K7SR/B?T(K"G3;T0Q!,O4W)J 6U='/5)QGVW=9,/$J?<BAF:;*K)M++1H#
MLJ>,%4'B@MK.KBZX]_2W2V_0P[U_C+"(R*$K]P;U_F73.KH9*@/+'4NN(.'T
M;>EM@G-/)R>KP+FUB?GP4E,1>(XE:X(\]->61E:,>PHYI8J]#=/5(DJ%^NC'
MO]]&R/43\J>JV\C22L!""(GR@$EKO9 !WYZV=GD+>CB!DM?%5_![ WV!7@/8
MLFHZ ]\1:\%ENGN/&0EFFU?H1[L@[/N0O+6&3[>[X^ZQ%W;YX9.]/M DU32&
MJM*U@\KYS?HON+^_P/46?<6'Z6V$CI8#Y@G'W 2 !C1T0?*IM9V!S='FWJ_G
MP? 323,UC1-_ Y.J#,>GY0"T#7T\\-6R!%+NY7@^Z:B_Y0!%88#_Z.S2 #2<
M>4U; LX826-!_/G;DMH:=.'!>(Y!,BOB1DF]6"I$AE)"949_VM7G<G_4,F;&
ME*&L<CI$+IT7Y&[7V3,F!8O"/I?YCA66&]]6[0%94E55D(Q*)>S0S3#=X':Z
M3J*>2',=.KXMPTPB;J%! WCY(.]J#8BUEO@ZW0O5T'0<+<'S#5R3+'EQ,Y[J
M6P"N W51<CPW)ZH!P$YW0C5,_0I)5J/4"7D>'IY2W[_>M-@F<0(#XB39C+UV
MK0(3.5I1,1H*HQU!GU\8B1!(47YL*82S5X93=#G 7#^NPO&0!#FY?>:3 F=)
M"=^_PF0;-3BO-&@$J)HY-GE;I!L20U?46X#FZ_ERC^*8+! H2G>!;IRW: RX
MDB)QSR78!_==P)^?@ZX7%@.3U,6R=(TM9%'8!\=P50<Y1,F8GF;RLJ9EVWOH
MY5P]"EX@VX3$5V["*/'_G0Z+_:5F4P6SCZ\ 7;$E39"KXE8\5RJEO8J(6_!J
M,<BF?!DH9'*@AMKPM1'U&'.C&$@O)#3H0]5Y1$Z(]Y2UO_,J\58O:+[=D"TC
MC.+4)R$(-_@00?Z:_DHR63GD!W^])9D)]ETEFMMV-P(:*K67[P$80]OE'B#+
MRG&%,G5%45W27C7!1YFT1WBU6B*'G$/\IJ80EC: C@S=%23M0!?>&X'E=G3K
MDA[R#B707\=S8BT@*"E+OEY( =)'NLC1G_:?'AV^_1$"4A37M)S"<>=*I\,L
M7?VJ^A7JTW( >0I2!;%<,DB6?AZC0SKXH[1S2.F/D?N*=.?G$ YE@6PY3M&7
MAO-;"*<2KF:C""5;),>\*"'>NG.X09/O?@49^5) DDW)Y9T1N04-5! ' OB*
M_R[<0#^H)V!7#MC&6!D+<@U&%6LE 6<@NE% />/=A$D2;KZBC8TB^@DN7P)H
MLN59@EQME BI<"JC LA$V>-Q>16^5LGQ\#.P=4ES!%%N6(58['TF04X6K8-#
MVXDS,-:X_/CW.Q3Y;^G)</_<$ES/ GP:V.YLLZF-A<$QL&7+0-6AIPB2S+!B
M1Z5?/_0%GN^=!*V#BV\!<A?)"XHFR0%FW>T30Q/ '&MC45SJ&_/=&"7?0-S<
M&X4/,%I$*5XW[6&FIY=3RE"92$L5Q1VC*9E-\!V],;HGP.B^=T[<?V[CW=79
M*IRXKD\$#=?D,:U9< M?_02N4USDM<JC:>-TAVW8"("Z92NB:4EU5'? V=^K
M,AUG;CH2\[XD3%.V4 OH)K0]00[W'>9J.;!!/CI3=!O>&^QH)L)"/E.JW_"^
M@2$Y#LNN!HO&,:'M>7"LZ:X@<2XETF2QX64P!F[#,\<&%"4#<XF$66UX&13N
M-KS)-QBY*_R!:B/>23%@RK*J"J*N-R&"CH*S&:_$%3_W)NG-^[', WPG_Y8B
M.<()7%9CX"6^!BP-05L0&QB=8_J\O*0L+F"9/*3)2,\3-V&PC=.$&54VMNHZ
MP("JJ0C"W$7I**@,C(*Y@%5T'@8_;^':]WSDYJ(ZZKEDJ B@Y9F.( _-79?0
M)M+I9JFENX:PSTGZB#,-U3;^D%.Q6AX95YR"?-/.Y:5 ^EC*[N%04EH)*+IB
MVZ(<GJ['<P/)9(SWF&*M9+5OL7/N^XHDJ"B"A( *L7&>R27CL!=#30^K<YV(
MRB0TWQ)8^X#9>/(&_371,[Z$T4\D)LQ22I;XBWT/2&-=DGC']=1KML55_O(B
MZ3.%M6!*8$OA=% $6WX1N*JM:.+>]=+'Y[6$PLVQM=0$?5SB<S;HPNL]53;H
MD30D*[0JZY;!*9EDZ^&U5V72L13/@@<4^:'[4Q3&50;4_C\&%,\Q=4$LL"6\
M]CNO&63!UZVC-;+=2O6PC9P7\A->J=)_OL!X*OD2<*#K.((<9*XRF.H$P=>/
MI.L<P7 \Y),PO<-$N=SB1/D8@#:$8T%,7]=<G*IDP3?K?%=DT^^O_L[=[@I#
MBO(QH)BV^D<<4E6RX);.I/0(*]..L(5W["J/L/*0CK!(AH[)^PJ_F2.%;=F*
M(8BYK$2:+(X4&8R!.U*,-5<7Y26D$@FS.E)D4+@[4I 'UGS7A]'[$A[RM54[
M5916 9HC0UL0/:L10;6(>#M;'+M%;-T+;X6WQ!@O UBDM:X3M74!=!77$L1?
MK)X+.H7L*#ESF25B2_M:=R-'*0QL7=%$"=UJ('8J;57X+N/#D'VQSF7AK!QP
MH:>+\E9;:ZE70^,<"'88"RAZ\QU4H@RLTX_O0IF0$SX'_K_3[!KXK'\;QDF\
M=YLG_SK9D$ARALG5[P<!1*HGBKFQXNQ1/2$O)!-N&8Y*U;#C),FI8<4WCJO4
M,&50:I@CZ44O6*'5,,5R'5.0\) 2:;*H81F,@:MA%D*>H&I8)F%6-2R#PET-
MNUW#.#ZD[%U$C_[S2U*MAI56 ;:J*K9H5]D,!-4CXGQTIW:P3O^JJ 0T4_=$
M>1*J7OKLI)W!$R3C2(.$+ZIJJ4.<0E00V6W*L!*^R+)MFH+,#:I8*PDX \&9
M@D>T)@'D#S!*WG.Z8GSSGO^E>GZPMP%,U4"F(!E?F\R>%A"SP%X!B*V;7\6R
M !FJK0ERL&XA_%H2SV!V(XONH8N57A3/*^,F\D6(PF#(@HB<9>\N&)#H<#+1
M]IFU-/W0TU.];+,RP#$<Z GBF]-!N 4\F73[#/Q)O_2/>N'NBP!5<71'$+-S
M!]F>P\E$V^=K-NF'?JL7[;X(D$T;68*D%^P@VG,XF6A[#(C9?>CKUWK99F6
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MJ/L?K]6,C]<TI9W#@QUX7%#[2I,>_3G>0K?D<-C8A3))!T[^\Y&?,>Y_VXW
M*!3N#<OPT /04=_V/7Q9/FI_V,ZMJ;GNIHJ8N,)"<7E@CZDP;D66.6FIV&C!
M[F9FHR7)9$ZYXLC>3>\_)RT5IJR&*26G,N5FZ)-3BPJUMG@K"S=7+2)"<;(K
M:Q[W8(I[2AZ\@@R5_O7N^'^NLK8[U?UW)U@!?8MX,C'&R&G#^PT'C3W;89OI
MGY&)DV&>8.>60YS_[<?(@..CWT2,G93U%5$A/BAZS2A]@:8X^:H-5'V%>7U9
MKGW@F)R[EL6Z)-^?4D4D4ZYH!(PLLQ'3WK#*R*0R6V257+QIL;7(8%)9<EL-
M7WM@:I'!I#*D))P[JDQ$2L=YL6=(9UN$/)F:U=-F$:FQ,6UJ%A39IJRQ1;;]
MR4'W"TMG?>.)5=2?!$*Y[SP;+U-O386M5="3UEG#7^%T.(H?E$SH<%PV)=L4
M8D7+N;AS[]14V4+1EXJQP0Z)-])7828L*(?;7I3J_A8V7@%U!N *%YMH)N92
M0"]V[+EM?Y&\Y^YL&7]9\+H2X75&#,%M7E?VY_6HU9@%KT=VAVA)[.V.O/_N
M;.AY6>2WJQ%)J#*X.\$4]Y0[:L:[LQFI87)W#HK49+@[U8U8!'=;9'V*;ODX
MLD!S-5'MMRUW8>+;77D)&<>)E[X&:I2L[:^_4M;N.25/Y<E#+)&SF.);*=[!
M#D2)S+[;A7H&;/(FI<)D[XD?&IR.482%TX-61EB:G.E[4\1XTL%^PB:R$&K.
MVHS2OW8DA?#C(#>I'[L\LYR2>1&7.WB2'^S\8&=$YB0E,?&#_92#G69^V=">
MYU%6Q$FS6DC!^/E,./AB>YX]*P84HFOA:#A!8)-X-KD/RC8$3B!1='DY)-0
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M$&0,8H#Y#V'=$[<D+"7FJU]7V/%Q&('AIH#>*MNP<>/.6LQTV]/1V "KXDK
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M/*["S5TEYYZY;:1?@ND-DCZU[^ZZO5^B>_KI?&3FN#J1OAO7W,^/K2JKV+I
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M]B-FA$PD]U&SQ@C&=3UN=['-H942;57>:)-JLE0W;I'? IMUK?'"<1#H>]V
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M4;SZP5N6EHK?6O*^]9 .:UEZ+C.K(=84WN*F $!LU ^JIW]!'"94#N$M10J
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M>F,!T\>: ,7D+F:8J)ANP)*.7"82,ZVTUJ6P5\/.>N4L[&5)3_TW/!.Q[@!
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MD.CH457&CR([Q,3"J/=-.F+_!:RQ\ P\<A@Q<\.I;_-!$$E9N"$/8K,D?-C
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M(SH:MS$!5!MH*YE<:+$\3G[8&'G L\$=\(59<8_:/[X'%=)<Y[&I[44PWHT
M1U[+D :8C5GA)?8#4.320HJ8^*%C^.:EFXQF!%'3#4'<F3P&>&<8B:?-5:VN
MC'TI5'C:CX,-O8RAVG(ZDT7Z/O%S_14%E2@Q09HV?'-:4>8!#@GQ<S+;,%A
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M+Z:Z[1"HGI*J?=J? ZH+WBGE$G$)._)S2?+<J4IYZ'.:GKEGM2WBHABXS.O
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M^C5S"#6;*/X/=^)_->*_N5+QKR_R61/2&HTY<@RV]^XW4P5H/%<%6 PW9N@
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MW$LY'I E*ICAI"[+&X^%ZP$?\1]("MU[OB\M= N =1[>T9:M!N)?JYV-\\I
M/WW5Q3TCYG^_8M-^+9:L=JTD8>+X>GX:X+PSF43A#\ 8NM;I,JM"NZKD&^O&
M^P+Q=[J'E9W8'C$ &J6QN0N<;H5Z>M%<KS<J3U?4@FB('6%,F.DJ^WT\37[
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M?C'\%HL>OGEFO%T^_W=Z<"DI#OL=K46"Z7M0JW"Z:"UR5N0=3EG*)UCTE"H
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MET>>GP6)$]QZL'<JZ(M/P'3PPSB-EI#^N[J3_EJS_@/N-U +T(\ E4(N<_G
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MQNXVF@2W(B&PT2HWN\=,C;/ %</IE+42,37GQ,]7E0YH_KT;,%/U9#6V/W'
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M8GT7#Y;PQ1AQ1S4SOG%^6,=IPE[A_PK[L05KV[+U-(8RL=&_U0^#- ;:GT1
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M %*O-L(")TDCAVU.-+WYAV##RN/F;+UA.$A12Y &G;EK:?!EN<ZP<3<%2W"
M1:*NMKXU6#RQSB%(RTH:?J:XR7G7VVOI.=DN.:.7%"YK[%4MNIJUOJ9^XGT'
M1H/>(V#=&$#U;HD( 7<)QXD(G,F#-(5,W$0+B'PX:K!;@9)@RXX76"/AN(2C
M@0 9SO05?\1/7G3LPW/?R=CM!>@:^M!:T2(;-2!C-3C87".^?ZF=UGJUR]IU
MS7KW!1 =D/)TXL'+A85!H%L16)<H0 (Y]N^:N/9>QET?; N0_LMI[_+:YIJ8
M6& UOU_%EQ>FF&@D4C N0@_H)4I&&(>2GKM5:XE+"PM,$1F:T0#<1?H]'#R
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M6&1;PB-EBM]&SL-C*U']+2S5.FKKR]%9^AMC7FU[I*>UB_2LN&&D-[ZUXFA
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MRMPWY1F6C\8RCT+GU[L>+)9BWOS]"(RE@3)@C9^R)A&'$PRL2+-.W173!?U
M[QOS> MFL;*UJF1W'_W;:/[G#'[>(*HQ#OH,]8@1E$$#+Y'&)\W-"220M#$=
M4G0%HW@RA5R>1D-MD<.;GXZ5RNW!Z^]U?K!\'SK2.08@C/"7/';VPCYJZXY)
M(KZXQ> H)_Y+,,8<;Y.9]'V$O^]2X!0TADD:X:VJ3-W,]&!6)ETF.IN1-*S
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M1-[@O)"I8L..]^M,WM'NS'RSU7F_N>>"LH;6?.?BIOV!A+3YK WG964O-1O
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MGV&,2"VEXE N:M5_+MS_#/AK]B]02P,$%     @ \4L.6_S4XP;C2P  *%,
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MBOV<F]GUP0H*_05IU+>/XEW6-]:R*D&?9OO"%6SCAHBLJ7":_<;0Q@5T!V
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M<?=A'>-G[OAEFS3FQR!6[9TOPX$I$>E?E =XVU;]8UC/!X9_[B _+;LVCWX
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M8'<"7.)XL'>95Y.F6MD!C6*YJSEJS3)(.X:*[\" <@=(834,B!,&'<"O9 M
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M7.DV(6/TIZ=IOJ1P,H]+@JJ.A+*B% I1:! &"^ E:%0U>HVA  -:EEHSLPP
MW0_)O%U"(%=?[EG(D_$NO&06O\Q2\"@Q T//%W4IQ PI' GVWT$-OB44^#NH
MLR\J2!^^P#GLRTG0P34,L+"[<%VY;@PL>,Q_PR=IE0,/7=/\Q5OZ*4TW.9OZ
M1[_+LNT>GLO4H%/&J-\BI'.[R127]B9!%GH.%H6L=%&[_H0!$8'R*\Y"?P9P
MNDBN((W-,%CRY\./S=0_/I-@)5A%3_GD"NAQ<;R_YH;N0;6WD<\":_82:)=
M]P6WNI\2^^]F2X),2?O.W-!.(#! ZG%+RA6<O<??J_]#M<W2+KC?+3.E=\PO
MS7R[ \]KV+LA%@5DZ*OXTKZX>]-*D.1=72MIRO?9_'V"D]NO1O8N&+#F)_2
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MJP>*2Q3N7Z><*!;]B+$MF.\@BY9N>[!8T#*C<L9QGU<-OYBCGSPF-:VET#(
MS5E/# :>++ID)5+M9-H@#4!T80##KZS+<7"&SY8O:60<1#,!W-HVTGR2!FC8
M'ZB&F)XI7K1=;\. \3)3QN2*TD"<#NPVC(M:]_X5(3=X5!L$23!$5EPI@6]W
M[M(D^W^_%  #-*5(6(OA[*(.'L'@HMQ?<))Y/GHI@/#Z_]*SJ!T3H$8!.'^_
M-T>D8U7CY.:1O6*HSZN4:N8>';9PCM\KT=I2B)38(M1K&JYG?$ P?#6]@O63
MH9UQ60AZTB.IUM#1ST)SN;!DU&%IR[DT54+$^\3:<Q?%N2A__WK^_=5BLJYG
MBOJB08<U=N)F!V;\#C_*ZSP>[EFF55W5<ELABN)Y=*?ANKFM<\]/H5'T2#'M
M=S3RK:R(#:<FF5>BEDME-5L_IS;X#7N115RS$161HSV(14Y)/C>6BK[)]'?K
M(Q7+%7MMI3$0ZXM*1QAGM[5VLIV/%N(>( H#%$3+'JH?17$(L3O.C,BAT47'
M:6"(NPL&'OQ(,#+X*7[6+YFG0>;$0I D-]]DH-'6=<.1#0-J#J6H)6)^4<1\
M]$J^Y>E/>!<FA+T!DM$MB3L922FWG8]968@JJQV.I' ^8$03TR>](7H\W4L-
MHCB8DRG2V;5!;(A/C90.B<6ZHEVWTUO7Z^A1HBGU37,MU,;,!D015+(1/WQ
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MX0!?;'_T-&FYIN,PH*?=G,QNB]LXI8#5I"]I=>%-ZSF3-^#TA22*LA/PC4(
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M*UR MM2H>I2IJ=K1O(5E:FF)CK]]X2\G)HH"D950F*8L.:>=>D*RG>5H\[=
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MJ4ZK+X<XDD%CQ,_NM+D;])@A ?,B^O;:Q:<_N*/<M:$'T]ON?!NPJ+2:((+
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M"9!-%.Z#V)! M[I75Q)?CC[A$U+4FY*O&&R#.T4*O:?K;C@F=Q0%KS0W29
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MCW 1$'$18+T -0 @/$;XXP#^<B \0D1ZC(R"BH:. 6]0AP,\0D!$? 3W'QX
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M67N58M;>KY=C\]E@H@P &8>F>IJ_OLW.3:0YYU,U[O6@>X.4:1/U\G5/#>G
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M\"Y1W>_%U&;HEH__ZGE+$7-)SZF1(GV<X*B[,?5Q.1EVK'N:@Y!CWIWXQ]$
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MHZ44+;]^=4_7H,-?'WY9O5F.QO;5B5FO85"37^ -QT@ZYGP>N%LD'P:,M\"
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MX?%^=^!0W"]GL8Q&S?)$Q=Z<D*H_X\ *=,#LY&%^9&GI@5E$<U7D53Z*EN]
MB__,+89G5S^IAV$8(KQ^DV *+S76?TMQR'M63W;AJL8D$;RC5:.[0@4#8I4Z
M;N_3X#SSG^CKGZTFV&$:2F2Q'\ZG79P0NE+Y1-91VJ4P42I92JIXK].\7(E5
MZFK;(Y;7/QI^8FC02_XI)R?^1OK'V9$DI?S[PU86KSPT?SJ&_&21=G.GKF7H
MG,_X?.K.?NIQ,-?Q:,6O@VUCP\K=;:;2*8IT:QM$P%GLL7LM?*UP:0Z+K0W@
MT6J>.F+C8ZK,1D@*'%;)1.LW[[IIQE\,LD$T[[6  =U"?VCW4N&.:'^!G#U/
MB&-.26]*@SJKFD')TJ]OSN)J$WZI*89MM2W'Y34RSK%8O2]/,KZOY$?A&KN4
MWZ-/.8IJ@=8I:6\-;/'6&#-7M&V)5,D9L3*&P?BZLTD*52Z&Y\X$QXF)NB6-
M9;:6?NVCYV*?%/*M:5/@".:M+7!/"^'JXJ_(NMV#2VWY>]I;COO;AH<'\$E9
M:TL@(R,;QQ;8%0;P6/]NK=8&;F4AA^(&$$,##*#0CFNXB$5MCX13\(H_*+@-
M_)*G(THW64L=WQ96.E8(G$R.T/OAZ&,B"P=%;3@SJX+R@KLY<N%RO R\.@^G
M\!SLJQ]<IZ#65QQG_ *Q1Q'#L])A7UL0W+"Z@U5(L+JV3PK_OKU%)MZ$U8<!
MOMA/8:6U,5(/MN)6]??@'XC1S]H9?_>1K$GW\XW+CMOK,^*90(\A:F3;N88*
M]HRBQ?+7;_7(;(GC?(_M3*[E$J%OZU>O"=DHIGXIEX!Y[E)N,N1.'M;D+J#'
ME0HV]3BK4DY^YGCT:U]V71B1,*_X\MM))Y8LV4:PU7BR'E)#GHMG?9C*AT[#
MKTOSF[_KCMY_6--=/8[<Z3C;6[VZ^&,'0[;6Y.;<Z>X6GM;7IP?7L<DI9Q)-
MX,\U\!PRP7-#&/T/N?N'-!D;=>#\++@?/S39LC^"IU&@ZBK$'-S-]CL7>?^5
M"XDUXDGP]FS'T3X,B"9.<>H5LOTCE#21?^72N<G-Q7^Y)/MS\>2)OLDWZ$^H
MU1@\ZKR_5L-_W_^\/]]G'\][F3\%\!SN37(U#/BS ]1_'BMRI&&=Z"_>PXN
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MR*?$(GB@+J*M<$H8^65#U"5")T#ZJ*0N@H59L<YFW0>3Z#US\L"GY0[T%I
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M.A:!)V_,!K&K:?!U;( JPK:3JPBSDR?5EO3'N@9][I/R= ;AC_-!DUGI/\<
ME'G:MM(<SN[%JQ=%@0(6V&F4/)(4E47%=BF!F*'K1ARV30T1BE_O_ OI\?@S
MO2N3][96QOI!(TU3&#:X!<F*Y':Y3$-F*I+ F%U*.'C3H.46^P%56Z=7R:!L
M/$2<_6MU0\+67@#5*9-IN))HS(2@EJIP@@*@^KCNI.C]:O?H>L$)>RH$_6)&
M=M@'<6OQZBRF-0"DWW\X!^U>@?:OBZ09?)K3M0I_Q_JAA[DS)COX"6CC#CLL
MD#NRQ^5>V.F)"37:2 $V@:"-061'-<$=$==5^V3=Y<,A3P2D?4:<Z=JIT^2[
MOE7X^FJMT;6 ?.PKX8":K[K++[)VGU9#2TZ"Y+A=HE11II(#&2>.^"H,Y,-4
M90+R1PB(XQN?_Q0MIN(; KB8I7ZDEI5Z;W1#Q/875O:3]ST(E^NBOCSE5B28
MI]XCG)5BZ:@6)-EJ=[N._'&$MR=<%>VA.>VO4"V[3HE^SY^(X7.%RY!+__4%
M?Q97GGU\3)30KKXX]U0KN 34?*^O'%KA1N&[&FH]9=%1YZGV572$+DX(_9J;
M:D","7$7(]I$J7[6OC8M0WJ%4OK! F1@'8?&B!MD6'HA(D4Z\&HNPW^,\3KN
MUNG])A'T&70Z[-7)H[U1%_P6MN,0_XIR8@2,[>'%+I)^G^+S'7'>'<CCW2^S
M_K+E>_I%[Y[.!,W2(>GMR7X4Y;*4U$$UV!3=M)A F?ZH$W&/DM9WM@L9/.&#
M=G@X?I6]M+FX$S)K#(_(XL%3*-MZ+K@C;IQTH/E/MQZ[<SZ&;N(&LQ!!R$=%
MQQ^W!24O#1NSOD2>I7%Y-]WF..6B6!9>]KG#;@8.-4021W"*'4+]YR^V:O+?
MM .^K=;9@<\QJ*\>P-VQ?_NWMCAOBRC@VYW2KG5S\@I( [&_=-6?DV9[>E>?
MM%2'S"'I6[O[W-ZIN>.O.)?=/M6W#--.CE/DSS/1T&O]2' $N_:\MY(@2SH@
M-[<(_=%(M57/Y*_ZHXB#!1\;203W)^9B[6R7\@]_3W73OW 69.0Z&/ 4SI7;
M5:"1=LM'NOKS]R'G)K<W$K=L95YMK[RL9L51;P/SBG,C\G#^<;+_.RMW^D_V
M]UF^!;+K??5V9-.??F60UKBIF^I&KKC9ZZH(0249$Q+C,<XPQ.[]V);8,]EG
M+2QZ9B@7!Q%K2&=T?#TA-N#YPRR(XUXTTZ J[/;5*6J[]Y )4W"!%X4[/6),
M'F/J_CY&#\YJWQJ(I(Y%RM*;[F&3&0=):/>NE>.G02V@A<:GS,V8P3#C$%]Q
MLE7V*GL@,ZUI0_PBL#5+ZQI<OKQ_FUP H@R6X1O(G/OZ[3"E7&[B*/Z4$"6(
M&XVR&'%"5$'J>';A( 0&3(38/TD:V--_50^'%(BRW!ID:H4I#01\3:*Q".89
M]40L^*?/^_[O3+UE^N 0(O!1T/NL+GXX/K.-Y=E^=[V ;U+&W?)J>7)(1*F1
MH/;@ )WHO(S2J%*$7\*47QXZ1.=+6TNHPA'#AZ^UUB %KACGP#I?MM=HCMI+
M [RNW,EJ]):N*/IM>F0K*5[%D,0B.XXBHU+N >'L@":JT*14??0Q%AGCV.ZF
M&_<*G]K&@^G>!(;AQ\L2"W') \9B^QK*R7JU(SZ%;Z:X+3^0#%T49L5-M]1%
MSJC)JLG]^VIZN00IZJ)6F?$@4-,T^T^R0/AWJ\["W]66*O+H/[)V%VI<<$VE
MJ"!;E2&1/#$"\3![:9LA&JD<LN]6B^^&O]0/&'#0%HBE<A 15TH[CA2/@H^Z
MZHL)5Z#+5V'.3(_FWVXTQW;>FAG3TZJPQF_&:9:8:=[G1VV0=HG.J^EF4DRN
M2A_?DX&6T#;EO+RT("V?(W'*%J0$$:?J=^"EO\8!I;<E@M1=)IJ#7$J,]0F4
MOS@LLF3T)>FF6THG@-EK$2:NXS9Z&MYSB,A3=7!6X9^H]&9]T X4FZ[UG-B<
M++=H4>@RHUAB_\%)?1AUIU.Q+SR7YK&FQNNET&$?*F2J(VBE34>A?5\_-X^.
MMX[T\3FF0)"SO,RX;W^%D#(#J>ZY,TFSKFV35GYA:GW#]*@[#['F/'_L=9'A
M"0R00%-Z**J$UVKSZC5.4B. 2%#G&0 #.$Z%Q/(EX@,EMDS!MOL=Y^P-4"0&
M:HCOT0,&7(V_13.H5;->/84!-)=Q4*UK&/ YY&^]?/S;%8Z3LEG@D?MW$)D;
MG0VH%?%E)OR&2>^#?TBK_6G4%EFB/X;$ML7^:1)[\\GD;^/(_^T*[0,"O:O[
MCD&X7TG_OU__ [_L0&VMPC#@]X!VH-5S]@[X@ 8S'DH!W(CT1?4NZ3JXA?[&
MQS$5Y?5)II6[5SIOXDQ#?^I=[[_-!*.KJ-3=@..CJC5S;PSAGEGK/93\X<Y?
MN^OXK^Z,(K6^)/ YU3*-F]ENJU=KO'/-RB"# 0*;.G.V3I97'6<\8T65N.-A
M)C#@$5Y-SHRHAK6EDQ-QR(L"!>UG-RBDF^<%<Z).N3OSR7/S.G$OYEU1WYS1
MHUN"#RM]L^R6PK2_)/.Y<9>(A>^^7%VY_W [2_0KMVH/!GP;$VX(?Y0@RI48
M@[*(?\]<5U^W/B\O((ZC^\G<AGC0[59[IKG@HUJ-SW#ODZ!Y@0)_R2D/)SQC
M&_YY7$4_"YT#SI*;G.4KMXN<JB.)3H:( J+$B'OPMX$9495R Q"$-Y!FPG1J
M(_F7/&):GQ/7,.=B5(!0)61#K;V^WB_<O1,7V<#^1WJ@U@8,(&K%7P<3>'<H
M9,YK!T-F*<UK95I<%:3,!J@/8X?;[##$7JN@RUN#6=7MJ"05*;EQLR@V1'_,
M\?X4$)(MLJR9UO@^H)I'P496NY6>G[%>5=CLZ(C8^$CD3"GBFT&T*@WU0GCG
MP+T_]G%10)$FG-&;@5=/H(2S;OU-.;)NB7:!3$IG%.(4H4H.@Z+3W@A==P,D
M!]IL1Q=#[.P)&R]BF/+>T+JX8W_BFB\B<'OJQK%+GINXKT<LD/K-,V'(*5^>
M=3@_ESQ(@*I'L-C]0$<C683D(H#-WKI)HTG=E$8.47#WY8[_\*4 ?-7/#?Y7
M;U3]SP3"?PL%N?VUH_>'5>Q5<@G)\UZZ9XQUSQCI\=R2=EZ_5O'_O6/Q!N29
M/-=.D(SAK2Z8$XW'AWA83 =H7^_J0AE@0+SCT8[$^5.M>X,JQ;6JQW:0>S+_
MVZ@Y_E%>S_H=HRUG<2W ;6A@39+R,>&)3NA%!\YUD<+UV[5=\:>KNGLUR[8I
MM@$5(VY%4AA$;+SHWY?1JT6TY# 04G?=6ZIP]L"8Y7S1$@:I\W<86DW39((7
M:9$U8$_&#_G)4Q2?>QY[SU(<( R-$R!<A/#B* +!\FJ[QLK'(WW1%7:0T8RK
M1?)> 7'+C<_I?+GEKK54FC1<S-7-2?2E*4*.4B0G58^NQ_N,B1KF^/AKCR=.
ML"-;E;TL'TJ*5\8)RZU6?5QXJ-<H6$V=%1CA[/@7.DMG;4>4.,\)QC55C_0D
MK\0!-<Y(28\;0U]OX4)@_PZ9@IZ<'@4/X>#Y=H7?SIC0_K_?S?J348M#IP6$
MHZBQ.-K[6*M?'&%ZJ<M>)1 Y4SQPS57+OPLD@-BT4S6#L)Y-K1"'_&*?[%5A
M_?0XT-EU,W.@S0_:D;VP7X^GORR=,$!+X![OQ5*RAWK(,LR;M3#=12971U3D
MD'^8@'+V- 84ELQD(#1,1X$^K)BI[,OM +E;E>DWZ.W X5M%O\Y:ITR)-I^B
MF70LB,$B'Y0+3Z ;'E812:LSK#OAB!7UV&B8YG7"EPAC99QPN)!7>S1\W/)$
MVKI0<3-S=E^_ZM?1CV637GR[^52_E,8X91=,KR=QAH+;;OU/T"I#5]<L0XHB
M*EL5':A3P&XV]8Y=8^// _="=KC>OARO9L>KCY^?M&U8W?,O*[$SICN)#8&2
MV^FGA#\+O@=-[1[PNC"NRG6/CY^81[E723O(#PB']6-Y]? ;L_D9L<C6!A\Z
MG7OX6'?>)/FQG\U<'A@G2G128QA>O^; '+)]/IW=XO<]#$*BD%!]\TEP,X#%
MO&<5M;8*&\2SU^P[0CC:5^N9()K(^SE&HEGHZ&@E4KS[(_WL1Y%%V=DL$7"W
MZ<FCH[6^H[[B5DO*6DYC[L+W;TSHAO7X;^Q7_7SVC8JZTWZV7N]O9"A.=+,[
MG-\,4Y4TBVX<CWII0,?:T;-ZL4O;DU=%88"MGYKS^L)/Z$VDB&)%_+&3K EU
M5;2ZD-ELIY8M;4:R /#&4:JK<SU2O,<YN3[R+L6C:*UIP3OZW>JUS\=-\DDX
MX/"Y/X2XWMZ+:VV'F:&(<*! @V9G/ E=EC//X2(&XQ+\Z98IM[SW#_+.#0.@
MTJG6#^[@!V NPWH5HNS"T#KQJEH1@X@\Q5F()/_RF0%Q"8AV?=40I*>]J%JO
M&)$1-8&'<+55]AURG<G#L7AA\+PF.M.HVM!E+-!)7^<4H[W_2ORCVZYN[F*O
M!(1AK,CV4H7CD41-QF+-O$BS5A:C#@S(&I0X&OK]^&J38D4N]H_650[K^,4O
M=HLA&)+Y"J%+AVS?WS67WPAWW$.E8$"@RO4DF&;KE+<#70)][-0#?//P#GJ?
M=9(W- L#MB^Q[T[!_1GWP5"YV#7Y-;V5UU5PPO0%O)H(Y?7YW4/77WOHB,^[
M5KO6]DK\O=7VB_IJ$P9$4_VIM<D@QZ8-E""0,&,3OER=W:$\W$ALR/^Y-?$I
MQ@V91 AUB/6?>IY!7C6!3M1YS+ %#N;?G-R@N$6YO,MDZH@S&82#Z/./_R$'
M_JMYK[24>A=B$]A]T=T3'K&5_3C.;6!908(?$KMYEW] X3A(GZ[S54V2(C#O
M60O'NZ<)IRSN20?KH +_4)W!)8!"YXVPML1_[WEHJ9#L)UZ#.IM7/["5ZT,=
M^(<-/C:H@KVU%!%C7 ;$9Q#,CGK$*6;PU2)@@.3T8:+&=PYMD(6+QQ=3T6^Q
M68B%;A$)JY(3!Q6_V [<02S>[AO-4X('D]K??T1E(Z([*VS,S+\%=_\Z$?;F
M>=DD3G^L>>5;F$=9!L(E[:@YK[,1G4K\V3%GX4#-27$6D\2>=>*USOBAXIZ\
M<$=I;:=.V?-.LUK@K(\%8LB6BVSP0?+-(H5CY_:^)-6==>[.K<?%3VA6@;[^
MLG']W>>U$+5M)QT:R]BY8B-OB>Z4YA?-8MNAO&71XK:I6TIZ]ALVF>JN%LQR
M&/A#8J NWM5P8[X3E&@HOMWI?K-5=.'^I1>NT8)BQU!3IM"<$*'X&XQ&ZA84
M$46A,;NK>[9Q:LB]8%K?U=':#IM376*>G@H]=[DV@B-]>"5[S$92]Q-BB@O1
M8X1#I;QKW^Z-EQ93YXMZK%H5Y^M/7W"B4'/+#HS$Y3WU?7M@D'1&$<@[ZP\2
M"#KD"Z]=''(?IPH(%I-1PF1SFG1@,&4U"-]@:PB6TZD($/I?QOU_-(KY<(E-
MEFP8,+\#IWADS1+ZVZ**< UGA +MD(=/^<G;&7E/)XT?87GW VJRA%8(__C,
MX]_9W[\34)':?WQU[VL$'VMS]980L)_\%R]WZ0BY;%!CZH_[/.YO %$D6Z#-
M=# I=E+=W[I7QK1N:QSS5Y2"O(3SFS,BOB4DFG5_AVYQHUJ8MF"E)Z@8;DP%
M"5?A""NM17ZF>[,S7*#W6@HI!F0-5*(BX09CN?K6AX&LUU /YO16?W'*HU-S
M%K_)QXP3Y)N/^8CPL1DYE/=J>E[V"Y$Z_U4]T=#/&M^D?K2K$HU7TWEWSV.Z
M%[ ^L3C5,U!)TB$Q4K/+HQ#FR )6,,#<]C&;.72D=L$*:ME\@_&!7&@IW;](
MK(_C4COM(>M9QD.&'6L^J_'JD G;5U?7QJZAS;EH H0,JL1"&:R*5F&/?&<(
M_YWW'"$&AMLPIG]1XN %7][__-4XA%'O1*AT,_9#8.P#0EG>1:5;+_B48 *\
M?P[>P3*BKGCA974ACNHK\0TNPK7?_+\HPO_;=!#*K@_/7L_585&Q$?"-ML8S
MM*@X$S)BEO\,!PZ IXBBB9*4?X,8[<Y=PYB2R@5C;W&1(/JH52F*R9RH=&0Z
M((Y+/W$/#OL0#;V%W1)G&DWV(\[7!J(([W8ER36U)18]8,#MHQZX+I*Y9[IS
M[( #D"[XF D< MBKZ<( AWD8L(.!#7V,?9QW %<R#PBF,* S!TJ 4"UK.E0,
M4NV=&BDP&""+JN'[CB!?(I@?IC%[F*U74;NHEVN:E"#2.;PJ_1APG/S[KDJ_
M[*?,X]<277JJO\H/C>9(^JRP'_<8</\'?YA1/8S4UPP7=^>F4;_G?3HBK/^R
M]P0%R5<5^8%P;'%?/V3QJ[[>]R7NAS7"TVIJ0_2ZRV4P-.@+#/BA"@/0@>^Y
M7Y#+2LG?V? NFKL2^X0=E+6RN[20C/&L%/UG@9H_-,#%6#:KQ#6!1'=L_3X,
M.'\<!E=G8=>JR'V$L9>C8.K3O_R@U29\= !Q)[:BPXUW54T_$.-*!5K^S5Q'
M$:H*\C#"%JL\@P%QD&;<J:8'/W@94C\$9#T0S4X\26)QL^M $J/>$HY@*N7Z
M5T]T_JG]'6K8S_WYS<]B1*M_J4HNL)_8I)8T$M^Z"R!O6Z?J^01D>6799XW5
M,V5C*@?R1G9?<;W(P<75TI(#@!AF/XD;$CZ)JZ=09;7K%*AL2T?V[RT]MTR.
MN0L.[-WFP[)\&8+YZH<D\QC[ X?18,'+9T$BS2R#YT>17U0J]\K<'*,+WD<H
MBVV\J:)-9SD<VCQB)('NEGZ]UYQ=^SK3>B".E# A(LM,N6Y/_*-(+2BC)E&2
M:E36)QT&$+#].+4(4TH]88QF0(V),%,N_]:;.//XKDUJ_9,X*V1I3[@_J^#:
M3[4ML_NY,5LVME@>\*6K7SBV O!JAGP6E2CNIP$%7YXRA>NXN&I&(:RT;K^&
M >^3!SJI""=Y'\A5:PQ>A/!),//%**QCA.K>_&PP%SQ(;<SDFJNJ5.Y6-LT>
M &&U?EVPL_N_>GG+H+BV+5QT02/!)<&"6R!8<'=I+&AP3P@$:!IH7(,3(+@&
MM^#N[@[!+;@T$ER"6R[[WG-?[7VJSJEWJ^Y[/V;5&E4]9XWUC?&-\<TU5R_/
M^1_^=(BD6^2^P.9%P4&+?OE>4UMR@O;L6R!!?Q\/EXU6VTRU1,?SV ?H_V !
M G6F4Y\ZMO'63=X_>6SFIQVJDQ/N+!]W@^?S:W\F)4OX76D-N0U.,-_ME(4+
M-*^[=-")S$ZZ\L?!.)*NU*>=K]2^1@*=VZ7+UW/:*2K5LZR.Q(ZDN\G>-:0-
M>#L<?3\Q4;986AS\Y ZPZ,=ZPIVQ"&U?R+*EP*#D_?-STM+O[>%Y)ST[8KWU
MMLO'XB34;2R&4C2'<RRF'H5T(2IQHY4I]IJZ[?L5H-/STN,@W.NBH=M;<F]P
M4XW?I27;I"IB>?)0^J=O.8T"3++DD)S)%JE"*5,WF'?![NUZZ(0MH0@W-!IA
MKV$0R9W,S\ZU@%LE1.]S\P;$BV95.9D94C%BZ<%<H)^90Y=]0>M_\Y3Y:ZNH
M$'8IMY)^U$N;8LL"*ZSWMB[8 TGFL=2;/UT$#W\)O9QHJ[_VS5^&H&@U3Y<F
M$Q^;\#Y'-DLAI5AA_P-T9Z1^VM6X\ YVWTXLV1/C"4OXRI)P.1' TFC@.4)3
MR:0=,S2$@HJ2^Q35YAZUZVPQM#0/F03=;"):71UO)^+^VYB4TQ8X[?9=(W\F
MMC(&98CJOIY1,RQW3\6+H+&N-8$]9?O+(::FBG!:H$JI4QMBQL:+IAK<Z[HY
M]?HSUK,1ACCHMKJH092B6^8.%>:'LNO(?KV@\'5RBLOQ!>,]ERK/5;,(^6R+
M\5CF K5F)$Q$5Z30XGQ/'3]OCJW*.YF&M&IN=2;KD!1K5RV!Z%;G\TP<C>R6
MO'TX:V!"VHLK"LI6(L[A&OWB8L\4ON,E_KOV[MDR*V/<-UN<"Y9-L*GZ04R8
M%5_16T:Z_M%NWPX1/J=,'(7LEG+5T]F*-K()F\/TOLF-;;0CAA@G>OHS;U\4
M,&::Q$ZDGE-D^+V$>W+<^*OT(^O\IKH:NZ'9H%<@ZQY\Y8.=S%UQBNS/N[=:
MGYY*V2:"Y>/N$Y7#8744;#,,IY_C+5UG)W;KZZ("=?R:6[O[#/SX;&1 69T4
M%_,6E&= [2WEP[-QE-S_)IF.6O\22#B/;7^ RQ1M<4%ML7+O 6VII\;8_I#W
MKUJ7T?TOQ02F_O]#,9'#%PVU]F7JE02%&K.?^SM@I1PD3:&2*LN"%U1$D)VY
M55')BV1*I-:^+:JV!7X,7>!P:>1J["2-.#A]M[2TR)L%@Z$4Y@QC[E.H;ZO:
M:?,+D[F4)<C!$W@C-+3!Q&;OHV0;BMI_-HD](%K_ 8Z[GC: @ -;LG4XQ>FZ
M\UGPQ]'5J(@ =R<>:EYS*6IO+"):Y"JNL!W*)+$TB.4*Q22K-3XH?W[$K]\[
MJF4KY/RJ../?ELK6%W^&?PUAD1=CWTQO'TTCZ,$UDG?#?"2+V!8GV)9%^.G^
M?'HV^]I%WE#S6*SZX+)&4NS-@!&[0WJ\PQV1[%-'4\IXN#8^R<1V=RME.\IJ
M;DKL=C"0>"S2)>-B&$^7D:2=DKDU#CQI:):*3S7AOW>_XJEU6U]^M0&1)22,
MON%">W9&M+-V.EGV!_CPI(+/T:K_ .T83QUSS&@$4OAL3BVQ6_O#JR4_9YR:
MV[#SO..JQ_''29SU\CJX[0(?#A=Q'Y_3;J^M4K8EO@2=Z=MJ]2%M4<G3Z/,"
M:VYRBH4NTG?Y\PKCF6!;:C<J+T;0JTE]"%*4SO!ZL6;<491D)RC#T^E[J"(_
MVX=&/Q4L&6[Y+5D:=LRO#^.R$H>&1)=LD4_]/47L[J1]7</DY#(:.]?%;I;7
MFLTY7H7ZLV$.:BWPT?_C&_,6G/4L)\&X!.OP,]#T\^G0$.AYW-1"[X>3H@4N
M6PM -; 5-B5Z,?W/&R20],;Y=6;%.R<Y-(A<MS:X62X4A&*!&&,<_,/LC:=H
M$/W/%+.^WG.R$WXR30/+%6MUG&LPJ$.G9Y7-E*&0(JDLY>_@%[D'^7XWM/RM
MAR4ZRI"&SNR&T7E? 'KYSI1;DB2EFQ-,S*Y%%>;K SM@&ADY6UZ0A[BXK>\>
MID(MOL?:LY]3I6KUZ+V*B,HF9QL)+5#W##P0C8/G_!K"X$W\"&S&(CZI&X>J
MUO@>6#_7M95T<#%-,R)N^3*5<[]5-!MK=OKVAD +?ZS!J5"QS^3E3:1W7TV)
MI]!W_6'GOJY1E1H%<[7--T//0.0B15=_!U2<[&S,.O&K>^PUU"9&[+4Y-JC(
MVY$BTT,K/<4[5W?73F^XY&=S7X.Y[C2B0[I 7@;.+JJVXG&E;H!.F*AQ3&JE
M]:-3UL/7G*?J\FKL\?[-M2JB-]3B"5["O^#=?>3^A\6CHO84/C?SV<+\^9X#
M3=\S(F%VT7BHHQ=)A]GDP3>*C1=BDSY$=Y"_$*W->/@#J)SF_,/*?>R;>))V
M!)_^ )^)[IGB([^<?]6A>%51'=W2YWF#T;<A1R[R"W'G<O;I!B4@8G>/&7#9
MOQN*?W=5D_OD,B8Y=>Z32C4S'818A=J5*L/6':A_J/WK-WICCW^ _.N)?UB3
M_Y8\"E?="S)=G>&BHV),FG$9U&X8TXZ9&!F+>F(/R"5/U+[U#J?\NP$"3P0/
M3)8,B)UW>G=E-DUP:]<D\$Z59/]^D6F*CHG/L2O^_$F]_F?\C,:D)M9K0E?O
M!$?!@82\_Y-.3/V7O!$HRO'_"Q-&X''A+XA8GTSOJ7N+?UA6@66^.3(N3F(_
M2S[JYV&&4BNSL\/V]2C_68K>0]P34EYEY7"[AQ<'- [C<:;EF-J[E<:6[%+^
M/XZH[XM/FC?7?=.=SZRW/VI3.$./'C%Z[)L4^_7\7[%1K[9N'$[F,&S_(597
MXWV+\==?5,[_>EGX'U9^P;6';/-47JT^!K_>^UKC 2.<+:TYF8FNP,?A:G[B
M/X#J$^?%V_\CH-03YR9H@IK?0#%OG\*AW-W=I%38@-(U:BQH_NWS^F=5=^PX
M!)?_FE"]?^'S+Z>9!94P9!(U_2Z@+)(=X:14@0*LD2>96#B'I92/?K/>5P]B
M?9%_NT[\._=+'J2Z;WDVF:U8#K)B?\BC'KVC8P9-G61B_ '^H_<\CEX$?5O_
M._/C?MURAM4]<?W(1.4D$_F_Q3$]8_WPU>@/O=; U+*2'RI1C5LAY*U[Q_\@
M-MI_R>,9F2<>/A3,Y:A4,WXXJW/#F'-VF"SS_D?E!_YS&K]K>9IN=]FCH]N_
MJ4!/.V#\#?.I<V"1@JGP<G6C/&[^FOW?R@!9$V^$J9F@6<P1J03[FW?7&KR"
MV)&VI@2%4P>Y%AJT?%&MWDQ [7_GH>E?"Z+_BX=@+%1PI&I#PQU6K%<FV_39
MN_"<5-BQ.)'W?TD]XP-#RD=?7N^K=>^N0@-7#[F$QU'8>W,_Q)NGKN)9)B*D
MBCSV'P(?97'+A5F6^%&VP%>LJWC50E!D- -FP[W/'Q8=O[KY9CAZ+A?0^UO$
MYNZM(H,V0Z&BVSH?=6DAC:%59/Z_G7G,R9_+13S;$#1+(5!M/"-*Q6YE.F?O
MML7O1I)_ 9G D_2]1@>2_]NI4S7/L'[S,<[J_$^52X_"3,?0MW (7N>(Y80X
M68;O>?$AI73"RN62;@@#IXP%_6\D#!_>HRNJ>KBAV=->%2/;0O1U[752"23Y
M">G9)!=KFGJ=X6))@K/"FE1'N@1R^;*]4$;0:!N-J[?1'-N]V*M(]*$$;5&'
M#+'AA263C$OW,P'RIKGL,'AZS9,>; _C5FRU5:Z*Z%TVKVOS6X-^ZT,O]IOO
M7X$+O\Q:6R;<49F^*%X,)SF/=>+%I[:CEW_Q/ 1M4&C4WN% 2-M6!M!L]C'4
M';/I]8DG00,S@<'\M/FS+>62)V(ACF-$KMZJC8@0"+.,;UCL,2Y@;$=R\Y5W
M2V"W<\3]XDGX1>P]8L^67XPHG"UV'V*"/PC'NO.NOD;%KQQU8<;M(#/!U*Y4
M$W_A^-.&U3%%"-+8<A><)9U@?%RABG:O9"_*.\%#;JHQZ5U]'LLEW=M>(WR2
M]\,//2H@;-,W1J"#MM4E3A65X.1.^I30/V>/=X6^V>_LR./&AM!"-\6]3D"H
MR2%=2*O\*ZO-&T]F-^2RF*::'RC#LBE#NMC>(:VHZD)P@G$U<0JE]3?/KK_*
MGFZZQUV6$Z;6T:QR+GVA,L%EQU&=AQ_YAI'-E; /11\JR@"N-8]8,]\A V+K
M+SCF#5=9@BN-_2Y]<-(U=I#JB1FB8XV&_#]:M:0" @(\]"\0MM,%3T;K2R&7
M5R_)O]4WX I_4K]37GJMA<Q[@1H%YA>YU3KV<81*29S$"3KG($HPR1U4%J,P
MY>=M\"_/Y1/,/07.M@>+J.<SU4G8K7'0<69-^KN[5?ZJF\+(!A)E;0:R6RV7
M0&&ALMVVUXWMTS,$1O@Q/V(2B*P5XFZ\ ZB0W2[*I;)]F%98IQ.X<E-#"*:H
M\83*MK3ZD2+@//!;%5]1.KT5B[$"""$?[Z7>L-&HGZ[+6^+?U ([?G9??(V"
MA8WS*?$5,[TBU8A@)LVD6GB!# CUYYTB^[ WUEMQ,N33;)M1! ;/H^="@5HC
M6;C8LVNXUJG(8Y:EBZU3[DC^H"5!U<!$BW@\@Y]S-1F%RF0KK]<[I;JIS>E/
M[?41DVQ&SE%(1DOU"LE"*6[?.7J%[?E5>S5]J2B^4 3Y<'B2OO?.O193GJJE
MGW>P)>Q3O3OAA,7NASG")ZN%O;*M!+<BTBB2K'^/V=J_DF30D%O"B4_3(=_#
M414HJV4[S'61;@A)(H4@VRED2/VRN#.K^TW<&-Q@>"<5!I^CB$/H=WTCW3)5
MRVI^>R4'95/,U\0K[4@0D-RY2I-?DJ?;J4.UVJT=MK05%O.V1)>GBQ4_#8R0
M(.4%LQ.?BUYP[O$:?U1,8C,-8OAE9M?^A:%4O&G[6[>:;8U/$ZQW&%=<)8[/
MZ!Y/G.+]^AC(-5_YU#FR8%DRNV]6C(UX,XEX09K/,[R>]+L )><);,2#'K:S
M\2:@+]*KF#=S&&)JEU"]_0JS2I0WO&%P=-WP=5N-&C6D03SX,"H)=< +)RL3
MAW:Z!6LCQ/-=R1[*LA.&8DJ& -S#)VB/C;<GORAP3PK6T>N>[F_I8K9^*#KZ
M:"NZ]PQ?X..H"SNQ\%71V76B]%?U2&6H^M+2(/47$SOG!L-%_;M\LK"+PN.+
M-#ZE\*WF)AF=-'RE?%A890<+JD2, #="G^OO;E&:64_9'"M!KGZ:!69D^6]N
MJD,Z>,SE6@"BJ!%$I4./,IB;G$'=OR?1;L5@S)N^:^QYM5MHA[V+XXZP(V*S
M'B,H_G0ELF"_#:-E\KS>+%T]H*A!B@8%.>IYQP"20Z\]!=Y)?BAW.87^GEY@
MJIIN;N)\B&)840$E(\;#P06E2T.Y;K8/^IF20\?4L&BEB^UZ0SY4X916TV]-
M=E.R^,<U'4I4Y0<1?I'BV5^9Z)<3;H11W8E">-ILBRF^2U<\/:ZK77RBM-/0
M_(H@4K?#TKS7'LW6?NJYIA(1\W097<VWC*"H:Z\<JY<X =E3M1A.]=$?S76Z
M44SR*5TCN%+/-S*O8W.LFOX  =[5-=\\YRE<%V3PD: ^.V$G;OTHS59/)=B3
M<KT<SS*=WN-!BSN8U#YV*!%%I99CL<+DC!< JQC,N;E6RYL*Z@/F%C_!& 2D
ME7URFPY:!9DX&..>R*<H$X[T3UX=6/.HN;&6Q%9&_^YNTSBD<@@4<8@=\<A]
MZ@01U_6=*RS3]Y#"/3UH0<SL1O]!4=^^"7.$.,G=_,'G=].I<UYKRX)_@+<G
MSAGY5@JFC?61IFP/FYBI'\]'.:9\%YH4&$$^U['KRPX]>IIA+ZF6'5YL'EDB
M?M<EQL=UCQ<.LQ?94T&V2&PRSR\V,MI5MSP68C'!\&5:0AX[5A%8Z8EQ&#=Q
M+CL*!09."5)O(X.<2)D-'QU/.!D2[DCIG&UFMD0)3QC"'%>?6PHFY)FZFM*5
M&)G,FU$HJS(*+-GC#,'F> YK5$$D4J_5Y9!,_4//2,<07#.&ZFLKHN-C=!]'
MG.@7N7024KR3QMAT.=OFR]]G^_#_ 4 6"T'AN<LR'M8LD[K^,E9/[=%5E:3Z
M<0KQYU5)Q@M7;<WV.=L+9N*%O86-6:2$F2.%D$O%QAS@)+/\\\6O:574;ZY\
M7>G<DY[OL?/+K;3F$D#*O 6AQTTXJ9QY.$B^4?IMS%.__OD0E^->HFSW\>5X
M66VK6AH4&L=U8V$8H0P 3ILSI+:DKO9>Z-UZ'A?5M=,$R4L&D:S?^QQ\/$ZU
MA6771YA[]>B21:LQABUIF:MHX^D*!S8]9BD*3U:[!6LC(DUAY$/ZEL]HZT,%
M*AJ(]U,W3P3VQ;%FVJA_Z9FGY5H]JS9:M+)K[<$AT?AAA<"PPSR*(S%8K @_
MQN1-(3^S>K;71_6K!$.2CE\=+O:F/5?Y$6,\K[JBIBGD**>B/F:6DC^HBQ^X
MW .(18I?B@52O- 78/D><61!%\&?1)<B\&S1EPY;V2/= M0<(9U,E_ *,P+T
MFKQ74;,4VEOZG7>8+B8XBLH-6]?G2,5!R^+_]9NS_S9 ,;,MKWE+"U8,RC*I
M[Z2U3@,7E%?9##<OCB<; Z]ES5X&U3<'3<(_RME0?;'VM_#:)+N PL44+IX2
M\T=->9#Q^VOO4E<K_:^?!*, S[#3UP"@4'GLH\RA=2^TIIA&VFNJ$[,]-2Q!
M32%-;Q8W0,1,^WSHU6J<:>@Y$R-H\+"->,^9:]509Z].]>V5HH,M950O)TD(
MFT-S5+\/K%?8\S4LJS9S9E)$8C/2Z0#V/DR"5Y[(8#WH<U*Y9K:/L,>[:S&1
M)=[*Q;W3X-+,<,(5G9"P 03PYT:D/%2*](MQG6O"WV]/V(JSPB5LCMC69629
M- CE9L0%&/RT+\HEGA;(]@[2=H^;,AHK9,U8=!D3R4]L8.FGT!T0/AC&\8Q4
MT/E,0#0-,C:85X20^=Q ;!P<^;AL,A@PUU)!NT:E,H ;3WN7= 1A76-C5;KH
M1VQHFW/LP)D_QYB0*VWKT_8%?4YC:K26-7>FMMO*^0_P\6>!Q$WH4?Q\B #P
MW'>VU3D4\'L6P'O:15R?D.5"D0\B*?SU?W!N\>_#_Q!WA\+3;;F:],O*^>V=
MQL6&WDZW&.&2:_)OS4D>9@M:J*K5>(Y<1T@BQJX/^D<O)<"#:P3S_=>AD'K2
M>ER.]*1\EH*>HJ9*X@%4_C&%4Z'5+^VX3LQWR\IP55\VV\,P?(8%11JL&R"\
MP?H-<%&JKX+F*1MJ<KQ!%Y(9Q!W<RX:O2P14EZUHE'TVFD;8CY>_(!?EH$ZX
M74:"U@XKY+P_%SZ!C#F^077=.B^6NY>"*PX<'9:OK-5@ENZ -<(#XG=CHX2T
M6*]\6N02ZL#=$N,)VQW"*G:3,7,I_B!F%'5.KN;MP3%/5=1*6>'GD@RA&J[!
M ]$Z!+3[:EB2'?UD7ST0(K3F2=&TL5=\=F(-$$Y83R>A.36-"7VCK&R*M%EN
MW0=G0F1'EB\^,<1&+\T2Y'>/?,9SH+NU27,B__%JA=0C!.SXN__85Q-]I%\5
M8<UAUD?$EPVZF:[HNA.^'8D\H4-H7'"HQ3SVU"^4%+NOQF6]W[^WNQRD::NB
M,W5PU]EAXYB;HSO?:$7W00^RS*H/R4O7""0J;D8&G?+PP"AQ[WF\-])0%B8[
M?5W98IP#,S[\ &B1HF21_/T$>@%G-!AFC#!L*&(W?*@$S>!\+%?%R&UM%<WJ
MEK"6=>2FEDIRHN;D>4J=N19RW#F:7TYL9]G1'FKZJ 6^%.D@*17LGB[,W.=E
M?9V-N&*!OL.W/CI4%L'RN852[>"G/2>FITQ^/Y2LW=1)%IT\=[A#BIG41S+\
MQZ)<ORK..Z-E<0*CL]G7=!&*#6IPI:-2*F3MZ8CNE7S,IY*/A!<EZW[F37B-
M8S3+DV9UK.2WP%\.E_XV"&LLBX?5,#))F]EY28PIG+_!TEFV_$PT5;._^N:0
M\(3%=@M?F\J9H12P&'&PM0F]XNI'KT9& :.CB:"*[)JFHR5+AWZ,SH:6$?@R
M/LFB,L5^48JV4ZRRU&1/O);+>@IK^Y8MY&8XHE(#]6GL6:KFFR_I^#,M+ O)
M>YS=5 VQ=O'*.TE5/8W\Q*ABCIMA3IG8]U$(=&O8WV?DCDOR+69)!^@L$1CQ
MQ141YHB%-U**] ==<HST^GQ7+(S8<X= 46 ^;-G9EC'9$[;&]U[K.X). 7B6
M4TE(V5YG$MC/SM 6,"[H<&5%',0IZC56'H>XJ&+.D#APZ;"H2-%VTUU'#,JI
M9SSQRA0+( X+OY*]?KP,[[L,W=C_?*:,N=_X60NMXUUTNH<J:KD3"8&1_E?7
MMY;<IWV3:07D/FQ>*.[)H5WSUN?#^M+J7S'EB;6@/0#0*?)8.W1=W=T44;W!
MBJ%:$41UB4](](:#0H[.YF'EF6<!;0$M-\(",_,G"$IG9^<HEFCC*OHOI?4'
MP:-^JQ(5#^Y3ID9KVCJP_ [/FY":95F=DZVCE-P]L?DK;;1*&TR/2_]I4]J"
M@3'K<92B)?V6;+IT7OOFKB"D^-U4=X^9T#-*3$^14\+(I^2\W=Z>,9DJ%2Y<
M06$8I58( ,*'<J@ROOF!8<D7>T YSTP-^HA(#XS)%.:,CN+^B8>?*BQ"QK6L
M^J2_-W$AO=*+MQI:R+KU0_M9H&?,HE11\2?[0_%N$!F\LMRX(D@?*KBP8@Y.
MX(\GR^R* 5!!%9D86#34",L:Z4G\([PDZPW!BK:<2J2.CB8=CS0M.WTK**<,
MP?<JD()Y2$6W&59-!<:GL*#@%C/=>-_-5-\8?H)QU^>2;2?'@313MI/$RX9)
MIL'^E2KB.@#QW9HJJOH/ D4. "%&Q<HBAM<D6X8NO ,T[?[ G'2ZXEMXG=%%
ME,P66Y@;,%4V]TFR2Z:?T4X".!TH>?/,E:LGF>'KHNXLSU?(K^^3&]6OR60P
MWP:\UX[AC7#;<Q@!W&7$S8,)?Q2A1Y%&=XH@Y#=5AOOQSE*M1:=2ZIW:7FL^
M\N ;)GFJ?;(K+Y8IQ+T\$!T?KF?9<4$R67=WS,2!%B3KS/A5%WQ  RXZ]M7G
M4JP>G\U>&%,N0[1?EA"]U.Q+$0E=J*H2IO;IP,21[*:#BQ2 )N+CISFCAMR0
MR/S5E&#(3:@-R?R:WQC9.B48,G=:54\. Q:,@[A'.#<+DV<7^ VR!H8*R+3X
M(AV9VW&O/>Y$9[L6MLV]XW>\\IY'7GR- LONA*WYBY._=>CFDJM4(JU1JNVJ
MH%?).N<1L6O#.]G.SW5-U&IOKJZL#MICA,];;064-?[XUM'G,&KOL-)TU\/Y
MTT!FLZ07;H97#<7IE_0P]\&S/= !F[8$!I2H<5 )_70"I2L9E!-.M9%!=C=8
M&?0]2$E10PU_Z_4S6E!1QQV%.U^IU5>.T25?)@/Y]!=Q4)IA%T1NG967XNB?
M\MS@/-:X8%F:EGR#$^><0JO;Y;%[VI>0[[\^U'G7 ),V?;N43/9KOO4"(#)[
MR 2WHNZ!IUC^S^4JGM[6)AGJ2"%%9  N/(Y\Z61@8\)I][3EW'T;ZLJP0ITN
MX,P[^[/C4/0+.9;#"O/)??*M)11!HZ&R+6+]HSFM"<F2.+FRH'G59W)7%8V3
MM/"'NLR3P>TA=,&ZG:BPK?D*P9VL0;(S"U!;T:I5'1<=S08MG4_5J],$4"&H
ME7ZYQL7YW<)0<TX2.CM2F!_'M#WSJ*,Q\NKN;7W0Y(YL-03*!& =O'N\<UTB
M<"/Y"7)$C7';%:?(4KT9#PE T<"O8,&M6)(M8[+Z?2C;M3 RUCLBU'-*7_\3
MNHY7S976\;Z*%RXP2$SENX<%N&-)<9\L]I@U)%&'NS=7J(H]?Z?]&F[(>Z5Q
MLJC[T](Y.;Y;KB'B\#(;._ &B1 XP2')Q/Z.VX%KCT,5ZO3)DA>2_ZM.BYD4
M7'?R_;WN57Q''X;+[6RDFCBFMM;H+):_O__XU'[R29G/"J6_1EU7B3;?V;(T
MP?![8W+Y'8$1QQH$M.0WPN)F$J])_6Q(@R_Z<Y4,R'<"G00>Z3K+<J0N-2TV
M?P]3\K(7#+T'W97H<.S4NL0A8(R\8'II2<C>P\@F/BB".IM7QM#_^>6TIPQR
M<(7.JS,]&8O\#T6Y<Q9Q=I\_"H?N'\(MH!]"-CDYJ=1WBG$%QY$N,-5[A25U
MS.15SS^:2-S+O)LMR9MV)'T075A;'(&!^F(BU^A,7O:>@$,\,G]-=7J\(!SA
MWM:LK8=.=/ 6K9%AYRI2"-8"3O$X&6C?.NBEF,)[05@=[AMY981C7;=I[3T>
MX?;@@$4N83^[_I$H3J9@N<>]>!:!8W'R&<G?4L]I!IEHY9PSS8'*<XI:'KLV
M]I.^_#+(2^A,CJ0Z_=FP0@_INU;]416MKOC#61^AHO D4\FC3DVP/ . 'E-Q
MKY9GL$]!TCH%I=-(UB252F5>\Z^Y(S-YL  9"= F\\3P:8-)M-Y%R1;PL#H\
M/I]BX_;&D;5TKNRGCI'W#(Y0!W[H@/,G)'H=_^TH5F2C56$??#*SDF5Z:5O3
M\P)LD_'1C065P7<U+(IK25M*U4 "^0>.K0.Z$J8_I)\F2(LB@*(&81/FJ3"[
M,ONX-IQO.^FS:OUKD#>[!VXM!0,B4FV06XL=E$Y'AGXE)J\4>N>IX,^3]E;6
M+-E06:])=S,P\!OU.X.9&Y08%,/TW=S-BAYB'\#4:IM_@.;^X6LUBJ3\GM_"
MSJJTRIU;9B$2T5\DE^PM0$.9UZTNEL@^LXYI]=8Q]#--_B"Z3+_O;@'O%<A^
M3X>AC[=>#^?JZHXXO?(OJ$+5K,>HYBH[S&VZ;Q )=^>^-4]SUBVKN;,<AL-B
MZ*WA>?9":FR)>6,D$1X8;FI-Q3W?*1QV]T< 18A=HK.=(4W5]XF24&(3'[!;
M,;</ (  Y]Q,Q$9CTGWWA"_KU6YYI!+V9IHCTZ&A1,6F,* .H6.,9T93OUA(
M\9=GRK!.F>D -"83%CV^-HZ*L_8'H!3[VJ)6N#NA.PBUA$(P3TB#*5Z;+<F9
M4P<! \1]D+;X'ACW%V)5%887Z0:?WT?1?*&UM':(5(CR >/0^ A'=/>W437A
MZM?V13_D7*XR+J)@,X [$?FT%GV26)8C4 3*#4O*#\AQKHQ/&:L>AHDBK]#.
M. 3H8)VO:BU  _<JI[+J4\)J119ZYHG^$/1GVXWA<=Q!,EJ>J:_#I9P&!H^-
M0M8?% R-NV<% TKRY#<P>W$+&-H01L6XM/-K:IO"X8UUH1^=?@[3H&"V?1%I
M+=*9H DW#4>D"6,JZ "-JZ(2G:+VQ5QS*5<E8+Q*UT\)"!N8$))]X>'SH5?6
M@ +507&MG&1X8T2VA[TU1Z\[W^"[*EUEDYQJF0N_";L\TIHC<=FDW*3&:QKF
MPKT2SM=(%E5< 0@9I-^PG\JG#]6TF07W<%*,A8EC^#=Y@8<%,B=;J[-2V@VC
M<I<-+U*9!JC(K.5'OSV=3A*AX+!R.DS?Z/#NZ="+03SZ\)QH4 XF9\4 [?@,
M?TWX*R+?]2G6#Q 3+4(Y#6+?/:((,71@HISBE*$GW ,\:^NXJ#5ETQGO60@G
MT7<<ML%)!"H64.G=A$%&W;HCWW?5;^YJ%K7NI%!3V M_$SNR]M-YC",E>XTM
M<B_JM^R,A="MRY'YN%/(P@W*P^Y5G-:_MO*ZEK&*#DTB.%COZ;E(VND"(JV^
M=-&&[1*^FJ^JJAL:@C8\Y,R2GW_[[H@YD:')D+\N3M;NXZDO%N;X=?_F4'3@
M\FIRL82>1%?5I.RP^]CD=^CR7-E.Y?C1$;3L$/I*^N95\Q] X\MJ]'VOQ7=8
MGTXVTY%0"HA$-"\%AD2D=?SO7-T6);Y.<BES;9<;-Z_2>9SXQ)+X/#B5^<>7
MHSYW E#AX.::=M&,:RFT%!Y"71_*$^C<1P \$T'-+'Z!L"68$5'KH:2B-P6?
M<12_W**8&3!M9]$>[#LRID*4)QZ$([8R#>EN5=8G['%'N(3K28.7BGKL$8ZX
M5C(3I29LGE0PS:@QS_T@7T>^QQ_ ]73PJGBO^"62#'H1.T ,J*(BP-^06%&0
MS+%JK>BCK<7P8EG-_^X^I-=9>U@*<[S8U#KVKRTNM04G0/K\=$T:/+Q%%T4U
MUF&_R^3AJ4XBS%:*&"1ELT?Z<D;K+[*')OS6551Q##3J+D_T%G-;:]"0&-DK
M^[(T/_NHHKSY6HNQS-#M0E1'I.4\QPCN:R;1$EL&T;*X8\LX&.&>CEP%.S50
M)P@9TVRCP,B$6@;0D8=YO0._DMD)NI1=[DTN7"Z7'K-F-P:VG=MG.HGYYLE\
MLD0ZA&'5J WMX:7AHIB1(] ^2="W<NI@KH@+>/*7GE8/Y99P0NC+VYECSVH8
MRF$6*C[C3>."'.E=ZKJ2QQLU?UW+3 LUN'GXAV^Q(\3U$E\>KY3;SA'RGE'A
MC?\V<MBP)8 L? IF*^%.22,TC_C9/G]$?[:"*#MPQL5.5H_@)3#B+F(^DF-Q
MQ<=IL&2I%:O"=.!&@6SN=$X7(0.\.QDMNET-LJY]+1"CT?/%9EP''UN EH0,
M5TG]-+W2(]NB<FG>2&=1^2QXW-#/<U;,F1N(D(<+K'V<4WRAUHDO@\X"RT0O
MR@%PQ)DPE@7[U4(^M%?Y[>+5,XT0V^5/?VH%WKM"=&=JR4WU*F9*2Z$+O>MG
MO<V) ZY79+&K KN&7#;/>@'6"(0U\R0R]A[=G!#5.@0F8)2?0 1P*RT/]53S
M=&0MS9=R<BE4LH195-;X]#^ON](>H$5'59N>R]5TJJN7Q8X"ES12!0)A%_=[
MO8#;=NO&"$1YQFF8EC<^7\(,$W]Q:8G0?G$8$?TT@0X 1&[G/GT?<W')F5_:
MPY,EF*XH'HKFW=*BC<*!*3=-GN]??&RKK&_2ZEOG5KCI5\ZIU0EE7 ^A"2'D
M'T?65/,!#I !D^M$[6E'-T?G*K\5.;;RC=H&2YT@:8>P G)E+TM/KN(]P>_N
M17MVG9BSVF?ZC+Y?7\MTJLL?^X_8"JL-O)#S[8KJMAM]]NMS#9U:GT[_RT*'
MQ@J.V#T+1+TU3^J-!RGC4W#M]U5]:<)A[$C@YMV.V4]].HZN'6$G6H)537T/
M(46M^-+2][YYT#/B\=?.%_Q[7K\09^SX/K^9ACXRZ;M^&@QE%<EYV\RV$[_$
M 4>EPFJUDRU\F@FNJ?6H:?:P2-YZD?U#E4C5W<?=5YQP/_DTHM@C^]K<XPZC
M6,@C>%3[4(KF+:(SX\!-!+M 64+1LJZ>L3CTF/5#8W#4VZ=L'OAE9X&(1?/[
M3E&Z<AI;;-)$7LY@#3_S--T*'E-9S<8'R"W9B;VT+]!$SP10 /)".<QGM%0G
M$IG8*IT+V[EEK[)8MT8SW)"X;NP,?L967M\D(L6>I?/!,A3VB^(34M[G]9WN
M7FI=!N\XL' $8'HI,QT"#MHO1W-MX8=BTF>L?X#JLD.SQ)$ESU6.9W!RH+,L
M(8L#/%D2^&(@,]#:'F'?_YTJ*L_&PR>U\?-FCV5!##<7PV[,%0^\.CZ[[P7D
M*CR3T^I2+PJK=&;FJ-:#P+(*"3XT40TA82;<WX2DR! ]S"M:J$N,(6TOOZA-
M9P61YL7H;,JA,>8:E".=N6O+J,EBVN4-3*C9*[\P<1#'G^/!KBSDZQ$J172%
MSO:R$.Z1$(1$?VN;71)$V#5DE=J2W7%;T;M)<3[NYS\?RP64#&2_MNAZ9UI=
M$M95BIM&>\X]_^3X!Q#,CZ<0B]Q>7O6=;'8OYRFM[0R5/X3'KT-/JS/I2:<_
M965B$(1L0-6A1-U\R7%XQ</XX<V/>YN^C:U!]I_CZU4'7RJ1RC QY_B5E' ^
M.Z?QX6AA+3: B%(J#N<\5Z@:1$N@O'"P_M \]Q ;-OL@@82[V!6EWQ,M0[Q0
M$$J@X0X(:IS_7_UV[?]' ^'/_/\ 4$L#!!0    ( /%+#ELOL-FP[6P  '5]
M   /    8W9M7S$P<6EM9S4N:G!G[+P%5%S9EC!\<8= <-?@[BX)%H*&X!(L
M6'"W%.ZNP2&X2X#"W=TAN&MP*R3PT_WZS>ONF5GSS:Q__?K=6ANJ[MEW^]EW
M[W-/U=/\TQKPXJV4K!0 !04%?'Q^ 4^+P&L #O;Y@/GM+SP<'#PB&B(B @+B
M"Q14)+27+[!?8KW PL+&(R' QB7&Q<(BI"(D)B6CH*# )J"FI29_14).0?X;
M$2@X>'A$!$0,1$0,<APL'/+_]O'4#F B0OE!?86!H@2@,:%@,*&>N@$R (""
M@_K] /XXH*!A8.'@$1"1D%&>$6I? -!0,##0S_(_*_ \ZO4\#L!BPF%1L(O#
MOU0V0*"TP^;PB<E&I)*HZL!1F3BEYC2T]T5"QL7#)R"D>45+1\_ Q<W#R\<O
M\/J-I)2TC.S;]ZH?U-0U-+6,C$T^F9J96S@X.CF[N+JY^_D'! 8%AX3&QL4G
M)"9]34[YEI.;EU]06%1<_;VFM@Y<W]#8V=7=T]O7/S X.34],SLW_V-A?6-S
M:WMG=V__X.S\XO+J^@9R>_>;7E  #-0_C_]0+\QGO:"?W0*+\)M>4- NOR%@
MPL)1L,-CB2LC&-B]I.3P0<26B,FNZD"BXE0YQ3&TGT#&I>9:ISG[3;7?-?M?
M4\SW?Z39ORGV+[T6 %08J&?GP6 "HL ]TV4YX=1&0=?B;JNV/N[\X"S[ -<:
M/Q$F.DF@]#!>*V?H,5)GG#[7_ /Z'$;G_=8,2SF+ISA<>0%N0E[-!'/M=YTF
M>P)IFOBH9AF"+(Q<BA3&8*H,/ SL8A)\1_)PO_<[K79-$+M-*YZN]Y,U$3S:
M$80'N^^2?HX4)GZFIM9)0-WD]VI0HY#90L[-Q!"A[3%=2S8)W#A4G1R79$M5
M4:N3Q*-Y_,SVL9/)(,GYRSXVU.4$%8EE.O@L*>#X09DWD+GVD-[IJ\..)G56
M?RX@TU<(:^R$LZV'<LH;Y5@1CB>P W9PXD[569%E7EV([G%"#6*C38K]H1R)
M"&77P5]2M ["T_.TG>2>.VW)3\[;=UBN2:)W(.JPC\W'50T&#FT58#B-/Q("
M)]EG3X!?P9FVJYHHYH)(=;D13W:DG$^L3R,>3&S6[D*CH':3]I!J4VU]Y :2
MR%95I8FU70>)&\Y:5WL&:]3&][%\5T]S 9J5(N;9 O)I%4NB>@+D9"Q<4F->
MM&@4"I@*[IC<!T%(P+H-HMG"I[#U:N/:JIF:PV"CF0\X&0[WJ5FR^SY3@<^Z
MBQ25F*<PIZP<@*L6M)N+$&-?>^LN6E1,Q\*9\RK47J ] 5UDP;SN :$6 N\/
MSGNYG'W/KMB*C(BAX(9?<:SRLQ" /^X*NY:7K)-D%'ELRKM?>QRFMF% OLC6
MI!.::Y[95] G+!W?]XAHW("J[<1(X[)<;SI)::>M'5<Q(+Y32DUUJ,:!/!3>
M:#4Q,?T(OE)NY17V=Z&WW^4AC!MR^H%3(\++W1FT$=;DM5,C@]*H/-5ZMY/=
MD7ZEA0!-2*]=C\/"F)_0^^L1WJZ^KO<C--L952SI^2S9_I.P460QC3I'KS@3
M>Q4X>P O=0<[&U.K9V(EV"\H8F7Q3T/A947:4:?5!"(2<PQL"C66^NRL'/!3
M"+#/*#&CNQ9QUF(]12 !K*'E3#MU>(2>*>%S(T6UYT?1LOEA7JUZ+J RV SV
M48L:/:BSJ]FJM6RW]7HKYAI7QT.W';GZ'P_U766=_,NQB.0!XA<P8Y3>PL=C
MW80L.0Y6<($Y.%/+8G-L7Q6N8KFM\OS0!=*<RO39^6[[A/DKDB]7 T2$*D_C
M"7G234@39U?(6J8T)-VS/R6?8$F2^T53AVA8'S3TB-CX/])/UUP%ZJ+^,,^K
ME3WB2IQV\?(?L ZSSDNH_)$@YT3A($8FIG>XP)-9-F\VUQB.>Q?XC7A!G,J@
M8)[CWLM64$T+<M^A?9D@0E.I-HN$"Y6';,VVJ# .6L"_X=YY9("X;.AC*:[)
MWMSRWJ%'\=Z9Q^."IZ$EM]EW=^%B?'KMD<JY1;!<'_;<%=)9HLPN5LW5$O'
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MGN@J[0T]@%+2@+^-1+J-5.0&YPV5[LU66.9[BGA8ND3W4\I+H14K</ID()#
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MZ.2GB,>4QZ*L<C&LA.T3,<1.A=H7CGY;E#WA-/!(NV!1O3>NJ?DC+&*RM'"
M+1I5H!#*_T>[H0(;WZ$8:<2?9($C\K-"BCT'T4M(O7X'(7I9-'!YHEH3UD*D
M,K66*9TRN=.#?RMOXT=8N;9)@CCP<% 1[E@28=-QUQKWZ0",Y[Q-M3R>D?5R
MSRZJ>P8#;M\](.FZY[&@(/_K7?K-@DHO/TPPME3,N7IX;/+FK+?@NS_UBO\
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M)O[=Q/K]B<_?9\7?9I:W0$K/&6XAERZ,\BPA$@O6X'(^^QN.,9\TY.Q_1Z_
M8X.HY)#@2+_CD3KB4WBO%DT B;V +_7:. (];<\>3D_2#R;JZ4V:/,S58_!Y
M'>,Q%AR_* ^;%!1L7.BAD/P&L[;DA,%,S3+EHI*OY+N<Y9_.+N24K[ #J>LX
MT]3Q'XFK74.CT%T[6')9:%I>6W]_&YY-R--E-:\*Y<W7ZYZRH$CYLB#P-"C4
M.$@Q\PBW4G;KZP:E<"C[CM<, 3FI?YP8:1B2$?Y*$QE0[9=&NLEMV,!UIGN
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MJVU6T= ++DUD^BZDG=/N9 T3#;DL[P6ANQJIF&]FRE36+SM<)P?%Y];,PWB
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M2RV^^HN [$GL7-NZB\*O",S&N=*6S*E&57^?-,J% ]QALN62]#'Z-BY "Y!
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M-Y9!2LONPJ9=\S2A%L-^.A_-M@RCX0@A<CD/KDO9MM_,7-XH9"DZ\<.:$R.
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M8*J+<I4D_MX3)6 MML33WR%(Q7UY@6=XE-& ]VEY/-*DM[/=/LD R(!JV6$
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MYSDX0(Z_>A"->^LU7C6@>/.6@$FXEY0^%@4Y??_9_>Q_WLB83LXPP"WY6%0
MV05"^"(MEX[/PZG!AR?@ \*RY*T#:28,X&Y:?/IP\&1WF(#2BO$@F;'ZX.8P
M:$#3-H=5K)_R-' -=!^[SN60>I0#8\W?["9N1825KWL+_K]&@Y'COZ&!]]Q2
MWQ@2]'\1#>0I0\7$0$-$;"#Y0D/O1"E!K:"NOOB[UA8.DJ#$]6"67 )%?)<N
MB&&1X^*VO'EMXYC0NF5M2V7BWI#<79M32I&N[DZ5M&5?N@J05.'<UM#<EBCU
M'2Z/.,4I%JOXYWVU%/SL@63W9Q,4X)UY#E[Y(H7^SFZ.N5^.CB(IGQJT 8VY
M/:PL"O?$EH<(_"4[W7YTK!BW6?/ZK4_Z">Z\4NAFL^:6.?OTW+_[L+27-KON
M]9V@!_&BM'IR;Q3+2S6TX*^\5+T=*0;F4'I3%N0X% 3/?S(H"-:'2G\OB26S
MB[=%"ABHLCFS)!JD]IB4%WK9<.941']G4@'&X^7#75W=O@!6"9J74K08 X+C
M;JQ+MWPL^3.5:%$0:1$ /)2I26=M^SFN&, [P!VHTG(RVR4;B.Y#+9P.X0XK
MUT.:P!*B?,>A:S+$\G=6T/#S]1_06:8/_Y\<1_3&+P #Q-WJ0D.)T('C^_S[
M?9T\"=_>?H:]'UA*)Y2<' 4S*4D3E7\E0MV#K).8"2B5?N>O5]1^TQ9$5N*/
M5H04;LQD\+^',.U(6?OK/480?85<%\FWXSOZF#:<3'W4X9A3LT;OV!N5,%K*
MI6$T7GJNO>#XW$XT)20F13T-:E?5,AHO9H/S?-KJ[$OZ^+(7K"O\L)'%\I,#
M+"3G*D2@@SOOK66+5/.FLG 9I;VO_7>SK91HU%MO7**X9*+,+DAGUM-#IP\C
M$VA59SX^%M #[F/8;&-Z%F'S A/5B:<4CQ-.947([(X#I/S4; K1F@']]KZ-
MEAYP&W#@ZTRGB5C2&&O2XLL[>^S@"'KC@\-\[1O8,T[$!W:/Q.?MDSUZU>D7
M/GD1L&7\N@<+QGAOZ!';NI!JX7#W O>B$L/-Q=8?Z$V8\N4'R"OK>2^+%++=
MU_(P  G?,0;X*I!^ZWJP5DP^^R+9R7DD:G!+_[ <:Z)^F_I8 /UDABO]!94,
M74XQQ1*J,RQQ-%TRI3T3))>F,[-ZB4Z?0UZ9K'<RTSR=;+6$Q/)I;]S# *UA
M4] Q9?0&6L=,&0.\N1V*>H%E:9D1Z;IFM]$6QQH0^[(\ 0SPY/MY&UIJ:1?=
M76H:TJPZ]K?E'N$PO/O+0Q1^N0>.;>XO#Z&_<(],@NR$WQ[RJW\@];^$+ED9
M6BG.VO>3-V4]NV8US/)/AO!R4\E6'C0N'_R$&MY_%KVO$6Y\R"W&=!^6%R,4
M+I+Y!>UQ&[A_I.I\NL"$VE><XH&NO8(<]U^0RO_-;WJ7;9/0?84CAS/#=5J^
M2Y =T=5Q[88'4-3'ZE2;B+_+']7Z87JJ*/B.N%IDB?/^++'7ES)Y5"8@35 ^
M>(Z.O8!\V0C?@K*JWN=Q92%1N;/1:-O3GXXVZHW*3G'K2^T99%7U3J5"=J[[
M7=Z9Q':$[=Z!$8*-J.(]L$0M>XP?H]]]U">;2\1V/XL(JCX]4H#XW71_(FE9
M[>.<F#%#Z6.'&C:M[+L^WE^[Z<*M;23/&(-F/7&%?6AC?FLW*0CK-K_74\=A
M+>C<=57]/K[OO+;0(+D??_SVTS&AN@GK&N*5[61SBLM&XE^L>V*=66.:N0:.
MV(_EZ:^+PP1U4!_RFG-;]@(J4>/'-]!<#IX3,R4TCO7<3VC9B>OFW08U#->V
M+,TP0&PW] >Z.E9?=^09+/&SXN1<Y0-^9?C$29-]U_;V&*2B&LL:GM9@L^9E
MK':8#$=_R]A3XX-NH: '5&6N9:\[,0"C:?[P @9X35%5,]%*@VKU'SV7'C=3
MK:Z5$ Z_=\<O# .$HN+T/F( 3?:S_%,=?W:T3"+3X2Y6Y7"E9I5I.5<8008O
M88#=%.D>1PP 8L4*+7M?3A7FL]NUY_!8]&G.S\2Y_5;PV>J%./U_>;-F;O\K
M>#<E_3\+&Q'B:,/I+A&DX1:%O8LR9:5)%YM2]A1D)?W*RR!U!5)70@=!Y3$_
MN2O--44N!:5U1Z/*!"7MFC[7L9'JDB#>J8@?+,,8*>_S+B/\T,@67V_2Z]E'
MV]S]M4K^_I5Y9TW&(74K%IH85W]!DYW4 D/[B<LOK'\.\S\]?5O$=9>S]_XR
M^7W\%X\(7\NSA5/LN,7>_S',)5&V,]3("&R?C%J&DJPJ32\?_I1^"WR)%9^Y
M-\UDBPJ +N@V7+WR[_.47UR% 94)69:_()/#O\AD7PK2X2@0FSFHL9E##P/(
MV)_&"B-)Y=";S09[ITF(C&R&%$&U?MJRS/I5TG[:CZM1P\_%42_0X%N_6*2\
M@T,72H#O&%QB==V4FO6D0HH3"XA?4<G@Y939/P%QPY3J3 #2(]3\#^XRT4)#
M>T$BY4/1=*RIJ <9.QDK.@<9I[CZD,DF"/)2T77(;\';\DOPDB&/8[$$AZH?
MRQX](SAR'_U3O@>K[S=JATZE?&C)8'A5JWYVM;24RD+//T+=AUTJL(2'75--
M[V$,XI9M+;56E.OC(BK0\?(C0MVD!:6JR'J;8/VQ%8-<.ZL8NVO!E;X?4F,D
MW3H)U&P6ZGB$V<;8QYRKB<,T<U[-]-Z0I:>O65!DQTM(,"&@Q E]L;#%M>^]
MKRS1Y_Y$^LD]$II$KSL#8E_7H,(.JJ.W1H16*FI]V$QV64$E]<N>3[ZU(WK8
M4D:R Z]P_-&"5,,L'4M/G.J C)6' DWMN3?YY-@M#@X++<-9M2A=?=@.P89
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MJ72O+-?\@V)6_)TI1OW]L3,]YX74K7Y5F8C-D]"W/9S<V8(WDJFFM-3R/ZX
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M\!R*Q-/KHRTKA-H.GK(?_?5&0P]D)JE(VN$>FHM&R#I!R+JY<O"W$2C%M8#
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MPU,YHPK)MYMI%S%Z2\^Y<&*ZKZR%BSL3HM1/_3W[PDR5]W->S@?J*46W)DX
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MR"'IRMFK FJ2G\_>2RKW1=K4ON?9''S2#_TAV/\(0PJS*K+B4]<@/I@>W><
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MA)-ZV^*<:V;F#\=,JY'EL%DU_[2&D^*N0]V!8BO7.@^/7JQ*((TDUSSQ^;?
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MC$O8#Q3%' $YXP#,:$B7?Q%'VU?TI_GM&=Z^T-H7H<<1.H0_NY3],9=IUI.
MZ+^.G$L\.BJ=TSM@7RHH>PF4VGX(V#Z8+(.BZ-U:E&:W!$X<:G+<SS$NG]S1
MPH%RK_DKA-+TBZ*$P_O90@P8%SPI8GL+C*G<T7LKY1U4+>JF7UR"2R1U>3QB
MP_RW@MVS=+<47&V&)8XK4*:&Y#0I90MUU(B)!<;":DKZ=/7D!>@=&W>T$LK;
M\2>Q&LKJ6\Y%'#J",ZVP\W6TP*:S,HYN8G[\1AR)PET[]OO#ZIM"SPH*?#/2
MNO;F-)QX>2:8Z94Y'[MBR<Q^]YOE1PJ=,"=;5A@[\1:X6EL3YJ&4V@O/<_<(
M/9YQ-V%'2.X+_@2L"_'(%=\J;6%D3HFSMB0NSJI9&I@VMZ0ST=N$?A2J!'X
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MNTD[3<2L6U/ST]K?[%Z.=.@L?3_B8\N83ALZSUJGM^-$Y?:Y?GTW7#/Z(*W
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M(CU#1Y:C!,&J\5$=(A]%_A;?*&PW]^Q&;F5F(2M<+D?V75A.5(_Z2Y4?'2<
M5FYN<WG+J(U":9:I<,H"RM%Z:-;;$S[AHO)1]B8^YS-#;+I-5WPMO6_($ZSE
M#.UL=(*?:V?"^AOI'@2-%UH1N?YTDU'\Z8R>Y:V#7FKS4=&N=/QLFGB5-1J!
MI?B;8]K%6GKU>72-?XQ\RN(H-\,H2C[,>;B<M5J?1+>/,9?7F.#1"Q70\ZW/
M>?KD#P05A@.:OGH8NW",-Z.X,]S--A_BMGRZT-'G^!HN6LTVDCMOI/NI*G7I
MM7TX1Z/P1IT[N';'2_+L(B@@8Q0/W?A:8E<=Q]K3F,A!KS>-HU>P>4NX:O?6
MY91YJFS[^$1HLO-I@!D'7_!D88_:KI' !P\\IH'Q^$*M[U4&FW4N%17?FX8Y
MGXE\B-*'Y):X+D1@*A2ALX-V3A66YI[1N3]HT/+[&$IQ)$[2);>MG;0\M7VE
M4;)$SE^C!9N[?5D^_X9!YE@^4A.P?E>]ZK[<2C"F,9G"Q7?U-!."^?UOMTO_
M:'5-Q'" #@X$M>X\1KT+9$;YVP],3%XLN.?4RU*LA$>,^6Z\W5 WD6<W F,,
MK1/511A:-0@B.1G37!-$UUEB7]^1/.KVCQI.:CM\$Y%Q/QF7NK!855RRQ1<'
M+67DS<Y9X0S8.KR+PFA9*$Q0/@(6,(U)MPTUE?5DLKV:?*@WXPQ)[EBV7#Q8
MM\C9L;M@3HUK3*;1(R\CV=[0\[5]&\1^3;9&.WJ20'M /T_,Q6JL=.!P(8+&
MDAD^YVY4USJTCQQ,_8.!^4/VM8>)=Y04X/5YV>U$7_I:<CC(W\:Z>NA"!KRD
MR-.8,V])'-/S8QH4I?%:DO; M6(&@>+# S-MV:3 J(,)M8N&W&V=.K_=$]*=
MM;#=/0:<+8L73VSHQ)ON=B4*:(Z'"LHJ-[YBQPEINJ.VESUR$UQJ]:U6,)I0
MJ*UN^/FD'-J1;F'^?F:\\V.H+@8?LLGM!&!OL'G0_KUL82A0@,A7D*C);T;.
M966EN3WZ*-KS9@?:\O0 Y?/R(RL9J'/O?LYGV00]J;=U#"#3+SC*JZ%VJ[++
M(G<U4THH5!79AI9O2FQ+]:>>4K23&++>90-P(.8AEXSL[OQK*ZU=QJHVM\Q5
M$AY99V%9:ZJF%8KU MBV-@\<..*9AP,3*=17%-6C(*XK?"O!^PKYSZO*;O^\
MJNRSU!!!#0=Z>0Z);_W7[@?1C_2IPT7R52^T#TJ&;KSE3O,]'75Y=+B2&K<J
M<S-,+<XPWD-,(?']+Q!N<.& >W-A:3"9XA(K&ZF2D(/^]]!B3C2VKW[,N]"X
M%IG!FHHT0ADII(VG"&(+F)J96SX4(PR'PA.?%NN.A%@QJ^2=,<VH7E?TEL,B
M)';K;*_9TQ>Y53M@;,%F9=L"<9G'VI-R!?(@"XN\E]EA&=I#/\34E;: +;G=
M\4KU)9CA1(9-LLPCWY3E) F$+812R/YWB$]\WA8Q++"$N1WYIXPUZP+R+$MY
MHK%M0EB*,?\@?Y?EZ5#[]&=C>Z--G[JS U(#UP"I+('<LU >5Z<>3&ETRN>.
MFKL9,WK1]Z5GYN'S;"=D39GLZ4W."^*."=>*UQ-*WLD[1]+$*S,_!(\XQ89J
M;+8A6,&NQ7/3.G/R6#E$L81;G10/:^$ 0Z7@8_[!)5X>L2ZW]1+YPB_%<*"D
M]0<!N:;03;ZP&%<]Z2"*50D8G<[-YE@YP)G$AF6G<_NVD$!V1:]4XD/GQ+X)
M$<E;035(>@"7IV")HWSUV)Z-,^N3^=W7.@^T]*5G>[!<;1".4]XN1'B465&V
MEFTKK9B1$&!]>,A3RE%MO*GK\2 WW=/^3+NZ65&].?9[N]7;OH]EASRO*AB'
MC2E[2Z.Q473RQW+J1O=O) E;LJU9!U*VL18*&H(%M5Z8%"ZX#CY[5?BY"L_?
MDX)"10ZYEX632Z5+DBX#UB<C@;9A>9=3:D76\\D2\N7<C^6+-GD 8T';,N-$
MB8W%4*Z^19V XIE7W AM_UKB8TT.O&63,$8L4M0>'.R$2,&D]O&H3&@HX^L8
MA7 N]7!2I:(OE*3-6D=R-X*J"G);-2A)NE&;L)+!N',\;7=YKH-J*BL:LS"M
M=R'4B_1X+R:0QRB>7<I2OSH%XVCUVI99G<%*D[-@;BY/UXCV*>QD.)\KSEQZ
MBKKI^OSTA^(G]3:$6NIX?EOD<V+>QJY$.B/RU;CCP;T[/&H3+'^<S-1A7,M7
M'&O:7,<Z:B4Y5)[GATI0CU3CT41FNMGP$^'G2>#!SU%6L]8D\Z^8%00H%AC@
M8M04/\&E^C"LOBZ>IHE3M%"8=,I%."D?;PQ%0H;()'GZ3_%3PFRK)\EWK8N]
M=A5#E'FEV.-^Q'YB95)5_MHQWZX8SB)RS$>%H1,*3N=VND"'['/T&.2GR.%\
MB%_J@I:3KJ:_QWM0$$M<Z<$!RZ[2&,F R?*F#_E*T]U\](3\!6>SK+?N9]15
M0NN^&\_L^)=+7#59/1?A .:< D]8'LQ2H83$-%Q7=DUKM <+EW?O^\K*V^.D
MSD-,GF@+V),ZD!EAS)92[[HX6H>1[,I3?=2#0!*^#32^PC#Y2CUKQPNJU&<\
MI8Z^23K,1I( GMBV7(UX#Q)7M1+B6S,^TM.<MI/,$. UYCJ22'4]U1=E,0 P
M0R+-0AHM(5!"\-T4 YP 92E J[RY?I2;65]BP$]/IZ>RH\,$136JV\>R876J
MASPA^HU@TM/,6;%G / 605X*>(+BZ)NN\_Q%"N;5R$^QAQ^[F?I)G]&F]FW9
MB9^B5I10RAN,UWP,%]94K6^2#3;1)O^@J-&VY3W$G2SU),85HSPSY-D'92D"
MX'_5-,[][NL;^.#\]B/-?37K?#O^MQ^D% /\1)9OGF81:/:D991)$6CB;CX@
M4!;[HYF(WY\$G<]OW;_!@8Q^G=,HU)NPB?G3==2[(%9N:/SP^#\O+D__<7%Y
M% X0.E*)PH%HT!+[->H '/A*!C'LB"@DN"/R>N:$ /$*/7Y3W1#==P<[P\F5
M=U<QP>3D949\L1NET$"CUZ+H$:]0"9)7KQF--E_P+- @C%;]J&'L&S-I1G@N
MH*NZKAFYG?KJ;+.T?7#[T6QO8QRR$9T%.J/+7"+Y)ZJNFI5#T,!LY_%6DFEX
MSH/5WD:>XZ* $)7GV@_+WZ(!N"D4#_T5#[JR\HO7>$+NSP'B3@STY*#\0?V+
M11\9:N7PI?S:> <(=UJ^RTYSXJ(?#GJT0L),FX>IWZWCIM9UV/35735U4PW+
ME@@MU%G7*I_]]>LZS6=.T_@V(U$)8VI8B %\2)-J\3ZTT5>D9-NO*^+NM#YR
M&E9RQ$*!%Z&[\Q]0;LP.UXJF-N(G-,^)5*7/'+]9L4XS=%@'69OKA>*FB2UE
M0IVFG'X:F<327YMFNUK5B3*UV&&W$LI)G(F[V\CE61Y9G.D$!%?5-M6V2FG3
MI7  !7WE3.+(>-X-!>D=FOM%0X6<DNL#YM8)($$7DI?\VQ/F-]L\Y+I%L;$E
M)8SU.*67F,KQD\)O4)&V-<M.F*]9799E AE;ZC\@SK\/2Z?)MU[ 7$X"25\%
MK!J==G^VL1&9?S;*0G2L4LM3%_^.I)<S$L7=^MFEVLU7DY BWD_[ZV,U^@HC
MU*)J 0LI#P0E:F=VU_V/0GSB%Z?#9%Y!:[1-/>4%'^4?>:>NLCX>Q'_(=YT=
M[49Y-<;OU%BV2\I2G)ET4T2HX8<J>(# IV<6>J7R*A4F::,;8\&:R<0/W3L5
M) ^P^ZFGQ=30Q:]'I(+E\5PTP,K0<HYBPMEJ0%*5+#?-!,*+VVU1J6[:1D(3
MB_YX.GJ9GS&/<&!Z:DZ_[U!G:LB>%K-2"I]?>4N,0D72RM7!A*@V9H8$VO@I
MRXP)U=&W+7LIN;DCN2:L$0X0&>I;C6[%5<B8F[9>^PSS$MGYB*U?5%PXR&U9
M\:I 5Z!AD 2ZNL I3'LI4B,"(A9W([E^#J$DEZQL/0O8]TW3@(X?%9R78JES
M1LP?4/5NVM3B[ZC'3FX]]E]ZDJXUU;C(R!JYS/J'M1DS>!^J$SZP0EKSC'76
MO:P)LSS6@,B.+^U)LJ1IM2%?:708L,3-=LZ6!N?H;KU[R'JB5 E9?17WD/RM
M-7Z/P:E?W 1GA59);I0ODT27'#)F5-OV!\7%-T2:)=;Q\J9VH!5Z^LPGDQW.
M"!7^PZ/VGS6,%/;,.Y<$+YR+6'6X/BI8@"@3)!+EC-2F*KKM^K\5UB5EG\<1
M:5#IV>EHHQQE?L+!X.@7-#GJ]DV70JK1U)6OK;;JK$XM45K,PZT(4\RP?JO>
M+"\%Y4JP?M+L&RVX[=P0'%+^0"N-4VP]='DX)%F*2[ 19V8+7W_3A<RI@#KF
MW9K[2_8?KN7O>Z]"ZHR+)4%&M:X>1,D%TJ':9$L\FGJGY%%?*J\IQ@@KFSW=
MV53Z%K^&HKB_?*TLOB'7!>1V6K@*X<V(6PB5M_^(EB'G[+X[1$(Z+++D*2\=
M]%,DF=7O="0JRK&X"E%T8//K"_=[@ONI32FT7ND#P+^I359:XEHTT\T]',(5
MR('Y7"R9UH_CI[(G9K2W''VT)9IU6:E:34ULQU:A7D+F>P09U;;-?:4=,*O)
MY#1)9$DX.J68Z*?\4-HT?P=;^VH-_TU-W TPK-0EOXE'FDB%0J3MLGMXF=)2
MGA))HV7"VLFT,FEN[_3[RZJ.WA0X0/QZ][QH37=&X[T^H8T5.FC7O[^!3>C,
MMR3IB:8*P+]BG+),"18(MV*>MO(%.9K:(Z_8X,KA,T=M^[T(<96H>$#(-5ZG
MT8^O!QM [&M<YNQ2$K@JE:&;4?G,/&IV]LW,#N18-W24W#^4NV/,M>?70:#Z
M0R4PZO4;,O:6AREY?.NCZ3JQ.V7&M;PJVGH,]:! C6 _E),9Z1>[4FUE4EK7
MA/M3:=L[FM1F$>2K1\E&Z[FZ)*0]N3DY,W&5^MT6@M,O[8Y9K)6Q&XV1#C,W
M6"2ES"T\>+**MC1J>5Q&7LST1-$E3+]EF1:GQT)Q'*K(#T_,OVVQ0BYOB-["
MD^R(K.)<;B#I(6B(W2$R?<5DSFJSE^VV"V*LCR*HHE>NBD4JH,%B5KW#G4Z_
MD'/:Q=C%=9]8FLE.$%0=5&=.N[$AO5):BUN6JR(*J>%)]T:2IJ^L5X\-Z>AZ
M@FA-X97B-1^@B;9#&4ORD=0(=7:=XLKQS8:D><%"55.C-MGXH&? )YO(3GP^
M\2T[/FJ=)B=->4&, IMEV?V2]Y"(E?=T_>_U\Y *F">^#G&E1&.\8 I)F9K[
M;,&F$-OFQXG48P3*5Q3[I<2V:DNB \RWLB)<7T(L! [4^_9^4U+L#SU,,2.Y
MUT,YLUC2V-N.@>=,$Q_-/;(;GS?^[@R5.DS!/K?7-G/S*NM5&.5QWR=_?D.6
M?/ZKO<SMMQ72(14@4U<7TI+=]]%<-'*TTC\J5A:(:.POQAIG\96JQYS)T797
MFP2\R@A&ON%S/LKVNZ_.X2>.S),L/_J8I?6)E8+$JB;(4'DT'>0(;' AN0(I
MQJDSCH/8.>H-54U5SO+]<KN)7:OXTCU:'J'A4@_E=HA,"-2VS=P9LN884O9!
MI.T_*CBDKFJ?/Y5GGGH<;;Y32O44*@CIZ%16E&8D09I+'=;R"_DY4FVU:W V
MCN%&KU7*AC>]^X2'0_J'&'D")E8S4VB^49)L<*\TD^R^?XBF9KEN?M_3S(3?
M!@>V;NQW,G  &SPI@7V+J?'HK^MJ:A=:='NB72&O0YA7(I0F,T.8/Y[X_>N<
M^^_W*_YR:SMI2W[#"OQO(XE-.!#R;Y,T]B69L8=@#)%G%6.#T5?5D@J5S=?>
M5;HVD,_N_HR"RR>V'ITK3O2XP^&9N0UP(")1I/H:0P;*+:\@PJ@6O67BJPU!
M_$& OSO@#9'33^<O&CYY6M.,NQ2W)3\9!R9^6>N1Y"<S61O*57)WTD@/!YQX
M2U0KQYV2P21R[ZNZK'>J)T:YMLNX.OP,CO:!+W-=BLD4MH2=^EKZVC]ZA3CI
M?:Q>5I%,T@>\05>1$194Z<^;P=@NLGH9?0E*"(Q&2_'[>KMCS"127PHVIKJ?
MHIYFE D*;H,D)@=LL_7DC6V9M0WI'?H+DF-PX_"*\%])CZFTTY@LI-DG=8R9
MC;[3?WBT-C>AY>O4LTLU)_@]C")?BV<WQ7>(,MRMU/UD$U\L2)N3,8JU?QKY
MCJ:OL./*&).I:7R"9UID%,1"9;2GR,.9')3?L^(Y)IW4/(J?7#$I[C(Q1UA7
M?7!6A.+/VKPS.C,MY_&.K:2NSVX=1>P#83>]\WU1M4QJB06[EK8;.S^X'VS=
MN$J;0!]]@GSN42?Q,E[U[LCHXC4C)5QC-7,FC1BJ32*,1-&(?@(4\,V.1@WI
M1"N(+._&:YQ%]7K4_OB6[<=(9\XW(\V9M1U"^;3.,TPAU::YC&'.MZS]T8K]
M$.M8YFYMO2NQ(&V4P>M(C/75&?O>]6:]0]O@5U.&W9E6@F3>#O)^(%/8H!^:
M1*V,H"O*6<]9*0)KJ4FM9\)NKAO=]5&Q2>:M+@FA$1Q0B%<,4HS3QNT\+8>(
MM7[/2;3S/LI-RD$>;IA^?>(MKSY2ECU&,_HDH%17/7I+4U]QA];)1*$2%0F[
MQG_%C,Y%C+_X5E(-9/-]CQ);LW*$/5[)8J]VCH3HT*M:+=8$U'B@WFN 94BC
M"8!L7C[BKTF0^(@2V>52((S US9DR5#;$.CLYZF=F5A1RQM:1''21B<$9>+0
MY8"$I1*'EBU!#CN2 FJ_QH<8U]I6M\EB]N.AT&6@TER1;7*_P$Q[?/@D Z7A
MP<ZYJX256XSF<^FS':T]-C3!+[NW<^*D@X_<?\2=/Y_Q3K*R,$JG<5<DU5S/
M0TUJ!&7.S3R2,GA2&_=]>E=%BLNZM+]9]7X,'+U4,"K'X-VZ@"XWN^&2QCRQ
MVY5:RO:Y2 9R=S0HS3-*.9)?32O9&-AU1W(8,U%BKCT[8^ &V;IK[\!Y1 ;B
M7*0IQ[\9_EKS]O%S,+J*R!FPS+_6U#9E@-%:41/;UB#DCO)D'@YX+7,7L34N
MR='$OXFVJ%32??4 $ASBA%L5,"<C[N>^*?=33ANL2[C+W2B(5M/,3SMRRHP+
M.F/6%^%+F_-6SE(WC;".XJY7T?4T64$D=Y$C64XZI.\Z?WFP.^,1JMI.Z*?+
MW0KCE<,,&8I42O$-:^7U84;3@N2LP^1JDL;4$DS#_"M84 2\LLV$EA(94E<$
M,<==<=T_-_!V]#<Y]]S;?32,+\^IUQ&D=5*_WE37<N!\>,C=')=HE@-K'FNJ
M(T>+6&-KT;RIF6NRPW+T#U4G%X0#PDVBKIEN@=,O1[F.?,:L6+OC?E)S)TYV
MPP'6N@SE+@\07RG3DK#1D:>Y#<AF-8G96=;X.<_BP]L93)/\]:2,;E6)S/MQ
MI@X<2)B5'"G-;FH<;A)E#ZK9<&*VK3$8HE#5]T[ND[1[U7JM*T,N+7NR5F@5
MD>,6W@?>297N&L0 &:PMY'3X4732=@<K8]/CDWL5]?20E+Z>WM:LLDABB3M_
M<+PZ]8U>2G&?G)&4E*9BT(*[^:DYK#K)KI'80>JHD86=!!,=&5C XULXX>;(
MC='9SN?GJ16<E? F5H.>XCEOT%13T5\;OXE!CFS[^4 ;7R@]X>TR@T=4IX)9
MT10,_*[F+@,$<K0HZQ0,@,(.LWPCBT2.WA!$<B*<T#\\NMPM!>FK;,&L7-XU
M:&CUX0E+R[QJS7,#:T!KW)SRK7-"MDS<<=^'Q3 5:J4E=J$:ZJDX&<65B1>&
M7]%5C)25.!696^^?)BON/FAIYIC-7G*NBY9WTLIE>=%FPXNY< S+_<G-_;/4
MZ:GS@,/XT=V\4MP6O\\(F\8X>Q4D<L1!Q)5)8N5V)N5]TYD\C[R5!1)1DHL3
MSYTN:F@!$BI=M..PAZ-R+\@>>0AY?*23";/:EE1#>8(>-TI]1[5Y;FG=?*YA
M; TJ!-! G8D;6Q14!Z22)/;RAV\ZS#+CD*:YJR?L%1>=8Y2@CS_ M+HI&[6V
MZ#^G%C]L9ZC8F'5H1Z(3FL#F;NZL*M2;[D?B#,1@(J"G^FA6URRE ['847PA
M\W5K^QWE?+BSZ&ZSB-:IIX5!+VV*X #$) 89NUX,-? ;_=N'DQ.E[ZL/<YN]
M"]P"YT#D.Q%(D^2AU1_;$"5H=B1C09-M78X&K\5H_/BXA7=7![,\67=WNCR#
MPPVDN[26*9L_%-\&_K(5.,I@M.=DO;Z^ZO!)6+Z!6_2<,-F$7#6QBZV]7P\H
MWLE \3!^"!F1OY>.4%(!BM!XL)9CL40.$I4<W<T*/^J2#RL.<%Q_%G2GD\C_
M#5AWP>+0>S V.W"RS3V3JTW$]8ECYU.&F@^ H*24;U&$JJK:_+DC2CS?C8J/
M^TGM*,N4:1I!I"_VE6K=4'CV8TI/;\N.%^)8\?D6K.X@QT*P!?>/RLYB=PQ[
M7"4ZVG?M._Q],5T[Q].#^;D;I7YGH2>ZMVK; MZWI9^+M"T\(INU;?1M7S-[
M?<;+K$^LW7OLSX%*REZ/I&[K+,A[495A&;U5>ZYQR),V.O>XSY00J:*'\F'*
M"EA@\6EV_E=G<L'>4^9=0?GQ/=LF!90LUIF?\KG=CR92^CE?4;PAOM-^(*:)
MBKS7Q9??I,X=5AH:O9FC=)$ZH9K$0')$I^=+/#RP5GZF7DI;8KC%FY0S#]O/
M.\Z9K/"O?JJN'* $ (#@0T)FKF^#6]V:>8K.SHO-9/.2AX0M8=RAE35+\JYG
M1GHM&EYPH%\,'\,WFN=DK:3=]3W79XR\L1)ZCDV!U)3T9HS'L3 -P\CC0,SG
M]O.45D,;A4YE$U=W"5]V/"C/@T5&ET ZQ..\FQ$9PL7VP:(.0V=2L$8/HF-4
M@P9"MCR?I-3FW?#[T].4(5=M92^=/H:](QZL*_GE1]\C/NL"X>-!YH&-G!V\
M&@@V3"0ORR)>SLJ>\*2%[K,R1$'F1TO*5H3-)^+W].H J0,2HIW/'L?@&[//
M9%WKLC*C92PK(1/JK51J#J4+T;)D/.I;:OE;?(1=RFH%.J\T406+* ?"9D;=
MP.WMLH>/6J*3K!I:_.33:2X#)>9<YB\M'X+T,*/J2-9J6^;SI)9TPS3ZM4*T
MYG63EA92%4JR D6?$T31&9XFQ_,OG$R''/4]$WAV^D"E.VOPRG3'A0<.'$2V
MF^5J6]6!GH:L6W7C]P0RAGF6H:X!NRMC[#BSW]C]1'KMA>NFEZ =!0\M%3R6
M>,+\>9;>(#QV^%5]%LTSE*MT=K!<A=F_QPN8?C:W9<O#UQ)BJPMS+. R(O9>
MS+SF6RAC[D6F6*<C-'QS2.JO?Z!?,(ZL8UJ:%*DOS=#Q2O<'5B7"-SX:QS0.
M W<I+#]0W<35K22,NV)3@"U3.F]1^-501QS$)B)/RI9PK#A>1#M@K-4SH74U
M]\C5!CA=)RD3:NR>WK/[%I1TP>2 _<,=M3[?/.^A5^E*GZ:X%(%&1\!_.E06
M4I9^6A;UCX<^Z?[RT"=^C<DT'.B9!<,! SOPAL-XG4=[T[5Z6BFW;,E*VKC6
MQQ?9DFS)<DP+8)S+!!S^#6F+[@KVACJ]H;_<WJAE<19\).-6#9'3?JXM+<D.
MI9(RN9A#+_6AWA[6_7ZLP!#:%]65D]@K^0'8LMS<5#:$$-1\KCA(';KQZCTM
M2J..8P83FA\/;E-P&(KM[?Y4D\V.V0T92?[F\SSZO?TBR! 9#@R%MMXHO+C#
MB2 !#Y<4P8$%S/MU[ZPBE!(GMX><^ECA=V=+@F \A>+[,ZE*%92>^JV?8 ;/
MIM!!/]-7.*!&B(04V6SOKU&3O'G*/!UQ(>4E8Y4GI%,S<_[:]D%K,N1UI\A.
M! >BO6_*V\-C33HX@"8:*KJA,7;O(13#NR<1%^(W[^" 1&D9'/C "0<.N8-8
M>-<,?5WCC<ON1@]VS@^W[ ?,N:85<>0=Z4$!@E3TZHE&0I7N(5KYJ( #4TWJ
M^9D)DY!9L7@I2U)J30>'C /[PP CTV0_EP(5E$$,#WN]B9O'(L_A0(:N)AQH
M(P5?)#D98!X6XV<?N)G=6WY20&#JU<-(![1+"YW4DA_$\<:Y<MSV7R]R%30[
MXJZ*5;B+?R;L=5Q26RK.85^N<71A8==1B*HUUT-M<JB(#REK4PZVZAQG.9J)
MYFPV'2FN*X4ZT;M09+O?6-%>RUZ$Y<.:2X:"G+G]Y) KZ064/[U:SA+I(/_4
MN[VM;7C@?]%^%Z!O" < 4SBP9*[7V,"^B=32^Z+B8& L-O4L@NL*ZJK!*<<^
MG1NO\KR3O*K<A.CB,M87E=ZQL98YXA O.XDXB.UQ0UVL4?DU_:?H(B$'EF@\
M4@_?0!)A++=L./"1NHOZA&D+#EP@L<,!?/E[Z17_5?I2MJ1XWN=),1H5HW#@
MNSJ7 6VBT;B:5O?B6"#?N3]V"BLQDJW$DCCTN-Y3Q3SI- 5B\ 56FVDV]J#F
MMAA_R$EYX;TY3'@$YQ6BT##)">MTB:/HP4>W>TJ@/RC=8Z"[Q\!L^4\,JOVO
MQB$80Q70SJ)O&-_R!H2;X_+.Y+]4M<0K7^O"9*]=BOI0<'#*_&.J6]P*-9+"
M2[+$"\'F%]$8G^' CKM1+;H+&Q7B:(=+$"GY)\PV1-FS8M$+":%?_JG]IW^X
MTO\FK 4L_?CQG'YXR,@=J\SKD3VS<2I]H_G7<32!]WWNV]]%VY/_>".-$P=$
MR@+O2[<\=G@@-AGV[PHEDD*O*$NJFC0-G-(L9W&VZ(7BT% ')BC1M_6";FCN
M_F(IPPL)K[^B*'D%!W ,],.#:SZQ<;WC@N4T)7U,$O[R^IR]T2EJ;@5UZPW.
M,^$W/W7L+>W$2V%6O)!,F %I:?8UXUGTW'3J^)&1VJ!7N59A@)%CNN52ZR+Z
M8=#M0UCK'= /!SI&P-^QE[&O")W!-PCQ<" X$]J:P,[6%7U1I&'XP(*)>]H7
M3%7 W'BY/JAUUB7&FCK-:\.WF3+,?I(,_CSA\3&Z_3;]['*.WV\_&,/F:*5M
MJ[!3=X-9\&\5@/IOP;3<5]3E+H$#>-YWW7*FGLZY4L;$GYHD'YUNCH-L6%/9
MI=IU,RN.<S@179@146:.0Y=#UC*3,.  =7 -I886:.XRN.D8W41_I0#3T7<T
M;=93^?=*H/Y/.\;_#0#NBJ97OTI2S(9+I"7$NSDM"38PUJ3I LN"N"?Y0LEF
M#6;'&!C3O\CB?B+=P$+UFL5;UQX54LBF=.RL/2KJM2-X)#-TU/^]C]X,^:.&
M45:TL)W !/]OQT2]Z?NGDC__#B(3>JK7K]342/DDV9TP+LHX3[X(UE["0O;Q
M^6SRAVWDO</(+O'(QB\"03N*!J?"@:5.Z3LKT-//GJF6(Z/*[^S7B^]>"9$$
MTC$^3O990V(D#RIECOVW))#[^T&#R&S='WO.!FTEI21%^#DY-[=Z]F^PLXD?
M9[/32O>3DC*FYM09SW,/:DK>[RGSU^KY-_=S5UM*,/5FZIE<49P2#M^G->XO
MH]3\;I2LOTEL6!OD),/2^)]L2@6C'';HKQA2UL>^>4SU%_.++J+]JSM_[F;,
MHOZ?3O^W[%3CW%_T7VY%BOYM,ZL+P^\^S\H/XSY[NBZ6Z#"[L;^+EN'A7%3C
MH[^%A<1F])U*=7'N>$<-E1#84MV/<[QX+Y0-F1U_0G]=:/QT(O&7!WR8B<Z6
M#N:?).99RP<I\FBO/(@C&$3H/N3@;^NAP/-&B^V8#2L4MA(9'+32<$U6;F@T
M0Z+5_XK]59VD>)]X?M;"!WV\AIS4JZC(BM\T^ !K_*$LGQ 9@2T#P:,I_>3+
M+-%UPJ-/%[.EF0'I>M!QI>??WM;1B<PSL-^P/S*^\[_*NT.:!A\2[H!-Q_=:
MJ8_X?!H4JT1*EJ>/LB)L^UI4X$# 8C%X&/SK)4]/VSO:B L#LNY;U%/%&]3:
M^UKY]*ZO9-9'=(6]5'5GJ,CM[";_II7I4OZ..+ "#HC?_GK;=;?U(D1TT<V*
M^H1Z3/2 ZGZH^"GKFJG.^0(.1'H[I+_WUDT_#GEQ9V_X#/S]8%QT0[00O"!<
M!P=P9?Z"D !LJO$+(/7$LS.SL29/'S4?PUBO'#B T:X%![[>_7HM]6S^1HKZ
MH(D[X@I[*_T"&W0?>N7;6%W(#;C'4"]O*EUC_68I% ZD:/89_FVK?^]FRKFQ
MK/O&?_O+]8NM.>%6)KZSFZ)5]K^Q_S=U=B"S$\MWXJ=]WHFGME3SL12>/NI'
M\7\C\C>:9^HVVX=P@.9J5>3'5=V]ZA']1V5?6O\FV;])6KGM:AAQB?J;' UP
M@.^W0/]GAWI\^]_7'?N/"-][XS^!5_0+'L;_$_U6+Y7O(?Z_ZJ9_L'*\LY<&
M#S+_!_ *_X1G QY\.G39^9];4.2WS+K?A?0^6O^Q@O^C /_N)=%U K.;I?\X
MB:G_VSFB_F>.S-SO\[])N.+__Q2N%7"4U/^"E-Z("(>51VYS[F;4-B3-9B_S
M0\RC>N %\,:K55+EJ*]7O^97".Y^<<RZ>5H<-D%]?,IX)WA'H)F^D^X(!N'?
MS_.+WWSX;[\)/Q31NI+B%O3[(XNV__<OP@>#N!14M6)4XA6JK+Z4?YC5BZ5Q
MMP\OZ5T_*(0H-+DFK:5:/)TE..=XN<S75_4!+*D\P%(Q\YHN=I@/MJ@5UCZ\
MG'^6,[K7TEXX-6]]+#(@Y&@]R MZ.SFT:&A35G ,,W>I=)-_+8K#M5'<-)V.
M-6_8:\G+0^\[''G 3TGR%@<<+"M2$V"ZZ KQZQX:*RZV.7T,Z1OWGLXE#RE@
M05##; N8<3^C&$O%Z%(U]WG:-*80K3\U]^8<;TIVDOSS"[J"G0U=_\VHX5%6
M(:D<M)/&,%69N'VE$67C.K<]9/O7A9U9>*4C;T; 'T,_()P6LZH3[[U@5_AI
M<\JJH2_JY!)F4RGGR/J-*6XCW3N95,BI;24%07?^($3<>?&6NSJYT>HZ>4#"
MO 6:$Z5"'Z!?5X29.Y\8W/TFL1C$JQ\]JMW<TE)'_-/R&8MFA<W46G$0JY_(
MYJ- 5.C#R>K#@-PPPE RHG@A99B^/+_GY]21-Y6=JQ .)<3#X;(W36.*,,-9
M G>/6) 0M7W!K'9GMJ7&1(7>("BTD^HQ03)IF]T"3C;S.XB=ATH$^KW-S::W
M@CK)WHZ:)DQS#TXIQC\'=J;K'#$I]I!(BN27N>N@UHP?+..5IF6/(//SI/(Q
MY#0 0(!0G[(0LZNW"75<-.=29+Q5GYYU;]B&<"O4WWMS_;#0X&<S6/&YUR<H
M&'W Y%QTVJ,D+8:"5_%]]"LJ<:[@L$X)1!=,/ZW#GKPZ_[T2T-Z>L_>;_M=^
M@SO:?4=$,2Q* E_0T)V9'*.FDRKRW?+D)\P:R-:B[.E1MN2+[*T<Z-R:VAJ7
MC=3\LO/YVVC6\JU\&&)T1_=8<ZIE,>M:+0U96[2&)6BUVH0."OGWY3PUK>[2
M/XA(51@9HNIIBWQU5G@#ZYOKV]!.#HM^%;[*ZW_TC"E'5C!<X&HMS_ A;&[2
M38>25RFX1MA(^YWIVT5T[8>!F-( @+"? HUTZ_HI).E<PEV:92LT1&Y=W8P6
M74A;%D\;^_A+[*!W3_ZNE[XI)DQJ)DD0HYGM3/?3QQ?('[OIXI_56=#XV6%Y
MN!3<[I_:S*]I-MQZ) Z;$\48R%M[29E>-Q>U/'W_A4C89\M[3(AH<S-I-/G[
M^'@:Y6R1H:Z%9ARL^$QUX,DE+TBV1UT-.1+=N)$2>UC#)V8)C86+=_1)R"E:
MP_4K>6/'%:X@<W)Z/OK\+FE^4I&:G(*+.MD)@UUG;Z+U_GHH Q1)9_:!D]E+
ME413FK)>:.C)C>I9RISA8S9=]]CU@Z8SB/!8T73Q5?X8Z^Y;-T.'ONB.'XV"
M.///4 KF+D"[);9/:J"[9?.*W;#E  IW29?9/BU@B^2#["EE0PG^LLJ _?-R
MGF,99Y!SWB6G5UPN\A39<YIX_68//)\:K*JEB@)MO7:$,>72>:=@>Y\129S!
M5[0+)OBW.PL(IT4&XU?^*Q72TV)XYO:6YTG91#AZ<O1*[A4]WZ8X(G\42CB(
MD6Z?K*5:+78WC] W54'?)BT)NC18*5-\^*@<1]ZWPX8BIW=":-9^1U\]7')\
M9K7YY++N>[R8SJP)#G)%+#^2,.1:?:/)"EDYZ)IP/PGF:#%D$^\)4B()]1QY
M+G!?HY&7^84W8OZO]MXR*JYN61=N@@<GN+L$"^X>+ 1W]T #C;L$"QH@- 2'
MQMVUT>!N 1H(C7MP)WB^O/OL??;9^WQ^Q_UU[X\U1J_5]8Q5<_5<755S5CU5
MYFUSA\[BR3 7(%P"+@%FO)_/:9O=@G'59#-BQ@R3--B&%K:%ZY!.BMMC,?=Z
M\2XK<9R4460XIA!K27M2:&(JXUM7< J^:,6*7S_7.0ZPXJ^NYMP*U8Y0$>#@
M\8BPHH@M+1<L"+EHWL84HJ^;>/>-\Y,]6&S:7J_Y!=P?J'OP*V"24;.R>\L>
MESL6>WDW?TZS3B_\Q*9OHWWL\PK5ZJJ/S1==F;.IX;<OQZF]2<F]$@/KU.WN
MQ=HF5L;5)\%]((SE,6[Y /E"S'!U@R_TP9+)SHOVKL UG"8:)(L3)T-*;D/S
M6:GXEA9+5"D-#3>I$6;*0\CT*:CQX=S5!1J&\2EE=&LXA>GY(@O79[CGNLIR
M>Y9N1!_6>+8,O6GH*1RS+>,U-5H:<@O_'KI/;X4) #@R1N]#XWG_"O]+,^:5
MJWA-ZF 6,;L8"MRHFE2ZKPM1U-^=?;0PK/-9V9U+KJJR@ (Y0493'4FT_:XC
MY*0QI2.NM&, [ONYZ.T9,<%<XZK.!"C$_T$T*A<D(UKB$;WX Y&DMT0*PTWI
MIC*KG-EVYS< J5TNS3#UT_9L5<VR@P"Q%A"*X>R/R?@;X&(0$[$L/X\0@<T;
MTU[L\XYIGL_7\()#3353,W1RF\%M(&XOUEF'O1+1(K+$OL!J,\2J]& A9W%Z
MZBG/DW JF<V&V/K9:9ZR9]_P\U84Z!;:!.,,VK1Q+G/JZKQ4M$N/[WX1C( I
M[W<FD:QYTUS_A-0JR)W4-PJWF.-L$@V4@ -W0]<FXA6PIR&R/&7H, 1(EZH]
M)+E0J1RC#') SB8JU)]*S+M=:9[%THW4\*H;\5[W)'TSCDVA#>)/3OF>;?CT
MQK93-W2=8N.#2IK0E*.UGV<EB%H'6A=ZWZ?>Z% E\83W(9Y5K!4/#*4OP)6B
MV0M%H\DHW/N@UIZ71QU679P=*U+T6?\I=HWQDI==#;]%X4 01=-7DW>(=+BT
M0[ 0F %I*#4T,_L$A=:W0H3GJ#&'/U688V[%KE]3:,_ZY"_K3Q3]V*]"R;E!
MK0]A2 T([JB@']T#$#&Z!@,0J9(S<P\2]LD*EHV7Q"<ZYB^6E"F<ZVX4PY4T
MI0&Q>V"%4PJ39]E?6G)CDICD4>RK6P;U=:D:S$=OIKIXXP9D\1'P*M[0$ WM
M3! ]X\.JZ0TZABU#!9*Y;!(2V,DD.QBOMLA=LQ>[=TLB^\GHBR'P^&A73\ZO
M8NTJ4&E=Q;#4MYD[(W"E'5?P4*<(-0G/TC)\69_]S#YQ1* :PZ)Z)>WK:]<+
MM)'1ZSV&O2)93S_4%@6NB,7-F(O-S5GEVOC152 G3MI&AOH[K%Q\:U!A@A )
M?Y#T66?<:HFM@[>OK:<%9X6S_4+*%*VM7ERF?:QKECLX(; \_5PN>R5CWZ\X
MD[W->[$J7^)]#Z,2K:X.6 G)C22TT.HB?VI U\_Z+.C#ST$V_\!W:^J*VRV<
M1J,RA;Q6%;;" (0?ZD\%*EANQO$X6&-!-OC[4P[L('\Q,T?+_:BM:)/T$ JZ
M4+7W23GV'(^T[D'\-3>F><@[E1=B*D+Q;R_2<8=E:4V&6 IC$=M)*.8RJ4GD
M"OA<?]Z\&G),U1K7=?BRRN?67U?OI/[&9]A<2.BJU.E1!>3.7^CD6?%9G[+H
M0XXF$VC;P@"-7+M&2&AD9$)R]0K'I1?& :IBUFZ"67;)&Z?$"\;FG516(Z T
M1D:L@LA ,F,:H<?'&\3X/12:+U[14%9KLR6S\R \GJN<,S5G'#6'T^<0?4_[
M..U)D[@94"=:: X0FD2M/7"P#R(?H+/G(LP^4"DU" 3G"P;]O!G"B(@1[\ L
M%1+G^=@$@M77XVNTMR;[;Q35\BRI5>L' ;LU/M21_Z*U1%#_ 1]OW9'>@K3P
MBT^%%37 :HY./"N057CI[C>4ZXV:GV*R.$U^7&% [NA1TDL=VCCS7"7*[QG&
M*HV'ZT=_ X!/O2,MO"(TY/7]5.@T3A*PH%XED&NYPU0I\)0SNTK5-I&D")V!
MG:*-AQO)VHD>'(I>9CJS=K9J=B:[@G06/C8YWA;>OM_[?8WC2O&D!M<E$@WE
MJ6?RY5;\H[M&ST9+<7-;%\AMCF_)-W'9E%VSK;W^A%2]51VP74MQQJN+&LV.
MO),A:UMJ8  \(W&$SUS:]-MDM;=++'-;JLH#$$GV=;?.XW)N'N&MC;"J#\[L
MB+8^=>ES!)CO7X+<^JT34!G.Y0Y^ W0I<]UN4EQ7[&6F3_-">/JFS,=+J%=>
M8@CX8[J;O/2Q83^^5G+*YJ(5$8,VNY=W!/&,1KE5(F"BFTM3'L1GU@S9U!R0
M?4V1%SJ=T1\UZ/IZT[,D'!TEJC@H\2G^NO29IR%CE8TM3N+&X>WLWFSZZF7
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M']YGA=/_B]UO#:T-2X5E;<USN0#P =F5AIP+).%?JEC>4E\(F@7]K7JOJ<8
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MN3$C60*\!O(OC=;//Q.^.:<H(POMH9*6>1[QO[]X'\J#-D >0HID-=\II>Q
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M7#<I"8(+MN].A[ SQ3=6V'359@N,/F*C$G1"0)BX39W\#D*RY?K2KQ81\K5
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M!R=T_ W $%BS O^8*V^_0^^SBEMK[9C8;G9O%Y;,YDJ3O?MF@9-UNC+YL>G
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M)9-T&V].$S/1KQ'"2'CQ<UA?>IV1]>W()F,=.9US%^AQ#UZ9F2J[BO<"9,K
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MZT88?5>JVA \/Q[]E=TR;CTOIB(B+CI5[@5K>4*@;**"!&4O#ZIYK)OVJ]!
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MGIH&^#) E$[LKG^M/\S<L-V;+;@^R'Z_%NW$'U-K:IS]-MG&L=KJ33!+AY(
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M4J%D_JW9TLM]Y Y-L>D>,K$<WV0 Q[7X@65>*M(+''6[_&#Z!XZNQX<_H4C
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M[Z,4WWKX%^CV7Z#>/U!+ 0(4 Q0    ( /%+#EN%"/F!'@\  /23   0
M          "  0    !C=FTM,C R-3 V,S N>'-D4$L! A0#%     @ \4L.
M6VOK7/7=#0  IIL  !0              ( !3 \  &-V;2TR,#(U,#8S,%]C
M86PN>&UL4$L! A0#%     @ \4L.6RQ",9_,%@  0EL! !0
M ( !6QT  &-V;2TR,#(U,#8S,%]D968N>&UL4$L! A0#%     @ \4L.6\)4
M%8A 2   8+,# !0              ( !630  &-V;2TR,#(U,#8S,%]L86(N
M>&UL4$L! A0#%     @ \4L.6REDEO)E-P  U?$" !0              ( !
MRWP  &-V;2TR,#(U,#8S,%]P<F4N>&UL4$L! A0#%     @ \4L.6Z#I\^S3
MW@  6+H+  L              ( !8K0  &-V;5\Q,'$N:'1M4$L! A0#%
M  @ \4L.6[.?)MDS2   )%(   \              ( !7I,! &-V;5\Q,'%I
M;6<Q+FIP9U!+ 0(4 Q0    ( /%+#EO\U.,&XTL  "A3   /
M  "  ;[; 0!C=FU?,3!Q:6UG,BYJ<&=02P$"% ,4    " #Q2PY;X8L3"Y-#
M   R3@  #P              @ '.)P( 8W9M7S$P<6EM9S,N:G!G4$L! A0#
M%     @ \4L.6ZMFU#M4:@  -'@   \              ( !CFL" &-V;5\Q
M,'%I;6<T+FIP9U!+ 0(4 Q0    ( /%+#ELOL-FP[6P  '5]   /
M      "  0_6 @!C=FU?,3!Q:6UG-2YJ<&=02P$"% ,4    " #Q2PY;<<=Y
M&2-3  !%7P  #P              @ $I0P, 8W9M7S$P<6EM9S8N:G!G4$L!
M A0#%     @ \4L.6Y#^BY6 >@  *(P   \              ( !>98# &-V
M;5\Q,'%I;6<W+FIP9U!+ 0(4 Q0    ( /%+#EN]C$DGRP<  &-7   ,
M          "  281! !C=FU?97@S,2YH=&U02P$"% ,4    " #Q2PY;DV,=
MWK8#  !C$@  #               @ $;&00 8W9M7V5X,S(N:'1M4$L%!@
0   /  \ G@,  /L<!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20250630.xsd" xlink:type="simple"/>
    <context id="From2024-10-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-14_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-14</instant>
        </period>
    </context>
    <context id="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-14</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-11_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-05-01to2025-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <context id="From2024-05-01to2024-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-04</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_ChangesInEquityWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_ChangesInEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_cvm_PreFundedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_cvm_PreFundedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:PreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:ChangesInEquityWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-04-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-19</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-12-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-05-01to2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-10-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_ConsultingAgreementsOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_TopMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_BottomMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_ConsultantsOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2025-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-08-13</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-10-01to2025-06-30" id="ixv-7985">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-10-01to2025-06-30" id="ixv-7986">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-10-01to2025-06-30" id="ixv-7987">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-10-01to2025-06-30" id="ixv-7988">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2024-10-01to2025-06-30" id="ixv-7989">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-7990"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-7991"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-7992"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="ixv-7993"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-7994"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-7995"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-7996"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="ixv-7997"
      unitRef="Shares">5321341</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-7998"
      unitRef="Shares">2126682</us-gaap:CommonStockSharesIssued>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-06-30" id="ixv-7999">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-06-30" id="ixv-8000">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-06-30" id="ixv-8001">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-06-30" id="ixv-8002">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-8003"
      unitRef="USD">250000</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets>
    <cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted20
      contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsOneMember"
      decimals="0"
      id="ixv-8004"
      unitRef="Shares">285917</cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted20>
    <cvm:LeaseExpenseUnderOperatingLeases
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-8005"
      unitRef="USD">100000</cvm:LeaseExpenseUnderOperatingLeases>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-8006"
      unitRef="USD">300000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="ixv-8007"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <dei:DocumentType contextRef="From2024-10-01to2025-06-30" id="ixv-8981">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-10-01to2025-06-30" id="ixv-8982">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-10-01to2025-06-30" id="ixv-8983">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-10-01to2025-06-30" id="ixv-8984">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-10-01to2025-06-30" id="ixv-8985">1-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-10-01to2025-06-30" id="ixv-8986">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-10-01to2025-06-30" id="ixv-8987">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-10-01to2025-06-30" id="ixv-8988">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-10-01to2025-06-30" id="ixv-8989">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-10-01to2025-06-30" id="ixv-8990">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-10-01to2025-06-30" id="ixv-8991">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-10-01to2025-06-30" id="ixv-8992">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-10-01to2025-06-30" id="ixv-8993">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-10-01to2025-06-30" id="ixv-8994">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-10-01to2025-06-30" id="ixv-8995">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-10-01to2025-06-30" id="ixv-8996">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-10-01to2025-06-30" id="ixv-8997">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-10-01to2025-06-30" id="ixv-8998">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-10-01to2025-06-30" id="ixv-8999">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-10-01to2025-06-30" id="ixv-9000">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-10-01to2025-06-30" id="ixv-9001">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-10-01to2025-06-30" id="ixv-9002">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-10-01to2025-06-30" id="ixv-9003">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-10-01to2025-06-30" id="ixv-9004">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-08-13"
      decimals="INF"
      id="ixv-9005"
      unitRef="Shares">6882156</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1"
      unitRef="USD">1792856</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_3"
      unitRef="USD">304133</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_4"
      unitRef="USD">294097</us-gaap:PrepaidExpenseCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_5"
      unitRef="USD">518040</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_6"
      unitRef="USD">1019908</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_7"
      unitRef="USD">7500</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_8"
      unitRef="USD">3500</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_9"
      unitRef="USD">2622529</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_10"
      unitRef="USD">6055678</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_11"
      unitRef="USD">5998731</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_12"
      unitRef="USD">7350364</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_13"
      unitRef="USD">1332096</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_14"
      unitRef="USD">1495937</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_15"
      unitRef="USD">6578679</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_16"
      unitRef="USD">8129753</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_17"
      unitRef="USD">130585</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_18"
      unitRef="USD">165492</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1170"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1171"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_21"
      unitRef="USD">1354478</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_22"
      unitRef="USD">1475441</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_23"
      unitRef="USD">20336199</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_24"
      unitRef="USD">26991766</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_27"
      unitRef="USD">1577215</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_28"
      unitRef="USD">1448467</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_29"
      unitRef="USD">475602</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_30"
      unitRef="USD">566042</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_31"
      unitRef="USD">1169520</cvm:DueToEmployeeCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_32"
      unitRef="USD">363306</cvm:DueToEmployeeCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_33"
      unitRef="USD">2205972</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_34"
      unitRef="USD">2010995</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_35"
      unitRef="USD">187739</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_36"
      unitRef="USD">226969</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_37"
      unitRef="USD">5616048</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_38"
      unitRef="USD">4615779</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_39"
      unitRef="USD">6271813</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_40"
      unitRef="USD">7957925</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_41"
      unitRef="USD">1298398</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_42"
      unitRef="USD">1425979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_43"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_44"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_45"
      unitRef="USD">13311259</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_46"
      unitRef="USD">14124683</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="fid_63"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_64"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_66"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_50"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_51"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="fid_71"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_72"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_76"
      unitRef="Shares">5321341</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_77"
      unitRef="Shares">2126682</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_52"
      unitRef="USD">53214</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_53"
      unitRef="USD">21266</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_54"
      unitRef="USD">540293742</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_55"
      unitRef="USD">526857678</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_56"
      unitRef="USD">-533322016</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_57"
      unitRef="USD">-514011861</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_58"
      unitRef="USD">7024940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_59"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_60"
      unitRef="USD">20336199</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_61"
      unitRef="USD">26991766</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_79"
      unitRef="USD">12184276</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_80"
      unitRef="USD">13684204</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_81"
      unitRef="USD">6592128</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_82"
      unitRef="USD">6547866</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_83"
      unitRef="USD">18776404</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_84"
      unitRef="USD">20232070</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_85"
      unitRef="USD">-18776404</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_86"
      unitRef="USD">-20232070</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_87"
      unitRef="USD">-520439</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_88"
      unitRef="USD">-571102</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_89"
      unitRef="USD">-13312</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_90"
      unitRef="USD">-7801</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_91"
      unitRef="USD">-19310155</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_92"
      unitRef="USD">-20810973</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_93"
      unitRef="USD">0</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_94"
      unitRef="USD">-659456</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_95"
      unitRef="USD">-19310155</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_96"
      unitRef="USD">-21470429</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2025-06-30"
      decimals="INF"
      id="fid_97"
      unitRef="USDPShares">-6.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="INF"
      id="fid_98"
      unitRef="USDPShares">-12.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_99"
      unitRef="Shares">3046400</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_100"
      unitRef="Shares">1715982</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_102"
      unitRef="USD">3739948</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_103"
      unitRef="USD">4703160</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_104"
      unitRef="USD">1748935</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_105"
      unitRef="USD">1967075</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_106"
      unitRef="USD">5488883</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_107"
      unitRef="USD">6670235</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_108"
      unitRef="USD">-5488883</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_109"
      unitRef="USD">-6670235</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_110"
      unitRef="USD">-172050</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_111"
      unitRef="USD">-190705</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_112"
      unitRef="USD">-3771</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_113"
      unitRef="USD">4382</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_114"
      unitRef="USD">-5664704</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_115"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_116"
      unitRef="USD">0</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_117"
      unitRef="USD">-659456</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_118"
      unitRef="USD">-5664704</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_119"
      unitRef="USD">-7516014</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-01to2025-06-30"
      decimals="INF"
      id="fid_120"
      unitRef="USDPShares">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="INF"
      id="fid_121"
      unitRef="USDPShares">-4.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_122"
      unitRef="Shares">4150702</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_123"
      unitRef="Shares">1799813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_717"
      unitRef="Shares">2126682</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_718"
      unitRef="USD">21266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_719"
      unitRef="USD">526857678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_720"
      unitRef="USD">-514011861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_939"
      unitRef="Shares">48333</cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_722"
      unitRef="USD">483</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1002"
      unitRef="USD">-483</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1003"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1004"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_918"
      unitRef="Shares">4761</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_726"
      unitRef="USD">48</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1005"
      unitRef="USD">57086</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1006"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1007"
      unitRef="USD">57134</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_925"
      unitRef="Shares">5154</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_730"
      unitRef="USD">52</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1008"
      unitRef="USD">396035</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1009"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1010"
      unitRef="USD">396087</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_932"
      unitRef="Shares">251750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_734"
      unitRef="USD">2518</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1011"
      unitRef="USD">4997782</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1012"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1013"
      unitRef="USD">5000300</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_738"
      unitRef="Shares">-100</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_739"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1014"
      unitRef="USD">711382</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1015"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1016"
      unitRef="USD">711381</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_743"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1017"
      unitRef="USD">-650291</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1018"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1019"
      unitRef="USD">-650291</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_747"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1020"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1021"
      unitRef="USD">-7073062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_1022"
      unitRef="USD">-7073062</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_751"
      unitRef="Shares">2436580</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_752"
      unitRef="USD">24366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_753"
      unitRef="USD">532369189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_754"
      unitRef="USD">-521084923</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_755"
      unitRef="USD">11308632</us-gaap:StockholdersEquity>
    <cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_940"
      unitRef="Shares">199250</cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_756"
      unitRef="USD">1993</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1023"
      unitRef="USD">-1993</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1024"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1025"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_919"
      unitRef="Shares">7524</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_760"
      unitRef="USD">75</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1026"
      unitRef="USD">53979</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1027"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1028"
      unitRef="USD">54054</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_926"
      unitRef="Shares">1667</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_764"
      unitRef="USD">17</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1029"
      unitRef="USD">60185</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1030"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1031"
      unitRef="USD">60202</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_933"
      unitRef="Shares">133750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_768"
      unitRef="USD">1338</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1032"
      unitRef="USD">2558662</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1033"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1034"
      unitRef="USD">2560000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsShares
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_950"
      unitRef="Shares">33333</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsShares>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_772"
      unitRef="USD">333</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1035"
      unitRef="USD">350552</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1036"
      unitRef="USD">0</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1037"
      unitRef="USD">350885</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCostsAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_776"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1038"
      unitRef="USD">685668</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1039"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1040"
      unitRef="USD">685668</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_780"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1041"
      unitRef="USD">-449197</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1042"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1043"
      unitRef="USD">-449197</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_784"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1044"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1045"
      unitRef="USD">-6572389</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_1046"
      unitRef="USD">-6572389</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_788"
      unitRef="Shares">2812104</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_789"
      unitRef="USD">28122</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_790"
      unitRef="USD">535627045</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_791"
      unitRef="USD">-527657312</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_792"
      unitRef="USD">7997855</us-gaap:StockholdersEquity>
    <cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_941"
      unitRef="Shares">486251</cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_793"
      unitRef="USD">4862</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1047"
      unitRef="USD">-4862</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1048"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1049"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_920"
      unitRef="Shares">22986</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_797"
      unitRef="USD">230</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1050"
      unitRef="USD">53093</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1051"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1052"
      unitRef="USD">53323</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_801"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1053"
      unitRef="USD">127158</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1054"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1055"
      unitRef="USD">127158</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_934"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_805"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1056"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1057"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1058"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_809"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1059"
      unitRef="USD">73442</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1061"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1063"
      unitRef="USD">73442</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_813"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1060"
      unitRef="USD">-562134</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1062"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1064"
      unitRef="USD">-562134</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_817"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1065"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1066"
      unitRef="USD">-5664704</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1067"
      unitRef="USD">-5664704</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_821"
      unitRef="Shares">5321341</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_822"
      unitRef="USD">53214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_823"
      unitRef="USD">540293742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_824"
      unitRef="USD">-533322016</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_825"
      unitRef="USD">7024940</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_826"
      unitRef="Shares">1581188</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_827"
      unitRef="USD">15811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_828"
      unitRef="USD">500290475</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_829"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_830"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_914"
      unitRef="Shares">591</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_831"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_951"
      unitRef="USD">48901</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_952"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_953"
      unitRef="USD">48907</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_921"
      unitRef="Shares">2952</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_835"
      unitRef="USD">30</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_954"
      unitRef="USD">202277</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_955"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_956"
      unitRef="USD">202307</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_928"
      unitRef="Shares">83000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_839"
      unitRef="USD">830</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_957"
      unitRef="USD">4979170</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_958"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_959"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_843"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_960"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_961"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_962"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_847"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_963"
      unitRef="USD">-470229</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_964"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_965"
      unitRef="USD">-470229</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_851"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_966"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_967"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_968"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_855"
      unitRef="Shares">1667731</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_856"
      unitRef="USD">16677</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_857"
      unitRef="USD">506434503</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_858"
      unitRef="USD">-493800920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_859"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_915"
      unitRef="Shares">912</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_860"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_969"
      unitRef="USD">53476</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_970"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_971"
      unitRef="USD">53485</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_922"
      unitRef="Shares">5425</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_864"
      unitRef="USD">54</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_972"
      unitRef="USD">380816</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_973"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_974"
      unitRef="USD">380870</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_929"
      unitRef="Shares">129167</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_868"
      unitRef="USD">1292</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_975"
      unitRef="USD">7748708</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_976"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_977"
      unitRef="USD">7750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_872"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_978"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_979"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_980"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_876"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_981"
      unitRef="USD">-717621</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_982"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_983"
      unitRef="USD">-717621</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_880"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_984"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_985"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_986"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_884"
      unitRef="Shares">1803235</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_885"
      unitRef="USD">18032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_886"
      unitRef="USD">515332422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_887"
      unitRef="USD">-501045811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_888"
      unitRef="USD">14304643</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_916"
      unitRef="Shares">1524</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_889"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_987"
      unitRef="USD">60562</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_988"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_989"
      unitRef="USD">60577</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_923"
      unitRef="Shares">2348</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_893"
      unitRef="USD">23</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_990"
      unitRef="USD">155632</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_991"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_992"
      unitRef="USD">155655</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:PurchaseOfStockByOfficersAndDirectorsShares
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_944"
      unitRef="Shares">1933</cvm:PurchaseOfStockByOfficersAndDirectorsShares>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_897"
      unitRef="USD">19</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_993"
      unitRef="USD">80601</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_994"
      unitRef="USD">0</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_995"
      unitRef="USD">80620</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_901"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_996"
      unitRef="USD">728120</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_997"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_998"
      unitRef="USD">728120</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_905"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_999"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1000"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1001"
      unitRef="USD">-6856558</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_909"
      unitRef="Shares">1809040</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_910"
      unitRef="USD">18089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_911"
      unitRef="USD">516357337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_912"
      unitRef="USD">-507902369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_913"
      unitRef="USD">8473057</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_234"
      unitRef="USD">-19310155</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_235"
      unitRef="USD">-20810973</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_237"
      unitRef="USD">2924303</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_238"
      unitRef="USD">2977603</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_239"
      unitRef="USD">2970</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_240"
      unitRef="USD">-5008</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_241"
      unitRef="USD">587285</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_242"
      unitRef="USD">778571</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_243"
      unitRef="USD">1470491</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_244"
      unitRef="USD">3544569</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_245"
      unitRef="USD">164510</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_246"
      unitRef="USD">162969</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_247"
      unitRef="USD">350885</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts>
    <cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_248"
      unitRef="USD">0</cvm:SharesIssuedForSettlementOfClinicalDevelopmentCosts>
    <cvm:GainLossOnPatentImpairment
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_249"
      unitRef="USD">13312</cvm:GainLossOnPatentImpairment>
    <cvm:GainLossOnPatentImpairment
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_250"
      unitRef="USD">0</cvm:GainLossOnPatentImpairment>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_252"
      unitRef="USD">13874</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_253"
      unitRef="USD">15708</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_254"
      unitRef="USD">-622831</cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing>
    <cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_255"
      unitRef="USD">304097</cvm:IncreaseDecreaseInSuppliesUsedForRDAndManufacturing>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_256"
      unitRef="USD">-4000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_257"
      unitRef="USD">-46884</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_259"
      unitRef="USD">2444</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_260"
      unitRef="USD">-592370</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_261"
      unitRef="USD">-60490</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_262"
      unitRef="USD">167568</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_263"
      unitRef="USD">806214</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_264"
      unitRef="USD">139243</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_265"
      unitRef="USD">-12449214</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_266"
      unitRef="USD">-13994501</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_268"
      unitRef="USD">32954</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_269"
      unitRef="USD">75122</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_270"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_271"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_272"
      unitRef="USD">-32954</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_273"
      unitRef="USD">-88333</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_275"
      unitRef="USD">12560300</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_276"
      unitRef="USD">12730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_277"
      unitRef="USD">1531832</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_278"
      unitRef="USD">1173577</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_279"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_280"
      unitRef="USD">80620</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_281"
      unitRef="USD">350000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_282"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_283"
      unitRef="USD">350000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_284"
      unitRef="USD">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_285"
      unitRef="USD">1491617</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_286"
      unitRef="USD">1315291</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_287"
      unitRef="USD">9536851</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_288"
      unitRef="USD">10321752</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_289"
      unitRef="USD">-2945317</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_290"
      unitRef="USD">-3761083</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_291"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_292"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_293"
      unitRef="USD">1792856</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_294"
      unitRef="USD">384652</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_296"
      unitRef="USD">838</cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_297"
      unitRef="USD">1296</cvm:NonCashFinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:PurchaseOfAssetsUnderFinanceLeases
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_298"
      unitRef="USD">0</cvm:PurchaseOfAssetsUnderFinanceLeases>
    <cvm:PurchaseOfAssetsUnderFinanceLeases
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_299"
      unitRef="USD">20797</cvm:PurchaseOfAssetsUnderFinanceLeases>
    <cvm:ObligationServicesPaidWithIssuanceOfCommonStock
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_300"
      unitRef="USD">583447</cvm:ObligationServicesPaidWithIssuanceOfCommonStock>
    <cvm:ObligationServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_301"
      unitRef="USD">738832</cvm:ObligationServicesPaidWithIssuanceOfCommonStock>
    <cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_302"
      unitRef="USD">0</cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_303"
      unitRef="USD">110000</cvm:NonCashAccruedConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:NonCashFinancingCostsIncludedInCurrentLiabilities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_304"
      unitRef="USD">168740</cvm:NonCashFinancingCostsIncludedInCurrentLiabilities>
    <cvm:NonCashFinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_305"
      unitRef="USD">91975</cvm:NonCashFinancingCostsIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_306"
      unitRef="USD">0</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_307"
      unitRef="USD">2770</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_309"
      unitRef="USD">592644</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_310"
      unitRef="USD">706517</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_311">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;A. &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the &#x201c;Company&#x201d;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#x2019;s financial position as of June 30, 2025 and the results of its operations for the nine months then ended. The condensed balance sheet as of September 30, 2024 is derived from the September 30, 2024 audited financial statements. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On May 19, 2025, the Company&#x2019;s shareholders approved a reverse split of the Company&#x2019;s common stock which became effective on the NYSE American on May 20, 2025. On that date, every thirty issued and outstanding shares of the Company&#x2019;s common stock automatically converted into one outstanding share. As a result of the reverse stock split, the number of the Company&#x2019;s outstanding shares of common stock decreased from 94,037,256 (pre-split) shares to 3,135,021 (post-split) shares. In addition, by reducing the number of the Company&#x2019;s outstanding shares, the Company&#x2019;s loss per share in all prior periods will increase by a factor of thirty. The reverse stock split affected all stockholders of the Company&#x2019;s common stock uniformly and did not affect any stockholder&#x2019;s percentage of ownership interest. The par value of the Company&#x2019;s stock remained unchanged at $0.01 per share and the number of authorized shares of common stock remained the same after the reverse stock split.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As the par value per share of the Company&#x2019;s common stock remained unchanged at $0.01 per share, a total of $909,021 was reclassified from common stock to additional paid-in capital. In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company&#x2019;s incentive and non-qualified stock option plans, as well as the shares of common stock underlying outstanding stock options and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities and are expensed as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and have been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at June 30, 2025 and September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2025 and September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Fair Value Measurements -&lt;/em&gt; In accordance with the provisions of ASC 820, &lt;em&gt;Fair Value Measurements&lt;/em&gt;, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#x2019;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#x2019;s money market funds approximated their fair value at $1,000 and $3,480,000 as of June 30, 2025 and September 30, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07,&#160;&lt;em&gt;Segment Reporting&lt;/em&gt;&#160;(Topic 280):&#160;&lt;em&gt;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;),&lt;/em&gt;&#160;which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. &#160;The Company is currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_cvm_TopMember"
      decimals="0"
      id="fid_639"
      unitRef="Shares">94037256</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_cvm_BottomMember"
      decimals="0"
      id="fid_638"
      unitRef="Shares">3135021</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="fid_640"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <cvm:AdjustmentsToAdditionalPaidInCapitalStockIssued
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_641"
      unitRef="USD">909021</cvm:AdjustmentsToAdditionalPaidInCapitalStockIssued>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_320">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_321">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_322">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-10-01to2025-06-30" id="fid_323">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:LeasesPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_324">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right-of-use assets or lease liabilities and are expensed as incurred.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-10-01to2025-06-30" id="fid_325">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and have been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-10-01to2025-06-30" id="fid_326">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_327">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;.&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-10-01to2025-06-30" id="fid_328">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing account balances were fully insured up to $250,000 at June 30, 2025 and September 30, 2024.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_633"
      unitRef="USD">250000</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_329">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2025 and September 30, 2024.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cvm:ImpairmentOfLongLivedAssetsPolicyTextblock contextRef="From2024-10-01to2025-06-30" id="fid_330">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</cvm:ImpairmentOfLongLivedAssetsPolicyTextblock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_331">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Fair Value Measurements -&lt;/em&gt; In accordance with the provisions of ASC 820, &lt;em&gt;Fair Value Measurements&lt;/em&gt;, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.&#160; The Company&#x2019;s money market funds included in cash equivalents are valued using Level 1 inputs and measured at fair value on a recurring basis. The cost of the Company&#x2019;s money market funds approximated their fair value at $1,000 and $3,480,000 as of June 30, 2025 and September 30, 2024, respectively.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsOwnedOtherAtFairValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_635"
      unitRef="USD">1000</us-gaap:FinancialInstrumentsOwnedOtherAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedOtherAtFairValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_636"
      unitRef="USD">3480000</us-gaap:FinancialInstrumentsOwnedOtherAtFairValue>
    <us-gaap:UseOfEstimates contextRef="From2024-10-01to2025-06-30" id="fid_332">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_333">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07,&#160;&lt;em&gt;Segment Reporting&lt;/em&gt;&#160;(Topic 280):&#160;&lt;em&gt;Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;),&lt;/em&gt;&#160;which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. &#160;The Company is currently evaluating the impact of new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:LiquidityDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_312">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;B. &lt;span style="text-decoration:underline"&gt;LIQUIDITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_313">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;C. &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In May 2025, the Company sold 2,000,000 shares of common stock at a public offering price of $2.50 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2025, the Company sold 133,750 shares of common stock at an offering price of $4.80 per share and pre-funded warrants to purchase up to 399,584 shares of common stock, at an offering price of $4.797 per pre-funded warrant, for proceeds of approximately $2.1 million, net of issuance costs of approximately $0.5 million. As of June 30, 2025, all of the pre-funded warrants in connection with the March 2025 offering have been exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2024, the Company sold 251,750 shares of common stock at an offering price of $9.30 per share and pre-funded warrants to purchase up to 285,917 shares of common stock, at an offering price of $9.297 per pre-funded warrant, for proceeds of approximately $4.4 million, net of issuance costs of approximately $0.6 million. As of June 30, 2025, 285,917 of the pre-funded warrants in connection with the December 2024 offering have been exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company determined that the pre-funded warrants sold in the March 2025 and December 2024 offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#x2019;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the financings.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In February 2024, the Company sold 129,167 shares of common stock at a public offering price of $60.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the Company sold 83,000 shares of common stock at a public offering price of $60.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Other Equity Transactions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In October 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (&#x201c;Ergomed&#x201d;) pursuant to which the Company issued 33,334 shares of common stock in exchange for services. The shares are legally issued and outstanding. The Company determined the issuance of shares to a non-employee for services rendered or to be rendered is within the scope of ASC 718. In accordance with ASC 718, the shares were not issued and outstanding for accounting purposes as they are unvested and forfeitable. The shares will be recognized on the settlement date and measured at fair value when the shares are settled for services rendered by Ergomed. The Company incurred share issuance costs of approximately $61,000 to issue the shares from this agreement which were immediately expensed. During the nine months ended June 30, 2025, 33,334 shares were sold by Ergomed and the proceeds used to settle $350,885 in outstanding payables for services provided to the Company. As of June 30, 2025, Ergomed held did not hold any shares of CEL-SCI&#x2019;s common stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Underlying share information for equity compensation plans as of June 30, 2025 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;709,573&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,460&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,134&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,334&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Option Activity&lt;/span&gt;:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,136&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,584&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,957&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,767&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;903&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,017&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,484&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,033&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;905&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On March 1, 2024, the Company accelerated the vesting of 7,811 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date.&#160; This resulted in remaining compensation cost of approximately $260,000 that will be amortized on a straight-line basis over the remaining service period. The remaining compensation cost of approximately $101,000 as of March 31, 2024 was expensed during the three months ended June 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Share-Based Compensation Expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,470,491&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,544,569&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;587,285&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600,841&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,442&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;728,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;80,525&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,678&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods.&#160; Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following chart represents the warrants and non-employee options outstanding at June 30, 2025:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:12%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2,845&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;90.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,120&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;84.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;277.50&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;360.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;11,115&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;55.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6,670&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;75.60&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;7,801&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;49.50&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 11/19/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;20,333&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$21.00 - $65.40&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 - 11/1/2034&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;1. &lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025, 399,583 and 285,917 pre-funded warrants at an offering price of $4.80 and $9.30, respectively, were issued. No pre-funded warrants or warrants recorded as equity were issued during the nine months ended June 30, 2024.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025, 733,834 pre-funded warrants were exercised. No pre-funded warrants or warrants recorded as equity were exercised during the nine months ended June 30, 2024.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity expired or were extended during the nine months ended June 30, 2025 and 2024. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;2. &lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025 and 2024, the Company issued 6,821 and 10,726 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $26.13 and $55.29 during the nine months ended June 30, 2025 and 2024, respectively. During the three months ended June 30, 2025 and 2024, the Company issued 0 and 2,348 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $39.86 during the three months ended June 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025, 16,667 options with an exercise price of $21.00 were issued to a consultant.&#160; The options vest immediately and will expire on November 1, 2034.&#160; No options were issued to a consultant during the nine months ended June 30, 2024.&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $587,000 and $601,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended June 30, 2025 and 2024, the Company recorded total expense of approximately $81,000 and $231,000, respectively, relating to the share-based compensation under various consulting agreements. On June 30, 2025 and September 30, 2024, consulting fees of approximately $48,000 and $52,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-01to2025-05-31"
      decimals="0"
      id="fid_658"
      unitRef="Shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="fid_660"
      unitRef="USDPShares">2.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-05-01to2025-05-31"
      decimals="-5"
      id="fid_661"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:StockIssuanceCost
      contextRef="From2025-05-01to2025-05-31"
      decimals="-5"
      id="fid_662"
      unitRef="USD">500000</cvm:StockIssuanceCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-01to2025-03-31"
      decimals="0"
      id="fid_665"
      unitRef="Shares">133750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_666"
      unitRef="USDPShares">4.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2025-05-31_cvm_PreFundedMember"
      decimals="0"
      id="fid_668"
      unitRef="Shares">399584</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-05-31_cvm_PreFundedMember"
      decimals="INF"
      id="fid_669"
      unitRef="USDPShares">4.79</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-01to2025-03-31"
      decimals="-5"
      id="fid_667"
      unitRef="USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:StockIssuanceCost
      contextRef="From2025-03-01to2025-03-31"
      decimals="-5"
      id="fid_670"
      unitRef="USD">500000</cvm:StockIssuanceCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-12-01to2024-12-31"
      decimals="0"
      id="fid_671"
      unitRef="Shares">251750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_526"
      unitRef="USDPShares">9.30</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ExcessStockSharesIssued
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="0"
      id="fid_519"
      unitRef="Shares">285917</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31_cvm_PreFundedMember"
      decimals="INF"
      id="fid_527"
      unitRef="USDPShares">9.29</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-01to2024-12-31"
      decimals="-5"
      id="fid_532"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:StockIssuanceCost
      contextRef="From2024-12-01to2024-12-31"
      decimals="-5"
      id="fid_534"
      unitRef="USD">600000</cvm:StockIssuanceCost>
    <cvm:StockWarrantsExercised
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="fid_672"
      unitRef="USDPShares">285917</cvm:StockWarrantsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-02-01to2024-02-29"
      decimals="0"
      id="fid_675"
      unitRef="Shares">129167</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-29"
      decimals="INF"
      id="fid_676"
      unitRef="USDPShares">60.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-01to2024-02-29"
      decimals="-5"
      id="fid_677"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:StockIssuanceCost
      contextRef="From2024-02-01to2024-02-29"
      decimals="-5"
      id="fid_678"
      unitRef="USD">700000</cvm:StockIssuanceCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-11-01to2023-11-30"
      decimals="0"
      id="fid_680"
      unitRef="Shares">83000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_528"
      unitRef="USDPShares">60.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_533"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:StockIssuanceCost
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_535"
      unitRef="USD">500000</cvm:StockIssuanceCost>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-10-31_cvm_ErgomedMember"
      decimals="0"
      id="fid_524"
      unitRef="Shares">33334</us-gaap:CommonStockSharesIssued>
    <cvm:StockIssuanceCost
      contextRef="From2024-10-01to2024-10-31_cvm_ErgomedMember"
      decimals="0"
      id="fid_517"
      unitRef="USD">61000</cvm:StockIssuanceCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_684"
      unitRef="Shares">33334</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_690"
      unitRef="USD">350885</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_334">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,613&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;709,573&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,460&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,134&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,334&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <cvm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93
      contextRef="AsOf2025-06-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_637"
      unitRef="Shares">4613</cvm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant93>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_630"
      unitRef="Shares">709573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_631"
      unitRef="Shares">59460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_632"
      unitRef="Shares">21134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_629"
      unitRef="Shares">21334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvm:ScheduleOfStockOptionActivityTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_335">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,136&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,584&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,957&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,767&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;906&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;903&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,017&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,484&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,033&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;905&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfStockOptionActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_457"
      unitRef="Shares">1136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_456"
      unitRef="Shares">65584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_460"
      unitRef="Shares">11957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_461"
      unitRef="Shares">9767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_463"
      unitRef="Shares">906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_462"
      unitRef="Shares">903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_642"
      unitRef="Shares">1017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_643"
      unitRef="Shares">65484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_646"
      unitRef="Shares">11033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_647"
      unitRef="Shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_648"
      unitRef="Shares">905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_649"
      unitRef="Shares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-04-01to2024-04-19"
      decimals="0"
      id="fid_691"
      unitRef="Shares">7811</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <cvm:CompensationCost
      contextRef="From2024-04-01to2024-04-19"
      decimals="0"
      id="fid_693"
      unitRef="USD">260000</cvm:CompensationCost>
    <cvm:CompensationCost
      contextRef="From2024-04-01to2024-06-30"
      decimals="-6"
      id="fid_696"
      unitRef="USD">101000000000</cvm:CompensationCost>
    <cvm:ScheduleOfCompensatingBalancesTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_336">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,470,491&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,544,569&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;587,285&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;600,841&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73,442&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;728,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;80,525&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;230,678&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfCompensatingBalancesTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-10-01to2025-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_464"
      unitRef="USD">1470491</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_650"
      unitRef="USD">3544569</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-10-01to2025-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_466"
      unitRef="USD">587285</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_651"
      unitRef="USD">600841</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2025-04-01to2025-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_652"
      unitRef="USD">73442</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-04-01to2024-06-30_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_653"
      unitRef="USD">728120</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2025-04-01to2025-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_654"
      unitRef="USD">80525</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-04-01to2024-06-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_655"
      unitRef="USD">230678</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_337">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:12%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2,845&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;90.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,120&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;84.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;277.50&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;867&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;360.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;11,115&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;55.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6,670&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;75.60&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;7,801&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;49.50&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 11/19/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;20,333&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$21.00 - $65.40&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 - 11/1/2034&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesNMember"
      id="fid_468">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_478"
      unitRef="Shares">2845</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_487"
      unitRef="USDPShares">90.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesNMember"
      id="fid_497">8/18/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesUUMember"
      id="fid_469">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_479"
      unitRef="Shares">3120</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_488"
      unitRef="USDPShares">84.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesUUMember"
      id="fid_498">6/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesXMember"
      id="fid_470">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_480"
      unitRef="Shares">4000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_489"
      unitRef="USDPShares">277.50</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesXMember"
      id="fid_499">7/13/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesYMember"
      id="fid_471">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_481"
      unitRef="Shares">867</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_490"
      unitRef="USDPShares">360.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesYMember"
      id="fid_500">8/15/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesMMMember"
      id="fid_472">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_482"
      unitRef="Shares">11115</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_491"
      unitRef="USDPShares">55.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesMMMember"
      id="fid_501">6/22/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesNNMember"
      id="fid_473">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_483"
      unitRef="Shares">6670</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_492"
      unitRef="USDPShares">75.60</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesNNMember"
      id="fid_502">7/24/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesRRMember"
      id="fid_474">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_484"
      unitRef="Shares">7801</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_493"
      unitRef="USDPShares">49.50</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_SeriesRRMember"
      id="fid_503">10/30/2026</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember"
      id="fid_476">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember"
      id="fid_477">11/19/2024</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2025-06-30_cvm_ConsultantsOptionMember"
      decimals="0"
      id="fid_486"
      unitRef="Shares">20333</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_BottomMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_495"
      unitRef="USDPShares">21.00</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2025-06-30_cvm_TopMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_496"
      unitRef="USDPShares">65.40</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_BottomMember_cvm_ConsultantsMember"
      id="fid_504">7/27/2027</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2024-10-01to2025-06-30_cvm_TopMember_cvm_ConsultantsMember"
      id="fid_505">11/1/2034</cvm:ExpirationDate>
    <cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted
      contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember"
      decimals="0"
      id="fid_698"
      unitRef="Shares">399583</cvm:ShareBasedPaymentArrangementNumberOfInstrumentsGranted>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-06-30_cvm_ChangesInEquityWarrantsMember"
      decimals="INF"
      id="fid_700"
      unitRef="USDPShares">4.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-06-30_cvm_ChangesInEquityWarrantsOneMember"
      decimals="INF"
      id="fid_702"
      unitRef="USDPShares">9.30</us-gaap:SaleOfStockPricePerShare>
    <cvm:ShareBasedPaymentArrangementNumberOfInstrumentsExercised
      contextRef="From2024-10-01to2025-06-30_cvm_ChangesInEquityWarrantsMember"
      decimals="0"
      id="fid_704"
      unitRef="Shares">733834</cvm:ShareBasedPaymentArrangementNumberOfInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_514"
      unitRef="Shares">6821</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_708"
      unitRef="Shares">10726</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_705"
      unitRef="USDPShares">26.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_709"
      unitRef="USDPShares">55.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2025-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_512"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_710"
      unitRef="Shares">2348</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-06-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_707"
      unitRef="USDPShares">39.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cvm:hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_711"
      unitRef="Shares">16667</cvm:hareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_508"
      unitRef="USDPShares">21.00</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_712"
      unitRef="USD">587000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_713"
      unitRef="USD">601000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-04-01to2025-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_716"
      unitRef="USD">81000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-01to2024-06-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_714"
      unitRef="USD">231000</us-gaap:ShareBasedCompensation>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-06-30_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_699"
      unitRef="USD">48000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsOtherMember"
      decimals="0"
      id="fid_510"
      unitRef="USD">52000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_314">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;There were no related party transactions during the nine months ended June 30, 2025. During the nine months ended June 30, 2024, certain officers and directors purchased 1,933 shares of restricted common stock at an aggregate fair market value of approximately $80,620.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:RestrictedCommonStockSharesIssued
      contextRef="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1069"
      unitRef="USD">1933</cvm:RestrictedCommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-06-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1070"
      unitRef="USD">80620</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:DescriptionOfModificationOfWarrants contextRef="From2024-05-01to2024-05-04" id="fid_1068">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend</cvm:DescriptionOfModificationOfWarrants>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_315">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;span style="text-decoration:underline"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of May 8, 2025, the Company entered into a promissory note agreement for a principal amount of $350,000 (the &#x201c;Note Payable&#x201d;). The Note Payable bears interest at a fixed rate of 10% per annum. As of June 30, 2025, the Note Payable was repaid in full.&lt;/p&gt;</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-05-01to2025-05-08"
      decimals="0"
      id="fid_1071"
      unitRef="USD">350000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2025-06-30"
      decimals="1"
      id="fid_1072"
      unitRef="Pure">0.10</us-gaap:InvestmentInterestRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_316">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;F. &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#x2019;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.7 million as of June 30, 2025. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of June 30, 2025 and September 30, 2024, respectively, the net book value of the finance lease right-of-use asset is approximately $6.0 million and $7.4 million and the balance of the finance lease liability is approximately $8.5 million and $10.0 million, of which approximately $2.2 million and $2.0 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the nine months ended June 30, 2025 and 2024, the finance right-of-use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.4 million in both periods, which is included in research and development expense on the accompanying condensed statements of operations. Total cash paid related to finance leases during the nine months ended June 30, 2025 and 2024, was approximately $2.1 million and $2.0 million, respectively, of which approximately $0.6 million and $0.7 million was for interest, respectively. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying condensed statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying condensed statements of cash flows. As of June 30, 2025, the weighted average discount rate of the Company&#x2019;s finance leases is 8.46% and the weighted average remaining lease term is 3.34 years. During the nine months ended June 30, 2025 and 2024, total finance lease costs were approximately $1.9 million and $2.1 million, respectively, consisting of approximately $1.4 million of lease asset amortization for both periods and approximately $0.6 million and $0.7 million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right-of-use assets or lease liabilities but rather are expensed as incurred. During the nine months ended June 30, 2025, there were approximately $0.7 million of variable finance lease costs, which are included in research and development expense on the accompanying condensed statements of operations. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of June 30, 2025 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,731,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,253,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,478,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,206,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,272,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of June 30, 2025 and September 30, 2024, respectively, the net book value of the operating lease right-of-use asset is approximately $1.3 million and $1.5 million and the balance of the operating lease liability is approximately $1.5 million and $1.7 million, of which approximately $0.2 million is current in both periods. During the nine months ended June 30, 2025 and 2024, the Company incurred lease expense under operating leases of approximately $0.1 million in both periods, respectively, which is included in general and administrative expense on the accompanying condensed statements of operations. Total cash paid related to operating leases during the nine months ended June 30, 2025 and 2024 was approximately $0.3 million for both periods. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying condensed statements of cash flows. The weighted average discount rate of the Company&#x2019;s operating leases is 8.95% and the weighted average the remaining lease term is 6.49 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of June 30, 2025, approximate future minimum lease payments on operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;303,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;443,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,982,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(496,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,486,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(188,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,298,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember"
      decimals="-4"
      id="fid_1116"
      unitRef="USD">70000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1098"
      unitRef="USD">6000000.0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1099"
      unitRef="USD">740000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1100"
      unitRef="USD">850000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1101"
      unitRef="USD">1000000.0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1102"
      unitRef="USD">2200000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1103"
      unitRef="USD">200000.0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:Depreciation
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1117"
      unitRef="USD">1400000</us-gaap:Depreciation>
    <cvm:FinanceLeasePrincipalPayment
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1118"
      unitRef="USD">2100000</cvm:FinanceLeasePrincipalPayment>
    <cvm:FinanceLeasePrincipalPayment
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1120"
      unitRef="USD">2000000.0</cvm:FinanceLeasePrincipalPayment>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1121"
      unitRef="USD">60000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1122"
      unitRef="USD">70000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <cvm:AnnualIncreaseToInterestPayments
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="4"
      id="fid_1096"
      unitRef="Pure">0.0846</cvm:AnnualIncreaseToInterestPayments>
    <cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      id="fid_1115">P3Y4M2D</cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1110"
      unitRef="USD">1900000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1119"
      unitRef="USD">2100000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1111"
      unitRef="USD">1400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1112"
      unitRef="USD">60000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-10-01to2024-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1123"
      unitRef="USD">700000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-10-01to2025-06-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_1124"
      unitRef="USD">700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-01-11_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1104"
      unitRef="USD">2300000</us-gaap:SecurityDeposit>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_338">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,731,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,253,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,478,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,206,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,272,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1073"
      unitRef="USD">688000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1074"
      unitRef="USD">2838000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1075"
      unitRef="USD">2929000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1076"
      unitRef="USD">3021000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1077"
      unitRef="USD">255000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1078"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1079"
      unitRef="USD">9731000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1080"
      unitRef="USD">1253000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1081"
      unitRef="USD">8478000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1082"
      unitRef="USD">-2206000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1083"
      unitRef="USD">6272000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1105"
      unitRef="USD">1300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1106"
      unitRef="USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1107"
      unitRef="USD">1500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1108"
      unitRef="USD">1700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-4"
      id="fid_1109"
      unitRef="USD">20000</us-gaap:OperatingLeaseLiabilityCurrent>
    <cvm:LeaseExpenseUnderOperatingLeases
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1113"
      unitRef="USD">100000</cvm:LeaseExpenseUnderOperatingLeases>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_1114"
      unitRef="USD">300000</us-gaap:OperatingLeasePaymentsUse>
    <cvm:AnnualIncreaseToInterestPaymentsOperating
      contextRef="AsOf2025-06-30_us-gaap_LeaseAgreementsMember"
      decimals="4"
      id="fid_1097"
      unitRef="Pure">0.0895</cvm:AnnualIncreaseToInterestPaymentsOperating>
    <cvm:OperatingLeaseWeightedAverageRemainingLeaseTerm
      contextRef="From2024-10-01to2025-06-30_us-gaap_LeaseAgreementsMember"
      id="fid_1127">P6Y5M26D</cvm:OperatingLeaseWeightedAverageRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_339">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;303,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;443,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,982,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(496,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,486,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(188,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,298,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1084"
      unitRef="USD">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1085"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1086"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1087"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1088"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1089"
      unitRef="USD">303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1090"
      unitRef="USD">443000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1091"
      unitRef="USD">1982000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1092"
      unitRef="USD">496000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1093"
      unitRef="USD">1486000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseLiabilityCurrentPortion
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1094"
      unitRef="USD">-188000</cvm:OperatingLeaseLiabilityCurrentPortion>
    <cvm:OperatingLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1095"
      unitRef="USD">1298000</cvm:OperatingLeaseLiabilityNoncurrentPortion>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_317">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;G. &lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the nine months ended June 30, 2025, the Company abandoned four patents which resulted in an impairment of $13,312 on patent costs. During the three months ended June 30, 2025, the Company abandoned one patent which resulted in an impairment of $3,770 on patent costs. During the nine and three months ended June 30, 2024, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;7&#160;years. For the nine months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $22,000 and $25,000, respectively. For the three months ended June 30, 2025 and 2024, amortization of patent costs totaled approximately $7,000 for both periods. The total estimated future amortization is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;131,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_1136"
      unitRef="USD">13312</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1169"
      unitRef="USD">3770</us-gaap:AssetImpairmentCharges>
    <cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod contextRef="From2024-10-01to2025-06-30" id="fid_1139">P7Y</cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_1137"
      unitRef="USD">22000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1140"
      unitRef="USD">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1138"
      unitRef="USD">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_340">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three months ending September 30, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;33,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;131,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1128"
      unitRef="USD">6000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1129"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1130"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1131"
      unitRef="USD">18000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1132"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1133"
      unitRef="USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1134"
      unitRef="USD">33000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="fid_1135"
      unitRef="USD">131000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_318">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;H. &lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants, unvested common stock and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(19,310,155&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21,470,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,664,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,516,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,046,400&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,715,982&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,150,702&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,799,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(6.34&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(12.51&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(1.36&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(4.18&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;583,312&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;583,249&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,809&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,909&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;588,121&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;588,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_450">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(19,310,155&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21,470,429&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,664,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,516,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,046,400&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,715,982&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,150,702&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,799,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(6.34&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(12.51&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(1.36&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(4.18&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_1142"
      unitRef="USD">-19310155</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1143"
      unitRef="USD">-21470429</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1149"
      unitRef="USD">-5664704</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1150"
      unitRef="USD">-7516014</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_1145"
      unitRef="Shares">3046400</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1146"
      unitRef="Shares">1715982</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-01to2025-06-30"
      decimals="0"
      id="fid_1151"
      unitRef="Shares">4150702</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-01to2024-06-30"
      decimals="0"
      id="fid_1152"
      unitRef="Shares">1799813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2025-06-30"
      decimals="INF"
      id="fid_1147"
      unitRef="USDPShares">-6.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-06-30"
      decimals="INF"
      id="fid_1148"
      unitRef="USDPShares">-12.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-01to2025-06-30"
      decimals="INF"
      id="fid_1153"
      unitRef="USDPShares">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-01to2024-06-30"
      decimals="INF"
      id="fid_1154"
      unitRef="USDPShares">-4.18</us-gaap:EarningsPerShareDiluted>
    <cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_451">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;583,312&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;583,249&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,809&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,909&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;588,121&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;588,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2025-06-30_cvm_OptionsMember"
      decimals="0"
      id="fid_1155"
      unitRef="Shares">583312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30_cvm_OptionsMember"
      decimals="0"
      id="fid_1156"
      unitRef="Shares">583249</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2025-06-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1157"
      unitRef="Shares">4809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1158"
      unitRef="Shares">4909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2025-06-30"
      decimals="0"
      id="fid_1159"
      unitRef="Shares">588121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-06-30"
      decimals="0"
      id="fid_1160"
      unitRef="Shares">588158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-10-01to2025-06-30" id="fid_319">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;I. &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On July 4, 2025, the One&#160;Big Beautiful Bill&#160;Act (&#x201c;OBBBA&#x201d;) was enacted in the United States. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, requires the effects of changes in tax rates and laws on deferred tax balances to be recognized in the period in which the legislation is enacted. Consequently, as of the date of enactment, we will evaluate all deferred tax balances under the newly enacted tax law and identify any other changes required to our financial statements as a result of the OBBBA. The Company is currently evaluating the impact of the OBBBA on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On July 14, 2025, the Company sold 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules, for gross proceeds of approximately $5.7 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On July 25, 2025, the CEO and a director purchased 32,116 shares of restricted common stock at an aggregate fair market value of approximately $219,995.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1164"
      unitRef="Shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-14_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1166"
      unitRef="USDPShares">3.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-01to2025-07-14_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_1165"
      unitRef="USD">5700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:RestrictedCommonStockSharesIssued
      contextRef="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1167"
      unitRef="USD">32116</cvm:RestrictedCommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-07-01to2025-07-25_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1168"
      unitRef="USD">219995</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
